practice_3_JupiterLab/data/gm_feature_engineered_fda.csv

1	report_id	country	occur_country	report_type	serious	death	life_threatening	hospitalization	disabling	receive_date	age	age_unit	gender	weight	drug	reaction	is_serious	severity_score	severity_norm	age_group	country_group	drug_risk	drug_freq	high_risk_drug	reaction_length	reaction_pain	reaction_infection	reaction_death	reaction_cancer	reaction_failure	reaction_pneumonia	reaction_bleeding	reaction_complexity	year	month	day	weekday	report_type_risk	age_drug_risk	gender_drug_risk
2	26016170	US	US	1	2.0	0	0	0	0	2025-11-10	42.0	801.0	Male	75.0	DUPIXENT	abdominal pain	0	0	0.0	Adult	US	0.015513897866839042	221	0	14	1	0	0	0	0	0	0	2	2025	11	10	0	0.08073634859349145	0.6515837104072397	0.0
3	26017452	NP	NP	1	1.0	1	0	1	0	2025-11-10	51.0	801.0	Male	75.0	METHOTREXATE	toxicity to various agents	1	8	0.5714285714285714	MidAge	Other	0.17346938775510204	7	1	26	0	0	0	0	0	0	0	4	2025	11	10	0	0.08073634859349145	8.846938775510203	0.0
4	26017586	US	US	1	2.0	0	0	0	0	2025-11-10	57.0	801.0	Female	75.0	PEPCID COMPLETE	exposure during pregnancy	0	0	0.0	MidAge	US	0.0	1	0	25	0	0	0	0	0	0	0	3	2025	11	10	0	0.08073634859349145	0.0	0.0
5	26018910	SG	SG	1	1.0	0	0	0	0	2025-11-10	62.0	801.0	Female	75.0	PACLITAXEL	drug ineffective	1	0	0.0	MidAge	Other	0.07142857142857142	3	0	16	0	0	0	0	0	0	0	2	2025	11	10	0	0.08073634859349145	4.428571428571428	0.07142857142857142
6	26018949	EU	EU	3	1.0	0	0	0	0	2025-11-10	57.0	801.0	Female	75.0	DULOXETINE	drug interaction	1	0	0.0	MidAge	EU	0.0	2	0	16	0	0	0	0	0	0	0	2	2025	11	10	0	0.17857142857142855	0.0	0.0
7	26019625	US	US	1	1.0	0	0	0	0	2025-11-10	67.0	801.0	Male	75.0	DOCETAXEL	osteoporosis	1	0	0.0	Senior	US	0.061224489795918366	7	0	12	0	0	0	0	0	0	0	1	2025	11	10	0	0.08073634859349145	4.1020408163265305	0.0
8	26019988	US	US	1	2.0	0	0	0	0	2025-11-10	57.0	801.0	Female	75.0	POLYETHYLENE GLYCOL 3350	incorrect product administration duration	0	0	0.0	MidAge	US	0.0	4	0	41	0	0	0	0	0	0	0	4	2025	11	10	0	0.08073634859349145	0.0	0.0
9	25942883	CA	CA	2	1.0	0	0	0	0	2025-10-21	46.0	801.0	Male	75.0	VEDOLIZUMAB	colitis ulcerative	1	0	0.0	Adult	CA	0.057692307692307696	26	0	18	0	0	0	0	0	0	0	2	2025	10	21	1	0.08936301793444651	2.653846153846154	0.0
10	25942964	JP	JP	1	1.0	1	0	0	0	2025-10-21	78.0	801.0	Male	75.0	BEVACIZUMAB	vascular stent thrombosis	1	5	0.35714285714285715	Senior	JP	0.17857142857142858	2	1	25	0	0	0	0	0	0	0	3	2025	10	21	1	0.08073634859349145	13.928571428571429	0.0
11	25943989	US	US	1	2.0	0	0	0	0	2025-10-21	57.0	801.0	Female	75.0	SKYRIZI	swelling of eyelid	0	0	0.0	MidAge	US	0.051587301587301584	36	0	18	0	0	0	0	0	0	0	3	2025	10	21	1	0.08073634859349145	2.9404761904761902	0.051587301587301584
12	25944665	US	US	1	2.0	0	0	0	0	2025-10-21	68.0	801.0	Female	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	Senior	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	10	21	1	0.08073634859349145	1.0549450549450547	0.015513897866839042
13	25945112	US	Unknown	1	1.0	0	0	1	0	2025-10-21	93.0	801.0	Male	75.0	ABIRATERONE ACETATE	blood potassium decreased	1	3	0.21428571428571427	Senior	US	0.21428571428571427	1	1	25	0	0	0	0	0	0	0	3	2025	10	21	1	0.08073634859349145	19.928571428571427	0.0
14	25945394	US	US	2	1.0	0	0	0	0	2025-10-21	57.0	801.0	Female	83.46	SKYRIZI	loss of consciousness	1	0	0.0	MidAge	US	0.051587301587301584	36	0	21	0	0	0	0	0	0	0	3	2025	10	21	1	0.08936301793444651	2.9404761904761902	0.051587301587301584
15	25945732	US	US	1	1.0	0	0	1	0	2025-10-21	16.0	801.0	Female	75.0	WEGOVY	asthma	1	3	0.21428571428571427	Child	US	0.14285714285714285	4	1	6	0	0	0	0	0	0	0	1	2025	10	21	1	0.08073634859349145	2.2857142857142856	0.14285714285714285
16	25946070	US	US	1	2.0	0	0	0	0	2025-10-21	64.0	801.0	Female	96.16	NEULASTA	needle issue	0	0	0.0	MidAge	US	0.0	5	0	12	0	0	0	0	0	0	0	2	2025	10	21	1	0.08073634859349145	0.0	0.0
17	25946757	US	US	1	2.0	0	0	0	0	2025-10-22	77.0	801.0	Female	98.866	REMODULIN	peripheral swelling	0	0	0.0	Senior	US	0.0	4	0	19	0	0	0	0	0	0	0	2	2025	10	22	2	0.08073634859349145	0.0	0.0
18	26022111	US	US	1	2.0	0	0	0	0	2025-11-10	57.0	801.0	Female	75.0	DUPIXENT	rash macular	0	0	0.0	MidAge	US	0.015513897866839042	221	0	12	0	0	0	0	0	0	0	2	2025	11	10	0	0.08073634859349145	0.8842921784098254	0.015513897866839042
19	26023703	CA	CA	1	1.0	0	0	0	0	2025-11-11	65.0	801.0	Female	75.0	LETROZOLE	drug intolerance	1	0	0.0	MidAge	CA	0.07142857142857142	3	0	16	0	0	0	0	0	0	0	2	2025	11	11	1	0.08073634859349145	4.642857142857142	0.07142857142857142
20	26024027	US	US	1	1.0	0	0	0	0	2025-11-11	82.0	801.0	Male	75.0	DUPIXENT	cataract	1	0	0.0	Senior	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	1	2025	11	11	1	0.08073634859349145	1.2721396250808015	0.0
21	26073427	JP	JP	1	2.0	0	0	0	0	2025-11-21	4.0	800.0	Male	75.0	MINOCYCLINE	therapy partial responder	0	0	0.0	Child	JP	0.0	1	0	25	0	0	0	0	0	0	0	3	2025	11	21	4	0.08073634859349145	0.0	0.0
22	26073603	CA	CA	1	1.0	0	1	0	0	2025-11-21	57.0	801.0	Male	75.0	DEXAMETHASONE	ventricular hypertrophy	1	4	0.2857142857142857	MidAge	CA	0.1857142857142857	5	1	23	0	0	0	0	0	0	0	2	2025	11	21	4	0.08073634859349145	10.585714285714284	0.0
23	26074251	CA	CA	2	1.0	0	0	0	0	2025-11-21	57.0	801.0	Female	75.0	RITUXIMAB	blood pressure increased	1	0	0.0	MidAge	CA	0.12406015037593986	19	0	24	0	0	0	0	0	0	0	3	2025	11	21	4	0.08936301793444651	7.071428571428572	0.12406015037593986
24	26075829	US	US	1	2.0	0	0	0	0	2025-11-21	27.0	801.0	Female	75.0	DUPIXENT	condition aggravated	0	0	0.0	Young	US	0.015513897866839042	221	0	20	0	0	0	0	0	0	0	2	2025	11	21	4	0.08073634859349145	0.4188752424046541	0.015513897866839042
25	26076396	US	US	2	1.0	0	0	0	0	2025-11-21	71.0	801.0	Female	75.0	AXICABTAGENE CILOLEUCEL	squamous cell carcinoma of skin	1	0	0.0	Senior	US	0.0	1	0	31	0	0	0	0	0	0	0	5	2025	11	21	4	0.08936301793444651	0.0	0.0
26	25946933	US	US	1	1.0	0	0	0	0	2025-10-22	68.0	801.0	Female	80.726	FIRDAPSE	carpal tunnel syndrome	1	0	0.0	Senior	US	0.0	3	0	22	0	0	0	0	0	0	0	3	2025	10	22	2	0.08073634859349145	0.0	0.0
27	25947729	US	US	1	2.0	0	0	0	0	2025-10-22	57.0	801.0	Female	52.608	REMODULIN	device maintenance issue	0	0	0.0	MidAge	US	0.0	4	0	24	0	0	0	0	0	0	0	3	2025	10	22	2	0.08073634859349145	0.0	0.0
28	25948863	US	US	1	2.0	0	0	0	0	2025-10-22	57.0	801.0	Male	75.0	DUPIXENT	illness	0	0	0.0	MidAge	US	0.015513897866839042	221	0	7	0	0	0	0	0	0	0	1	2025	10	22	2	0.08073634859349145	0.8842921784098254	0.0
29	25949525	US	US	1	1.0	0	0	0	0	2025-10-22	53.0	801.0	Male	75.0	TRULICITY	hepatobiliary cancer	1	0	0.0	MidAge	US	0.04285714285714286	5	0	20	0	0	0	1	0	0	0	2	2025	10	22	2	0.08073634859349145	2.2714285714285714	0.0
30	25949592	EU	EU	2	1.0	0	0	1	0	2025-10-22	57.0	801.0	Female	75.0	METHOTREXATE SODIUM	chest pain	1	3	0.21428571428571427	MidAge	EU	0.125	4	1	10	1	0	0	0	0	0	0	2	2025	10	22	2	0.08936301793444651	7.125	0.125
31	25950497	US	US	1	2.0	0	0	0	0	2025-10-23	57.0	801.0	Female	75.0	DUPIXENT	weight increased	0	0	0.0	MidAge	US	0.015513897866839042	221	0	16	0	0	0	0	0	0	0	2	2025	10	23	3	0.08073634859349145	0.8842921784098254	0.015513897866839042
32	26024809	EU	EU	3	1.0	0	0	1	0	2025-11-11	57.0	801.0	Female	75.0	ACETAMINOPHEN	cholestasis	1	3	0.21428571428571427	MidAge	EU	0.10267857142857142	16	0	11	0	0	0	0	0	0	0	1	2025	11	11	1	0.17857142857142855	5.852678571428571	0.10267857142857142
33	26025781	US	US	2	2.0	0	0	0	0	2025-11-11	72.0	801.0	Male	75.0	VONJO	off label use	0	0	0.0	Senior	US	0.0	3	0	13	0	0	0	0	0	0	0	3	2025	11	11	1	0.08936301793444651	0.0	0.0
34	26025862	EU	EU	1	1.0	0	0	1	0	2025-11-11	57.0	801.0	Female	75.0	RIVAROXABAN	cerebellar ischaemia	1	3	0.21428571428571427	MidAge	EU	0.21428571428571427	2	1	20	0	0	0	0	0	0	0	2	2025	11	11	1	0.08073634859349145	12.214285714285714	0.21428571428571427
35	26026281	US	US	1	2.0	0	0	0	0	2025-11-11	9.0	801.0	Female	75.0	DUPIXENT	breast mass	0	0	0.0	Child	US	0.015513897866839042	221	0	11	0	0	0	0	0	0	0	2	2025	11	11	1	0.08073634859349145	0.13962508080155137	0.015513897866839042
36	26027334	CA	CA	1	1.0	0	0	0	0	2025-11-11	56.0	801.0	Female	75.0	VOLTAREN	blindness unilateral	1	0	0.0	MidAge	CA	0.0	1	0	20	0	0	0	0	0	0	0	2	2025	11	11	1	0.08073634859349145	0.0	0.0
37	26027792	US	US	1	2.0	0	0	0	0	2025-11-11	57.0	801.0	Male	75.0	PLUVICTO	general physical health deterioration	0	0	0.0	MidAge	US	0.0	8	0	37	0	0	0	0	0	0	0	4	2025	11	11	1	0.08073634859349145	0.0	0.0
38	26027806	US	US	2	1.0	0	0	0	0	2025-11-11	57.0	801.0	Female	75.0	NUPLAZID	hallucination	1	0	0.0	MidAge	US	0.09523809523809523	6	0	13	0	0	0	0	0	0	0	1	2025	11	11	1	0.08936301793444651	5.428571428571428	0.09523809523809523
39	26079555	US	US	1	2.0	0	0	0	0	2025-11-23	64.0	801.0	Female	75.0	DUPIXENT	drug ineffective	0	0	0.0	MidAge	US	0.015513897866839042	221	0	16	0	0	0	0	0	0	0	2	2025	11	23	6	0.08073634859349145	0.9928894634776987	0.015513897866839042
40	26079812	CN	CN	1	1.0	0	0	0	0	2025-11-23	74.0	801.0	Male	76.0	TISLELIZUMAB	myelosuppression	1	0	0.0	Senior	CN	0.0	3	0	16	0	0	0	0	0	0	0	1	2025	11	23	6	0.08073634859349145	0.0	0.0
41	26080164	KR	KR	1	1.0	0	0	0	0	2025-11-24	80.0	801.0	Female	75.0	ISONIAZID	thrombocytopenia	1	0	0.0	Senior	Other	0.0	1	0	16	0	0	0	0	0	0	0	1	2025	11	24	0	0.08073634859349145	0.0	0.0
42	26028683	US	US	1	1.0	0	0	1	0	2025-11-11	57.0	801.0	Female	75.0	LENALIDOMIDE	infusion related hypersensitivity reaction	1	3	0.21428571428571427	MidAge	US	0.15413533834586465	19	1	42	0	0	0	0	0	0	0	4	2025	11	11	1	0.08073634859349145	8.785714285714285	0.15413533834586465
43	26028764	US	US	1	1.0	0	0	0	0	2025-11-11	14.0	801.0	Male	75.0	DUPIXENT	neuropathy peripheral	1	0	0.0	Child	US	0.015513897866839042	221	0	21	0	0	0	0	0	0	0	2	2025	11	11	1	0.08073634859349145	0.21719457013574658	0.0
44	26030831	GB	GB	1	1.0	0	0	0	0	2025-11-12	57.0	801.0	Female	75.0	CARBOPLATIN	contusion	1	0	0.0	MidAge	GB	0.12244897959183673	7	0	9	0	0	0	0	0	0	0	1	2025	11	12	2	0.08073634859349145	6.979591836734694	0.12244897959183673
45	26032761	US	US	2	1.0	0	0	0	0	2025-11-12	58.0	801.0	Male	75.0	CREON	pancreatic carcinoma	1	0	0.0	MidAge	US	0.03296703296703297	13	0	20	0	0	0	0	0	0	0	2	2025	11	12	2	0.08936301793444651	1.9120879120879122	0.0
46	26033409	US	US	1	2.0	0	0	0	0	2025-11-12	57.0	801.0	Female	75.0	CYCLOSPORINE	burning sensation	0	0	0.0	MidAge	US	0.0	5	0	17	0	0	0	0	0	0	0	2	2025	11	12	2	0.08073634859349145	0.0	0.0
47	26081541	US	US	2	1.0	0	0	1	0	2025-11-24	80.0	801.0	Female	58.0	HUMAN IMMUNOGLOBULIN G	hip fracture	1	3	0.21428571428571427	Senior	US	0.10714285714285714	8	0	12	0	0	0	0	0	0	0	2	2025	11	24	0	0.08936301793444651	8.571428571428571	0.10714285714285714
48	26082823	US	Unknown	1	1.0	0	1	0	1	2025-11-23	55.0	801.0	Male	96.75	LOSARTAN	therapy interrupted	1	6	0.42857142857142855	MidAge	US	0.2857142857142857	2	1	19	0	0	0	0	0	0	0	2	2025	11	23	6	0.08073634859349145	15.714285714285714	0.0
49	25956114	US	US	1	2.0	0	0	0	0	2025-10-24	57.0	801.0	Female	75.0	SIROLIMUS	mouth ulceration	0	0	0.0	MidAge	US	0.0	1	0	16	0	0	0	0	0	0	0	2	2025	10	24	4	0.08073634859349145	0.0	0.0
50	25956734	US	US	1	2.0	0	0	0	0	2025-10-24	85.0	801.0	Female	75.0	AYVAKIT	peripheral swelling	0	0	0.0	Senior	US	0.0	2	0	19	0	0	0	0	0	0	0	2	2025	10	24	4	0.08073634859349145	0.0	0.0
51	25957410	PR	PR	1	2.0	0	0	0	0	2025-10-24	69.0	801.0	Female	75.0	LENALIDOMIDE	asthenia	0	0	0.0	Senior	Other	0.15413533834586465	19	1	8	0	0	0	0	0	0	0	1	2025	10	24	4	0.08073634859349145	10.63533834586466	0.15413533834586465
52	26037054	US	US	2	2.0	0	0	0	0	2025-11-12	57.0	801.0	Female	75.0	CORTICOTROPIN	arthralgia	0	0	0.0	MidAge	US	0.0	3	0	10	0	0	0	0	0	0	0	1	2025	11	12	2	0.08936301793444651	0.0	0.0
53	26037579	US	US	2	1.0	0	0	1	0	2025-11-12	31.0	801.0	Female	75.0	SPRAVATO	hyperventilation	1	3	0.21428571428571427	Young	US	0.026785714285714284	8	0	16	0	0	0	0	0	0	0	1	2025	11	12	2	0.08936301793444651	0.8303571428571428	0.026785714285714284
54	26037984	US	US	2	1.0	1	0	1	0	2025-11-12	80.0	801.0	Female	75.0	SKYRIZI	pneumonia aspiration	1	8	0.5714285714285714	Senior	US	0.051587301587301584	36	0	20	0	0	0	0	0	1	0	2	2025	11	12	2	0.08936301793444651	4.1269841269841265	0.051587301587301584
55	26038660	US	US	1	2.0	0	0	0	0	2025-11-13	57.0	801.0	Female	75.0	TRELEGY ELLIPTA	nausea	0	0	0.0	MidAge	US	0.0	4	0	6	0	0	0	0	0	0	0	1	2025	11	13	3	0.08073634859349145	0.0	0.0
56	26039780	US	US	1	2.0	0	0	0	0	2025-11-13	57.0	801.0	Female	75.0	ACETAMINOPHEN	toxicity to various agents	0	0	0.0	MidAge	US	0.10267857142857142	16	0	26	0	0	0	0	0	0	0	4	2025	11	13	3	0.08073634859349145	5.852678571428571	0.10267857142857142
57	25960555	US	US	1	2.0	0	0	0	0	2025-10-27	69.0	801.0	Male	129.25	GEMTESA	glycosylated haemoglobin increased	0	0	0.0	Senior	US	0.0	1	0	34	0	0	0	0	0	0	0	3	2025	10	27	0	0.08073634859349145	0.0	0.0
58	25960784	US	US	1	2.0	0	0	0	0	2025-10-27	57.0	801.0	Male	79.55	DUPIXENT	cough	0	0	0.0	MidAge	US	0.015513897866839042	221	0	5	0	0	0	0	0	0	0	1	2025	10	27	0	0.08073634859349145	0.8842921784098254	0.0
59	25960865	US	US	1	2.0	0	0	0	0	2025-10-27	71.0	801.0	Male	75.0	ORGOVYX	pollakiuria	0	0	0.0	Senior	US	0.0	4	0	11	0	0	0	0	0	0	0	1	2025	10	27	0	0.08073634859349145	0.0	0.0
60	25961851	US	IL	1	1.0	0	0	0	0	2025-10-27	67.0	801.0	Male	75.0	OPDIVO	hepatitis	1	0	0.0	Senior	US	0.08928571428571429	4	0	9	0	0	0	0	0	0	0	1	2025	10	27	0	0.08073634859349145	5.982142857142858	0.0
61	25962337	MX	MX	1	1.0	0	0	0	0	2025-10-27	41.0	801.0	Male	76.0	OCREVUS	multiple sclerosis	1	0	0.0	Adult	Other	0.0	3	0	18	0	0	0	0	0	0	0	2	2025	10	27	0	0.08073634859349145	0.0	0.0
62	25962418	EU	EU	1	1.0	1	0	0	0	2025-10-27	51.0	801.0	Male	75.0	BUPRENORPHINE	asphyxia	1	5	0.35714285714285715	MidAge	EU	0.2857142857142857	2	1	8	0	0	0	0	0	0	0	1	2025	10	27	0	0.08073634859349145	14.571428571428571	0.0
63	26040942	US	Unknown	1	2.0	0	0	0	0	2025-11-12	57.0	801.0	Female	75.0	DUPIXENT	conjunctivitis	0	0	0.0	MidAge	US	0.015513897866839042	221	0	14	0	0	0	0	0	0	0	1	2025	11	12	2	0.08073634859349145	0.8842921784098254	0.015513897866839042
64	26041752	US	US	1	2.0	0	0	0	0	2025-11-13	57.0	801.0	Female	59.09	DUPIXENT	oropharyngeal discomfort	0	0	0.0	MidAge	US	0.015513897866839042	221	0	24	0	0	0	0	0	0	0	2	2025	11	13	3	0.08073634859349145	0.8842921784098254	0.015513897866839042
65	26041819	US	US	1	2.0	0	0	0	0	2025-11-13	64.0	801.0	Male	75.0	DUPIXENT	sensitive skin	0	0	0.0	MidAge	US	0.015513897866839042	221	0	14	0	0	0	0	0	0	0	2	2025	11	13	3	0.08073634859349145	0.9928894634776987	0.0
66	26042023	CN	CN	1	1.0	0	0	1	0	2025-11-13	57.0	801.0	Female	75.0	TORIPALIMAB	myelosuppression	1	3	0.21428571428571427	MidAge	CN	0.21428571428571427	1	1	16	0	0	0	0	0	0	0	1	2025	11	13	3	0.08073634859349145	12.214285714285714	0.21428571428571427
67	26086588	EU	EU	1	1.0	0	0	1	0	2025-11-25	63.0	801.0	Male	75.0	MIRTAZAPINE	hepatotoxicity	1	3	0.21428571428571427	MidAge	EU	0.19047619047619047	3	1	14	0	0	0	0	0	0	0	1	2025	11	25	1	0.08073634859349145	12.0	0.0
68	26087035	EU	EU	1	1.0	0	0	0	0	2025-11-25	29.0	801.0	Female	75.0	ESOMEPRAZOLE	rash maculo-papular	1	0	0.0	Young	EU	0.0	1	0	19	0	0	0	0	0	0	0	2	2025	11	25	1	0.08073634859349145	0.0	0.0
69	26087817	US	US	2	1.0	0	0	0	0	2025-11-25	57.0	801.0	Female	75.0	VENCLEXTA	pancytopenia	1	0	0.0	MidAge	US	0.18571428571428572	5	1	12	0	0	0	0	0	0	0	1	2025	11	25	1	0.08936301793444651	10.585714285714285	0.18571428571428572
70	26088412	US	US	1	1.0	0	0	1	0	2025-11-25	80.0	801.0	Male	75.0	XGEVA	compression fracture	1	3	0.21428571428571427	Senior	US	0.10714285714285714	2	0	20	0	0	0	0	0	0	0	2	2025	11	25	1	0.08073634859349145	8.571428571428571	0.0
71	25964429	CA	CA	2	1.0	0	0	0	0	2025-10-27	57.0	801.0	Female	75.0	BENRALIZUMAB	chest discomfort	1	0	0.0	MidAge	CA	0.0	1	0	16	0	0	0	0	0	0	0	2	2025	10	27	0	0.08936301793444651	0.0	0.0
72	25965077	GB	GB	1	1.0	0	0	0	0	2025-10-27	57.0	801.0	Female	57.0	CITALOPRAM	muscle twitching	1	0	0.0	MidAge	GB	0.42857142857142855	2	1	16	0	0	0	0	0	0	0	2	2025	10	27	0	0.08073634859349145	24.428571428571427	0.42857142857142855
73	25965105	US	US	2	1.0	0	0	0	0	2025-10-27	35.0	801.0	Female	75.0	SPRAVATO	sedation	1	0	0.0	Young	US	0.026785714285714284	8	0	8	0	0	0	0	0	0	0	1	2025	10	27	0	0.08936301793444651	0.9375	0.026785714285714284
74	25965415	US	US	1	2.0	0	0	0	0	2025-10-27	91.0	801.0	Female	75.0	DUPIXENT	injection site pain	0	0	0.0	Senior	US	0.015513897866839042	221	0	19	1	0	0	0	0	0	0	3	2025	10	27	0	0.08073634859349145	1.4117647058823528	0.015513897866839042
75	25965482	US	US	1	2.0	0	0	0	0	2025-10-27	40.0	801.0	Male	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	Adult	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	10	27	0	0.08073634859349145	0.6205559146735616	0.0
76	25966454	US	US	1	2.0	0	0	0	0	2025-10-28	74.0	801.0	Female	75.0	ORENCIA	pain	0	0	0.0	Senior	US	0.10204081632653061	14	0	4	1	0	0	0	0	0	0	1	2025	10	28	1	0.08073634859349145	7.551020408163265	0.10204081632653061
77	26044249	US	US	1	2.0	0	0	0	0	2025-11-14	71.0	801.0	Male	75.0	TIGECYCLINE	diarrhoea	0	0	0.0	Senior	US	0.0	1	0	9	0	0	0	0	0	0	0	1	2025	11	14	4	0.08073634859349145	0.0	0.0
78	26044397	GB	GB	1	1.0	0	0	0	0	2025-11-14	67.0	801.0	Male	75.0	FINASTERIDE	disorder of sex development	1	0	0.0	Senior	GB	0.0	2	0	27	0	0	0	0	0	0	0	4	2025	11	14	4	0.08073634859349145	0.0	0.0
79	26045369	US	US	2	1.0	0	0	0	0	2025-11-14	78.0	801.0	Male	75.0	IXAZOMIB	compression fracture	1	0	0.0	Senior	US	0.0	2	0	20	0	0	0	0	0	0	0	2	2025	11	14	4	0.08936301793444651	0.0	0.0
80	26045950	AU	AU	1	1.0	0	0	1	0	2025-11-14	65.0	801.0	Male	91.9	LENALIDOMIDE	pyrexia	1	3	0.21428571428571427	MidAge	AU	0.15413533834586465	19	1	7	0	0	0	0	0	0	0	1	2025	11	14	4	0.08073634859349145	10.018796992481203	0.0
81	26089046	US	US	1	2.0	0	0	0	0	2025-11-25	71.0	801.0	Female	75.0	DUPIXENT	injury associated with device	0	0	0.0	Senior	US	0.015513897866839042	221	0	29	0	0	0	0	0	0	0	4	2025	11	25	1	0.08073634859349145	1.101486748545572	0.015513897866839042
82	26089451	US	US	1	2.0	0	0	0	0	2025-11-25	70.0	801.0	Male	75.0	DUPIXENT	drug effect less than expected	0	0	0.0	Senior	US	0.015513897866839042	221	0	30	0	0	0	0	0	0	0	5	2025	11	25	1	0.08073634859349145	1.085972850678733	0.0
83	26092152	US	US	1	1.0	0	1	1	0	2025-11-26	17.0	801.0	Male	75.0	IBUPROFEN	hypotension	1	7	0.5	Child	US	0.11607142857142858	8	0	11	0	0	0	0	0	0	0	1	2025	11	26	2	0.08073634859349145	1.9732142857142858	0.0
84	26092624	CN	CN	1	2.0	0	0	0	0	2025-11-26	63.0	801.0	Male	75.0	MYCOPHENOLATE MOFETIL	aspartate aminotransferase increased	0	0	0.0	MidAge	CN	0.10150375939849625	19	0	36	0	0	0	0	0	0	0	3	2025	11	26	2	0.08073634859349145	6.394736842105264	0.0
85	26051768	US	US	2	1.0	0	0	0	0	2025-11-17	57.0	801.0	Female	75.0	RISPERIDONE	adverse drug reaction	1	0	0.0	MidAge	US	0.125	4	1	21	0	0	0	0	0	0	0	3	2025	11	17	0	0.08936301793444651	7.125	0.125
86	26052620	EU	EU	2	1.0	0	0	0	0	2025-11-17	44.0	801.0	Male	75.0	SKYRIZI	chronic lymphocytic leukaemia	1	0	0.0	Adult	EU	0.051587301587301584	36	0	29	0	0	0	0	0	0	0	3	2025	11	17	0	0.08936301793444651	2.2698412698412698	0.0
87	26053807	US	US	1	2.0	0	0	0	0	2025-11-17	53.0	801.0	Female	75.0	DUPIXENT	nasopharyngitis	0	0	0.0	MidAge	US	0.015513897866839042	221	0	15	0	0	0	0	0	0	0	1	2025	11	17	0	0.08073634859349145	0.8222365869424693	0.015513897866839042
88	26053821	US	US	1	2.0	0	0	0	0	2025-11-17	38.0	801.0	Male	75.0	DUPIXENT	idiopathic urticaria	0	0	0.0	Adult	US	0.015513897866839042	221	0	20	0	0	0	0	0	0	0	2	2025	11	17	0	0.08073634859349145	0.5895281189398835	0.0
89	26054011	EU	EU	1	1.0	0	0	0	0	2025-11-17	47.0	801.0	Female	75.0	AZATHIOPRINE	toxicity to various agents	1	0	0.0	Adult	EU	0.0	2	0	26	0	0	0	0	0	0	0	4	2025	11	17	0	0.08073634859349145	0.0	0.0
90	25973973	US	Unknown	1	1.0	0	0	0	0	2025-10-28	37.0	801.0	Female	87.75	TALTZ	migraine	1	0	0.0	Adult	US	0.0	1	0	8	0	0	0	0	0	0	0	1	2025	10	28	1	0.08073634859349145	0.0	0.0
91	25974378	US	Unknown	1	1.0	0	0	1	0	2025-10-29	79.0	801.0	Female	52.71	DARATUMUMAB\HYALURONIDASE-FIHJ	renal failure	1	3	0.21428571428571427	Senior	US	0.21428571428571427	2	1	13	0	0	0	0	1	0	0	2	2025	10	29	2	0.08073634859349145	16.928571428571427	0.21428571428571427
92	25974459	EU	EU	1	1.0	0	0	1	0	2025-10-29	57.0	804.0	Female	1.88	METOPROLOL	bradycardia neonatal	1	3	0.21428571428571427	MidAge	EU	0.21428571428571427	1	1	20	0	0	0	0	0	0	0	2	2025	10	29	2	0.08073634859349145	12.214285714285714	0.21428571428571427
93	25974554	US	US	2	1.0	0	0	0	0	2025-10-29	76.0	801.0	Female	75.0	CREON	hip arthroplasty	1	0	0.0	Senior	US	0.03296703296703297	13	0	16	0	0	0	0	0	0	0	2	2025	10	29	2	0.08936301793444651	2.5054945054945055	0.03296703296703297
94	25975621	US	US	1	2.0	0	0	0	0	2025-10-29	30.0	801.0	Male	75.0	XELJANZ XR	therapeutic product effect incomplete	0	0	0.0	Young	US	0.0	9	0	37	0	0	0	0	0	0	0	4	2025	10	29	2	0.08073634859349145	0.0	0.0
95	26056547	US	US	1	2.0	0	0	0	0	2025-11-18	57.0	801.0	Female	75.0	ISOTRETINOIN	adverse drug reaction	0	0	0.0	MidAge	US	0.023809523809523808	9	0	21	0	0	0	0	0	0	0	3	2025	11	18	1	0.08073634859349145	1.357142857142857	0.023809523809523808
96	26056790	US	US	1	2.0	0	0	0	0	2025-11-18	57.0	801.0	Female	75.0	ISOTRETINOIN	alopecia	0	0	0.0	MidAge	US	0.023809523809523808	9	0	8	0	0	0	0	0	0	0	1	2025	11	18	1	0.08073634859349145	1.357142857142857	0.023809523809523808
97	26056938	US	US	1	2.0	0	0	0	0	2025-11-18	57.0	801.0	Female	75.0	ISOTRETINOIN	adverse event	0	0	0.0	MidAge	US	0.023809523809523808	9	0	13	0	0	0	0	0	0	0	2	2025	11	18	1	0.08073634859349145	1.357142857142857	0.023809523809523808
98	26057223	US	US	1	2.0	0	0	0	0	2025-11-18	17.0	801.0	Female	75.0	ISOTRETINOIN	oropharyngeal pain	0	0	0.0	Child	US	0.023809523809523808	9	0	18	1	0	0	0	0	0	0	2	2025	11	18	1	0.08073634859349145	0.40476190476190477	0.023809523809523808
99	26057276	US	US	1	2.0	0	0	0	0	2025-11-18	16.0	801.0	Female	75.0	ISOTRETINOIN	intentional dose omission	0	0	0.0	Child	US	0.023809523809523808	9	0	25	0	0	0	0	0	0	0	3	2025	11	18	1	0.08073634859349145	0.38095238095238093	0.023809523809523808
100	26059368	CN	CN	1	1.0	0	0	1	0	2025-11-18	73.0	801.0	Male	59.0	DICLOFENAC SODIUM	upper gastrointestinal haemorrhage	1	3	0.21428571428571427	Senior	CN	0.4047619047619048	3	1	34	0	0	0	0	0	0	0	3	2025	11	18	1	0.08073634859349145	29.54761904761905	0.0
101	26059692	US	US	1	1.0	1	0	0	0	2025-11-18	57.0	801.0	Female	75.0	XEOMIN	death	1	5	0.35714285714285715	MidAge	US	0.08928571428571429	4	0	5	0	0	1	0	0	0	0	1	2025	11	18	1	0.08073634859349145	5.089285714285714	0.08928571428571429
102	26093258	US	US	1	2.0	0	0	0	0	2025-11-26	49.0	801.0	Female	75.0	DUPIXENT	dyspnoea	0	0	0.0	Adult	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	1	2025	11	26	2	0.08073634859349145	0.7601809954751131	0.015513897866839042
103	26094244	US	US	2	1.0	0	0	0	0	2025-11-26	41.0	801.0	Male	75.0	XYWAV	impaired gastric emptying	1	0	0.0	Adult	US	0.04285714285714286	5	0	25	0	0	0	0	0	0	0	3	2025	11	26	2	0.08936301793444651	1.7571428571428571	0.0
104	26094325	US	US	1	1.0	0	0	0	0	2025-11-26	65.0	801.0	Female	75.0	BENLYSTA	osteoarthritis	1	0	0.0	MidAge	US	0.0	1	0	14	0	0	0	0	0	0	0	1	2025	11	26	2	0.08073634859349145	0.0	0.0
105	26094998	US	US	2	1.0	0	0	0	0	2025-11-26	57.0	801.0	Female	100.0	HUMAN IMMUNOGLOBULIN G	lower respiratory tract infection	1	0	0.0	MidAge	US	0.10714285714285714	8	0	33	0	1	0	0	0	0	0	4	2025	11	26	2	0.08936301793444651	6.107142857142857	0.10714285714285714
106	26095702	US	US	1	2.0	0	0	0	0	2025-11-27	70.0	801.0	Female	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	Senior	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	11	27	3	0.08073634859349145	1.085972850678733	0.015513897866839042
107	26096699	US	US	1	1.0	0	0	0	0	2025-11-27	76.0	801.0	Female	99.787	ALBUTEROL SULFATE	wrong technique in product usage process	1	0	0.0	Senior	US	0.0	8	0	40	0	0	0	0	0	0	0	6	2025	11	27	3	0.08073634859349145	0.0	0.0
108	26096903	EU	EU	1	1.0	0	0	0	0	2025-11-27	77.0	801.0	Male	88.0	DAPTOMYCIN	interstitial lung disease	1	0	0.0	Senior	EU	0.16666666666666666	3	1	25	0	0	0	0	0	0	0	3	2025	11	27	3	0.08073634859349145	12.833333333333332	0.0
109	26059706	CA	CA	2	1.0	0	0	0	0	2025-11-18	31.0	801.0	Male	75.0	VEDOLIZUMAB	colitis ulcerative	1	0	0.0	Young	CA	0.057692307692307696	26	0	18	0	0	0	0	0	0	0	2	2025	11	18	1	0.08936301793444651	1.7884615384615385	0.0
110	26059854	EU	EU	1	1.0	0	0	1	0	2025-11-18	59.0	801.0	Male	60.0	LOVENOX	deep vein thrombosis	1	3	0.21428571428571427	MidAge	EU	0.21428571428571427	1	1	20	0	0	0	0	0	0	0	3	2025	11	18	1	0.08073634859349145	12.642857142857142	0.0
111	26060854	US	US	1	2.0	0	0	0	0	2025-11-18	57.0	801.0	Female	75.0	PLUVICTO	general physical health deterioration	0	0	0.0	MidAge	US	0.0	8	0	37	0	0	0	0	0	0	0	4	2025	11	18	1	0.08073634859349145	0.0	0.0
112	26097227	US	US	1	2.0	0	0	0	0	2025-11-27	71.0	801.0	Male	75.0	ORGOVYX	pollakiuria	0	0	0.0	Senior	US	0.0	4	0	11	0	0	0	0	0	0	0	1	2025	11	27	3	0.08073634859349145	0.0	0.0
113	26097766	EU	EU	1	1.0	0	0	0	0	2025-11-27	34.0	801.0	Female	75.0	SPINRAZA	caesarean section	1	0	0.0	Young	EU	0.0	1	0	17	0	0	0	0	0	0	0	2	2025	11	27	3	0.08073634859349145	0.0	0.0
114	26097861	US	US	1	2.0	0	0	0	0	2025-11-27	35.0	801.0	Male	75.0	OXYCODONE HYDROCHLORIDE	drug diversion	0	0	0.0	Young	US	0.0	1	0	14	0	0	0	0	0	0	0	2	2025	11	27	3	0.08073634859349145	0.0	0.0
115	26098037	US	US	1	2.0	0	0	0	0	2025-11-27	66.0	801.0	Male	75.0	RITUXIMAB	treatment failure	0	0	0.0	Senior	US	0.12406015037593986	19	0	17	0	0	0	0	1	0	0	2	2025	11	27	3	0.08073634859349145	8.18796992481203	0.0
116	26098509	CA	CA	1	1.0	0	0	1	0	2025-11-27	96.0	801.0	Female	53.0	JANUMET	atrial fibrillation	1	3	0.21428571428571427	Senior	CA	0.21428571428571427	1	1	19	0	0	0	0	0	0	0	2	2025	11	27	3	0.08073634859349145	20.57142857142857	0.21428571428571427
117	26098657	EU	EU	1	1.0	0	0	0	0	2025-11-27	8.0	801.0	Female	75.0	MYCOPHENOLATE MOFETIL	lymphadenitis	1	0	0.0	Child	EU	0.10150375939849625	19	0	13	0	0	0	0	0	0	0	1	2025	11	27	3	0.08073634859349145	0.81203007518797	0.10150375939849625
118	26099858	EU	EU	1	1.0	0	0	0	0	2025-11-28	13.0	801.0	Female	75.0	QUETIAPINE FUMARATE	pericardial effusion	1	0	0.0	Child	EU	0.0	1	0	20	0	0	0	0	0	0	0	2	2025	11	28	4	0.08073634859349145	0.0	0.0
119	26064337	US	US	1	2.0	0	0	0	0	2025-11-19	57.0	801.0	Female	75.0	DUPIXENT	condition aggravated	0	0	0.0	MidAge	US	0.015513897866839042	221	0	20	0	0	0	0	0	0	0	2	2025	11	19	2	0.08073634859349145	0.8842921784098254	0.015513897866839042
120	26065147	GB	GB	1	1.0	0	0	1	0	2025-11-19	57.0	801.0	Male	75.0	ELEXACAFTOR\IVACAFTOR\TEZACAFTOR	lower respiratory tract infection	1	3	0.21428571428571427	MidAge	GB	0.21428571428571427	2	1	33	0	1	0	0	0	0	0	4	2025	11	19	2	0.08073634859349145	12.214285714285714	0.0
121	26066186	BR	BR	1	1.0	0	0	1	0	2025-11-19	57.0	801.0	Female	76.0	TYSABRI	seizure	1	3	0.21428571428571427	MidAge	BR	0.21428571428571427	1	1	7	0	0	0	0	0	0	0	1	2025	11	19	2	0.08073634859349145	12.214285714285714	0.21428571428571427
122	25982210	US	Unknown	1	1.0	0	0	0	0	2025-10-31	76.0	801.0	Female	112.0	ZILBRYSQ	influenza like illness	1	0	0.0	Senior	US	0.10714285714285714	2	0	22	0	0	0	0	0	0	0	3	2025	10	31	4	0.08073634859349145	8.142857142857142	0.10714285714285714
123	25982964	US	US	1	1.0	0	0	0	0	2025-10-31	57.0	801.0	Male	129.25	ORENITRAM	skin laceration	1	0	0.0	MidAge	US	0.0	2	0	15	0	0	0	0	0	0	0	2	2025	10	31	4	0.08073634859349145	0.0	0.0
124	25983464	EU	EU	1	1.0	0	0	0	0	2025-10-31	72.0	801.0	Female	75.0	OLANZAPINE	urinary retention	1	0	0.0	Senior	EU	0.11904761904761905	6	0	17	0	0	0	0	0	0	0	2	2025	10	31	4	0.08073634859349145	8.571428571428571	0.11904761904761905
125	25984489	EU	EU	1	1.0	1	0	0	0	2025-10-31	34.0	801.0	Male	75.0	FENTANYL	toxicity to various agents	1	5	0.35714285714285715	Young	EU	0.35714285714285715	1	1	26	0	0	0	0	0	0	0	4	2025	10	31	4	0.08073634859349145	12.142857142857142	0.0
126	25984612	US	US	1	2.0	0	0	0	0	2025-10-31	66.0	801.0	Female	75.0	BIVIGAM	urticaria	0	0	0.0	Senior	US	0.0	1	0	9	0	0	0	0	0	0	0	1	2025	10	31	4	0.08073634859349145	0.0	0.0
127	26104154	US	US	1	2.0	0	0	0	0	2025-11-29	57.0	801.0	Female	75.0	DUPIXENT	accidental exposure to product	0	0	0.0	MidAge	US	0.015513897866839042	221	0	30	0	0	0	0	0	0	0	4	2025	11	29	5	0.08073634859349145	0.8842921784098254	0.015513897866839042
128	26104774	JP	JP	1	2.0	0	0	0	0	2025-11-30	37.0	801.0	Female	49.0	MYCOPHENOLATE MOFETIL	therapy partial responder	0	0	0.0	Adult	JP	0.10150375939849625	19	0	25	0	0	0	0	0	0	0	3	2025	11	30	6	0.08073634859349145	3.755639097744361	0.10150375939849625
129	26104989	US	US	1	2.0	0	0	0	0	2025-11-30	47.0	801.0	Male	75.0	MYCOPHENOLATE MOFETIL	treatment failure	0	0	0.0	Adult	US	0.10150375939849625	19	0	17	0	0	0	0	1	0	0	2	2025	11	30	6	0.08073634859349145	4.7706766917293235	0.0
130	26105126	US	US	1	2.0	0	0	0	0	2025-12-01	4.0	801.0	Male	75.0	DUPIXENT	dry skin	0	0	0.0	Child	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	2	2025	12	1	0	0.08073634859349145	0.06205559146735617	0.0
131	26067778	US	US	1	1.0	0	0	0	0	2025-11-20	57.0	801.0	Female	75.0	SKYRIZI	renal cancer stage iv	1	0	0.0	MidAge	US	0.051587301587301584	36	0	21	0	0	0	1	0	0	0	4	2025	11	20	3	0.08073634859349145	2.9404761904761902	0.051587301587301584
132	26067859	CA	CA	2	1.0	0	0	0	0	2025-11-20	57.0	801.0	Female	75.0	VEDOLIZUMAB	oral herpes	1	0	0.0	MidAge	CA	0.057692307692307696	26	0	11	0	0	0	0	0	0	0	2	2025	11	20	3	0.08936301793444651	3.2884615384615388	0.057692307692307696
133	26068197	US	US	2	1.0	0	0	0	0	2025-11-20	57.0	801.0	Male	75.0	DUPILUMAB	pleurisy	1	0	0.0	MidAge	US	0.04285714285714286	5	0	8	0	0	0	0	0	0	0	1	2025	11	20	3	0.08936301793444651	2.442857142857143	0.0
134	26068993	CA	CA	1	1.0	1	1	1	1	2025-11-20	43.0	801.0	Female	96.0	DICLOFENAC SODIUM	type 2 diabetes mellitus	1	14	1.0	Adult	CA	0.4047619047619048	3	1	24	0	0	0	0	0	0	0	4	2025	11	20	3	0.08073634859349145	17.40476190476191	0.4047619047619048
135	26069507	EU	EU	1	1.0	0	1	0	0	2025-11-20	65.0	801.0	Male	65.0	AMLODIPINE	intentional overdose	1	4	0.2857142857142857	MidAge	EU	0.16964285714285715	8	1	20	0	0	0	0	0	0	0	2	2025	11	20	3	0.08073634859349145	11.026785714285715	0.0
136	26070088	CA	CA	1	1.0	0	0	1	0	2025-11-20	88.0	801.0	Male	75.0	SEMAGLUTIDE	balance disorder	1	3	0.21428571428571427	Senior	CA	0.14285714285714285	3	1	16	0	0	0	0	0	0	0	2	2025	11	20	3	0.08073634859349145	12.571428571428571	0.0
137	26070426	US	US	1	2.0	0	0	0	0	2025-11-20	57.0	801.0	Female	75.0	XEOMIN	blister	0	0	0.0	MidAge	US	0.08928571428571429	4	0	7	0	0	0	0	0	0	0	1	2025	11	20	3	0.08073634859349145	5.089285714285714	0.08928571428571429
138	25985260	US	US	1	2.0	0	0	0	0	2025-10-31	57.0	801.0	Female	75.0	XDEMVY	therapeutic product effect variable	0	0	0.0	MidAge	US	0.0	1	0	35	0	0	0	0	0	0	0	4	2025	10	31	4	0.08073634859349145	0.0	0.0
139	25985880	EU	EU	1	1.0	0	0	1	0	2025-11-01	32.0	801.0	Male	75.0	PRAZEPAM	coma	1	3	0.21428571428571427	Young	EU	0.21428571428571427	1	1	4	0	0	0	0	0	0	0	1	2025	11	1	5	0.08073634859349145	6.857142857142857	0.0
140	25987176	EU	EU	1	1.0	0	0	0	0	2025-11-03	57.0	801.0	Female	75.0	IBUPROFEN	meningitis aseptic	1	0	0.0	MidAge	EU	0.11607142857142858	8	0	18	0	0	0	0	0	0	0	2	2025	11	3	0	0.08073634859349145	6.616071428571429	0.11607142857142858
141	25988472	US	US	2	1.0	1	0	0	0	2025-11-03	75.0	801.0	Male	75.0	NUPLAZID	death	1	5	0.35714285714285715	Senior	US	0.09523809523809523	6	0	5	0	0	1	0	0	0	0	1	2025	11	3	0	0.08936301793444651	7.142857142857142	0.0
142	26105665	US	US	2	1.0	1	0	0	0	2025-12-01	93.0	801.0	Female	75.0	VABYSMO	death	1	5	0.35714285714285715	Senior	US	0.35714285714285715	1	1	5	0	0	1	0	0	0	0	1	2025	12	1	0	0.08936301793444651	33.214285714285715	0.35714285714285715
143	26106570	US	US	1	2.0	0	0	0	0	2025-12-01	28.0	801.0	Male	75.0	DUPIXENT	nasal congestion	0	0	0.0	Young	US	0.015513897866839042	221	0	16	0	0	0	0	0	0	0	2	2025	12	1	0	0.08073634859349145	0.43438914027149317	0.0
144	26072356	EU	EU	2	1.0	0	0	1	0	2025-11-20	8.0	800.0	Male	75.0	DARATUMUMAB	infection	1	3	0.21428571428571427	Child	EU	0.14285714285714285	3	1	9	0	1	0	0	0	0	0	1	2025	11	20	3	0.08936301793444651	1.1428571428571428	0.0
145	26072518	US	US	1	2.0	0	0	0	0	2025-11-20	68.0	801.0	Female	75.0	DUPIXENT	psoriasis	0	0	0.0	Senior	US	0.015513897866839042	221	0	9	0	0	0	0	0	0	0	1	2025	11	20	3	0.08073634859349145	1.0549450549450547	0.015513897866839042
146	26072923	US	US	1	2.0	0	0	0	0	2025-11-21	57.0	801.0	Female	75.0	TRIAMCINOLONE ACETONIDE	product closure issue	0	0	0.0	MidAge	US	0.19047619047619047	3	1	21	0	0	0	0	0	0	0	3	2025	11	21	4	0.08073634859349145	10.857142857142856	0.19047619047619047
147	26073814	CA	CA	1	1.0	0	0	1	0	2025-11-21	59.0	801.0	Female	75.0	IBUPROFEN	arthralgia	1	3	0.21428571428571427	MidAge	CA	0.11607142857142858	8	0	10	0	0	0	0	0	0	0	1	2025	11	21	4	0.08073634859349145	6.848214285714286	0.11607142857142858
148	26075043	US	US	1	2.0	0	0	0	0	2025-11-21	77.0	801.0	Female	75.0	TYLENOL	drug ineffective	0	0	0.0	Senior	US	0.0	1	0	16	0	0	0	0	0	0	0	2	2025	11	21	4	0.08073634859349145	0.0	0.0
149	25988634	US	US	2	2.0	0	0	0	0	2025-11-03	14.0	801.0	Male	75.0	OMNITROPE	injection site pain	0	0	0.0	Child	US	0.0	5	0	19	1	0	0	0	0	0	0	3	2025	11	3	0	0.08936301793444651	0.0	0.0
150	25990620	EU	EU	2	1.0	0	0	1	0	2025-11-03	77.0	801.0	Male	168.0	POMALIDOMIDE	deep vein thrombosis	1	3	0.21428571428571427	Senior	EU	0.21428571428571427	1	1	20	0	0	0	0	0	0	0	3	2025	11	3	0	0.08936301793444651	16.5	0.0
151	25991469	US	US	1	2.0	0	0	0	0	2025-11-03	57.0	801.0	Female	75.0	DUPIXENT	accidental exposure to product	0	0	0.0	MidAge	US	0.015513897866839042	221	0	30	0	0	0	0	0	0	0	4	2025	11	3	0	0.08073634859349145	0.8842921784098254	0.015513897866839042
152	25991645	US	US	1	2.0	0	0	0	0	2025-11-03	19.0	801.0	Female	75.0	DUPIXENT	off label use	0	0	0.0	Young	US	0.015513897866839042	221	0	13	0	0	0	0	0	0	0	3	2025	11	3	0	0.08073634859349145	0.2947640594699418	0.015513897866839042
153	26110377	US	US	1	2.0	0	0	0	0	2025-12-02	59.0	801.0	Female	56.961	REMODULIN	dyspnoea	0	0	0.0	MidAge	US	0.0	4	0	8	0	0	0	0	0	0	0	1	2025	12	2	1	0.08073634859349145	0.0	0.0
154	26110391	JP	JP	1	1.0	0	0	1	0	2025-12-02	57.0	801.0	Female	75.0	METHOTREXATE	hepatic cancer metastatic	1	3	0.21428571428571427	MidAge	JP	0.17346938775510204	7	1	25	0	0	0	1	0	0	0	3	2025	12	2	1	0.08073634859349145	9.887755102040817	0.17346938775510204
155	26076082	ZA	ZA	2	1.0	0	0	0	0	2025-11-21	71.0	801.0	Female	75.0	BUDESONIDE\FORMOTEROL	fall	1	0	0.0	Senior	ZA	0.10714285714285714	2	0	4	0	0	0	0	0	0	0	1	2025	11	21	4	0.08936301793444651	7.607142857142857	0.10714285714285714
156	26077579	JP	JP	1	1.0	1	0	0	0	2025-11-21	70.0	801.0	Male	75.0	TREPROSTINIL	interstitial lung disease	1	5	0.35714285714285715	Senior	JP	0.2857142857142857	2	1	25	0	0	0	0	0	0	0	3	2025	11	21	4	0.08073634859349145	20.0	0.0
157	26078107	US	US	1	2.0	0	0	0	0	2025-11-22	57.0	801.0	Female	75.0	LENALIDOMIDE	fatigue	0	0	0.0	MidAge	US	0.15413533834586465	19	1	7	0	0	0	0	0	0	0	1	2025	11	22	5	0.08073634859349145	8.785714285714285	0.15413533834586465
158	26078174	US	US	1	2.0	0	0	0	0	2025-11-22	57.0	801.0	Female	80.726	REMODULIN	contusion	0	0	0.0	MidAge	US	0.0	4	0	9	0	0	0	0	0	0	0	1	2025	11	22	5	0.08073634859349145	0.0	0.0
159	26114265	EU	EU	1	1.0	0	0	0	0	2025-12-02	53.0	801.0	Male	75.0	DOCETAXEL	prostate cancer metastatic	1	0	0.0	MidAge	EU	0.061224489795918366	7	0	26	0	0	0	1	0	0	0	3	2025	12	2	1	0.08073634859349145	3.2448979591836733	0.0
160	26114751	US	US	1	2.0	0	0	0	0	2025-12-02	37.0	801.0	Female	75.0	NEULASTA	device adhesion issue	0	0	0.0	Adult	US	0.0	5	0	21	0	0	0	0	0	0	0	3	2025	12	2	1	0.08073634859349145	0.0	0.0
161	26116452	US	US	1	2.0	0	0	0	0	2025-12-03	57.0	801.0	Male	75.0	DUPIXENT	sleep disorder due to a general medical condition	0	0	0.0	MidAge	US	0.015513897866839042	221	0	49	0	0	0	0	0	0	0	8	2025	12	3	2	0.08073634859349145	0.8842921784098254	0.0
162	26117033	US	US	1	2.0	0	0	0	0	2025-12-03	64.0	801.0	Male	75.0	LENALIDOMIDE	product dose omission in error	0	0	0.0	MidAge	US	0.15413533834586465	19	1	30	0	0	0	0	0	0	0	5	2025	12	3	2	0.08073634859349145	9.864661654135338	0.0
163	26080012	US	US	1	2.0	0	0	0	0	2025-11-24	57.0	801.0	Male	75.0	DUPIXENT	nasal congestion	0	0	0.0	MidAge	US	0.015513897866839042	221	0	16	0	0	0	0	0	0	0	2	2025	11	24	0	0.08073634859349145	0.8842921784098254	0.0
164	26080928	US	US	1	2.0	0	0	0	0	2025-11-24	57.0	801.0	Female	75.0	DUPIXENT	nasopharyngitis	0	0	0.0	MidAge	US	0.015513897866839042	221	0	15	0	0	0	0	0	0	0	1	2025	11	24	0	0.08073634859349145	0.8842921784098254	0.015513897866839042
165	26080942	US	US	1	2.0	0	0	0	0	2025-11-24	82.0	801.0	Male	72.7	POMALYST	fatigue	0	0	0.0	Senior	US	0.11428571428571428	5	0	7	0	0	0	0	0	0	0	1	2025	11	24	0	0.08073634859349145	9.371428571428572	0.0
166	26081495	US	Unknown	2	2.0	0	0	0	0	2025-11-24	57.0	801.0	Female	75.0	ACETAMINOPHEN	toxicity to various agents	0	0	0.0	MidAge	US	0.10267857142857142	16	0	26	0	0	0	0	0	0	0	4	2025	11	24	0	0.08936301793444651	5.852678571428571	0.10267857142857142
167	26081576	GB	GB	3	1.0	0	0	0	0	2025-11-24	36.0	801.0	Female	75.0	GABAPENTIN	diarrhoea	1	0	0.0	Adult	GB	0.061224489795918366	7	0	9	0	0	0	0	0	0	0	1	2025	11	24	0	0.17857142857142855	2.204081632653061	0.061224489795918366
168	26083048	JP	JP	1	1.0	0	0	0	1	2025-11-24	88.0	801.0	Male	46.9	CUBICIN	suspected drug-induced liver injury	1	2	0.14285714285714285	Senior	JP	0.14285714285714285	1	1	35	0	0	0	0	0	0	0	4	2025	11	24	0	0.08073634859349145	12.571428571428571	0.0
169	25992846	US	US	1	2.0	0	0	0	0	2025-11-03	56.0	801.0	Female	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	MidAge	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	11	3	0	0.08073634859349145	0.8687782805429863	0.015513897866839042
170	25994642	CA	CA	2	1.0	0	0	1	0	2025-11-04	58.0	801.0	Male	75.0	DUPILUMAB	pneumonia	1	3	0.21428571428571427	MidAge	CA	0.04285714285714286	5	0	9	0	0	0	0	0	1	0	1	2025	11	4	1	0.08936301793444651	2.4857142857142858	0.0
171	25995128	EU	EU	1	1.0	0	0	0	0	2025-11-04	39.0	801.0	Female	75.0	RITUXIMAB	epstein-barr virus infection	1	0	0.0	Adult	EU	0.12406015037593986	19	0	28	0	1	0	0	0	0	0	3	2025	11	4	1	0.08073634859349145	4.838345864661655	0.12406015037593986
172	25995896	US	US	1	1.0	0	0	0	0	2025-11-04	73.0	801.0	Female	79.95	KEVZARA	atrial fibrillation	1	0	0.0	Senior	US	0.14285714285714285	4	1	19	0	0	0	0	0	0	0	2	2025	11	4	1	0.08073634859349145	10.428571428571429	0.14285714285714285
173	26117600	US	Unknown	1	1.0	0	0	0	0	2025-12-03	74.0	801.0	Male	99.79	ATORVASTATIN CALCIUM	vitreous floaters	1	0	0.0	Senior	US	0.0	1	0	17	0	0	0	0	0	0	0	2	2025	12	3	2	0.08073634859349145	0.0	0.0
174	26118801	US	US	2	1.0	0	0	1	0	2025-12-03	66.0	801.0	Female	75.0	SKYRIZI	vertigo	1	3	0.21428571428571427	Senior	US	0.051587301587301584	36	0	7	0	0	0	0	0	0	0	1	2025	12	3	2	0.08936301793444651	3.4047619047619047	0.051587301587301584
175	26119273	US	US	1	1.0	0	0	1	0	2025-12-04	63.0	801.0	Female	75.0	ACETAMINOPHEN	upper gastrointestinal haemorrhage	1	3	0.21428571428571427	MidAge	US	0.10267857142857142	16	0	34	0	0	0	0	0	0	0	3	2025	12	4	3	0.08073634859349145	6.46875	0.10267857142857142
176	26119583	US	US	2	1.0	0	0	0	0	2025-12-04	75.0	801.0	Male	75.0	CREON	pancreatectomy	1	0	0.0	Senior	US	0.03296703296703297	13	0	14	0	0	0	0	0	0	0	1	2025	12	4	3	0.08936301793444651	2.4725274725274726	0.0
177	26119798	US	US	1	2.0	0	0	0	0	2025-12-04	69.0	801.0	Male	75.0	DUPIXENT	dry eye	0	0	0.0	Senior	US	0.015513897866839042	221	0	7	0	0	0	0	0	0	0	2	2025	12	4	3	0.08073634859349145	1.070458952811894	0.0
178	26121393	US	Unknown	1	1.0	1	0	0	0	2025-12-03	82.0	801.0	Male	75.0	QUTENZA	death	1	5	0.35714285714285715	Senior	US	0.35714285714285715	1	1	5	0	0	1	0	0	0	0	1	2025	12	3	2	0.08073634859349145	29.285714285714285	0.0
179	25998921	CA	CA	2	1.0	0	0	1	0	2025-11-05	82.0	801.0	Female	75.0	VEDOLIZUMAB	alcohol withdrawal syndrome	1	3	0.21428571428571427	Senior	CA	0.057692307692307696	26	0	27	0	0	0	0	0	0	0	3	2025	11	5	2	0.08936301793444651	4.730769230769231	0.057692307692307696
180	25999421	US	US	1	1.0	0	0	1	0	2025-11-05	57.0	801.0	Female	75.0	LENALIDOMIDE	adverse event	1	3	0.21428571428571427	MidAge	US	0.15413533834586465	19	1	13	0	0	0	0	0	0	0	2	2025	11	5	2	0.08073634859349145	8.785714285714285	0.15413533834586465
181	25999502	JP	JP	1	1.0	1	0	1	0	2025-11-05	8.0	800.0	Male	51.5	TRIAMCINOLONE ACETONIDE	ascites	1	8	0.5714285714285714	Child	JP	0.19047619047619047	3	1	7	0	0	0	0	0	0	0	1	2025	11	5	2	0.08073634859349145	1.5238095238095237	0.0
182	25999960	US	US	1	1.0	0	0	0	0	2025-11-05	68.0	801.0	Female	75.0	MELOXICAM	renal impairment	1	0	0.0	Senior	US	0.0	1	0	16	0	0	0	0	0	0	0	2	2025	11	5	2	0.08073634859349145	0.0	0.0
183	26088137	US	US	1	1.0	0	0	0	0	2025-11-25	73.0	801.0	Female	87.09	KEYTRUDA	hallucination	1	0	0.0	Senior	US	0.11904761904761905	3	0	13	0	0	0	0	0	0	0	1	2025	11	25	1	0.08073634859349145	8.690476190476192	0.11904761904761905
184	26095980	EU	EU	1	1.0	0	0	0	0	2025-11-27	57.0	801.0	Female	75.0	OMEPRAZOLE	spinal fracture	1	0	0.0	MidAge	EU	0.07142857142857142	3	0	15	0	0	0	0	0	0	0	2	2025	11	27	3	0.08073634859349145	4.071428571428571	0.07142857142857142
185	26097142	US	US	1	2.0	0	0	0	0	2025-11-27	57.0	801.0	Female	75.0	DUPIXENT	rash	0	0	0.0	MidAge	US	0.015513897866839042	221	0	4	0	0	0	0	0	0	0	1	2025	11	27	3	0.08073634859349145	0.8842921784098254	0.015513897866839042
186	26097519	GB	GB	1	1.0	0	0	0	0	2025-11-27	57.0	801.0	Female	75.0	EPIRUBICIN	neuropathy peripheral	1	0	0.0	MidAge	GB	0.10714285714285714	2	0	21	0	0	0	0	0	0	0	2	2025	11	27	3	0.08073634859349145	6.107142857142857	0.10714285714285714
187	26097843	CA	CA	2	1.0	0	0	1	0	2025-11-27	57.0	801.0	Female	75.0	OMALIZUMAB	asthenia	1	3	0.21428571428571427	MidAge	CA	0.21428571428571427	1	1	8	0	0	0	0	0	0	0	1	2025	11	27	3	0.08936301793444651	12.214285714285714	0.21428571428571427
188	26098734	EU	EU	1	1.0	0	0	1	0	2025-11-27	94.0	801.0	Female	56.0	LANSOPRAZOLE	subacute cutaneous lupus erythematosus	1	3	0.21428571428571427	Senior	EU	0.21428571428571427	1	1	38	0	0	0	0	0	0	0	4	2025	11	27	3	0.08073634859349145	20.142857142857142	0.21428571428571427
189	26099139	US	Unknown	1	1.0	0	0	1	0	2025-11-28	42.0	801.0	Female	76.385	MYALEPT	illness	1	3	0.21428571428571427	Adult	US	0.21428571428571427	1	1	7	0	0	0	0	0	0	0	1	2025	11	28	4	0.08073634859349145	9.0	0.21428571428571427
190	26099410	AU	AU	1	1.0	0	0	0	0	2025-11-28	52.0	801.0	Female	75.0	METHOTREXATE	aplastic anaemia	1	0	0.0	MidAge	AU	0.17346938775510204	7	1	16	0	0	0	0	0	0	0	2	2025	11	28	4	0.08073634859349145	9.020408163265307	0.17346938775510204
191	26099625	EU	EU	1	1.0	0	0	1	0	2025-11-28	54.0	801.0	Male	88.0	CLOZAPINE	respiratory distress	1	3	0.21428571428571427	MidAge	EU	0.23214285714285715	4	1	20	0	0	0	0	0	0	0	2	2025	11	28	4	0.08073634859349145	12.535714285714286	0.0
192	26135149	US	US	1	2.0	0	0	0	0	2025-12-09	57.0	801.0	Female	75.0	ESTRADIOL	product dose omission in error	0	0	0.0	MidAge	US	0.0	8	0	30	0	0	0	0	0	0	0	5	2025	12	9	1	0.08073634859349145	0.0	0.0
193	26135730	IN	IN	1	1.0	0	0	0	0	2025-12-09	68.0	801.0	Female	75.0	PALBOCICLIB	cataract	1	0	0.0	Senior	IN	0.0	1	0	8	0	0	0	0	0	0	0	1	2025	12	9	1	0.08073634859349145	0.0	0.0
194	26135945	ID	ID	1	1.0	0	0	1	0	2025-12-09	45.0	801.0	Female	75.0	METHYLPREDNISOLONE	pulmonary tuberculosis	1	3	0.21428571428571427	Adult	Other	0.14285714285714285	3	1	22	0	0	0	0	0	0	0	2	2025	12	9	1	0.08073634859349145	6.428571428571428	0.14285714285714285
195	26012842	US	US	1	1.0	0	0	0	0	2025-11-07	52.0	801.0	Female	75.0	ORENCIA	adverse event	1	0	0.0	MidAge	US	0.10204081632653061	14	0	13	0	0	0	0	0	0	0	2	2025	11	7	4	0.08073634859349145	5.3061224489795915	0.10204081632653061
196	26014448	US	US	1	2.0	0	0	0	0	2025-11-08	57.0	801.0	Female	75.0	ALBUTEROL SULFATE	wrong technique in device usage process	0	0	0.0	MidAge	US	0.0	8	0	39	0	0	0	0	0	0	0	6	2025	11	8	5	0.08073634859349145	0.0	0.0
197	26014758	US	US	1	2.0	0	0	0	0	2025-11-08	49.0	801.0	Female	75.0	ZEPBOUND	drug ineffective	0	0	0.0	Adult	US	0.0	2	0	16	0	0	0	0	0	0	0	2	2025	11	8	5	0.08073634859349145	0.0	0.0
198	26015582	US	US	1	2.0	0	0	0	0	2025-11-09	57.0	801.0	Male	109.31	DUPIXENT	injection site pain	0	0	0.0	MidAge	US	0.015513897866839042	221	0	19	1	0	0	0	0	0	0	3	2025	11	9	6	0.08073634859349145	0.8842921784098254	0.0
199	26099759	CH	CH	1	1.0	0	0	0	0	2025-11-28	59.0	801.0	Male	75.0	OLANZAPINE	arrhythmia	1	0	0.0	MidAge	Other	0.11904761904761905	6	0	10	0	0	0	0	0	0	0	1	2025	11	28	4	0.08073634859349145	7.023809523809525	0.0
200	26100181	EU	EU	1	1.0	0	0	0	0	2025-11-28	60.0	801.0	Male	75.0	BORTEZOMIB	plasma cell myeloma	1	0	0.0	MidAge	EU	0.0	3	0	19	0	0	0	0	0	0	0	3	2025	11	28	4	0.08073634859349145	0.0	0.0
201	26102301	EU	EU	1	1.0	0	0	1	0	2025-11-28	63.0	801.0	Male	75.0	ATORVASTATIN	clostridium difficile colitis	1	3	0.21428571428571427	MidAge	EU	0.10714285714285714	2	0	29	0	0	0	0	0	0	0	3	2025	11	28	4	0.08073634859349145	6.75	0.0
202	26140266	EU	EU	1	1.0	0	0	0	0	2025-12-10	66.0	801.0	Female	75.0	DOXYCYCLINE	symptom recurrence	1	0	0.0	Senior	EU	0.19642857142857142	4	1	18	0	0	0	0	0	0	0	2	2025	12	10	2	0.08073634859349145	12.964285714285714	0.19642857142857142
203	26140738	US	US	1	2.0	0	0	0	0	2025-12-10	15.0	801.0	Male	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	Child	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	12	10	2	0.08073634859349145	0.23270846800258563	0.0
204	26104918	US	US	1	1.0	0	0	0	0	2025-11-30	69.0	801.0	Male	75.0	MYCOPHENOLATE MOFETIL	lung transplant rejection	1	0	0.0	Senior	US	0.10150375939849625	19	0	25	0	0	0	0	0	0	0	3	2025	11	30	6	0.08073634859349145	7.003759398496241	0.0
205	26104932	US	US	1	2.0	0	0	0	0	2025-11-30	50.0	801.0	Male	75.0	MYCOPHENOLATE MOFETIL	treatment failure	0	0	0.0	Adult	US	0.10150375939849625	19	0	17	0	0	0	0	1	0	0	2	2025	11	30	6	0.08073634859349145	5.075187969924812	0.0
206	26105175	GB	GB	1	1.0	0	0	1	0	2025-12-01	57.0	801.0	Female	75.0	BISOPROLOL	brash syndrome	1	3	0.21428571428571427	MidAge	GB	0.21428571428571427	1	1	14	0	0	0	0	0	0	0	2	2025	12	1	0	0.08073634859349145	12.214285714285714	0.21428571428571427
207	26107429	EU	EU	1	1.0	0	1	0	0	2025-12-01	57.0	801.0	Male	75.0	MIDAZOLAM	loss of consciousness	1	4	0.2857142857142857	MidAge	EU	0.2857142857142857	1	1	21	0	0	0	0	0	0	0	3	2025	12	1	0	0.08073634859349145	16.285714285714285	0.0
208	26107658	US	Unknown	1	1.0	1	0	0	0	2025-11-26	100.0	801.0	Female	75.0	VELTASSA	death	1	5	0.35714285714285715	Senior	US	0.2619047619047619	3	1	5	0	0	1	0	0	0	0	1	2025	11	26	2	0.08073634859349145	26.190476190476193	0.2619047619047619
209	26016688	US	US	1	2.0	0	0	0	0	2025-11-10	50.0	801.0	Female	75.0	ORENCIA	arthralgia	0	0	0.0	Adult	US	0.10204081632653061	14	0	10	0	0	0	0	0	0	0	1	2025	11	10	0	0.08073634859349145	5.1020408163265305	0.10204081632653061
210	26017593	CA	CA	1	1.0	0	0	0	0	2025-11-10	57.0	801.0	Female	75.0	INFLIXIMAB	blood pressure systolic increased	1	0	0.0	MidAge	CA	0.07142857142857142	9	0	33	0	0	0	0	0	0	0	4	2025	11	10	0	0.08073634859349145	4.071428571428571	0.07142857142857142
211	26018808	US	US	2	1.0	0	0	0	0	2025-11-10	57.0	801.0	Female	75.0	SKYRIZI	breast cyst	1	0	0.0	MidAge	US	0.051587301587301584	36	0	11	0	0	0	0	0	0	0	2	2025	11	10	0	0.08936301793444651	2.9404761904761902	0.051587301587301584
212	26020294	US	US	1	2.0	0	0	0	0	2025-11-10	76.0	801.0	Male	90.703	POLYETHYLENE GLYCOL 3350	incorrect product administration duration	0	0	0.0	Senior	US	0.0	4	0	41	0	0	0	0	0	0	0	4	2025	11	10	0	0.08073634859349145	0.0	0.0
213	26021051	US	US	1	2.0	0	0	0	0	2025-11-10	57.0	801.0	Female	75.0	ACETAMINOPHEN	toxicity to various agents	0	0	0.0	MidAge	US	0.10267857142857142	16	0	26	0	0	0	0	0	0	0	4	2025	11	10	0	0.08073634859349145	5.852678571428571	0.10267857142857142
214	26141953	EU	EU	1	1.0	0	0	0	0	2025-12-10	51.0	801.0	Male	75.0	OZEMPIC	optic ischaemic neuropathy	1	0	0.0	MidAge	EU	0.0	1	0	26	0	0	0	0	0	0	0	3	2025	12	10	2	0.08073634859349145	0.0	0.0
215	26142277	US	US	1	1.0	0	0	0	0	2025-12-10	57.0	801.0	Female	75.0	SEMAGLUTIDE	arteriosclerosis coronary artery	1	0	0.0	MidAge	US	0.14285714285714285	3	1	32	0	0	0	0	0	0	0	3	2025	12	10	2	0.08073634859349145	8.142857142857142	0.14285714285714285
216	26143168	US	US	1	1.0	0	0	0	0	2025-12-11	60.0	801.0	Female	75.0	SPRAVATO	dizziness	1	0	0.0	MidAge	US	0.026785714285714284	8	0	9	0	0	0	0	0	0	0	1	2025	12	11	3	0.08073634859349145	1.607142857142857	0.026785714285714284
217	26143506	JP	JP	1	1.0	0	0	0	0	2025-12-11	9.0	800.0	Male	75.0	CABOMETYX	immune-mediated hepatic disorder	1	0	0.0	Child	JP	0.10714285714285714	4	0	32	0	0	0	0	0	0	0	3	2025	12	11	3	0.08073634859349145	0.9642857142857142	0.0
218	26145894	US	US	1	2.0	0	0	0	0	2025-12-11	2.0	801.0	Male	75.0	DUPIXENT	rash macular	0	0	0.0	Child	US	0.015513897866839042	221	0	12	0	0	0	0	0	0	0	2	2025	12	11	3	0.08073634859349145	0.031027795733678084	0.0
219	26145908	US	US	1	2.0	0	0	0	0	2025-12-11	74.0	801.0	Female	75.0	DUPIXENT	asthma	0	0	0.0	Senior	US	0.015513897866839042	221	0	6	0	0	0	0	0	0	0	1	2025	12	11	3	0.08073634859349145	1.1480284421460891	0.015513897866839042
220	26145975	US	US	1	2.0	0	0	0	0	2025-12-11	17.0	801.0	Male	75.0	DUPIXENT	keratitis	0	0	0.0	Child	US	0.015513897866839042	221	0	9	0	0	0	0	0	0	0	1	2025	12	11	3	0.08073634859349145	0.2637362637362637	0.0
221	26022548	EU	EU	1	1.0	0	0	0	0	2025-11-10	61.0	801.0	Male	75.0	VENLAFAXINE	drug withdrawal syndrome	1	0	0.0	MidAge	EU	0.25	2	1	24	0	0	0	0	0	0	0	3	2025	11	10	0	0.08073634859349145	15.25	0.0
222	26022791	EU	EU	1	1.0	0	0	1	0	2025-11-10	44.0	801.0	Female	75.0	MOUNJARO	blood iron decreased	1	3	0.21428571428571427	Adult	EU	0.2142857142857143	4	1	20	0	0	0	0	0	0	0	3	2025	11	10	0	0.08073634859349145	9.428571428571429	0.2142857142857143
223	26023143	JP	JP	1	1.0	0	0	0	0	2025-11-10	57.0	801.0	Male	75.0	MOMELOTINIB	renal impairment	1	0	0.0	MidAge	JP	0.0	3	0	16	0	0	0	0	0	0	0	2	2025	11	10	0	0.08073634859349145	0.0	0.0
224	26023763	AU	AU	1	1.0	0	0	0	0	2025-11-11	86.0	801.0	Female	75.0	PREDNISOLONE SODIUM PHOSPHATE	staphylococcal bacteraemia	1	0	0.0	Senior	AU	0.0	2	0	26	0	0	0	0	0	0	0	2	2025	11	11	1	0.08073634859349145	0.0	0.0
225	26024478	US	US	1	2.0	0	0	0	0	2025-11-11	57.0	801.0	Female	75.0	ACETAMINOPHEN	toxicity to various agents	0	0	0.0	MidAge	US	0.10267857142857142	16	0	26	0	0	0	0	0	0	0	4	2025	11	11	1	0.08073634859349145	5.852678571428571	0.10267857142857142
226	26024788	US	US	1	2.0	0	0	0	0	2025-11-11	57.0	801.0	Female	75.0	TRULICITY	blood glucose abnormal	0	0	0.0	MidAge	US	0.04285714285714286	5	0	22	0	0	0	0	0	0	0	3	2025	11	11	1	0.08073634859349145	2.442857142857143	0.04285714285714286
227	26025369	US	US	1	1.0	0	0	1	0	2025-11-11	51.0	801.0	Female	75.0	ACCRUFER	pneumonia	1	3	0.21428571428571427	MidAge	US	0.07142857142857142	3	0	9	0	0	0	0	0	1	0	1	2025	11	11	1	0.08073634859349145	3.642857142857143	0.07142857142857142
228	26108172	US	US	1	1.0	0	0	1	0	2025-12-01	30.0	801.0	Female	90.0	TAZVERIK	hospitalisation	1	3	0.21428571428571427	Young	US	0.21428571428571427	1	1	15	0	0	0	0	0	0	0	1	2025	12	1	0	0.08073634859349145	6.428571428571428	0.21428571428571427
229	26109630	US	US	1	2.0	0	0	0	0	2025-12-01	70.0	801.0	Female	75.0	CYTOMEL	hypersensitivity	0	0	0.0	Senior	US	0.0	1	0	16	0	0	0	0	0	0	0	1	2025	12	1	0	0.08073634859349145	0.0	0.0
230	26109993	US	US	1	2.0	0	0	0	0	2025-12-01	57.0	801.0	Male	75.0	DUPIXENT	pruritus	0	0	0.0	MidAge	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	1	2025	12	1	0	0.08073634859349145	0.8842921784098254	0.0
231	26110588	US	US	1	2.0	0	0	0	0	2025-12-02	57.0	801.0	Female	75.0	LITHIUM	mobility decreased	0	0	0.0	MidAge	US	0.0	1	0	18	0	0	0	0	0	0	0	2	2025	12	2	1	0.08073634859349145	0.0	0.0
232	26111602	US	US	1	1.0	0	0	1	0	2025-12-02	55.0	801.0	Female	75.0	ETOPOSIDE	respiratory failure	1	3	0.21428571428571427	MidAge	US	0.21428571428571427	2	1	19	0	0	0	0	1	0	0	2	2025	12	2	1	0.08073634859349145	11.785714285714285	0.21428571428571427
233	26146947	US	US	1	1.0	0	1	0	0	2025-12-11	48.0	801.0	Male	75.0	DAPTOMYCIN	drug resistance	1	4	0.2857142857142857	Adult	US	0.16666666666666666	3	1	15	0	0	0	0	0	0	0	2	2025	12	11	3	0.08073634859349145	8.0	0.0
234	26147218	GB	GB	1	1.0	0	1	1	1	2025-12-11	33.0	801.0	Male	83.0	MOUNJARO	palpitations	1	9	0.6428571428571429	Young	GB	0.2142857142857143	4	1	12	0	0	0	0	0	0	0	1	2025	12	11	3	0.08073634859349145	7.071428571428572	0.0
235	26147757	CA	CA	1	1.0	1	0	0	0	2025-12-11	58.0	801.0	Female	75.0	FLUTICASONE PROPIONATE	thrombocytopenia	1	5	0.35714285714285715	MidAge	CA	0.35714285714285715	1	1	16	0	0	0	0	0	0	0	1	2025	12	11	3	0.08073634859349145	20.714285714285715	0.35714285714285715
236	26027947	US	US	2	1.0	0	0	0	0	2025-11-11	87.0	801.0	Female	75.0	NUPLAZID	hallucination	1	0	0.0	Senior	US	0.09523809523809523	6	0	13	0	0	0	0	0	0	0	1	2025	11	11	1	0.08936301793444651	8.285714285714285	0.09523809523809523
237	26028285	US	US	1	1.0	0	0	0	0	2025-11-11	0.0	801.0	Female	3.4	ABILIFY MAINTENA	tremor neonatal	1	0	0.0		US	0.0	1	0	15	0	0	0	0	0	0	0	2	2025	11	11	1	0.08073634859349145	0.0	0.0
238	26028919	US	US	1	2.0	0	0	0	0	2025-11-12	15.0	801.0	Female	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	Child	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	11	12	2	0.08073634859349145	0.23270846800258563	0.015513897866839042
239	26030877	US	US	1	2.0	0	0	0	0	2025-11-12	57.0	801.0	Female	163.26	BESREMI	nausea	0	0	0.0	MidAge	US	0.0	1	0	6	0	0	0	0	0	0	0	1	2025	11	12	2	0.08073634859349145	0.0	0.0
240	26112331	US	Unknown	1	1.0	0	0	1	0	2025-12-01	57.0	801.0	Female	75.0	AMBRISENTAN	sinus disorder	1	3	0.21428571428571427	MidAge	US	0.21428571428571427	1	1	14	0	0	0	0	0	0	0	2	2025	12	1	0	0.08073634859349145	12.214285714285714	0.21428571428571427
241	26112775	US	US	1	2.0	0	0	0	0	2025-12-02	57.0	801.0	Male	75.0	DUPIXENT	poor quality product administered	0	0	0.0	MidAge	US	0.015513897866839042	221	0	33	0	0	0	0	0	0	0	4	2025	12	2	1	0.08073634859349145	0.8842921784098254	0.0
242	26113451	EU	EU	1	1.0	0	0	1	0	2025-12-02	53.0	801.0	Male	77.0	EVEROLIMUS	abdominal pain	1	3	0.21428571428571427	MidAge	EU	0.21428571428571427	1	1	14	1	0	0	0	0	0	0	2	2025	12	2	1	0.08073634859349145	11.357142857142856	0.0
243	26114557	JP	JP	1	1.0	0	0	0	0	2025-12-02	57.0	801.0	Male	75.0	MOMELOTINIB	leukaemia	1	0	0.0	MidAge	JP	0.0	3	0	9	0	0	0	0	0	0	0	1	2025	12	2	1	0.08073634859349145	0.0	0.0
244	26150391	US	US	1	2.0	0	0	0	0	2025-12-12	47.0	801.0	Male	75.0	DUPIXENT	hyperkeratosis	0	0	0.0	Adult	US	0.015513897866839042	221	0	14	0	0	0	0	0	0	0	1	2025	12	12	4	0.08073634859349145	0.729153199741435	0.0
245	26150553	US	Unknown	1	2.0	0	0	0	0	2025-12-12	59.0	801.0	Female	84.354	JAKAFI	product dose omission issue	0	0	0.0	MidAge	US	0.0	3	0	27	0	0	0	0	0	0	0	4	2025	12	12	4	0.08073634859349145	0.0	0.0
246	26034279	US	US	1	2.0	0	0	0	0	2025-11-12	57.0	801.0	Female	75.0	ACETAMINOPHEN	toxicity to various agents	0	0	0.0	MidAge	US	0.10267857142857142	16	0	26	0	0	0	0	0	0	0	4	2025	11	12	2	0.08073634859349145	5.852678571428571	0.10267857142857142
247	26034589	US	US	1	1.0	0	0	0	0	2025-11-12	65.0	801.0	Female	75.0	DUPIXENT	thyroid cancer	1	0	0.0	MidAge	US	0.015513897866839042	221	0	14	0	0	0	1	0	0	0	2	2025	11	12	2	0.08073634859349145	1.0084033613445378	0.015513897866839042
248	26036251	US	US	1	1.0	0	0	1	0	2025-11-12	57.0	801.0	Female	75.0	HYDROCORTISONE	adverse event	1	3	0.21428571428571427	MidAge	US	0.21428571428571427	1	1	13	0	0	0	0	0	0	0	2	2025	11	12	2	0.08073634859349145	12.214285714285714	0.21428571428571427
249	26117244	US	US	1	2.0	0	0	0	0	2025-12-03	77.0	801.0	Female	75.0	DUPIXENT	night sweats	0	0	0.0	Senior	US	0.015513897866839042	221	0	12	0	0	0	0	0	0	0	2	2025	12	3	2	0.08073634859349145	1.1945701357466063	0.015513897866839042
250	26119040	US	US	1	2.0	0	0	0	0	2025-12-04	33.0	801.0	Female	75.0	CLINDAMYCIN PHOSPHATE	drug ineffective	0	0	0.0	Young	US	0.0	1	0	16	0	0	0	0	0	0	0	2	2025	12	4	3	0.08073634859349145	0.0	0.0
251	26156223	US	US	1	2.0	0	0	0	0	2025-12-15	57.0	801.0	Female	75.0	ACOLTREMON	abnormal sensation in eye	0	0	0.0	MidAge	US	0.0	1	0	25	0	0	0	0	0	0	0	4	2025	12	15	0	0.08073634859349145	0.0	0.0
252	26156667	CA	CA	1	1.0	0	0	0	0	2025-12-15	57.0	801.0	Female	75.0	DULOXETINE HYDROCHLORIDE	pulmonary malformation	1	0	0.0	MidAge	CA	0.0	1	0	22	0	0	0	0	0	0	0	2	2025	12	15	0	0.08073634859349145	0.0	0.0
253	26157639	US	Unknown	1	2.0	0	0	0	0	2025-12-12	79.0	801.0	Male	75.0	LENALIDOMIDE	rash maculo-papular	0	0	0.0	Senior	US	0.15413533834586465	19	1	19	0	0	0	0	0	0	0	2	2025	12	12	4	0.08073634859349145	12.176691729323307	0.0
254	26057650	CA	CA	3	1.0	1	1	1	1	2025-11-18	57.0	801.0	Female	96.0	APREMILAST	arthropathy	1	14	1.0	MidAge	CA	1.0	1	1	11	0	0	0	0	0	0	0	1	2025	11	18	1	0.17857142857142855	57.0	1.0
255	26058231	US	US	1	2.0	0	0	0	0	2025-11-18	67.0	801.0	Male	81.6	CLONAZEPAM	drug ineffective	0	0	0.0	Senior	US	0.07142857142857142	3	0	16	0	0	0	0	0	0	0	2	2025	11	18	1	0.08073634859349145	4.785714285714286	0.0
256	26059566	US	Unknown	1	1.0	0	0	1	0	2025-11-18	76.0	801.0	Male	220.0	DARATUMUMAB\HYALURONIDASE-FIHJ	speech disorder	1	3	0.21428571428571427	Senior	US	0.21428571428571427	2	1	15	0	0	0	0	0	0	0	2	2025	11	18	1	0.08073634859349145	16.285714285714285	0.0
257	26060122	US	US	1	2.0	0	0	0	0	2025-11-18	52.0	801.0	Female	75.0	XELJANZ XR	conjunctivitis	0	0	0.0	MidAge	US	0.0	9	0	14	0	0	0	0	0	0	0	1	2025	11	18	1	0.08073634859349145	0.0	0.0
258	26060661	US	US	1	2.0	0	0	0	0	2025-11-18	87.0	801.0	Male	75.0	DUPIXENT	incorrect dose administered	0	0	0.0	Senior	US	0.015513897866839042	221	0	27	0	0	0	0	0	0	0	3	2025	11	18	1	0.08073634859349145	1.3497091144149966	0.0
259	26158139	CA	US	2	1.0	0	0	0	0	2025-12-15	63.0	801.0	Male	75.0	VEDOLIZUMAB	hypoaesthesia	1	0	0.0	MidAge	CA	0.057692307692307696	26	0	13	0	0	0	0	0	0	0	1	2025	12	15	0	0.08936301793444651	3.634615384615385	0.0
260	26158706	US	US	1	2.0	0	0	0	0	2025-12-15	57.0	801.0	Female	103.0	DUPIXENT	feeling abnormal	0	0	0.0	MidAge	US	0.015513897866839042	221	0	16	0	0	0	0	0	0	0	2	2025	12	15	0	0.08073634859349145	0.8842921784098254	0.015513897866839042
261	26159125	US	US	1	2.0	0	0	0	0	2025-12-16	57.0	801.0	Male	75.0	DUPIXENT	confusional state	0	0	0.0	MidAge	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	12	16	1	0.08073634859349145	0.8842921784098254	0.0
262	26160125	US	US	1	2.0	0	0	0	0	2025-12-16	57.0	801.0	Female	75.0	DOCIVYX	off label use	0	0	0.0	MidAge	US	0.0	1	0	13	0	0	0	0	0	0	0	3	2025	12	16	1	0.08073634859349145	0.0	0.0
263	26160206	BR	BR	2	1.0	0	0	0	0	2025-12-16	57.0	801.0	Female	75.0	RISPERIDONE	suicide attempt	1	0	0.0	MidAge	BR	0.125	4	1	15	0	0	0	0	0	0	0	2	2025	12	16	1	0.08936301793444651	7.125	0.125
264	26160907	CN	CN	1	1.0	0	0	0	0	2025-12-16	23.0	801.0	Female	70.0	DACTINOMYCIN	urticaria	1	0	0.0	Young	CN	0.0	1	0	9	0	0	0	0	0	0	0	1	2025	12	16	1	0.08073634859349145	0.0	0.0
265	26120970	EU	EU	1	1.0	0	0	1	0	2025-12-04	24.0	801.0	Male	97.0	OLANZAPINE PAMOATE	pulmonary embolism	1	3	0.21428571428571427	Young	EU	0.21428571428571427	1	1	18	0	0	0	0	0	0	0	2	2025	12	4	3	0.08073634859349145	5.142857142857142	0.0
266	26122132	CN	CN	1	1.0	0	0	1	0	2025-12-04	74.0	801.0	Male	60.0	EPIRUBICIN	chemical cystitis	1	3	0.21428571428571427	Senior	CN	0.10714285714285714	2	0	17	0	0	0	0	0	0	0	2	2025	12	4	3	0.08073634859349145	7.928571428571428	0.0
267	26122819	US	US	1	2.0	0	0	0	0	2025-12-04	61.0	801.0	Female	89.36	REVLIMID	blister	0	0	0.0	MidAge	US	0.05357142857142857	4	0	7	0	0	0	0	0	0	0	1	2025	12	4	3	0.08073634859349145	3.267857142857143	0.05357142857142857
268	26123548	EU	EU	1	1.0	0	1	1	0	2025-12-04	58.0	801.0	Female	75.0	ARIPIPRAZOLE	coma	1	7	0.5	MidAge	EU	0.5	1	1	4	0	0	0	0	0	0	0	1	2025	12	4	3	0.08073634859349145	29.0	0.5
269	26123805	US	US	1	1.0	0	0	0	0	2025-12-05	57.0	801.0	Female	75.0	NOURIANZ	hallucination	1	0	0.0	MidAge	US	0.0	1	0	13	0	0	0	0	0	0	0	1	2025	12	5	4	0.08073634859349145	0.0	0.0
270	26037452	US	US	1	2.0	0	0	0	0	2025-11-12	57.0	801.0	Male	75.0	MOUNJARO	injection site mass	0	0	0.0	MidAge	US	0.2142857142857143	4	1	19	0	0	0	0	0	0	0	3	2025	11	12	2	0.08073634859349145	12.214285714285715	0.0
271	26038639	US	US	1	2.0	0	0	0	0	2025-11-13	57.0	801.0	Female	75.0	ACETAMINOPHEN	toxicity to various agents	0	0	0.0	MidAge	US	0.10267857142857142	16	0	26	0	0	0	0	0	0	0	4	2025	11	13	3	0.08073634859349145	5.852678571428571	0.10267857142857142
272	26039720	US	US	1	2.0	0	0	0	0	2025-11-13	57.0	801.0	Female	75.0	ACETAMINOPHEN	toxicity to various agents	0	0	0.0	MidAge	US	0.10267857142857142	16	0	26	0	0	0	0	0	0	0	4	2025	11	13	3	0.08073634859349145	5.852678571428571	0.10267857142857142
273	26040625	US	Unknown	1	2.0	0	0	0	0	2025-11-12	60.0	801.0	Male	75.0	LENALIDOMIDE	petechiae	0	0	0.0	MidAge	US	0.15413533834586465	19	1	9	0	0	0	0	0	0	0	1	2025	11	12	2	0.08073634859349145	9.248120300751879	0.0
274	26040854	EU	EU	1	1.0	0	0	0	0	2025-11-13	47.0	801.0	Male	75.0	MORPHINE	drug dependence	1	0	0.0	Adult	EU	0.0	1	0	15	0	0	0	0	0	0	0	2	2025	11	13	3	0.08073634859349145	0.0	0.0
275	26041192	US	US	1	2.0	0	0	0	0	2025-11-13	57.0	801.0	Female	75.0	ACETAMINOPHEN	toxicity to various agents	0	0	0.0	MidAge	US	0.10267857142857142	16	0	26	0	0	0	0	0	0	0	4	2025	11	13	3	0.08073634859349145	5.852678571428571	0.10267857142857142
276	26041273	US	US	1	2.0	0	0	0	0	2025-11-13	69.0	801.0	Male	75.0	CLARITIN	illness	0	0	0.0	Senior	US	0.0	1	0	7	0	0	0	0	0	0	0	1	2025	11	13	3	0.08073634859349145	0.0	0.0
277	26064144	GB	GB	1	1.0	0	0	0	0	2025-11-19	54.0	801.0	Female	88.0	ROSUVASTATIN	joint swelling	1	0	0.0	MidAge	GB	0.0	2	0	14	0	0	0	0	0	0	0	2	2025	11	19	2	0.08073634859349145	0.0	0.0
278	26064926	GB	GB	1	1.0	0	0	0	0	2025-11-19	33.0	801.0	Female	75.0	VARENICLINE TARTRATE	muscle spasms	1	0	0.0	Young	GB	0.0	1	0	13	0	0	0	0	0	0	0	2	2025	11	19	2	0.08073634859349145	0.0	0.0
279	26064993	EU	EU	3	1.0	0	0	0	0	2025-11-19	57.0	801.0	Female	75.0	PITAVASTATIN CALCIUM	mobility decreased	1	0	0.0	MidAge	EU	0.0	1	0	18	0	0	0	0	0	0	0	2	2025	11	19	2	0.17857142857142855	0.0	0.0
280	26124897	US	US	1	2.0	0	0	0	0	2025-12-05	57.0	801.0	Male	75.0	DUPIXENT	eye swelling	0	0	0.0	MidAge	US	0.015513897866839042	221	0	12	0	0	0	0	0	0	0	2	2025	12	5	4	0.08073634859349145	0.8842921784098254	0.0
281	26125344	EU	EU	1	1.0	0	0	1	0	2025-12-05	63.0	801.0	Male	75.0	CAPECITABINE	infusion site infection	1	3	0.21428571428571427	MidAge	EU	0.10714285714285714	2	0	23	0	1	0	0	0	0	0	3	2025	12	5	4	0.08073634859349145	6.75	0.0
282	26125425	US	US	1	2.0	0	0	0	0	2025-12-05	68.0	801.0	Female	50.91	DUPIXENT	injection site pain	0	0	0.0	Senior	US	0.015513897866839042	221	0	19	1	0	0	0	0	0	0	3	2025	12	5	4	0.08073634859349145	1.0549450549450547	0.015513897866839042
283	26126369	US	US	1	2.0	0	0	0	0	2025-12-05	32.0	801.0	Female	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	Young	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	12	5	4	0.08073634859349145	0.49644473173884934	0.015513897866839042
284	26127436	US	US	1	2.0	0	0	0	0	2025-12-05	57.0	801.0	Male	75.0	SKYRIZI	injection site papule	0	0	0.0	MidAge	US	0.051587301587301584	36	0	21	0	0	0	0	0	0	0	3	2025	12	5	4	0.08073634859349145	2.9404761904761902	0.0
285	26128031	US	US	1	2.0	0	0	0	0	2025-12-06	35.0	801.0	Female	75.0	DUPIXENT	asthma	0	0	0.0	Young	US	0.015513897866839042	221	0	6	0	0	0	0	0	0	0	1	2025	12	6	5	0.08073634859349145	0.5429864253393665	0.015513897866839042
286	26162284	EU	EU	1	1.0	1	0	0	0	2025-12-16	75.0	801.0	Male	89.5	VALSARTAN	cardiogenic shock	1	5	0.35714285714285715	Senior	EU	0.35714285714285715	1	1	17	0	0	0	0	0	0	0	2	2025	12	16	1	0.08073634859349145	26.785714285714285	0.0
287	26164147	US	US	1	2.0	0	0	0	0	2025-12-16	28.0	801.0	Female	75.0	DUPIXENT	maternal exposure during pregnancy	0	0	0.0	Young	US	0.015513897866839042	221	0	34	0	0	0	0	0	0	0	4	2025	12	16	1	0.08073634859349145	0.43438914027149317	0.015513897866839042
288	26164633	US	US	1	2.0	0	0	0	0	2025-12-16	85.0	801.0	Male	75.0	DUPIXENT	accidental exposure to product	0	0	0.0	Senior	US	0.015513897866839042	221	0	30	0	0	0	0	0	0	0	4	2025	12	16	1	0.08073634859349145	1.3186813186813187	0.0
289	26165658	EU	EU	1	1.0	0	0	1	0	2025-12-16	57.0	801.0	Male	75.0	ALPRAZOLAM	drug use disorder	1	3	0.21428571428571427	MidAge	EU	0.14285714285714285	3	1	17	0	0	0	0	0	0	0	3	2025	12	16	1	0.08073634859349145	8.142857142857142	0.0
290	26165834	GB	GB	1	1.0	0	0	0	0	2025-12-16	56.0	801.0	Female	68.0	IBUPROFEN	angioedema	1	0	0.0	MidAge	GB	0.11607142857142858	8	0	10	0	0	0	0	0	0	0	1	2025	12	16	1	0.08073634859349145	6.5	0.11607142857142858
291	26065655	US	US	1	1.0	0	0	1	1	2025-11-19	32.0	801.0	Female	75.0	SUMATRIPTAN	susac^s syndrome	1	5	0.35714285714285715	Young	US	0.35714285714285715	1	1	16	0	0	0	0	0	0	0	2	2025	11	19	2	0.08073634859349145	11.428571428571429	0.35714285714285715
292	26066331	US	US	1	2.0	0	0	0	0	2025-11-19	59.0	801.0	Female	95.0	LINZESS	discomfort	0	0	0.0	MidAge	US	0.0	1	0	10	0	0	0	0	0	0	0	1	2025	11	19	2	0.08073634859349145	0.0	0.0
293	26067451	CA	CA	2	1.0	0	0	1	0	2025-11-20	43.0	801.0	Female	85.0	BELIMUMAB	loss of consciousness	1	3	0.21428571428571427	Adult	CA	0.21428571428571427	1	1	21	0	0	0	0	0	0	0	3	2025	11	20	3	0.08936301793444651	9.214285714285714	0.21428571428571427
294	26067585	US	US	1	1.0	0	0	1	0	2025-11-20	9.0	801.0	Female	75.0	DUPIXENT	suicidal ideation	1	3	0.21428571428571427	Child	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	11	20	3	0.08073634859349145	0.13962508080155137	0.015513897866839042
295	26069057	PH	PH	1	1.0	0	1	1	0	2025-11-20	48.0	801.0	Female	92.0	XIGDUO XR	septic shock	1	7	0.5	Adult	Other	0.5	1	1	12	0	0	0	0	0	0	0	2	2025	11	20	3	0.08073634859349145	24.0	0.5
296	26128341	US	US	1	2.0	0	0	0	0	2025-12-07	66.0	801.0	Female	75.0	DUPIXENT	dry skin	0	0	0.0	Senior	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	2	2025	12	7	6	0.08073634859349145	1.0239172592113768	0.015513897866839042
297	26128475	US	US	2	1.0	0	0	0	0	2025-12-07	62.0	801.0	Female	75.0	CREON	pancreatic carcinoma	1	0	0.0	MidAge	US	0.03296703296703297	13	0	20	0	0	0	0	0	0	0	2	2025	12	7	6	0.08936301793444651	2.043956043956044	0.03296703296703297
298	26131514	EU	EU	1	1.0	0	0	0	0	2025-12-08	72.0	801.0	Female	75.0	OXALIPLATIN	anaphylactic reaction	1	0	0.0	Senior	EU	0.08571428571428572	5	0	21	0	0	0	0	0	0	0	2	2025	12	8	0	0.08073634859349145	6.171428571428572	0.08571428571428572
299	26131581	US	US	1	2.0	0	0	0	0	2025-12-08	57.0	801.0	Male	85.36	DUPIXENT	neurodermatitis	0	0	0.0	MidAge	US	0.015513897866839042	221	0	15	0	0	0	0	0	0	0	1	2025	12	8	0	0.08073634859349145	0.8842921784098254	0.0
300	26069772	GB	GB	1	1.0	0	0	0	0	2025-11-20	57.0	801.0	Female	75.0	RISPERIDONE	tearfulness	1	0	0.0	MidAge	GB	0.125	4	1	11	0	0	0	0	0	0	0	1	2025	11	20	3	0.08073634859349145	7.125	0.125
301	26071649	CH	CH	1	1.0	0	0	1	0	2025-11-20	75.0	801.0	Male	91.0	ZOLPIDEM TARTRATE	chest pain	1	3	0.21428571428571427	Senior	Other	0.21428571428571427	1	1	10	1	0	0	0	0	0	0	2	2025	11	20	3	0.08073634859349145	16.07142857142857	0.0
302	26071825	US	US	2	1.0	0	0	0	0	2025-11-20	62.0	801.0	Male	75.0	SKYRIZI	skin cancer	1	0	0.0	MidAge	US	0.051587301587301584	36	0	11	0	0	0	1	0	0	0	2	2025	11	20	3	0.08936301793444651	3.198412698412698	0.0
303	26072635	US	US	1	2.0	0	0	0	0	2025-11-20	63.0	801.0	Female	83.007	VYALEV	catheter site cellulitis	0	0	0.0	MidAge	US	0.0	1	0	24	0	0	0	0	0	0	0	3	2025	11	20	3	0.08073634859349145	0.0	0.0
304	26166091	US	US	1	2.0	0	0	0	0	2025-12-16	57.0	801.0	Female	75.0	SKYRIZI	feeling abnormal	0	0	0.0	MidAge	US	0.051587301587301584	36	0	16	0	0	0	0	0	0	0	2	2025	12	16	1	0.08073634859349145	2.9404761904761902	0.051587301587301584
305	26166387	US	US	1	2.0	0	0	0	0	2025-12-17	55.0	801.0	Female	75.0	DUPIXENT	sinusitis	0	0	0.0	MidAge	US	0.015513897866839042	221	0	9	0	0	0	0	0	0	0	1	2025	12	17	2	0.08073634859349145	0.8532643826761473	0.015513897866839042
306	26166873	EU	EU	1	1.0	0	0	1	0	2025-12-17	74.0	801.0	Female	75.0	OBINUTUZUMAB	septic shock	1	3	0.21428571428571427	Senior	EU	0.21428571428571427	1	1	12	0	0	0	0	0	0	0	2	2025	12	17	2	0.08073634859349145	15.857142857142856	0.21428571428571427
307	26168426	US	US	1	1.0	0	0	0	0	2025-12-17	57.0	801.0	Female	75.0	XOLAIR	underdose	1	0	0.0	MidAge	US	0.14285714285714285	4	1	9	0	0	0	0	0	0	0	1	2025	12	17	2	0.08073634859349145	8.142857142857142	0.14285714285714285
308	26168440	CA	CA	2	1.0	0	0	1	0	2025-12-17	57.0	801.0	Female	75.0	TEZEPELUMAB	musculoskeletal discomfort	1	3	0.21428571428571427	MidAge	CA	0.10714285714285714	2	0	26	0	0	0	0	0	0	0	2	2025	12	17	2	0.08936301793444651	6.107142857142857	0.10714285714285714
309	26169007	EU	EU	1	1.0	0	0	0	0	2025-12-17	73.0	801.0	Male	56.0	OXALIPLATIN	hyperkalaemia	1	0	0.0	Senior	EU	0.08571428571428572	5	0	13	0	0	0	0	0	0	0	1	2025	12	17	2	0.08073634859349145	6.257142857142857	0.0
310	26169951	US	US	2	1.0	0	0	0	0	2025-12-17	57.0	801.0	Female	75.0	BRINSUPRI	angina pectoris	1	0	0.0	MidAge	US	0.0	1	0	15	0	0	0	0	0	0	0	2	2025	12	17	2	0.08936301793444651	0.0	0.0
311	26134740	US	US	1	1.0	0	0	0	0	2025-12-09	17.0	801.0	Male	75.0	DUPIXENT	loss of consciousness	1	0	0.0	Child	US	0.015513897866839042	221	0	21	0	0	0	0	0	0	0	3	2025	12	9	1	0.08073634859349145	0.2637362637362637	0.0
312	26135455	US	US	1	2.0	0	0	0	0	2025-12-09	57.0	801.0	Female	75.0	ESTRADIOL	product adhesion issue	0	0	0.0	MidAge	US	0.0	8	0	22	0	0	0	0	0	0	0	3	2025	12	9	1	0.08073634859349145	0.0	0.0
313	26135927	BR	BR	1	1.0	0	0	0	0	2025-12-09	57.0	801.0	Male	75.0	CABOMETYX	intestinal obstruction	1	0	0.0	MidAge	BR	0.10714285714285714	4	0	22	0	0	0	0	0	0	0	2	2025	12	9	1	0.08073634859349145	6.107142857142857	0.0
314	26136184	US	US	1	2.0	0	0	0	0	2025-12-09	57.0	801.0	Male	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	MidAge	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	12	9	1	0.08073634859349145	0.8842921784098254	0.0
315	26136346	US	US	1	2.0	0	0	0	0	2025-12-09	57.0	801.0	Female	75.0	PLUVICTO	general physical health deterioration	0	0	0.0	MidAge	US	0.0	8	0	37	0	0	0	0	0	0	0	4	2025	12	9	1	0.08073634859349145	0.0	0.0
316	26074646	US	Unknown	1	1.0	0	0	0	1	2025-11-20	86.0	801.0	Female	45.36	DESVENLAFAXINE SUCCINATE	vision blurred	1	2	0.14285714285714285	Senior	US	0.14285714285714285	1	1	14	0	0	0	0	0	0	0	2	2025	11	20	3	0.08073634859349145	12.285714285714285	0.14285714285714285
317	26076185	AU	AU	1	1.0	0	0	0	1	2025-11-21	57.0	801.0	Female	75.0	WEGOVY	blindness	1	2	0.14285714285714285	MidAge	AU	0.14285714285714285	4	1	9	0	0	0	0	0	0	0	1	2025	11	21	4	0.08073634859349145	8.142857142857142	0.14285714285714285
318	26076752	EU	EU	1	1.0	1	0	1	1	2025-11-21	64.0	801.0	Male	75.0	LENALIDOMIDE	plasma cell myeloma	1	10	0.7142857142857143	MidAge	EU	0.15413533834586465	19	1	19	0	0	0	0	0	0	0	3	2025	11	21	4	0.08073634859349145	9.864661654135338	0.0
319	26137413	US	US	1	2.0	0	0	0	0	2025-12-09	57.0	801.0	Female	75.0	COMBIGAN	product temperature excursion issue	0	0	0.0	MidAge	US	0.0	1	0	35	0	0	0	0	0	0	0	4	2025	12	9	1	0.08073634859349145	0.0	0.0
320	26138290	US	US	1	2.0	0	0	0	0	2025-12-10	70.0	801.0	Female	55.338	FINASTERIDE	off label use	0	0	0.0	Senior	US	0.0	2	0	13	0	0	0	0	0	0	0	3	2025	12	10	2	0.08073634859349145	0.0	0.0
321	26140248	US	US	2	1.0	0	0	0	0	2025-12-10	29.0	801.0	Male	75.0	PREDNISONE	drug ineffective	1	0	0.0	Young	US	0.1607142857142857	8	1	16	0	0	0	0	0	0	0	2	2025	12	10	2	0.08936301793444651	4.660714285714286	0.0
322	26140600	US	US	1	2.0	0	0	0	0	2025-12-10	66.0	801.0	Female	75.0	DUPIXENT	product use in unapproved indication	0	0	0.0	Senior	US	0.015513897866839042	221	0	36	0	0	0	0	0	0	0	5	2025	12	10	2	0.08073634859349145	1.0239172592113768	0.015513897866839042
323	26077953	US	US	1	2.0	0	0	0	0	2025-11-22	65.0	801.0	Male	90.7	ONAPGO	balance disorder	0	0	0.0	MidAge	US	0.0	1	0	16	0	0	0	0	0	0	0	2	2025	11	22	5	0.08073634859349145	0.0	0.0
324	26079830	US	US	1	2.0	0	0	0	0	2025-11-23	49.0	801.0	Female	75.0	SKYRIZI	covid-19	0	0	0.0	Adult	US	0.051587301587301584	36	0	8	0	0	0	0	0	0	0	1	2025	11	23	6	0.08073634859349145	2.5277777777777777	0.051587301587301584
325	26080182	US	US	1	2.0	0	0	0	0	2025-11-24	57.0	801.0	Male	75.0	DUPIXENT	anxiety	0	0	0.0	MidAge	US	0.015513897866839042	221	0	7	0	0	0	0	0	0	0	1	2025	11	24	0	0.08073634859349145	0.8842921784098254	0.0
326	26171208	US	US	1	2.0	0	0	0	0	2025-12-17	57.0	801.0	Female	83.4	VIZAMYL	back pain	0	0	0.0	MidAge	US	0.0	1	0	9	1	0	0	0	0	0	0	2	2025	12	17	2	0.08073634859349145	0.0	0.0
327	26171370	CA	CA	1	1.0	0	1	1	1	2025-12-17	43.0	801.0	Female	70.0	ORENCIA	drug ineffective	1	9	0.6428571428571429	Adult	CA	0.10204081632653061	14	0	16	0	0	0	0	0	0	0	2	2025	12	17	2	0.08073634859349145	4.387755102040816	0.10204081632653061
328	26172652	CN	CN	1	1.0	0	0	0	0	2025-12-18	86.0	801.0	Male	43.0	ENOXAPARIN SODIUM	mucosal haemorrhage	1	0	0.0	Senior	CN	0.0	2	0	19	0	0	0	0	0	0	0	2	2025	12	18	3	0.08073634859349145	0.0	0.0
329	26185746	US	Unknown	1	2.0	0	0	0	0	2025-12-19	67.0	801.0	Male	121.5	VANCOMYCIN	arthralgia	0	0	0.0	Senior	US	0.0	1	0	10	0	0	0	0	0	0	0	1	2025	12	19	4	0.08073634859349145	0.0	0.0
330	26216688	CA	CA	2	1.0	0	0	0	0	2025-12-31	57.0	801.0	Female	75.0	OCREVUS	infusion related reaction	1	0	0.0	MidAge	CA	0.0	3	0	25	0	0	0	0	0	0	0	3	2025	12	31	2	0.08936301793444651	0.0	0.0
331	26150409	US	Unknown	1	1.0	0	0	0	0	2025-12-12	72.0	801.0	Male	75.0	BORTEZOMIB	hepatitis acute	1	0	0.0	Senior	US	0.0	3	0	15	0	0	0	0	0	0	0	2	2025	12	12	4	0.08073634859349145	0.0	0.0
332	26150557	US	US	1	1.0	0	0	1	0	2025-12-12	28.0	801.0	Female	75.0	DOXYCYCLINE	acute generalised exanthematous pustulosis	1	3	0.21428571428571427	Young	US	0.19642857142857142	4	1	42	0	0	0	0	0	0	0	4	2025	12	12	4	0.08073634859349145	5.5	0.19642857142857142
333	26150881	US	Unknown	2	1.0	0	0	1	0	2025-12-12	57.0	801.0	Female	75.0	ACETAMINOPHEN	overdose	1	3	0.21428571428571427	MidAge	US	0.10267857142857142	16	0	8	0	0	0	0	0	0	0	1	2025	12	12	4	0.08936301793444651	5.852678571428571	0.10267857142857142
334	26151286	US	US	1	1.0	0	0	0	0	2025-12-12	25.0	801.0	Female	75.0	PREDNISONE	renal failure	1	0	0.0	Young	US	0.1607142857142857	8	1	13	0	0	0	0	1	0	0	2	2025	12	12	4	0.08073634859349145	4.017857142857142	0.1607142857142857
335	26153297	US	US	1	2.0	0	0	0	0	2025-12-14	57.0	801.0	Female	75.0	VALIUM	drug hypersensitivity	0	0	0.0	MidAge	US	0.0	1	0	21	0	0	0	0	0	0	0	2	2025	12	14	6	0.08073634859349145	0.0	0.0
336	26198702	GB	GB	1	1.0	0	0	1	0	2025-12-25	36.0	801.0	Male	75.0	PREGABALIN	priapism	1	3	0.21428571428571427	Adult	GB	0.10714285714285714	6	0	8	0	0	0	0	0	0	0	1	2025	12	25	3	0.08073634859349145	3.8571428571428568	0.0
337	26205143	US	US	1	2.0	0	0	0	0	2025-12-28	43.0	801.0	Female	75.0	DUPIXENT	hiatus hernia	0	0	0.0	Adult	US	0.015513897866839042	221	0	13	0	0	0	0	0	0	0	2	2025	12	28	6	0.08073634859349145	0.6670976082740788	0.015513897866839042
338	26205615	CN	CN	1	1.0	0	0	0	0	2025-12-28	73.0	801.0	Male	87.5	TISLELIZUMAB	myelosuppression	1	0	0.0	Senior	CN	0.0	3	0	16	0	0	0	0	0	0	0	1	2025	12	28	6	0.08073634859349145	0.0	0.0
339	26205682	US	US	1	2.0	0	0	0	0	2025-12-29	57.0	801.0	Female	61.36	DUPIXENT	drug ineffective	0	0	0.0	MidAge	US	0.015513897866839042	221	0	16	0	0	0	0	0	0	0	2	2025	12	29	0	0.08073634859349145	0.8842921784098254	0.015513897866839042
340	26155794	CN	CN	1	2.0	0	0	0	0	2025-12-15	57.0	801.0	Female	75.0	TACROLIMUS	upper respiratory tract infection	0	0	0.0	MidAge	CN	0.09183673469387754	7	0	33	0	1	0	0	0	0	0	4	2025	12	15	0	0.08073634859349145	5.23469387755102	0.09183673469387754
341	26157266	US	US	1	1.0	1	0	0	0	2025-12-15	57.0	801.0	Male	75.0	PREDNISONE	death	1	5	0.35714285714285715	MidAge	US	0.1607142857142857	8	1	5	0	0	1	0	0	0	0	1	2025	12	15	0	0.08073634859349145	9.160714285714285	0.0
342	26158076	US	US	1	1.0	0	0	0	0	2025-12-15	18.0	801.0	Female	75.0	ADVIL	nausea	1	0	0.0	Child	US	0.0	1	0	6	0	0	0	0	0	0	0	1	2025	12	15	0	0.08073634859349145	0.0	0.0
343	26158791	US	US	1	2.0	0	0	0	0	2025-12-15	57.0	801.0	Male	75.0	PLUVICTO	drug effect less than expected	0	0	0.0	MidAge	US	0.0	8	0	30	0	0	0	0	0	0	0	5	2025	12	15	0	0.08073634859349145	0.0	0.0
344	26159048	US	US	1	1.0	0	0	1	0	2025-12-16	77.0	801.0	Female	59.42	POMALYST	pneumonia	1	3	0.21428571428571427	Senior	US	0.11428571428571428	5	0	9	0	0	0	0	0	1	0	1	2025	12	16	1	0.08073634859349145	8.799999999999999	0.11428571428571428
345	26160992	CA	CA	1	1.0	0	0	0	1	2025-12-16	71.0	801.0	Female	75.0	DEXAMETHASONE	cough	1	2	0.14285714285714285	Senior	CA	0.1857142857142857	5	1	5	0	0	0	0	0	0	0	1	2025	12	16	1	0.08073634859349145	13.185714285714285	0.1857142857142857
346	26042999	US	US	1	2.0	0	0	0	0	2025-11-13	28.0	801.0	Female	75.0	CORTICOTROPIN	drug ineffective	0	0	0.0	Young	US	0.0	3	0	16	0	0	0	0	0	0	0	2	2025	11	13	3	0.08073634859349145	0.0	0.0
347	26043608	CA	CA	1	1.0	0	0	0	0	2025-11-13	41.0	801.0	Male	75.0	TETRABENAZINE	tardive dyskinesia	1	0	0.0	Adult	CA	0.0	1	0	18	0	0	0	0	0	0	0	2	2025	11	13	3	0.08073634859349145	0.0	0.0
348	26044580	US	US	2	2.0	0	0	0	0	2025-11-14	70.0	801.0	Female	46.719	SKYRIZI	insomnia	0	0	0.0	Senior	US	0.051587301587301584	36	0	8	0	0	0	0	0	0	0	1	2025	11	14	4	0.08936301793444651	3.6111111111111107	0.051587301587301584
349	26045147	RU	RU	1	1.0	0	0	0	0	2025-11-14	57.0	801.0	Female	75.0	NUVARING	pregnancy with contraceptive device	1	0	0.0	MidAge	Other	0.0	1	0	35	0	0	0	0	0	0	0	4	2025	11	14	4	0.08073634859349145	0.0	0.0
350	26207059	CA	Unknown	1	1.0	1	1	1	1	2025-12-29	40.0	801.0	Female	96.0	CIMZIA	abdominal discomfort	1	14	1.0	Adult	CA	0.5	2	1	20	0	0	0	0	0	0	0	2	2025	12	29	0	0.08073634859349145	20.0	0.5
351	26207369	GB	GB	1	1.0	0	0	0	0	2025-12-29	65.0	801.0	Female	63.0	METRONIDAZOLE	faeces discoloured	1	0	0.0	MidAge	GB	0.14285714285714285	2	1	18	0	0	0	0	0	0	0	2	2025	12	29	0	0.08073634859349145	9.285714285714285	0.14285714285714285
352	26207950	US	US	1	1.0	0	0	0	0	2025-12-29	57.0	801.0	Female	75.0	ORENCIA	omphalitis	1	0	0.0	MidAge	US	0.10204081632653061	14	0	10	0	0	0	0	0	0	0	1	2025	12	29	0	0.08073634859349145	5.816326530612245	0.10204081632653061
353	26208140	US	Unknown	1	1.0	1	0	1	0	2025-12-29	60.0	801.0	Male	75.0	DOXYCYCLINE	aspergillus infection	1	8	0.5714285714285714	MidAge	US	0.19642857142857142	4	1	21	0	1	0	0	0	0	0	2	2025	12	29	0	0.08073634859349145	11.785714285714285	0.0
354	26208612	US	US	1	2.0	0	0	0	0	2025-12-29	57.0	801.0	Female	75.0	TIOCONAZOLE	drug ineffective	0	0	0.0	MidAge	US	0.0	2	0	16	0	0	0	0	0	0	0	2	2025	12	29	0	0.08073634859349145	0.0	0.0
355	26208665	US	US	1	2.0	0	0	0	0	2025-12-29	57.0	801.0	Female	75.0	TIOCONAZOLE	application site papules	0	0	0.0	MidAge	US	0.0	2	0	24	0	0	0	0	0	0	0	3	2025	12	29	0	0.08073634859349145	0.0	0.0
356	26208975	US	Unknown	1	1.0	0	0	0	0	2025-12-26	67.0	801.0	Female	75.0	COSENTYX	condition aggravated	1	0	0.0	Senior	US	0.05714285714285714	10	0	20	0	0	0	0	0	0	0	2	2025	12	26	4	0.08073634859349145	3.8285714285714283	0.05714285714285714
357	26209556	US	US	1	1.0	0	1	1	0	2025-12-29	4.0	802.0	Male	75.0	NITROGLYCERIN	drug ineffective	1	7	0.5	Child	US	0.5	1	1	16	0	0	0	0	0	0	0	2	2025	12	29	0	0.08073634859349145	2.0	0.0
358	26209732	CN	CN	1	1.0	0	0	1	0	2025-12-29	29.0	801.0	Male	76.0	CYTARABINE	myelosuppression	1	3	0.21428571428571427	Young	CN	0.21428571428571427	1	1	16	0	0	0	0	0	0	0	1	2025	12	29	0	0.08073634859349145	6.2142857142857135	0.0
359	26210260	US	US	2	1.0	0	0	0	0	2025-12-29	67.0	801.0	Male	75.0	CILTACABTAGENE AUTOLEUCEL	rectal cancer	1	0	0.0	Senior	US	0.17857142857142858	2	1	13	0	0	0	1	0	0	0	2	2025	12	29	0	0.08936301793444651	11.964285714285715	0.0
360	18629916	US	US	1	1.0	0	0	0	0	2020-12-17	58.0	801.0	Female	71.61	XELJANZ XR	knee arthroplasty	1	0	0.0	MidAge	US	0.0	9	0	17	0	0	0	0	0	0	0	2	2020	12	17	3	0.08073634859349145	0.0	0.0
361	18711888	JP	JP	1	1.0	0	1	1	0	2021-01-07	79.0	801.0	Male	59.0	METHYLPREDNISOLONE SODIUM SUCCINATE	immunosuppression	1	7	0.5	Senior	JP	0.5	1	1	17	0	0	0	0	0	0	0	1	2021	1	7	3	0.08073634859349145	39.5	0.0
362	19072609	CA	CA	1	1.0	0	0	0	0	2021-03-30	10.0	802.0	Female	75.0	VALPROIC ACID	drug resistance	1	0	0.0	Child	CA	0.0	1	0	15	0	0	0	0	0	0	0	2	2021	3	30	1	0.08073634859349145	0.0	0.0
363	19084798	US	US	2	1.0	0	0	0	0	2021-04-01	69.0	801.0	Male	75.0	VEDOLIZUMAB	seizure	1	0	0.0	Senior	US	0.057692307692307696	26	0	7	0	0	0	0	0	0	0	1	2021	4	1	3	0.08936301793444651	3.980769230769231	0.0
364	19266523	US	US	1	1.0	0	0	1	0	2021-05-18	34.0	801.0	Male	75.0	NOVOLOG MIX 70/30	device failure	1	3	0.21428571428571427	Young	US	0.21428571428571427	1	1	14	0	0	0	0	1	0	0	2	2021	5	18	1	0.08073634859349145	7.285714285714286	0.0
365	19565561	EU	EU	1	1.0	1	0	0	0	2021-07-14	70.0	801.0	Female	75.0	YERVOY	bone marrow failure	1	5	0.35714285714285715	Senior	EU	0.35714285714285715	4	1	19	0	0	0	0	1	0	0	3	2021	7	14	2	0.08073634859349145	25.0	0.35714285714285715
366	19716626	CO	CO	2	1.0	0	0	1	0	2021-08-18	21.0	801.0	Female	47.0	VEDOLIZUMAB	intestinal stenosis	1	3	0.21428571428571427	Young	Other	0.057692307692307696	26	0	19	0	0	0	0	0	0	0	2	2021	8	18	2	0.08936301793444651	1.2115384615384617	0.057692307692307696
367	19806455	JP	JP	1	1.0	0	0	1	0	2021-09-09	12.0	802.0	Male	8.3	SABRIL	retinal degeneration	1	3	0.21428571428571427	Child	JP	0.21428571428571427	1	1	20	0	0	0	0	0	0	0	2	2021	9	9	3	0.08073634859349145	2.571428571428571	0.0
368	19929547	CA	CA	1	1.0	0	0	1	0	2021-10-07	58.0	801.0	Female	75.0	REVATIO	hospitalisation	1	3	0.21428571428571427	MidAge	CA	0.21428571428571427	1	1	15	0	0	0	0	0	0	0	1	2021	10	7	3	0.08073634859349145	12.428571428571427	0.21428571428571427
369	20054843	CA	CA	2	1.0	0	0	0	0	2021-11-10	57.0	801.0	Female	52.0	REMICADE	colitis ulcerative	1	0	0.0	MidAge	CA	0.0	3	0	18	0	0	0	0	0	0	0	2	2021	11	10	2	0.08936301793444651	0.0	0.0
370	20057826	US	US	2	1.0	0	0	1	0	2021-11-11	15.0	801.0	Female	99.79	LANADELUMAB	loss of consciousness	1	3	0.21428571428571427	Child	US	0.12857142857142856	5	1	21	0	0	0	0	0	0	0	3	2021	11	11	3	0.08936301793444651	1.9285714285714284	0.12857142857142856
371	20108870	EU	EU	2	1.0	0	0	1	0	2021-11-24	6.0	801.0	Male	75.0	TEDUGLUTIDE	gastrointestinal anastomotic stenosis	1	3	0.21428571428571427	Child	EU	0.14285714285714285	3	1	37	0	0	0	0	0	0	0	3	2021	11	24	2	0.08936301793444651	0.8571428571428571	0.0
372	20311546	US	US	1	2.0	0	0	0	0	2022-01-08	56.0	801.0	Female	75.0	OTEZLA	therapy non-responder	0	0	0.0	MidAge	US	0.0	4	0	21	0	0	0	0	0	0	0	2	2022	1	8	5	0.08073634859349145	0.0	0.0
373	20701332	US	US	2	1.0	0	0	1	0	2022-04-12	57.0	801.0	Female	61.0	HUMAN IMMUNOGLOBULIN G	white blood cell count increased	1	3	0.21428571428571427	MidAge	US	0.10714285714285714	8	0	32	0	0	0	0	0	0	0	5	2022	4	12	1	0.08936301793444651	6.107142857142857	0.10714285714285714
374	20715870	JP	JP	2	1.0	1	0	1	0	2022-04-15	76.0	801.0	Male	75.0	LEUPROLIDE ACETATE	pneumonia	1	8	0.5714285714285714	Senior	JP	0.38095238095238093	3	1	9	0	0	0	0	0	1	0	1	2022	4	15	4	0.08936301793444651	28.95238095238095	0.0
375	26212271	US	US	1	2.0	0	0	0	0	2025-12-30	34.0	801.0	Female	75.0	DUPIXENT	pruritus	0	0	0.0	Young	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	1	2025	12	30	1	0.08073634859349145	0.5274725274725274	0.015513897866839042
376	26212419	US	US	1	2.0	0	0	0	0	2025-12-30	67.0	801.0	Male	77.11	DUPIXENT	accidental exposure to product	0	0	0.0	Senior	US	0.015513897866839042	221	0	30	0	0	0	0	0	0	0	4	2025	12	30	1	0.08073634859349145	1.0394311570782158	0.0
377	26212972	US	US	1	1.0	0	0	1	0	2025-12-30	53.0	801.0	Female	75.0	CEFADROXIL	drug ineffective	1	3	0.21428571428571427	MidAge	US	0.21428571428571427	1	1	16	0	0	0	0	0	0	0	2	2025	12	30	1	0.08073634859349145	11.357142857142856	0.21428571428571427
378	26213687	US	US	1	1.0	0	1	0	0	2025-12-30	67.0	801.0	Female	75.0	METHOTREXATE SODIUM	histoplasmosis disseminated	1	4	0.2857142857142857	Senior	US	0.125	4	1	27	0	0	0	0	0	0	0	2	2025	12	30	1	0.08073634859349145	8.375	0.125
379	26214053	US	US	1	2.0	0	0	0	0	2025-12-30	57.0	801.0	Male	75.0	SKYRIZI	product storage error	0	0	0.0	MidAge	US	0.051587301587301584	36	0	21	0	0	0	0	0	0	0	3	2025	12	30	1	0.08073634859349145	2.9404761904761902	0.0
380	26215335	US	US	1	2.0	0	0	0	0	2025-12-30	73.0	801.0	Male	75.0	DUPIXENT	rash pruritic	0	0	0.0	Senior	US	0.015513897866839042	221	0	13	0	0	0	0	0	0	0	2	2025	12	30	1	0.08073634859349145	1.1325145442792501	0.0
381	21035577	US	US	2	1.0	0	0	0	0	2022-07-01	57.0	801.0	Female	75.0	XYWAV	surgery	1	0	0.0	MidAge	US	0.04285714285714286	5	0	7	0	0	0	0	0	0	0	1	2022	7	1	4	0.08936301793444651	2.442857142857143	0.04285714285714286
382	21079021	US	US	1	1.0	0	0	0	0	2022-07-13	57.0	801.0	Female	75.0	ELMIRON	pigmentary maculopathy	1	0	0.0	MidAge	US	0.0	1	0	22	0	0	0	0	0	0	0	2	2022	7	13	2	0.08073634859349145	0.0	0.0
383	21134601	EU	EU	1	1.0	0	1	0	0	2022-07-27	3.0	801.0	Female	75.0	LEVETIRACETAM	apnoea	1	4	0.2857142857142857	Child	EU	0.05714285714285714	5	0	6	0	0	0	0	0	0	0	1	2022	7	27	2	0.08073634859349145	0.17142857142857143	0.05714285714285714
384	21237605	JP	JP	2	1.0	0	0	0	0	2022-08-22	74.0	801.0	Male	75.0	ATEZOLIZUMAB	ascites	1	0	0.0	Senior	JP	0.0	1	0	7	0	0	0	0	0	0	0	1	2022	8	22	0	0.08936301793444651	0.0	0.0
385	26216860	US	US	1	1.0	0	0	0	0	2025-12-31	57.0	801.0	Female	75.0	SPRAVATO	product administration error	1	0	0.0	MidAge	US	0.026785714285714284	8	0	28	0	0	0	0	0	0	0	3	2025	12	31	2	0.08073634859349145	1.5267857142857142	0.026785714285714284
386	26164299	US	US	1	2.0	0	0	0	0	2025-12-16	64.0	801.0	Female	75.0	DUPIXENT	sleep disorder due to a general medical condition	0	0	0.0	MidAge	US	0.015513897866839042	221	0	49	0	0	0	0	0	0	0	8	2025	12	16	1	0.08073634859349145	0.9928894634776987	0.015513897866839042
387	26164475	US	US	1	2.0	0	0	0	0	2025-12-16	57.0	801.0	Female	81.82	DUPIXENT	incorrect dose administered	0	0	0.0	MidAge	US	0.015513897866839042	221	0	27	0	0	0	0	0	0	0	3	2025	12	16	1	0.08073634859349145	0.8842921784098254	0.015513897866839042
388	26165003	US	US	1	2.0	0	0	0	0	2025-12-16	57.0	801.0	Female	75.0	NURTEC ODT	nausea	0	0	0.0	MidAge	US	0.0	2	0	6	0	0	0	0	0	0	0	1	2025	12	16	1	0.08073634859349145	0.0	0.0
389	26165285	GB	GB	1	1.0	0	0	1	0	2025-12-16	57.0	801.0	Male	75.0	CLOZARIL	white blood cell count increased	1	3	0.21428571428571427	MidAge	GB	0.10714285714285714	4	0	32	0	0	0	0	0	0	0	5	2025	12	16	1	0.08073634859349145	6.107142857142857	0.0
390	26165528	US	US	1	1.0	0	0	1	0	2025-12-16	63.0	801.0	Female	75.0	DUPIXENT	blood glucose decreased	1	3	0.21428571428571427	MidAge	US	0.015513897866839042	221	0	23	0	0	0	0	0	0	0	3	2025	12	16	1	0.08073634859349145	0.9773755656108597	0.015513897866839042
391	26165986	US	US	1	2.0	0	0	0	0	2025-12-16	68.0	801.0	Female	56.699	PAROXETINE	discomfort	0	0	0.0	Senior	US	0.0	2	0	10	0	0	0	0	0	0	0	1	2025	12	16	1	0.08073634859349145	0.0	0.0
392	26166271	US	US	1	2.0	0	0	0	0	2025-12-16	57.0	801.0	Female	75.0	DUPIXENT	eyelid margin crusting	0	0	0.0	MidAge	US	0.015513897866839042	221	0	22	0	0	0	0	0	0	0	3	2025	12	16	1	0.08073634859349145	0.8842921784098254	0.015513897866839042
393	26168039	US	US	1	2.0	0	0	0	0	2025-12-17	57.0	801.0	Female	75.0	EXPAREL	labelled drug-drug interaction medication error	0	0	0.0	MidAge	US	0.0	1	0	47	0	0	0	0	0	0	0	5	2025	12	17	2	0.08073634859349145	0.0	0.0
394	26168349	CN	CN	1	1.0	0	0	0	0	2025-12-17	38.0	801.0	Female	75.0	METHYLPREDNISOLONE	therapy partial responder	1	0	0.0	Adult	CN	0.14285714285714285	3	1	25	0	0	0	0	0	0	0	3	2025	12	17	2	0.08073634859349145	5.428571428571428	0.14285714285714285
395	26168497	US	US	1	1.0	0	0	1	0	2025-12-17	57.0	801.0	Female	75.0	LAMOTRIGINE	nausea	1	3	0.21428571428571427	MidAge	US	0.10714285714285714	2	0	6	0	0	0	0	0	0	0	1	2025	12	17	2	0.08073634859349145	6.107142857142857	0.10714285714285714
396	21326800	EU	EU	1	1.0	1	1	1	0	2022-09-13	32.0	801.0	Male	75.0	CITALOPRAM	acute hepatic failure	1	12	0.8571428571428571	Young	EU	0.42857142857142855	2	1	21	0	0	0	0	1	0	0	3	2022	9	13	1	0.08073634859349145	13.714285714285714	0.0
397	21477418	DZ	DZ	2	1.0	0	0	0	0	2022-10-19	34.0	801.0	Female	75.0	REBIF	abortion spontaneous	1	0	0.0	Young	Other	0.0	1	0	20	0	0	0	0	0	0	0	2	2022	10	19	2	0.08936301793444651	0.0	0.0
398	21482588	US	US	2	1.0	0	0	1	0	2022-10-20	46.0	801.0	Female	75.0	LANADELUMAB	covid-19	1	3	0.21428571428571427	Adult	US	0.12857142857142856	5	1	8	0	0	0	0	0	0	0	1	2022	10	20	3	0.08936301793444651	5.914285714285714	0.12857142857142856
399	21627444	US	US	2	1.0	0	0	0	0	2022-11-22	58.0	801.0	Female	79.0	LANADELUMAB	vascular device infection	1	0	0.0	MidAge	US	0.12857142857142856	5	1	25	0	1	0	0	0	0	0	3	2022	11	22	1	0.08936301793444651	7.457142857142856	0.12857142857142856
400	22523709	EU	EU	1	1.0	0	0	0	0	2023-06-06	32.0	801.0	Female	75.0	DUPILUMAB	myopericarditis	1	0	0.0	Young	EU	0.04285714285714286	5	0	15	0	0	0	0	0	0	0	1	2023	6	6	1	0.08073634859349145	1.3714285714285714	0.04285714285714286
401	22760014	CA	CA	2	1.0	0	0	0	0	2023-07-28	57.0	801.0	Female	75.0	RITUXIMAB	productive cough	1	0	0.0	MidAge	CA	0.12406015037593986	19	0	16	0	0	0	0	0	0	0	2	2023	7	28	4	0.08936301793444651	7.071428571428572	0.12406015037593986
402	26169335	EU	EU	1	1.0	0	0	0	0	2025-12-17	20.0	801.0	Male	75.0	CLOZAPINE	visual impairment	1	0	0.0	Young	EU	0.23214285714285715	4	1	17	0	0	0	0	0	0	0	2	2025	12	17	2	0.08073634859349145	4.642857142857143	0.0
403	26170201	CA	CA	1	1.0	0	0	1	0	2025-12-17	57.0	801.0	Female	75.0	ORENCIA	arthritis	1	3	0.21428571428571427	MidAge	CA	0.10204081632653061	14	0	9	0	0	0	0	0	0	0	1	2025	12	17	2	0.08073634859349145	5.816326530612245	0.10204081632653061
404	26170955	US	US	1	2.0	0	0	0	0	2025-12-17	66.0	801.0	Male	75.0	DUPIXENT	inappropriate schedule of product administration	0	0	0.0	Senior	US	0.015513897866839042	221	0	48	0	0	0	0	0	0	0	5	2025	12	17	2	0.08073634859349145	1.0239172592113768	0.0
405	26171307	US	US	1	1.0	0	1	1	0	2025-12-17	75.0	801.0	Female	75.0	CARBOPLATIN	hyperglycaemia	1	7	0.5	Senior	US	0.12244897959183673	7	0	14	0	0	0	0	0	0	0	1	2025	12	17	2	0.08073634859349145	9.183673469387754	0.12244897959183673
406	26171684	US	US	1	1.0	0	0	0	0	2025-12-17	57.0	801.0	Female	75.0	HUMALOG	thyroid cancer	1	0	0.0	MidAge	US	0.05357142857142857	4	0	14	0	0	0	1	0	0	0	2	2025	12	17	2	0.08073634859349145	3.0535714285714284	0.05357142857142857
407	26171899	AU	AU	1	1.0	0	0	0	0	2025-12-17	57.0	801.0	Female	75.0	PREDNISOLONE SODIUM PHOSPHATE	adrenocortical insufficiency acute	1	0	0.0	MidAge	AU	0.0	2	0	34	0	0	0	0	0	0	0	3	2025	12	17	2	0.08073634859349145	0.0	0.0
408	26172360	EU	EU	1	1.0	0	0	1	0	2025-12-18	55.0	801.0	Male	75.0	PEMETREXED	immune-mediated encephalitis	1	3	0.21428571428571427	MidAge	EU	0.21428571428571427	3	1	28	0	0	0	0	0	0	0	2	2025	12	18	3	0.08073634859349145	11.785714285714285	0.0
409	26172427	JP	JP	1	1.0	0	0	0	0	2025-12-18	85.0	801.0	Male	75.0	MOMELOTINIB	interstitial lung disease	1	0	0.0	Senior	JP	0.0	3	0	25	0	0	0	0	0	0	0	3	2025	12	18	3	0.08073634859349145	0.0	0.0
410	22864705	CA	CA	1	1.0	0	0	0	0	2023-08-25	58.0	801.0	Female	75.0	ABACAVIR SULFATE\LAMIVUDINE	asthma	1	0	0.0	MidAge	CA	0.0	1	0	6	0	0	0	0	0	0	0	1	2023	8	25	4	0.08073634859349145	0.0	0.0
411	22869618	CA	CA	1	1.0	0	1	1	0	2023-08-26	26.0	801.0	Female	75.0	ONDANSETRON	febrile neutropenia	1	7	0.5	Young	CA	0.5	1	1	19	0	0	0	0	0	0	0	2	2023	8	26	5	0.08073634859349145	13.0	0.5
412	22915601	CA	CA	2	1.0	0	0	0	0	2023-09-07	70.0	801.0	Female	75.0	VEDOLIZUMAB	haematochezia	1	0	0.0	Senior	CA	0.057692307692307696	26	0	13	0	0	0	0	0	0	0	1	2023	9	7	3	0.08936301793444651	4.038461538461538	0.057692307692307696
413	22927008	EU	EU	1	1.0	0	0	1	0	2023-09-11	61.0	801.0	Male	85.0	GLIMEPIRIDE	necrotising oesophagitis	1	3	0.21428571428571427	MidAge	EU	0.21428571428571427	1	1	24	0	0	0	0	0	0	0	2	2023	9	11	0	0.08073634859349145	13.071428571428571	0.0
414	23021253	US	US	2	1.0	0	0	1	0	2023-10-03	56.0	801.0	Female	112.0	ICATIBANT	atrial fibrillation	1	3	0.21428571428571427	MidAge	US	0.21428571428571427	1	1	19	0	0	0	0	0	0	0	2	2023	10	3	1	0.08936301793444651	12.0	0.21428571428571427
415	23067004	US	US	1	1.0	0	0	1	0	2023-10-16	63.0	801.0	Male	79.0	DUPIXENT	vertigo	1	3	0.21428571428571427	MidAge	US	0.015513897866839042	221	0	7	0	0	0	0	0	0	0	1	2023	10	16	0	0.08073634859349145	0.9773755656108597	0.0
416	23133086	CA	CA	2	1.0	0	0	0	0	2023-11-01	68.0	801.0	Male	75.0	VEDOLIZUMAB	colitis ulcerative	1	0	0.0	Senior	CA	0.057692307692307696	26	0	18	0	0	0	0	0	0	0	2	2023	11	1	2	0.08936301793444651	3.9230769230769234	0.0
417	23248120	US	US	2	1.0	0	0	0	0	2023-11-30	61.0	801.0	Female	72.575	RINVOQ	femur fracture	1	0	0.0	MidAge	US	0.0	3	0	14	0	0	0	0	0	0	0	2	2023	11	30	3	0.08936301793444651	0.0	0.0
418	23251346	US	US	1	1.0	0	0	0	0	2023-12-01	57.0	801.0	Male	75.0	ILUVIEN	glaucoma	1	0	0.0	MidAge	US	0.0	3	0	8	0	0	0	0	0	0	0	1	2023	12	1	4	0.08073634859349145	0.0	0.0
419	23279263	US	US	1	2.0	0	0	0	0	2023-12-09	37.0	801.0	Female	75.0	DUPIXENT	dry skin	0	0	0.0	Adult	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	2	2023	12	9	5	0.08073634859349145	0.5740142210730446	0.015513897866839042
420	15255440	GB	GB	1	1.0	0	0	1	1	2018-08-08	60.0	801.0	Female	97.0	HUMIRA	platelet count increased	1	5	0.35714285714285715	MidAge	GB	0.17857142857142858	2	1	24	0	0	0	0	0	0	0	3	2018	8	8	2	0.08073634859349145	10.714285714285715	0.17857142857142858
421	16386549	CA	CA	2	1.0	0	0	0	0	2019-06-04	44.0	801.0	Female	75.0	VEDOLIZUMAB	crohn^s disease	1	0	0.0	Adult	CA	0.057692307692307696	26	0	15	0	0	0	0	0	0	0	2	2019	6	4	1	0.08936301793444651	2.5384615384615388	0.057692307692307696
422	16643132	US	US	1	1.0	0	0	0	0	2019-07-29	80.0	801.0	Female	75.0	XELJANZ XR	hip arthroplasty	1	0	0.0	Senior	US	0.0	9	0	16	0	0	0	0	0	0	0	2	2019	7	29	0	0.08073634859349145	0.0	0.0
423	17472287	CA	Unknown	1	1.0	0	0	0	0	2020-02-28	39.0	801.0	Female	75.0	LEFLUNOMIDE	rheumatoid arthritis	1	0	0.0	Adult	CA	0.0	1	0	20	0	0	0	0	0	0	0	2	2020	2	28	4	0.08073634859349145	0.0	0.0
424	18323100	US	US	1	1.0	1	0	0	0	2020-09-28	57.0	801.0	Female	75.0	OXYCONTIN	death	1	5	0.35714285714285715	MidAge	US	0.35714285714285715	1	1	5	0	0	1	0	0	0	0	1	2020	9	28	0	0.08073634859349145	20.357142857142858	0.35714285714285715
425	18330267	JP	JP	1	2.0	0	0	0	0	2020-09-30	57.0	801.0	Male	75.0	OPSUMIT	haemoptysis	0	0	0.0	MidAge	JP	0.10714285714285714	2	0	11	0	0	0	0	0	0	0	1	2020	9	30	2	0.08073634859349145	6.107142857142857	0.0
426	18354634	BR	BR	2	1.0	0	0	0	0	2020-10-07	57.0	801.0	Female	75.0	VEDOLIZUMAB	thermal burn	1	0	0.0	MidAge	BR	0.057692307692307696	26	0	12	0	0	0	0	0	0	0	2	2020	10	7	2	0.08936301793444651	3.2884615384615388	0.057692307692307696
427	18599765	US	US	1	2.0	0	0	0	0	2020-12-10	56.0	801.0	Male	75.0	XELJANZ XR	drug effect less than expected	0	0	0.0	MidAge	US	0.0	9	0	30	0	0	0	0	0	0	0	5	2020	12	10	3	0.08073634859349145	0.0	0.0
428	18669615	TH	TH	1	1.0	0	0	1	0	2020-12-28	63.0	801.0	Male	75.0	MYCOPHENOLATE MOFETIL	burkholderia pseudomallei infection	1	3	0.21428571428571427	MidAge	Other	0.10150375939849625	19	0	35	0	1	0	0	0	0	0	3	2020	12	28	0	0.08073634859349145	6.394736842105264	0.0
429	26173413	TW	TW	1	1.0	0	0	0	0	2025-12-18	27.0	801.0	Female	75.0	TECENTRIQ	off label use	1	0	0.0	Young	Other	0.14285714285714285	3	1	13	0	0	0	0	0	0	0	3	2025	12	18	3	0.08073634859349145	3.8571428571428568	0.14285714285714285
430	26173561	US	US	1	2.0	0	0	0	0	2025-12-18	57.0	801.0	Female	64.989	DUPIXENT	injection site pain	0	0	0.0	MidAge	US	0.015513897866839042	221	0	19	1	0	0	0	0	0	0	3	2025	12	18	3	0.08073634859349145	0.8842921784098254	0.015513897866839042
431	26173642	US	US	1	1.0	0	0	0	0	2025-12-18	57.0	801.0	Female	75.0	SPRAVATO	heart rate decreased	1	0	0.0	MidAge	US	0.026785714285714284	8	0	20	0	0	0	0	0	0	0	3	2025	12	18	3	0.08073634859349145	1.5267857142857142	0.026785714285714284
432	26173938	US	US	1	2.0	0	0	0	0	2025-12-18	23.0	801.0	Male	75.0	DUPIXENT	injection site pruritus	0	0	0.0	Young	US	0.015513897866839042	221	0	23	0	0	0	0	0	0	0	3	2025	12	18	3	0.08073634859349145	0.35681965093729795	0.0
433	26175343	GB	GB	1	1.0	0	0	1	0	2025-12-18	57.0	801.0	Male	75.0	ELEXACAFTOR\IVACAFTOR\TEZACAFTOR	hospitalisation	1	3	0.21428571428571427	MidAge	GB	0.21428571428571427	2	1	15	0	0	0	0	0	0	0	1	2025	12	18	3	0.08073634859349145	12.214285714285714	0.0
434	26175600	CA	CA	1	1.0	0	0	0	0	2025-12-18	43.0	801.0	Female	96.0	ORENCIA	abdominal pain upper	1	0	0.0	Adult	CA	0.10204081632653061	14	0	20	1	0	0	0	0	0	0	3	2025	12	18	3	0.08073634859349145	4.387755102040816	0.10204081632653061
435	26175653	CA	CA	1	1.0	1	0	0	0	2025-12-18	43.0	801.0	Female	96.0	ORENCIA	death	1	5	0.35714285714285715	Adult	CA	0.10204081632653061	14	0	5	0	0	1	0	0	0	0	1	2025	12	18	3	0.08073634859349145	4.387755102040816	0.10204081632653061
436	26176005	CN	CN	1	1.0	0	0	0	0	2025-12-18	34.0	801.0	Female	75.0	CYCLOSPORINE	graft versus host disease	1	0	0.0	Young	CN	0.0	5	0	25	0	0	0	0	0	0	0	4	2025	12	18	3	0.08073634859349145	0.0	0.0
437	26176678	US	US	1	2.0	0	0	0	0	2025-12-18	57.0	801.0	Female	75.0	JOENJA	infection	0	0	0.0	MidAge	US	0.0	3	0	9	0	1	0	0	0	0	0	1	2025	12	18	3	0.08073634859349145	0.0	0.0
438	23590937	CA	CA	1	1.0	0	0	1	0	2024-03-04	68.0	801.0	Female	75.0	RITUXIMAB	drug ineffective	1	3	0.21428571428571427	Senior	CA	0.12406015037593986	19	0	16	0	0	0	0	0	0	0	2	2024	3	4	0	0.08073634859349145	8.43609022556391	0.12406015037593986
439	23597417	EU	EU	1	1.0	1	0	0	0	2024-03-05	57.0	801.0	Male	75.0	MYCOPHENOLATE MOFETIL	septic shock	1	5	0.35714285714285715	MidAge	EU	0.10150375939849625	19	0	12	0	0	0	0	0	0	0	2	2024	3	5	1	0.08073634859349145	5.7857142857142865	0.0
440	23629574	JP	JP	1	1.0	1	0	0	0	2024-03-14	57.0	801.0	Female	75.0	YERVOY	death	1	5	0.35714285714285715	MidAge	JP	0.35714285714285715	4	1	5	0	0	1	0	0	0	0	1	2024	3	14	3	0.08073634859349145	20.357142857142858	0.35714285714285715
441	23634057	EU	EU	1	1.0	0	0	1	0	2024-03-14	70.0	801.0	Female	63.0	PREDNISONE	confusional state	1	3	0.21428571428571427	Senior	EU	0.1607142857142857	8	1	17	0	0	0	0	0	0	0	2	2024	3	14	3	0.08073634859349145	11.249999999999998	0.1607142857142857
442	23653159	CA	CA	2	1.0	0	0	1	0	2024-03-20	57.0	801.0	Female	75.0	ADALIMUMAB-AATY	fatigue	1	3	0.21428571428571427	MidAge	CA	0.21428571428571427	1	1	7	0	0	0	0	0	0	0	1	2024	3	20	2	0.08936301793444651	12.214285714285714	0.21428571428571427
443	23713613	CA	CA	1	1.0	0	0	0	0	2024-04-05	52.0	801.0	Male	75.0	ESCITALOPRAM	neoplasm skin	1	0	0.0	MidAge	CA	0.25	2	1	13	0	0	0	0	0	0	0	2	2024	4	5	4	0.08073634859349145	13.0	0.0
444	23715529	US	US	2	1.0	0	0	1	0	2024-04-07	39.0	801.0	Female	88.45	SKYRIZI	nephrolithiasis	1	3	0.21428571428571427	Adult	US	0.051587301587301584	36	0	15	0	0	0	0	0	0	0	1	2024	4	7	6	0.08936301793444651	2.011904761904762	0.051587301587301584
445	23784594	US	US	1	2.0	0	0	0	0	2024-04-25	20.0	801.0	Female	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	Young	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2024	4	25	3	0.08073634859349145	0.3102779573367808	0.015513897866839042
446	23831144	CA	CA	3	1.0	0	0	0	0	2024-05-08	57.0	801.0	Female	75.0	GABAPENTIN	asthma	1	0	0.0	MidAge	CA	0.061224489795918366	7	0	6	0	0	0	0	0	0	0	1	2024	5	8	2	0.17857142857142855	3.489795918367347	0.061224489795918366
447	24007724	CA	CA	2	1.0	0	0	1	0	2024-06-25	31.0	801.0	Male	75.0	HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN	urinary bladder rupture	1	3	0.21428571428571427	Young	CA	0.07142857142857142	3	0	23	0	0	0	0	0	0	0	3	2024	6	25	1	0.08936301793444651	2.214285714285714	0.0
448	24096472	US	US	1	1.0	1	0	1	0	2024-07-16	76.0	801.0	Female	75.0	KEVZARA	death	1	8	0.5714285714285714	Senior	US	0.14285714285714285	4	1	5	0	0	1	0	0	0	0	1	2024	7	16	1	0.08073634859349145	10.857142857142856	0.14285714285714285
449	26178326	GB	GB	1	1.0	0	0	0	0	2025-12-19	69.0	801.0	Female	113.0	ALENDRONIC ACID	pain in jaw	1	0	0.0	Senior	GB	0.0	1	0	11	1	0	0	0	0	0	0	3	2025	12	19	4	0.08073634859349145	0.0	0.0
450	26178946	EU	EU	1	1.0	1	0	1	0	2025-12-19	57.0	801.0	Female	75.0	MELPHALAN	acute respiratory distress syndrome	1	8	0.5714285714285714	MidAge	EU	0.5714285714285714	1	1	35	0	0	0	0	0	0	0	4	2025	12	19	4	0.08073634859349145	32.57142857142857	0.5714285714285714
451	26179527	US	US	1	1.0	0	0	0	0	2025-12-19	32.0	801.0	Female	75.0	TACROLIMUS	drug ineffective for unapproved indication	1	0	0.0	Young	US	0.09183673469387754	7	0	42	0	0	0	0	0	0	0	5	2025	12	19	4	0.08073634859349145	2.9387755102040813	0.09183673469387754
452	26179851	US	US	1	2.0	0	0	0	0	2025-12-19	57.0	801.0	Female	38.77	DUPIXENT	injection site irritation	0	0	0.0	MidAge	US	0.015513897866839042	221	0	25	0	0	0	0	0	0	0	3	2025	12	19	4	0.08073634859349145	0.8842921784098254	0.015513897866839042
453	26181108	EU	EU	1	1.0	0	0	1	0	2025-12-21	57.0	801.0	Male	75.0	ALPRAZOLAM	drug use disorder	1	3	0.21428571428571427	MidAge	EU	0.14285714285714285	3	1	17	0	0	0	0	0	0	0	3	2025	12	21	6	0.08073634859349145	8.142857142857142	0.0
454	26181122	US	US	1	2.0	0	0	0	0	2025-12-21	75.0	801.0	Female	75.0	SUTAB	nausea	0	0	0.0	Senior	US	0.0	2	0	6	0	0	0	0	0	0	0	1	2025	12	21	6	0.08073634859349145	0.0	0.0
455	26183281	GB	GB	1	1.0	0	0	1	1	2025-12-21	18.0	801.0	Female	50.0	NAPROXEN	platelet dysfunction	1	5	0.35714285714285715	Child	GB	0.2857142857142857	2	1	20	0	0	0	0	0	0	0	2	2025	12	21	6	0.08073634859349145	5.142857142857142	0.2857142857142857
456	26183591	JP	JP	1	1.0	0	0	1	0	2025-12-21	47.0	801.0	Female	75.0	LENALIDOMIDE	condition aggravated	1	3	0.21428571428571427	Adult	JP	0.15413533834586465	19	1	20	0	0	0	0	0	0	0	2	2025	12	21	6	0.08073634859349145	7.244360902255639	0.15413533834586465
457	26048306	GB	GB	1	1.0	0	1	0	0	2025-11-14	21.0	801.0	Female	75.0	METRONIDAZOLE	haemolytic uraemic syndrome	1	4	0.2857142857142857	Young	GB	0.14285714285714285	2	1	27	0	0	0	0	0	0	0	3	2025	11	14	4	0.08073634859349145	3.0	0.14285714285714285
458	26049965	JP	JP	1	1.0	0	0	0	0	2025-11-15	5.0	802.0	Female	3.9	SUGAMMADEX SODIUM	anaphylactic reaction	1	0	0.0	Child	JP	0.0	1	0	21	0	0	0	0	0	0	0	2	2025	11	15	5	0.08073634859349145	0.0	0.0
459	26050264	US	US	1	2.0	0	0	0	0	2025-11-16	54.0	801.0	Female	75.0	TRULICITY	accidental overdose	0	0	0.0	MidAge	US	0.04285714285714286	5	0	19	0	0	0	0	0	0	0	2	2025	11	16	6	0.08073634859349145	2.3142857142857145	0.04285714285714286
460	26051384	US	US	2	2.0	0	0	0	0	2025-11-17	64.0	801.0	Female	75.0	OTEZLA	therapy interrupted	0	0	0.0	MidAge	US	0.0	4	0	19	0	0	0	0	0	0	0	2	2025	11	17	0	0.08936301793444651	0.0	0.0
461	26051465	EU	EU	1	1.0	0	0	1	0	2025-11-17	73.0	801.0	Female	75.0	OXALIPLATIN	neurotoxicity	1	3	0.21428571428571427	Senior	EU	0.08571428571428572	5	0	13	0	0	0	0	0	0	0	1	2025	11	17	0	0.08073634859349145	6.257142857142857	0.08571428571428572
462	26051599	US	US	1	2.0	0	0	0	0	2025-11-17	46.0	801.0	Male	75.0	DUPIXENT	nasal polyps	0	0	0.0	Adult	US	0.015513897866839042	221	0	12	0	0	0	0	0	0	0	2	2025	11	17	0	0.08073634859349145	0.7136393018745959	0.0
463	26052141	GB	GB	3	1.0	0	0	0	0	2025-11-17	49.0	801.0	Female	70.0	LEVETIRACETAM	dyspnoea	1	0	0.0	Adult	GB	0.05714285714285714	5	0	8	0	0	0	0	0	0	0	1	2025	11	17	0	0.17857142857142855	2.8	0.05714285714285714
464	26052437	US	US	1	1.0	0	1	1	0	2025-11-17	14.0	801.0	Male	75.0	AMLODIPINE	hypotension	1	7	0.5	Child	US	0.16964285714285715	8	1	11	0	0	0	0	0	0	0	1	2025	11	17	0	0.08073634859349145	2.375	0.0
465	26052532	EU	EU	1	1.0	0	0	1	0	2025-11-17	74.0	801.0	Male	82.0	PACLITAXEL	erythema	1	3	0.21428571428571427	Senior	EU	0.07142857142857142	3	0	8	0	0	0	0	0	0	0	1	2025	11	17	0	0.08073634859349145	5.285714285714286	0.0
466	26052585	GB	GB	1	1.0	0	0	0	1	2025-11-17	77.0	801.0	Male	75.0	AMLODIPINE	loose tooth	1	2	0.14285714285714285	Senior	GB	0.16964285714285715	8	1	11	0	0	0	0	0	0	0	2	2025	11	17	0	0.08073634859349145	13.0625	0.0
467	26052909	US	US	1	1.0	0	1	1	0	2025-11-17	71.0	801.0	Male	75.0	RISPERIDONE	rhabdomyolysis	1	7	0.5	Senior	US	0.125	4	1	14	0	0	0	0	0	0	0	1	2025	11	17	0	0.08073634859349145	8.875	0.0
468	24160409	CA	CA	2	1.0	0	0	1	0	2024-08-01	57.0	801.0	Female	75.0	RITUXIMAB-ABBS	rheumatoid arthritis	1	3	0.21428571428571427	MidAge	CA	0.10714285714285714	2	0	20	0	0	0	0	0	0	0	2	2024	8	1	3	0.08936301793444651	6.107142857142857	0.10714285714285714
469	24165026	JP	JP	2	1.0	1	0	1	0	2024-08-02	57.0	801.0	Male	74.2	HEMLIBRA	haemorrhage subcutaneous	1	8	0.5714285714285714	MidAge	JP	0.5714285714285714	1	1	24	0	0	0	0	0	0	0	2	2024	8	2	4	0.08936301793444651	32.57142857142857	0.0
470	24194792	US	US	1	1.0	0	0	0	0	2024-08-09	26.0	801.0	Female	75.0	XELJANZ	product dose omission in error	1	0	0.0	Young	US	0.0	3	0	30	0	0	0	0	0	0	0	5	2024	8	9	4	0.08073634859349145	0.0	0.0
471	24196736	CA	CA	1	1.0	0	0	0	0	2024-08-10	57.0	801.0	Female	75.0	INFLIXIMAB	large intestinal stenosis	1	0	0.0	MidAge	CA	0.07142857142857142	9	0	25	0	0	0	0	0	0	0	3	2024	8	10	5	0.08073634859349145	4.071428571428571	0.07142857142857142
472	24272890	CA	CA	2	1.0	0	0	1	0	2024-09-02	88.0	801.0	Male	75.0	SARILUMAB	pneumonia aspiration	1	3	0.21428571428571427	Senior	CA	0.21428571428571427	1	1	20	0	0	0	0	0	1	0	2	2024	9	2	0	0.08936301793444651	18.857142857142858	0.0
473	24403786	US	US	1	2.0	0	0	0	0	2024-10-07	57.0	801.0	Female	75.0	CEQUA	expired product administered	0	0	0.0	MidAge	US	0.0	1	0	28	0	0	0	0	0	0	0	3	2024	10	7	0	0.08073634859349145	0.0	0.0
474	24416841	EU	EU	2	1.0	0	1	1	0	2024-10-09	57.0	801.0	Female	75.0	VORASIDENIB	acute myocardial infarction	1	7	0.5	MidAge	EU	0.5	1	1	27	0	0	0	0	0	0	0	3	2024	10	9	2	0.08936301793444651	28.5	0.5
475	24468262	EU	EU	1	1.0	0	0	1	0	2024-10-18	77.0	801.0	Female	75.0	METFORMIN	lactic acidosis	1	3	0.21428571428571427	Senior	EU	0.21428571428571427	2	1	15	0	0	0	0	0	0	0	2	2024	10	18	4	0.08073634859349145	16.5	0.21428571428571427
476	24580933	US	US	2	2.0	0	0	0	0	2024-11-05	34.0	801.0	Male	65.76	ADCETRIS	weight decreased	0	0	0.0	Young	US	0.0	2	0	16	0	0	0	0	0	0	0	2	2024	11	5	1	0.08936301793444651	0.0	0.0
477	24592435	US	US	1	1.0	0	1	0	0	2024-11-08	57.0	801.0	Female	75.0	PADCEV	stevens-johnson syndrome	1	4	0.2857142857142857	MidAge	US	0.2857142857142857	1	1	24	0	0	0	0	0	0	0	2	2024	11	8	4	0.08073634859349145	16.285714285714285	0.2857142857142857
478	24593717	US	US	2	1.0	0	0	0	0	2024-11-08	81.0	801.0	Male	99.773	VYNDAMAX	neuropathy peripheral	1	0	0.0	Senior	US	0.0	1	0	21	0	0	0	0	0	0	0	2	2024	11	8	4	0.08936301793444651	0.0	0.0
479	24653886	US	US	1	2.0	0	0	0	0	2024-11-22	57.0	801.0	Female	75.0	TRESIBA	cataract	0	0	0.0	MidAge	US	0.0	1	0	8	0	0	0	0	0	0	0	1	2024	11	22	4	0.08073634859349145	0.0	0.0
480	24680200	US	US	1	1.0	0	1	1	0	2024-11-29	69.0	801.0	Female	149.0	LUMASON	anaphylactic shock	1	7	0.5	Senior	US	0.25	2	1	18	0	0	0	0	0	0	0	2	2024	11	29	4	0.08073634859349145	17.25	0.25
481	24710857	JP	JP	1	1.0	0	0	1	0	2024-12-09	7.0	800.0	Male	75.0	TECENTRIQ	type 1 diabetes mellitus	1	3	0.21428571428571427	Child	JP	0.14285714285714285	3	1	24	0	0	0	0	0	0	0	4	2024	12	9	0	0.08073634859349145	1.0	0.0
482	24724775	US	US	1	2.0	0	0	0	0	2024-12-12	50.0	801.0	Male	75.0	DUPIXENT	pruritus	0	0	0.0	Adult	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	1	2024	12	12	3	0.08073634859349145	0.7756948933419521	0.0
483	24741785	CA	CA	1	1.0	0	0	0	0	2024-12-17	57.0	801.0	Female	75.0	DICLOFENAC SODIUM	glossodynia	1	0	0.0	MidAge	CA	0.4047619047619048	3	1	11	0	0	0	0	0	0	0	1	2024	12	17	1	0.08073634859349145	23.071428571428577	0.4047619047619048
484	24750723	JP	JP	1	1.0	0	0	0	0	2024-12-18	80.0	801.0	Male	62.7	NUCALA	compression fracture	1	0	0.0	Senior	JP	0.0	2	0	20	0	0	0	0	0	0	0	2	2024	12	18	2	0.08073634859349145	0.0	0.0
485	24757647	US	Unknown	1	2.0	0	0	0	0	2024-12-20	64.0	801.0	Female	75.0	BIMZELX	abdominal pain upper	0	0	0.0	MidAge	US	0.0	22	0	20	1	0	0	0	0	0	0	3	2024	12	20	4	0.08073634859349145	0.0	0.0
486	24757661	US	Unknown	1	2.0	0	0	0	0	2024-12-20	34.0	801.0	Female	136.0	BIMZELX	arthralgia	0	0	0.0	Young	US	0.0	22	0	10	0	0	0	0	0	0	0	1	2024	12	20	4	0.08073634859349145	0.0	0.0
487	24757890	US	Unknown	1	2.0	0	0	0	0	2024-12-20	72.0	801.0	Female	63.492	BIMZELX	eating disorder	0	0	0.0	Senior	US	0.0	22	0	15	0	0	0	0	0	0	0	2	2024	12	20	4	0.08073634859349145	0.0	0.0
488	24758147	US	Unknown	1	2.0	0	0	0	0	2024-12-20	55.0	801.0	Female	75.0	BIMZELX	pain in extremity	0	0	0.0	MidAge	US	0.0	22	0	17	1	0	0	0	0	0	0	3	2024	12	20	4	0.08073634859349145	0.0	0.0
489	24758228	US	Unknown	1	2.0	0	0	0	0	2024-12-20	82.0	801.0	Female	75.0	BIMZELX	psoriasis	0	0	0.0	Senior	US	0.0	22	0	9	0	0	0	0	0	0	0	1	2024	12	20	4	0.08073634859349145	0.0	0.0
490	24758295	US	Unknown	1	2.0	0	0	0	0	2024-12-20	45.0	801.0	Female	75.0	BIMZELX	condition aggravated	0	0	0.0	Adult	US	0.0	22	0	20	0	0	0	0	0	0	0	2	2024	12	20	4	0.08073634859349145	0.0	0.0
491	24781880	CA	Unknown	2	1.0	0	0	0	0	2024-12-27	57.0	801.0	Female	75.0	CERTOLIZUMAB PEGOL	pneumonia	1	0	0.0	MidAge	CA	0.04285714285714286	5	0	9	0	0	0	0	0	1	0	1	2024	12	27	4	0.08936301793444651	2.442857142857143	0.04285714285714286
492	24790547	US	US	1	2.0	0	0	0	0	2024-12-30	69.0	801.0	Male	75.0	DUPIXENT	dyspnoea	0	0	0.0	Senior	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	1	2024	12	30	0	0.08073634859349145	1.070458952811894	0.0
493	24808934	EU	EU	1	1.0	0	1	1	0	2025-01-06	80.0	801.0	Female	75.0	ESCITALOPRAM	anaphylactic reaction	1	7	0.5	Senior	EU	0.25	2	1	21	0	0	0	0	0	0	0	2	2025	1	6	0	0.08073634859349145	20.0	0.25
494	24821098	US	US	1	2.0	0	0	0	0	2025-01-08	14.0	801.0	Male	64.857	FABRAZYME	weight decreased	0	0	0.0	Child	US	0.0	1	0	16	0	0	0	0	0	0	0	2	2025	1	8	2	0.08073634859349145	0.0	0.0
495	24850205	GB	GB	2	1.0	0	0	0	0	2025-01-16	65.0	801.0	Male	75.0	VEDOLIZUMAB	lower respiratory tract infection	1	0	0.0	MidAge	GB	0.057692307692307696	26	0	33	0	1	0	0	0	0	0	4	2025	1	16	3	0.08936301793444651	3.75	0.0
496	24867025	CA	CA	2	1.0	0	0	1	0	2025-01-21	69.0	801.0	Female	75.0	VELTASSA	hospitalisation	1	3	0.21428571428571427	Senior	CA	0.2619047619047619	3	1	15	0	0	0	0	0	0	0	1	2025	1	21	1	0.08936301793444651	18.071428571428573	0.2619047619047619
497	24879228	US	US	1	2.0	0	0	0	0	2025-01-23	65.0	801.0	Female	75.0	DUPIXENT	asthma	0	0	0.0	MidAge	US	0.015513897866839042	221	0	6	0	0	0	0	0	0	0	1	2025	1	23	3	0.08073634859349145	1.0084033613445378	0.015513897866839042
498	24880376	EU	EU	2	1.0	0	0	0	0	2025-01-23	58.0	801.0	Male	75.0	FOSCARBIDOPA\FOSLEVODOPA	suicidal ideation	1	0	0.0	MidAge	EU	0.0	1	0	17	0	0	0	0	0	0	0	2	2025	1	23	3	0.08936301793444651	0.0	0.0
499	24891163	US	US	1	2.0	0	0	0	0	2025-01-27	27.0	801.0	Female	75.0	DUPIXENT	sleep disorder due to a general medical condition	0	0	0.0	Young	US	0.015513897866839042	221	0	49	0	0	0	0	0	0	0	8	2025	1	27	0	0.08073634859349145	0.4188752424046541	0.015513897866839042
500	24953586	CA	CA	1	1.0	1	0	0	0	2025-02-11	97.0	801.0	Female	97.0	RITUXIMAB	abdominal discomfort	1	5	0.35714285714285715	Senior	CA	0.12406015037593986	19	0	20	0	0	0	0	0	0	0	2	2025	2	11	1	0.08073634859349145	12.033834586466167	0.12406015037593986
501	24971610	US	US	2	1.0	0	0	1	0	2025-02-14	57.0	801.0	Female	75.0	MAVENCLAD	bladder mass	1	3	0.21428571428571427	MidAge	US	0.21428571428571427	1	1	12	0	0	0	0	0	0	0	2	2025	2	14	4	0.08936301793444651	12.214285714285714	0.21428571428571427
502	24983394	EU	EU	2	1.0	0	0	1	0	2025-02-19	75.0	801.0	Male	70.0	CARBIDOPA\LEVODOPA	influenza	1	3	0.21428571428571427	Senior	EU	0.3333333333333333	3	1	9	0	0	0	0	0	0	0	1	2025	2	19	2	0.08936301793444651	25.0	0.0
503	26185292	US	US	1	1.0	0	0	1	0	2025-12-22	35.0	801.0	Female	75.0	AMPICILLIN AND SULBACTAM	septic cardiomyopathy	1	3	0.21428571428571427	Young	US	0.21428571428571427	1	1	21	0	0	0	0	0	0	0	2	2025	12	22	0	0.08073634859349145	7.5	0.21428571428571427
504	26187627	CA	CA	2	1.0	0	0	0	0	2025-12-22	66.0	801.0	Female	75.0	ROSUVASTATIN	throat cancer	1	0	0.0	Senior	CA	0.0	2	0	13	0	0	0	1	0	0	0	2	2025	12	22	0	0.08936301793444651	0.0	0.0
505	26187775	US	US	1	1.0	0	0	0	0	2025-12-22	70.0	801.0	Female	75.0	WEGOVY	skin neoplasm excision	1	0	0.0	Senior	US	0.14285714285714285	4	1	22	0	0	0	0	0	0	0	3	2025	12	22	0	0.08073634859349145	10.0	0.14285714285714285
506	26188141	EU	EU	1	1.0	0	0	0	0	2025-12-22	45.0	801.0	Male	75.0	ADALIMUMAB	enterocolitis	1	0	0.0	Adult	EU	0.07142857142857142	3	0	13	0	0	0	0	0	0	0	1	2025	12	22	0	0.08073634859349145	3.214285714285714	0.0
507	26188747	US	US	1	1.0	0	0	1	0	2025-12-22	57.0	801.0	Female	75.0	RITUXIMAB	infection	1	3	0.21428571428571427	MidAge	US	0.12406015037593986	19	0	9	0	1	0	0	0	0	0	1	2025	12	22	0	0.08073634859349145	7.071428571428572	0.12406015037593986
508	21662498	US	US	2	1.0	0	0	0	0	2022-11-30	63.0	801.0	Male	149.69	BOSULIF	suicidal ideation	1	0	0.0	MidAge	US	0.0	1	0	17	0	0	0	0	0	0	0	2	2022	11	30	2	0.08936301793444651	0.0	0.0
509	21719011	CA	CA	2	1.0	0	0	0	0	2022-12-13	40.0	801.0	Female	75.0	HUMAN IMMUNOGLOBULIN G	haemorrhage	1	0	0.0	Adult	CA	0.10714285714285714	8	0	11	0	0	0	0	0	0	0	1	2022	12	13	1	0.08936301793444651	4.285714285714286	0.10714285714285714
510	21723304	JP	JP	1	1.0	0	0	1	1	2022-12-13	75.0	801.0	Female	75.0	YERVOY	coagulation factor deficiency	1	5	0.35714285714285715	Senior	JP	0.35714285714285715	4	1	29	0	0	0	0	0	0	0	3	2022	12	13	1	0.08073634859349145	26.785714285714285	0.35714285714285715
511	22056267	US	US	1	1.0	1	0	1	0	2023-03-02	67.0	801.0	Female	75.0	PRIVIGEN	death	1	8	0.5714285714285714	Senior	US	0.39285714285714285	2	1	5	0	0	1	0	0	0	0	1	2023	3	2	3	0.08073634859349145	26.32142857142857	0.39285714285714285
512	22314833	US	US	1	1.0	0	0	0	0	2023-05-12	57.0	801.0	Female	75.0	TRIKAFTA	hunger	1	0	0.0	MidAge	US	0.0	1	0	6	0	0	0	0	0	0	0	1	2023	5	12	4	0.08073634859349145	0.0	0.0
513	22667236	CA	CA	2	1.0	0	0	0	0	2023-07-04	57.0	801.0	Female	75.0	RITUXIMAB-ABBS	covid-19	1	0	0.0	MidAge	CA	0.10714285714285714	2	0	8	0	0	0	0	0	0	0	1	2023	7	4	1	0.08936301793444651	6.107142857142857	0.10714285714285714
514	22757375	US	US	2	2.0	0	0	0	0	2023-07-27	70.0	801.0	Female	75.0	XELJANZ XR	movement disorder	0	0	0.0	Senior	US	0.0	9	0	17	0	0	0	0	0	0	0	2	2023	7	27	3	0.08936301793444651	0.0	0.0
515	22812740	EU	EU	1	1.0	0	0	0	0	2023-08-11	55.0	801.0	Female	52.0	CIPROFLOXACIN	hallucination	1	0	0.0	MidAge	EU	0.07142857142857142	3	0	13	0	0	0	0	0	0	0	1	2023	8	11	4	0.08073634859349145	3.9285714285714284	0.07142857142857142
516	26054705	CO	CO	2	1.0	0	0	1	0	2025-11-17	35.0	801.0	Male	62.0	INVEGA SUSTENNA	rhabdomyolysis	1	3	0.21428571428571427	Young	Other	0.21428571428571427	1	1	14	0	0	0	0	0	0	0	1	2025	11	17	0	0.08936301793444651	7.5	0.0
517	26056244	US	US	2	1.0	0	0	0	0	2025-11-18	43.0	801.0	Male	75.0	SPRAVATO	hypertension	1	0	0.0	Adult	US	0.026785714285714284	8	0	12	0	0	0	0	0	0	0	1	2025	11	18	1	0.08936301793444651	1.1517857142857142	0.0
518	26056769	US	US	1	1.0	0	0	1	0	2025-11-18	17.0	801.0	Female	52.154	ISOTRETINOIN	suicide attempt	1	3	0.21428571428571427	Child	US	0.023809523809523808	9	0	15	0	0	0	0	0	0	0	2	2025	11	18	1	0.08073634859349145	0.40476190476190477	0.023809523809523808
519	26191705	EU	EU	1	1.0	0	0	1	0	2025-12-23	79.0	801.0	Female	75.0	DAPTOMYCIN	leukopenia	1	3	0.21428571428571427	Senior	EU	0.16666666666666666	3	1	10	0	0	0	0	0	0	0	1	2025	12	23	1	0.08073634859349145	13.166666666666666	0.16666666666666666
520	26192258	US	US	1	2.0	0	0	0	0	2025-12-23	85.0	801.0	Female	75.0	DUPIXENT	dermatitis	0	0	0.0	Senior	US	0.015513897866839042	221	0	10	0	0	0	0	0	0	0	1	2025	12	23	1	0.08073634859349145	1.3186813186813187	0.015513897866839042
521	26192568	US	US	1	2.0	0	0	0	0	2025-12-23	34.0	801.0	Female	75.0	DUPIXENT	allergy to animal	0	0	0.0	Young	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	3	2025	12	23	1	0.08073634859349145	0.5274725274725274	0.015513897866839042
522	26057889	EU	EU	1	1.0	0	0	1	0	2025-11-18	33.0	801.0	Female	75.0	PREDNISONE	salpingitis	1	3	0.21428571428571427	Young	EU	0.1607142857142857	8	1	11	0	0	0	0	0	0	0	1	2025	11	18	1	0.08073634859349145	5.303571428571428	0.1607142857142857
523	26058646	EU	EU	2	1.0	0	0	0	0	2025-11-18	68.0	801.0	Male	75.0	OXALIPLATIN	type ii hypersensitivity	1	0	0.0	Senior	EU	0.08571428571428572	5	0	24	0	0	0	0	0	0	0	3	2025	11	18	1	0.08936301793444651	5.828571428571428	0.0
524	26058699	GB	GB	1	1.0	0	0	0	0	2025-11-18	57.0	801.0	Female	75.0	CISPLATIN	lower limb fracture	1	0	0.0	MidAge	GB	0.10714285714285714	2	0	19	0	0	0	0	0	0	0	3	2025	11	18	1	0.08073634859349145	6.107142857142857	0.10714285714285714
525	26058727	US	US	1	2.0	0	0	0	0	2025-11-18	57.0	801.0	Female	75.0	SYNTHROID	muscular weakness	0	0	0.0	MidAge	US	0.17857142857142858	2	1	17	0	0	0	0	0	0	0	2	2025	11	18	1	0.08073634859349145	10.178571428571429	0.17857142857142858
526	26058875	EU	EU	1	1.0	0	0	1	0	2025-11-18	58.0	801.0	Female	75.0	LEVOFLOXACIN	gastrointestinal disorder	1	3	0.21428571428571427	MidAge	EU	0.25	4	1	25	0	0	0	0	0	0	0	2	2025	11	18	1	0.08073634859349145	14.5	0.25
527	26059146	US	US	1	2.0	0	0	0	0	2025-11-18	57.0	801.0	Female	75.0	BELBUCA	product solubility abnormal	0	0	0.0	MidAge	US	0.0	1	0	27	0	0	0	0	0	0	0	3	2025	11	18	1	0.08073634859349145	0.0	0.0
528	26060780	CN	CN	1	1.0	0	0	0	0	2025-11-18	11.0	801.0	Male	75.0	CYCLOSPORINE	skin graft rejection	1	0	0.0	Child	CN	0.0	5	0	20	0	0	0	0	0	0	0	3	2025	11	18	1	0.08073634859349145	0.0	0.0
529	25016202	US	US	2	1.0	0	0	0	0	2025-02-27	25.0	801.0	Male	75.0	SKYRIZI	ileectomy	1	0	0.0	Young	US	0.051587301587301584	36	0	9	0	0	0	0	0	0	0	1	2025	2	27	3	0.08936301793444651	1.2896825396825395	0.0
530	25044362	JP	JP	1	1.0	0	0	0	0	2025-03-06	6.0	800.0	Male	75.0	LUTATHERA	peptic ulcer	1	0	0.0	Child	JP	0.0	1	0	12	0	0	0	0	0	0	0	2	2025	3	6	3	0.08073634859349145	0.0	0.0
531	25052071	US	US	1	2.0	0	0	0	0	2025-03-07	57.0	801.0	Female	75.0	OPZELURA	intentional product use issue	0	0	0.0	MidAge	US	0.0	2	0	29	0	0	0	0	0	0	0	4	2025	3	7	4	0.08073634859349145	0.0	0.0
532	25056431	US	US	2	1.0	0	0	1	0	2025-03-10	40.0	801.0	Female	75.0	XYWAV	hospitalisation	1	3	0.21428571428571427	Adult	US	0.04285714285714286	5	0	15	0	0	0	0	0	0	0	1	2025	3	10	0	0.08936301793444651	1.7142857142857144	0.04285714285714286
533	25098428	US	US	1	2.0	0	0	0	0	2025-03-20	73.0	801.0	Female	59.42	POMALYST	eye irritation	0	0	0.0	Senior	US	0.11428571428571428	5	0	14	0	0	0	0	0	0	0	2	2025	3	20	3	0.08073634859349145	8.342857142857143	0.11428571428571428
534	25112740	US	Unknown	1	2.0	0	0	0	0	2025-03-24	57.0	801.0	Female	75.0	BIMZELX	fatigue	0	0	0.0	MidAge	US	0.0	22	0	7	0	0	0	0	0	0	0	1	2025	3	24	0	0.08073634859349145	0.0	0.0
535	25119921	US	US	1	1.0	0	0	1	0	2025-03-25	77.0	801.0	Female	75.0	DUPIXENT	hospitalisation	1	3	0.21428571428571427	Senior	US	0.015513897866839042	221	0	15	0	0	0	0	0	0	0	1	2025	3	25	1	0.08073634859349145	1.1945701357466063	0.015513897866839042
536	26061833	US	US	2	1.0	0	0	0	0	2025-11-18	51.0	801.0	Female	109.0	SKYRIZI	cholecystectomy	1	0	0.0	MidAge	US	0.051587301587301584	36	0	15	0	0	0	0	0	0	0	1	2025	11	18	1	0.08936301793444651	2.630952380952381	0.051587301587301584
537	26061886	US	US	2	1.0	0	0	1	0	2025-11-19	64.0	801.0	Male	83.0	SKYRIZI	knee operation	1	3	0.21428571428571427	MidAge	US	0.051587301587301584	36	0	14	0	0	0	0	0	0	0	2	2025	11	19	2	0.08936301793444651	3.3015873015873014	0.0
538	26061967	US	US	1	2.0	0	0	0	0	2025-11-19	27.0	801.0	Female	75.0	DUPIXENT	eczema	0	0	0.0	Young	US	0.015513897866839042	221	0	6	0	0	0	0	0	0	0	1	2025	11	19	2	0.08073634859349145	0.4188752424046541	0.015513897866839042
539	26064425	US	US	1	2.0	0	0	0	0	2025-11-19	20.0	801.0	Female	75.0	DUPIXENT	influenza	0	0	0.0	Young	US	0.015513897866839042	221	0	9	0	0	0	0	0	0	0	1	2025	11	19	2	0.08073634859349145	0.3102779573367808	0.015513897866839042
540	26065059	EU	EU	1	1.0	0	1	1	0	2025-11-19	63.0	801.0	Male	75.0	PREDNISOLONE	drug ineffective	1	7	0.5	MidAge	EU	0.35714285714285715	2	1	16	0	0	0	0	0	0	0	2	2025	11	19	2	0.08073634859349145	22.5	0.0
541	26194311	US	US	1	1.0	0	0	0	0	2025-12-24	62.0	801.0	Female	75.0	TEMOZOLOMIDE	neoplasm progression	1	0	0.0	MidAge	US	0.0	1	0	20	0	0	0	0	0	0	0	2	2025	12	24	2	0.08073634859349145	0.0	0.0
542	26195875	US	US	3	1.0	1	0	1	0	2025-12-24	57.0	801.0	Female	75.0	CLOZAPINE	toxicity to various agents	1	8	0.5714285714285714	MidAge	US	0.23214285714285715	4	1	26	0	0	0	0	0	0	0	4	2025	12	24	2	0.17857142857142855	13.232142857142858	0.23214285714285715
543	26196766	US	US	1	2.0	0	0	0	0	2025-12-24	57.0	801.0	Female	75.0	OMEPRAZOLE	product storage error	0	0	0.0	MidAge	US	0.07142857142857142	3	0	21	0	0	0	0	0	0	0	3	2025	12	24	2	0.08073634859349145	4.071428571428571	0.07142857142857142
544	26197185	JP	JP	1	1.0	0	0	0	0	2025-12-24	57.0	801.0	Male	75.0	VONOPRAZAN FUMARATE	gastric haemorrhage	1	0	0.0	MidAge	JP	0.0	1	0	19	0	0	0	0	0	0	0	2	2025	12	24	2	0.08073634859349145	0.0	0.0
545	26197590	US	US	1	2.0	0	0	0	0	2025-12-24	69.0	801.0	Male	75.0	DUPIXENT	incorrect dose administered	0	0	0.0	Senior	US	0.015513897866839042	221	0	27	0	0	0	0	0	0	0	3	2025	12	24	2	0.08073634859349145	1.070458952811894	0.0
546	26066179	NZ	NZ	1	1.0	0	0	0	0	2025-11-19	32.0	801.0	Female	75.0	CLOZARIL	faecaloma	1	0	0.0	Young	Other	0.10714285714285714	4	0	9	0	0	0	0	0	0	0	1	2025	11	19	2	0.08073634859349145	3.4285714285714284	0.10714285714285714
547	26067246	US	US	1	2.0	0	0	0	0	2025-11-20	22.0	801.0	Male	75.0	DUPIXENT	pruritus	0	0	0.0	Young	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	1	2025	11	20	3	0.08073634859349145	0.3413057530704589	0.0
548	26067299	US	US	1	1.0	0	0	0	0	2025-11-20	9.0	801.0	Female	75.0	COSENTYX	crohn^s disease	1	0	0.0	Child	US	0.05714285714285714	10	0	15	0	0	0	0	0	0	0	2	2025	11	20	3	0.08073634859349145	0.5142857142857142	0.05714285714285714
549	26067718	US	US	2	1.0	0	0	0	0	2025-11-20	35.0	801.0	Male	75.0	CREON	pulmonary embolism	1	0	0.0	Young	US	0.03296703296703297	13	0	18	0	0	0	0	0	0	0	2	2025	11	20	3	0.08936301793444651	1.153846153846154	0.0
550	26069514	AU	AU	1	1.0	0	0	0	0	2025-11-20	16.0	801.0	Male	75.0	ISOTRETINOIN	granuloma skin	1	0	0.0	Child	AU	0.023809523809523808	9	0	14	0	0	0	0	0	0	0	2	2025	11	20	3	0.08073634859349145	0.38095238095238093	0.0
551	22985228	CA	CA	2	1.0	0	0	0	0	2023-09-26	28.0	801.0	Female	75.0	VEDOLIZUMAB	crohn^s disease	1	0	0.0	Young	CA	0.057692307692307696	26	0	15	0	0	0	0	0	0	0	2	2023	9	26	1	0.08936301793444651	1.6153846153846154	0.057692307692307696
552	23013810	US	US	1	1.0	0	1	1	0	2023-10-01	28.0	801.0	Male	75.0	OLANZAPINE	gastric hypomotility	1	7	0.5	Young	US	0.11904761904761905	6	0	20	0	0	0	0	0	0	0	2	2023	10	1	6	0.08073634859349145	3.3333333333333335	0.0
553	23086087	US	US	2	1.0	0	0	0	0	2023-10-19	57.0	801.0	Female	75.0	XYWAV	suicidal ideation	1	0	0.0	MidAge	US	0.04285714285714286	5	0	17	0	0	0	0	0	0	0	2	2023	10	19	3	0.08936301793444651	2.442857142857143	0.04285714285714286
554	23156733	EU	EU	1	1.0	0	0	0	0	2023-11-07	57.0	801.0	Female	75.0	LAMOTRIGINE	epilepsy	1	0	0.0	MidAge	EU	0.10714285714285714	2	0	8	0	0	0	0	0	0	0	1	2023	11	7	1	0.08073634859349145	6.107142857142857	0.10714285714285714
555	23202001	US	US	1	2.0	0	0	0	0	2023-11-20	59.0	801.0	Male	75.0	DUPIXENT	dry skin	0	0	0.0	MidAge	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	2	2023	11	20	0	0.08073634859349145	0.9153199741435035	0.0
556	23226999	US	US	2	1.0	0	0	0	0	2023-11-24	57.0	801.0	Female	91.0	HUMAN IMMUNOGLOBULIN G	pneumonia	1	0	0.0	MidAge	US	0.10714285714285714	8	0	9	0	0	0	0	0	1	0	1	2023	11	24	4	0.08936301793444651	6.107142857142857	0.10714285714285714
557	23258011	CA	CA	2	1.0	0	0	0	0	2023-12-04	68.0	801.0	Male	75.0	DUPILUMAB	dermatitis exfoliative generalised	1	0	0.0	Senior	CA	0.04285714285714286	5	0	34	0	0	0	0	0	0	0	3	2023	12	4	0	0.08936301793444651	2.914285714285714	0.0
558	23353482	US	US	1	2.0	0	0	0	0	2023-12-31	57.0	801.0	Female	75.0	DARZALEX FASPRO	product complaint	0	0	0.0	MidAge	US	0.0	1	0	17	0	0	0	0	0	0	0	2	2023	12	31	6	0.08073634859349145	0.0	0.0
559	23411869	US	US	1	1.0	0	0	0	0	2024-01-17	57.0	801.0	Female	75.0	XCOPRI	loss of consciousness	1	0	0.0	MidAge	US	0.0	1	0	21	0	0	0	0	0	0	0	3	2024	1	17	2	0.08073634859349145	0.0	0.0
560	23483149	US	US	1	2.0	0	0	0	0	2024-02-05	72.0	801.0	Female	51.71	IBRANCE	hypoacusis	0	0	0.0	Senior	US	0.07142857142857142	3	0	10	0	0	0	0	0	0	0	1	2024	2	5	0	0.08073634859349145	5.142857142857142	0.07142857142857142
561	23560046	CA	CA	2	1.0	0	0	0	0	2024-02-23	57.0	801.0	Female	75.0	KESIMPTA	colitis	1	0	0.0	MidAge	CA	0.0	2	0	7	0	0	0	0	0	0	0	1	2024	2	23	4	0.08936301793444651	0.0	0.0
562	23647903	US	US	1	1.0	0	0	1	0	2024-03-19	79.0	801.0	Female	75.0	DUPIXENT	hip fracture	1	3	0.21428571428571427	Senior	US	0.015513897866839042	221	0	12	0	0	0	0	0	0	0	2	2024	3	19	1	0.08073634859349145	1.2255979314802843	0.015513897866839042
563	23661525	US	US	1	1.0	0	0	0	0	2024-03-22	64.0	801.0	Male	75.0	XTANDI	malignant neoplasm progression	1	0	0.0	MidAge	US	0.0	1	0	30	0	0	0	0	0	0	0	3	2024	3	22	4	0.08073634859349145	0.0	0.0
564	23672594	CA	CA	1	1.0	0	0	1	0	2024-03-26	78.0	801.0	Female	93.0	ACETAMINOPHEN	abdominal pain upper	1	3	0.21428571428571427	Senior	CA	0.10267857142857142	16	0	20	1	0	0	0	0	0	0	3	2024	3	26	1	0.08073634859349145	8.008928571428571	0.10267857142857142
565	25151916	US	US	1	1.0	0	0	1	0	2025-04-02	57.0	801.0	Male	75.0	ACETAMINOPHEN	overdose	1	3	0.21428571428571427	MidAge	US	0.10267857142857142	16	0	8	0	0	0	0	0	0	0	1	2025	4	2	2	0.08073634859349145	5.852678571428571	0.0
566	25161731	US	US	2	1.0	0	0	0	0	2025-04-04	17.0	801.0	Female	54.43	COSENTYX	leukoplakia oral	1	0	0.0	Child	US	0.05714285714285714	10	0	16	0	0	0	0	0	0	0	2	2025	4	4	4	0.08936301793444651	0.9714285714285714	0.05714285714285714
567	25174177	US	US	1	2.0	0	0	0	0	2025-04-08	68.0	801.0	Male	75.0	DUPIXENT	dyspnoea	0	0	0.0	Senior	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	1	2025	4	8	1	0.08073634859349145	1.0549450549450547	0.0
568	25179118	US	US	1	2.0	0	0	0	0	2025-04-09	23.0	801.0	Female	75.0	DUPIXENT	rash erythematous	0	0	0.0	Young	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	4	9	2	0.08073634859349145	0.35681965093729795	0.015513897866839042
569	25184693	US	US	1	2.0	0	0	0	0	2025-04-10	57.0	801.0	Male	75.0	DUPIXENT	abdominal pain	0	0	0.0	MidAge	US	0.015513897866839042	221	0	14	1	0	0	0	0	0	0	2	2025	4	10	3	0.08073634859349145	0.8842921784098254	0.0
570	25206524	US	US	1	1.0	0	0	0	0	2025-04-17	56.0	801.0	Male	75.0	REVLIMID	gait disturbance	1	0	0.0	MidAge	US	0.05357142857142857	4	0	16	0	0	0	0	0	0	0	2	2025	4	17	3	0.08073634859349145	3.0	0.0
571	25221495	US	US	1	1.0	0	0	1	0	2025-04-21	54.0	801.0	Female	50.794	DUPIXENT	pneumonia	1	3	0.21428571428571427	MidAge	US	0.015513897866839042	221	0	9	0	0	0	0	0	1	0	1	2025	4	21	0	0.08073634859349145	0.8377504848093082	0.015513897866839042
572	26198104	CN	CN	1	1.0	0	0	0	0	2025-12-24	30.0	801.0	Female	56.0	TOBRAMYCIN	conjunctival oedema	1	0	0.0	Young	CN	0.0	1	0	19	0	0	0	0	0	0	0	2	2025	12	24	2	0.08073634859349145	0.0	0.0
573	26198858	US	US	1	2.0	0	0	0	0	2025-12-25	57.0	801.0	Female	75.0	BUPROPION HYDROCHLORIDE	product odour abnormal	0	0	0.0	MidAge	US	0.0	1	0	22	0	0	0	0	0	0	0	3	2025	12	25	3	0.08073634859349145	0.0	0.0
574	26199048	US	US	1	1.0	0	0	1	0	2025-12-25	31.0	801.0	Female	75.0	MYCOPHENOLATE MOFETIL	toxicity to various agents	1	3	0.21428571428571427	Young	US	0.10150375939849625	19	0	26	0	0	0	0	0	0	0	4	2025	12	25	3	0.08073634859349145	3.1466165413533838	0.10150375939849625
575	26199224	GB	GB	1	1.0	0	0	1	0	2025-12-25	57.0	801.0	Male	75.0	GABAPENTIN	gastritis	1	3	0.21428571428571427	MidAge	GB	0.061224489795918366	7	0	9	0	0	0	0	0	0	0	1	2025	12	25	3	0.08073634859349145	3.489795918367347	0.0
576	26199305	US	US	1	1.0	0	0	1	0	2025-12-25	81.0	801.0	Male	79.55	DUPIXENT	respiration abnormal	1	3	0.21428571428571427	Senior	US	0.015513897866839042	221	0	20	0	0	0	0	0	0	0	2	2025	12	25	3	0.08073634859349145	1.2566257272139625	0.0
577	26199587	US	US	1	2.0	0	0	0	0	2025-12-25	54.0	801.0	Female	75.0	DUPIXENT	headache	0	0	0.0	MidAge	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	1	2025	12	25	3	0.08073634859349145	0.8377504848093082	0.015513897866839042
578	26200009	CN	CN	1	1.0	0	0	0	0	2025-12-25	55.0	801.0	Female	75.0	XGEVA	white blood cell count decreased	1	0	0.0	MidAge	CN	0.10714285714285714	2	0	32	0	0	0	0	0	0	0	5	2025	12	25	3	0.08073634859349145	5.892857142857142	0.10714285714285714
579	26201048	EU	EU	1	1.0	0	0	0	0	2025-12-26	57.0	801.0	Female	75.0	ADALIMUMAB	enterocolitis	1	0	0.0	MidAge	EU	0.07142857142857142	3	0	13	0	0	0	0	0	0	0	1	2025	12	26	4	0.08073634859349145	4.071428571428571	0.07142857142857142
580	26201358	US	US	1	1.0	0	0	1	0	2025-12-26	57.0	801.0	Female	75.0	RITUXIMAB	upper respiratory tract infection	1	3	0.21428571428571427	MidAge	US	0.12406015037593986	19	0	33	0	1	0	0	0	0	0	4	2025	12	26	4	0.08073634859349145	7.071428571428572	0.12406015037593986
581	23936034	US	Unknown	2	1.0	0	0	0	0	2024-06-04	12.0	801.0	Female	114.0	FENFLURAMINE	seizure	1	0	0.0	Child	US	0.0	1	0	7	0	0	0	0	0	0	0	1	2024	6	4	1	0.08936301793444651	0.0	0.0
582	24010568	CA	CA	2	1.0	0	0	0	0	2024-06-25	49.0	801.0	Female	75.0	RITUXIMAB	bronchitis	1	0	0.0	Adult	CA	0.12406015037593986	19	0	10	0	0	0	0	0	0	0	1	2024	6	25	1	0.08936301793444651	6.078947368421053	0.12406015037593986
583	24090663	JP	JP	2	1.0	0	0	0	0	2024-07-15	4.0	801.0	Female	16.4	FENFLURAMINE HYDROCHLORIDE	epilepsy	1	0	0.0	Child	JP	0.0	1	0	8	0	0	0	0	0	0	0	1	2024	7	15	0	0.08936301793444651	0.0	0.0
584	24173931	US	US	1	1.0	0	0	1	0	2024-08-05	57.0	801.0	Male	75.0	IDELVION	wrist surgery	1	3	0.21428571428571427	MidAge	US	0.10714285714285714	2	0	13	0	0	0	0	0	0	0	2	2024	8	5	0	0.08073634859349145	6.107142857142857	0.0
585	24201351	US	US	1	2.0	0	0	0	0	2024-08-12	67.0	801.0	Male	75.0	KEVZARA	gait disturbance	0	0	0.0	Senior	US	0.14285714285714285	4	1	16	0	0	0	0	0	0	0	2	2024	8	12	0	0.08073634859349145	9.571428571428571	0.0
586	24249490	US	US	1	2.0	0	0	0	0	2024-08-26	71.0	801.0	Male	75.0	DUPIXENT	rash macular	0	0	0.0	Senior	US	0.015513897866839042	221	0	12	0	0	0	0	0	0	0	2	2024	8	26	0	0.08073634859349145	1.101486748545572	0.0
587	25249130	US	US	1	1.0	0	0	0	0	2025-04-29	57.0	801.0	Female	63.492	PARAGARD T 380A	surgery	1	0	0.0	MidAge	US	0.0	4	0	7	0	0	0	0	0	0	0	1	2025	4	29	1	0.08073634859349145	0.0	0.0
588	25254839	US	US	3	2.0	0	0	0	0	2025-04-30	57.0	801.0	Male	75.0	FILSPARI	influenza	0	0	0.0	MidAge	US	0.0	4	0	9	0	0	0	0	0	0	0	1	2025	4	30	2	0.17857142857142855	0.0	0.0
589	25261914	US	US	1	1.0	0	0	0	0	2025-05-02	28.0	801.0	Male	75.0	VIREAD	osteonecrosis	1	0	0.0	Young	US	0.0	1	0	13	0	0	0	0	0	0	0	1	2025	5	2	4	0.08073634859349145	0.0	0.0
590	25265288	US	US	2	1.0	0	0	0	0	2025-05-02	57.0	801.0	Female	75.0	XYWAV	surgery	1	0	0.0	MidAge	US	0.04285714285714286	5	0	7	0	0	0	0	0	0	0	1	2025	5	2	4	0.08936301793444651	2.442857142857143	0.04285714285714286
591	25265545	AU	AU	2	1.0	0	0	0	1	2025-05-02	66.0	801.0	Female	75.0	LENVIMA	palmar-plantar erythrodysaesthesia syndrome	1	2	0.14285714285714285	Senior	AU	0.07142857142857142	2	0	43	0	0	0	0	0	0	0	3	2025	5	2	4	0.08936301793444651	4.714285714285714	0.07142857142857142
592	25286267	CA	CA	2	1.0	0	0	0	0	2025-05-09	29.0	801.0	Female	75.0	SKYRIZI	obstruction	1	0	0.0	Young	CA	0.051587301587301584	36	0	11	0	0	0	0	0	0	0	1	2025	5	9	4	0.08936301793444651	1.496031746031746	0.051587301587301584
593	25303791	US	US	1	1.0	0	0	0	0	2025-05-13	43.0	801.0	Male	75.0	OCREVUS	headache	1	0	0.0	Adult	US	0.0	3	0	8	0	0	0	0	0	0	0	1	2025	5	13	1	0.08073634859349145	0.0	0.0
594	25306101	EU	EU	1	1.0	0	0	1	0	2025-05-13	17.0	801.0	Female	57.0	PRIVIGEN	hallucination, visual	1	3	0.21428571428571427	Child	EU	0.39285714285714285	2	1	21	0	0	0	0	0	0	0	2	2025	5	13	1	0.08073634859349145	6.678571428571429	0.39285714285714285
595	26205112	US	US	1	1.0	0	0	0	0	2025-12-28	57.0	801.0	Female	75.0	ESTRADIOL	circumstance or information capable of leading to medication error	1	0	0.0	MidAge	US	0.0	8	0	66	0	0	0	0	0	0	0	9	2025	12	28	6	0.08073634859349145	0.0	0.0
596	26205165	CA	CA	2	1.0	0	0	0	0	2025-12-28	46.0	801.0	Female	75.0	REMICADE	breast conserving surgery	1	0	0.0	Adult	CA	0.0	3	0	25	0	0	0	0	0	0	0	3	2025	12	28	6	0.08936301793444651	0.0	0.0
597	25385478	JP	JP	1	1.0	1	0	0	0	2025-06-02	70.0	801.0	Male	75.0	KEYTRUDA	myocarditis	1	5	0.35714285714285715	Senior	JP	0.11904761904761905	3	0	11	0	0	0	0	0	0	0	1	2025	6	2	0	0.08073634859349145	8.333333333333334	0.0
598	25389056	US	US	1	2.0	0	0	0	0	2025-06-03	57.0	801.0	Female	75.0	LEVALBUTEROL TARTRATE	product ineffective	0	0	0.0	MidAge	US	0.0	1	0	19	0	0	0	0	0	0	0	2	2025	6	3	1	0.08073634859349145	0.0	0.0
599	25407295	US	US	2	1.0	1	0	0	0	2025-06-06	69.0	801.0	Male	75.0	CILTACABTAGENE AUTOLEUCEL	neoplasm malignant	1	5	0.35714285714285715	Senior	US	0.17857142857142858	2	1	18	0	0	0	0	0	0	0	2	2025	6	6	4	0.08936301793444651	12.321428571428571	0.0
600	25423495	US	Unknown	1	1.0	0	0	0	0	2025-06-11	51.0	801.0	Female	75.0	CIMZIA	rheumatoid arthritis	1	0	0.0	MidAge	US	0.5	2	1	20	0	0	0	0	0	0	0	2	2025	6	11	2	0.08073634859349145	25.5	0.5
601	25424319	US	US	1	2.0	0	0	0	0	2025-06-11	22.0	801.0	Female	75.0	DUPIXENT	mental status changes	0	0	0.0	Young	US	0.015513897866839042	221	0	21	0	0	0	0	0	0	0	3	2025	6	11	2	0.08073634859349145	0.3413057530704589	0.015513897866839042
602	25427330	JP	JP	1	1.0	0	0	1	0	2025-06-12	65.0	801.0	Female	75.0	TECENTRIQ	pneumothorax	1	3	0.21428571428571427	MidAge	JP	0.14285714285714285	3	1	12	0	0	0	0	0	0	0	1	2025	6	12	3	0.08073634859349145	9.285714285714285	0.14285714285714285
603	25431623	US	US	2	1.0	0	0	0	0	2025-06-13	57.0	801.0	Female	75.0	NUPLAZID	glaucoma	1	0	0.0	MidAge	US	0.09523809523809523	6	0	8	0	0	0	0	0	0	0	1	2025	6	13	4	0.08936301793444651	5.428571428571428	0.09523809523809523
604	25437737	US	US	1	1.0	0	0	0	0	2025-06-16	35.0	801.0	Female	75.0	MYCOPHENOLATE MOFETIL	abortion spontaneous	1	0	0.0	Young	US	0.10150375939849625	19	0	20	0	0	0	0	0	0	0	2	2025	6	16	0	0.08073634859349145	3.5526315789473686	0.10150375939849625
605	25440977	US	Unknown	1	2.0	0	0	0	0	2025-06-16	57.0	801.0	Female	75.0	BIMZELX	product leakage	0	0	0.0	MidAge	US	0.0	22	0	15	0	0	0	0	0	0	0	2	2025	6	16	0	0.08073634859349145	0.0	0.0
606	25444016	US	Unknown	1	1.0	0	0	0	0	2025-06-17	57.0	801.0	Female	75.0	BIMZELX	pruritus	1	0	0.0	MidAge	US	0.0	22	0	8	0	0	0	0	0	0	0	1	2025	6	17	1	0.08073634859349145	0.0	0.0
607	25444164	US	Unknown	1	2.0	0	0	0	0	2025-06-17	45.0	801.0	Female	75.0	BIMZELX	hidradenitis	0	0	0.0	Adult	US	0.0	22	0	12	0	0	0	0	0	0	0	1	2025	6	17	1	0.08073634859349145	0.0	0.0
608	19001201	CA	CA	1	1.0	1	0	0	0	2021-03-12	34.0	801.0	Female	81.0	DUAC	maternal exposure during pregnancy	1	5	0.35714285714285715	Young	CA	0.35714285714285715	1	1	34	0	0	0	0	0	0	0	4	2021	3	12	4	0.08073634859349145	12.142857142857142	0.35714285714285715
609	19042011	CA	CA	2	1.0	0	0	0	0	2021-03-22	74.0	801.0	Female	75.0	VEDOLIZUMAB	crohn^s disease	1	0	0.0	Senior	CA	0.057692307692307696	26	0	15	0	0	0	0	0	0	0	2	2021	3	22	0	0.08936301793444651	4.269230769230769	0.057692307692307696
610	19330477	JP	JP	2	1.0	1	0	1	0	2021-05-28	60.0	801.0	Male	75.0	LEUPROLIDE ACETATE	hepatic cirrhosis	1	8	0.5714285714285714	MidAge	JP	0.38095238095238093	3	1	17	0	0	0	0	0	0	0	2	2021	5	28	4	0.08936301793444651	22.857142857142854	0.0
611	19760478	EU	EU	1	1.0	1	0	0	0	2021-08-30	62.0	801.0	Male	75.0	IRINOTECAN	tumour lysis syndrome	1	5	0.35714285714285715	MidAge	EU	0.35714285714285715	1	1	21	0	0	0	0	0	0	0	3	2021	8	30	0	0.08073634859349145	22.142857142857142	0.0
612	19903309	EU	EU	1	1.0	1	0	1	0	2021-10-01	57.0	801.0	Female	75.0	RITUXIMAB	multiple organ dysfunction syndrome	1	8	0.5714285714285714	MidAge	EU	0.12406015037593986	19	0	35	0	0	0	0	0	0	0	4	2021	10	1	4	0.08073634859349145	7.071428571428572	0.12406015037593986
613	20372475	EU	EU	3	1.0	1	0	1	0	2022-01-25	57.0	801.0	Female	75.0	LEVOFLOXACIN	condition aggravated	1	8	0.5714285714285714	MidAge	EU	0.25	4	1	20	0	0	0	0	0	0	0	2	2022	1	25	1	0.17857142857142855	14.25	0.25
614	20595588	AU	AU	1	1.0	0	0	1	0	2022-03-15	37.0	801.0	Male	75.0	CLOZARIL	hospitalisation	1	3	0.21428571428571427	Adult	AU	0.10714285714285714	4	0	15	0	0	0	0	0	0	0	1	2022	3	15	1	0.08073634859349145	3.964285714285714	0.0
615	20687713	CA	CA	1	1.0	0	0	0	0	2022-04-08	57.0	801.0	Female	75.0	INFLIXIMAB	blood pressure systolic increased	1	0	0.0	MidAge	CA	0.07142857142857142	9	0	33	0	0	0	0	0	0	0	4	2022	4	8	4	0.08073634859349145	4.071428571428571	0.07142857142857142
616	20934992	US	US	1	2.0	0	0	0	0	2022-06-08	57.0	801.0	Female	75.0	ACTEMRA	arthralgia	0	0	0.0	MidAge	US	0.17857142857142858	6	1	10	0	0	0	0	0	0	0	1	2022	6	8	2	0.08073634859349145	10.178571428571429	0.17857142857142858
617	20957443	AU	AU	2	1.0	0	0	0	0	2022-06-14	55.0	801.0	Female	75.0	TEDUGLUTIDE	renal impairment	1	0	0.0	MidAge	AU	0.14285714285714285	3	1	16	0	0	0	0	0	0	0	2	2022	6	14	1	0.08936301793444651	7.857142857142857	0.14285714285714285
618	21290596	EU	EU	1	1.0	0	0	1	0	2022-09-03	72.0	801.0	Female	75.0	LEVOFLOXACIN	acinetobacter infection	1	3	0.21428571428571427	Senior	EU	0.25	4	1	23	0	1	0	0	0	0	0	2	2022	9	3	5	0.08073634859349145	18.0	0.25
619	26092923	EU	EU	1	1.0	0	0	1	0	2025-11-26	72.0	801.0	Female	75.0	TRASTUZUMAB	pneumonia	1	3	0.21428571428571427	Senior	EU	0.21428571428571427	1	1	9	0	0	0	0	0	1	0	1	2025	11	26	2	0.08073634859349145	15.428571428571427	0.21428571428571427
620	25624102	US	US	1	2.0	0	0	0	0	2025-07-30	59.0	801.0	Female	75.0	DUPIXENT	asthma	0	0	0.0	MidAge	US	0.015513897866839042	221	0	6	0	0	0	0	0	0	0	1	2025	7	30	2	0.08073634859349145	0.9153199741435035	0.015513897866839042
621	25628487	JP	JP	1	1.0	1	0	1	0	2025-07-31	73.0	801.0	Male	75.0	DEFITELIO	sepsis	1	8	0.5714285714285714	Senior	JP	0.5714285714285714	1	1	6	0	0	0	0	0	0	0	1	2025	7	31	3	0.08073634859349145	41.714285714285715	0.0
622	26093652	US	US	1	1.0	0	0	1	0	2025-11-26	57.0	801.0	Female	75.0	CABOMETYX	encephalopathy	1	3	0.21428571428571427	MidAge	US	0.10714285714285714	4	0	14	0	0	0	0	0	0	0	1	2025	11	26	2	0.08073634859349145	6.107142857142857	0.10714285714285714
623	25869196	US	US	1	1.0	0	0	0	0	2025-10-01	69.0	801.0	Male	75.0	GABAPENTIN	adrenal insufficiency	1	0	0.0	Senior	US	0.061224489795918366	7	0	21	0	0	0	0	0	0	0	2	2025	10	1	2	0.08073634859349145	4.224489795918367	0.0
624	25869400	CN	CN	2	1.0	0	0	1	0	2025-10-01	73.0	801.0	Female	50.0	BRENTUXIMAB VEDOTIN	agranulocytosis	1	3	0.21428571428571427	Senior	CN	0.21428571428571427	1	1	15	0	0	0	0	0	0	0	1	2025	10	1	2	0.08936301793444651	15.642857142857142	0.21428571428571427
625	25869587	CN	CN	1	1.0	0	0	0	0	2025-10-01	48.0	801.0	Female	42.4	EPIRUBICIN HYDROCHLORIDE	alanine aminotransferase increased	1	0	0.0	Adult	CN	0.0	1	0	34	0	0	0	0	0	0	0	3	2025	10	1	2	0.08073634859349145	0.0	0.0
626	25870453	US	US	1	2.0	0	0	0	0	2025-10-01	14.0	801.0	Female	75.0	DUPIXENT	white blood cell count increased	0	0	0.0	Child	US	0.015513897866839042	221	0	32	0	0	0	0	0	0	0	5	2025	10	1	2	0.08073634859349145	0.21719457013574658	0.015513897866839042
627	25870534	US	US	1	2.0	0	0	0	0	2025-10-01	57.0	801.0	Male	99.09	DUPIXENT	dry eye	0	0	0.0	MidAge	US	0.015513897866839042	221	0	7	0	0	0	0	0	0	0	2	2025	10	1	2	0.08073634859349145	0.8842921784098254	0.0
628	25872020	US	US	1	2.0	0	0	0	0	2025-10-02	33.0	801.0	Female	75.0	EBGLYSS	food allergy	0	0	0.0	Young	US	0.0	1	0	12	0	0	0	0	0	0	0	2	2025	10	2	3	0.08073634859349145	0.0	0.0
629	25872059	AR	AR	1	1.0	0	0	1	1	2025-10-02	85.0	801.0	Male	75.0	XOLAIR	lower limb fracture	1	5	0.35714285714285715	Senior	Other	0.14285714285714285	4	1	19	0	0	0	0	0	0	0	3	2025	10	2	3	0.08073634859349145	12.142857142857142	0.0
630	25873207	JP	JP	1	1.0	0	0	0	0	2025-10-02	64.0	801.0	Female	75.0	DOCETAXEL	scleroderma	1	0	0.0	MidAge	JP	0.061224489795918366	7	0	11	0	0	0	0	0	0	0	1	2025	10	2	3	0.08073634859349145	3.9183673469387754	0.061224489795918366
631	25873355	EU	EU	1	1.0	0	0	0	0	2025-10-02	81.0	801.0	Male	75.0	PREGABALIN	hepatic cytolysis	1	0	0.0	Senior	EU	0.10714285714285714	6	0	17	0	0	0	0	0	0	0	2	2025	10	2	3	0.08073634859349145	8.678571428571429	0.0
632	25873436	US	US	1	1.0	0	0	0	0	2025-10-02	57.0	801.0	Female	75.0	CRESTOR	atrial fibrillation	1	0	0.0	MidAge	US	0.0	1	0	19	0	0	0	0	0	0	0	2	2025	10	2	3	0.08073634859349145	0.0	0.0
633	25873517	US	US	1	1.0	0	0	1	0	2025-10-02	59.0	801.0	Female	75.0	ENBREL	femur fracture	1	3	0.21428571428571427	MidAge	US	0.21428571428571427	1	1	14	0	0	0	0	0	0	0	2	2025	10	2	3	0.08073634859349145	12.642857142857142	0.21428571428571427
634	25874475	US	Unknown	1	1.0	0	0	0	0	2025-10-02	51.0	801.0	Female	75.0	CALQUENCE	myalgia	1	0	0.0	MidAge	US	0.0	1	0	7	0	0	0	0	0	0	0	1	2025	10	2	3	0.08073634859349145	0.0	0.0
635	25874637	US	US	1	1.0	0	0	1	0	2025-10-02	46.0	801.0	Female	98.0	GAMUNEX-C	dysphagia	1	3	0.21428571428571427	Adult	US	0.21428571428571427	1	1	9	0	0	0	0	0	0	0	1	2025	10	2	3	0.08073634859349145	9.857142857142856	0.21428571428571427
636	25875461	US	US	1	2.0	0	0	0	0	2025-10-03	2.0	801.0	Male	75.0	DUPIXENT	hypersensitivity	0	0	0.0	Child	US	0.015513897866839042	221	0	16	0	0	0	0	0	0	0	1	2025	10	3	4	0.08073634859349145	0.031027795733678084	0.0
637	25875609	US	US	1	2.0	0	0	0	0	2025-10-03	63.0	801.0	Female	75.0	DUPIXENT	accidental exposure to product	0	0	0.0	MidAge	US	0.015513897866839042	221	0	30	0	0	0	0	0	0	0	4	2025	10	3	4	0.08073634859349145	0.9773755656108597	0.015513897866839042
638	25876095	US	US	2	1.0	0	0	0	0	2025-10-03	57.0	801.0	Female	75.0	CREON	hospice care	1	0	0.0	MidAge	US	0.03296703296703297	13	0	12	0	0	0	0	0	0	0	2	2025	10	3	4	0.08936301793444651	1.879120879120879	0.03296703296703297
639	25876204	CA	CA	2	1.0	0	0	0	0	2025-10-03	57.0	801.0	Male	75.0	SKYRIZI	lung neoplasm malignant	1	0	0.0	MidAge	CA	0.051587301587301584	36	0	23	0	0	0	0	0	0	0	3	2025	10	3	4	0.08936301793444651	2.9404761904761902	0.0
640	25877296	GB	GB	1	1.0	0	0	0	0	2025-10-03	67.0	801.0	Female	64.0	APIXABAN	diarrhoea	1	0	0.0	Senior	GB	0.07142857142857142	3	0	9	0	0	0	0	0	0	0	1	2025	10	3	4	0.08073634859349145	4.785714285714286	0.07142857142857142
641	25676749	GB	GB	1	1.0	0	0	0	0	2025-08-13	76.0	801.0	Female	75.0	RITUXIMAB	renal impairment	1	0	0.0	Senior	GB	0.12406015037593986	19	0	16	0	0	0	0	0	0	0	2	2025	8	13	2	0.08073634859349145	9.428571428571429	0.12406015037593986
642	25677397	US	US	1	1.0	0	0	0	0	2025-08-13	13.0	801.0	Female	75.0	DUPIXENT	loss of consciousness	1	0	0.0	Child	US	0.015513897866839042	221	0	21	0	0	0	0	0	0	0	3	2025	8	13	2	0.08073634859349145	0.20168067226890754	0.015513897866839042
643	25677478	US	US	1	1.0	0	0	0	0	2025-08-13	87.0	801.0	Male	75.0	LENALIDOMIDE	anxiety	1	0	0.0	Senior	US	0.15413533834586465	19	1	7	0	0	0	0	0	0	0	1	2025	8	13	2	0.08073634859349145	13.409774436090224	0.0
644	25689695	US	US	1	2.0	0	0	0	0	2025-08-18	77.0	801.0	Female	72.562	ALBUTEROL SULFATE	wrong technique in product usage process	0	0	0.0	Senior	US	0.0	8	0	40	0	0	0	0	0	0	0	6	2025	8	18	0	0.08073634859349145	0.0	0.0
645	25698066	US	US	1	1.0	0	0	1	0	2025-08-19	72.0	801.0	Female	75.0	INCLISIRAN	stevens-johnson syndrome	1	3	0.21428571428571427	Senior	US	0.21428571428571427	1	1	24	0	0	0	0	0	0	0	2	2025	8	19	1	0.08073634859349145	15.428571428571427	0.21428571428571427
646	25698242	US	US	1	2.0	0	0	0	0	2025-08-19	76.0	801.0	Female	75.0	AIMOVIG	injection site bruising	0	0	0.0	Senior	US	0.0	1	0	23	0	0	0	0	0	0	0	3	2025	8	19	1	0.08073634859349145	0.0	0.0
647	25700943	US	US	1	2.0	0	0	0	0	2025-08-19	10.0	801.0	Female	75.0	DUPIXENT	skin abrasion	0	0	0.0	Child	US	0.015513897866839042	221	0	13	0	0	0	0	0	0	0	2	2025	8	19	1	0.08073634859349145	0.1551389786683904	0.015513897866839042
648	25701577	US	US	1	1.0	0	0	0	0	2025-08-19	64.0	801.0	Female	75.0	BASAGLAR	cerebrovascular accident	1	0	0.0	MidAge	US	0.0	2	0	24	0	0	0	0	0	0	0	2	2025	8	19	1	0.08073634859349145	0.0	0.0
649	25703616	US	US	3	2.0	0	0	0	0	2025-08-20	57.0	801.0	Female	75.0	AVMAPKI FAKZYNJA CO-PACK	product dose omission issue	0	0	0.0	MidAge	US	0.0	2	0	27	0	0	0	0	0	0	0	4	2025	8	20	2	0.17857142857142855	0.0	0.0
650	25703630	US	US	1	2.0	0	0	0	0	2025-08-20	57.0	801.0	Female	75.0	AVMAPKI FAKZYNJA CO-PACK	ear discomfort	0	0	0.0	MidAge	US	0.0	2	0	14	0	0	0	0	0	0	0	2	2025	8	20	2	0.08073634859349145	0.0	0.0
651	25704493	US	US	1	2.0	0	0	0	0	2025-08-20	47.0	801.0	Male	75.0	COSENTYX	device malfunction	0	0	0.0	Adult	US	0.05714285714285714	10	0	18	0	0	0	0	0	0	0	2	2025	8	20	2	0.08073634859349145	2.6857142857142855	0.0
652	25709582	US	US	1	2.0	0	0	0	0	2025-08-21	57.0	801.0	Female	75.0	PLUVICTO	general physical health deterioration	0	0	0.0	MidAge	US	0.0	8	0	37	0	0	0	0	0	0	0	4	2025	8	21	3	0.08073634859349145	0.0	0.0
653	25710339	US	US	1	2.0	0	0	0	0	2025-08-21	57.0	801.0	Female	75.0	MIRENA	condition aggravated	0	0	0.0	MidAge	US	0.0	1	0	20	0	0	0	0	0	0	0	2	2025	8	21	3	0.08073634859349145	0.0	0.0
654	25712364	US	US	1	2.0	0	0	0	0	2025-08-21	10.0	801.0	Female	30.84	GENOTROPIN	product reconstitution quality issue	0	0	0.0	Child	US	0.0	1	0	36	0	0	0	0	0	0	0	4	2025	8	21	3	0.08073634859349145	0.0	0.0
655	22935544	CA	CA	1	1.0	0	0	0	0	2023-09-12	45.0	801.0	Male	75.0	ABRILADA	lumbar vertebral fracture	1	0	0.0	Adult	CA	0.0	1	0	25	0	0	0	0	0	0	0	3	2023	9	12	1	0.08073634859349145	0.0	0.0
656	23140921	US	US	2	1.0	0	0	0	0	2023-11-03	25.0	801.0	Female	68.0	HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN	autism spectrum disorder	1	0	0.0	Young	US	0.07142857142857142	3	0	24	0	0	0	0	0	0	0	3	2023	11	3	4	0.08936301793444651	1.7857142857142856	0.07142857142857142
657	23187306	US	US	1	1.0	0	0	1	0	2023-11-15	84.0	801.0	Female	75.0	DUPIXENT	dehydration	1	3	0.21428571428571427	Senior	US	0.015513897866839042	221	0	11	0	0	0	0	0	0	0	1	2023	11	15	2	0.08073634859349145	1.3031674208144794	0.015513897866839042
658	23187979	US	US	1	2.0	0	0	0	0	2023-11-15	78.0	801.0	Female	75.0	XELJANZ XR	respiratory disorder	0	0	0.0	Senior	US	0.0	9	0	20	0	0	0	0	0	0	0	2	2023	11	15	2	0.08073634859349145	0.0	0.0
659	23241361	IN	IN	1	1.0	0	0	0	0	2023-11-29	75.0	801.0	Female	60.2	LORLATINIB	cardiac failure congestive	1	0	0.0	Senior	IN	0.0	1	0	26	0	0	0	0	1	0	0	3	2023	11	29	2	0.08073634859349145	0.0	0.0
660	23252606	EU	EU	2	1.0	0	0	0	0	2023-12-01	39.0	801.0	Female	75.0	HIZENTRA	pericarditis	1	0	0.0	Adult	EU	0.0	1	0	12	0	0	0	0	0	0	0	1	2023	12	1	4	0.08936301793444651	0.0	0.0
661	23306538	US	US	1	1.0	0	0	0	0	2023-12-18	70.0	801.0	Male	75.0	BORTEZOMIB	autonomic neuropathy	1	0	0.0	Senior	US	0.0	3	0	20	0	0	0	0	0	0	0	2	2023	12	18	0	0.08073634859349145	0.0	0.0
662	23340329	US	US	1	2.0	0	0	0	0	2023-12-27	31.0	801.0	Female	61.678	DUPIXENT	rash	0	0	0.0	Young	US	0.015513897866839042	221	0	4	0	0	0	0	0	0	0	1	2023	12	27	2	0.08073634859349145	0.4809308338720103	0.015513897866839042
663	23360202	CA	CA	1	1.0	0	0	1	0	2024-01-03	45.0	801.0	Female	95.0	ASPIRIN	full blood count abnormal	1	3	0.21428571428571427	Adult	CA	0.21428571428571427	1	1	25	0	0	0	0	0	0	0	4	2024	1	3	2	0.08073634859349145	9.642857142857142	0.21428571428571427
664	23497508	US	US	1	2.0	0	0	0	0	2024-02-08	13.0	801.0	Male	56.0	DUPIXENT	off label use	0	0	0.0	Child	US	0.015513897866839042	221	0	13	0	0	0	0	0	0	0	3	2024	2	8	3	0.08073634859349145	0.20168067226890754	0.0
665	23638800	IN	IN	1	1.0	0	0	0	0	2024-03-15	59.0	801.0	Female	75.0	DACOMITINIB	skin disorder	1	0	0.0	MidAge	IN	0.0	1	0	13	0	0	0	0	0	0	0	2	2024	3	15	4	0.08073634859349145	0.0	0.0
666	23699494	JP	JP	1	1.0	1	0	0	0	2024-04-02	57.0	801.0	Male	75.0	YERVOY	acute myocardial infarction	1	5	0.35714285714285715	MidAge	JP	0.35714285714285715	4	1	27	0	0	0	0	0	0	0	3	2024	4	2	1	0.08073634859349145	20.357142857142858	0.0
667	26098808	EU	EU	1	1.0	0	0	0	0	2025-11-27	28.0	801.0	Female	75.0	MYCOPHENOLATE MOFETIL	transplant rejection	1	0	0.0	Young	EU	0.10150375939849625	19	0	20	0	0	0	0	0	0	0	2	2025	11	27	3	0.08073634859349145	2.842105263157895	0.10150375939849625
668	26098970	GB	GB	1	1.0	0	0	0	0	2025-11-27	70.0	801.0	Male	99.0	AMITRIPTYLINE	depression	1	0	0.0	Senior	GB	0.0	1	0	10	0	0	0	0	0	0	0	1	2025	11	27	3	0.08073634859349145	0.0	0.0
669	26099322	US	US	1	1.0	0	0	1	0	2025-11-28	77.0	801.0	Female	75.0	DUPIXENT	sciatica	1	3	0.21428571428571427	Senior	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	1	2025	11	28	4	0.08073634859349145	1.1945701357466063	0.015513897866839042
670	26099780	AE	AE	1	1.0	0	0	0	0	2025-11-28	30.0	801.0	Male	75.0	OLANZAPINE	thrombocytopenia	1	0	0.0	Young	Other	0.11904761904761905	6	0	16	0	0	0	0	0	0	0	1	2025	11	28	4	0.08073634859349145	3.5714285714285716	0.0
671	26100121	US	US	1	2.0	0	0	0	0	2025-11-28	68.0	801.0	Male	86.7	ZYTIGA	aspartate aminotransferase increased	0	0	0.0	Senior	US	0.0	1	0	36	0	0	0	0	0	0	0	3	2025	11	28	4	0.08073634859349145	0.0	0.0
672	26100389	US	US	1	1.0	0	1	1	0	2025-11-28	60.0	801.0	Female	38.0	LIDOCAINE	generalised tonic-clonic seizure	1	7	0.5	MidAge	US	0.5	1	1	32	0	0	0	0	0	0	0	3	2025	11	28	4	0.08073634859349145	30.0	0.5
673	25878349	US	US	1	2.0	0	0	0	0	2025-10-03	25.0	801.0	Male	75.0	EPCLUSA	inappropriate schedule of product administration	0	0	0.0	Young	US	0.0	1	0	48	0	0	0	0	0	0	0	5	2025	10	3	4	0.08073634859349145	0.0	0.0
674	25879335	US	US	2	2.0	0	0	0	0	2025-10-03	57.0	801.0	Female	75.0	SKYRIZI	unevaluable event	0	0	0.0	MidAge	US	0.051587301587301584	36	0	17	0	0	0	0	0	0	0	2	2025	10	3	4	0.08936301793444651	2.9404761904761902	0.051587301587301584
675	25879483	US	US	1	2.0	0	0	0	0	2025-10-03	57.0	801.0	Female	75.0	ORENCIA	loss of therapeutic response	0	0	0.0	MidAge	US	0.10204081632653061	14	0	28	0	0	0	0	0	0	0	4	2025	10	3	4	0.08073634859349145	5.816326530612245	0.10204081632653061
676	26114902	EU	EU	1	1.0	0	0	1	0	2025-12-03	72.0	801.0	Female	94.0	AMLODIPINE	cough	1	3	0.21428571428571427	Senior	EU	0.16964285714285715	8	1	5	0	0	0	0	0	0	0	1	2025	12	3	2	0.08073634859349145	12.214285714285715	0.16964285714285715
677	26115941	EU	EU	1	1.0	1	0	0	0	2025-12-03	70.0	801.0	Male	73.0	OPDIVO	immune-mediated myocarditis	1	5	0.35714285714285715	Senior	EU	0.08928571428571429	4	0	27	0	0	0	0	0	0	0	2	2025	12	3	2	0.08073634859349145	6.25	0.0
678	25806715	US	US	1	2.0	0	0	0	0	2025-09-16	92.0	801.0	Male	73.923	TYVASO DPI	haemoglobin increased	0	0	0.0	Senior	US	0.0	4	0	21	0	0	0	0	0	0	0	2	2025	9	16	1	0.08073634859349145	0.0	0.0
679	25810145	US	US	1	2.0	0	0	0	0	2025-09-17	29.0	801.0	Male	75.0	DUPIXENT	dry skin	0	0	0.0	Young	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	2	2025	9	17	2	0.08073634859349145	0.4499030381383322	0.0
680	25811832	US	US	1	2.0	0	0	0	0	2025-09-17	43.0	801.0	Female	75.0	TOLVAPTAN	nausea	0	0	0.0	Adult	US	0.0	1	0	6	0	0	0	0	0	0	0	1	2025	9	17	2	0.08073634859349145	0.0	0.0
681	25812547	US	US	1	2.0	0	0	0	0	2025-09-17	41.0	801.0	Male	75.0	TRUVADA	tooth loss	0	0	0.0	Adult	US	0.0	1	0	10	0	0	0	0	0	0	0	2	2025	9	17	2	0.08073634859349145	0.0	0.0
682	25897870	US	US	1	2.0	0	0	0	0	2025-10-08	56.0	801.0	Male	75.0	XELJANZ	back pain	0	0	0.0	MidAge	US	0.0	3	0	9	1	0	0	0	0	0	0	2	2025	10	8	2	0.08073634859349145	0.0	0.0
683	25898451	EU	EU	1	1.0	0	0	0	0	2025-10-09	76.0	801.0	Female	70.0	CARBOPLATIN	diarrhoea	1	0	0.0	Senior	EU	0.12244897959183673	7	0	9	0	0	0	0	0	0	0	1	2025	10	9	3	0.08073634859349145	9.306122448979592	0.12244897959183673
684	25900222	AU	Unknown	1	1.0	1	0	0	0	2025-10-09	52.0	801.0	Female	75.0	MIRTAZAPINE	completed suicide	1	5	0.35714285714285715	MidAge	AU	0.19047619047619047	3	1	17	0	0	0	0	0	0	0	2	2025	10	9	3	0.08073634859349145	9.904761904761905	0.19047619047619047
685	25900437	EU	EU	1	1.0	0	0	1	0	2025-10-09	73.0	801.0	Female	75.0	ETOPOSIDE	condition aggravated	1	3	0.21428571428571427	Senior	EU	0.21428571428571427	2	1	20	0	0	0	0	0	0	0	2	2025	10	9	3	0.08073634859349145	15.642857142857142	0.21428571428571427
686	25901409	US	Unknown	1	1.0	0	0	1	0	2025-10-09	75.0	801.0	Female	66.68	ZILBRYSQ	pneumonia fungal	1	3	0.21428571428571427	Senior	US	0.10714285714285714	2	0	16	0	0	0	0	0	1	0	2	2025	10	9	3	0.08073634859349145	8.035714285714285	0.10714285714285714
687	26119910	US	US	1	2.0	0	0	0	0	2025-12-04	7.0	801.0	Female	49.8	DUPIXENT	eczema	0	0	0.0	Child	US	0.015513897866839042	221	0	6	0	0	0	0	0	0	0	1	2025	12	4	3	0.08073634859349145	0.10859728506787329	0.015513897866839042
688	26120086	US	US	2	1.0	0	0	0	0	2025-12-04	72.0	801.0	Female	75.0	SKYRIZI	skin cancer	1	0	0.0	Senior	US	0.051587301587301584	36	0	11	0	0	0	1	0	0	0	2	2025	12	4	3	0.08936301793444651	3.714285714285714	0.051587301587301584
689	26120572	US	US	1	2.0	0	0	0	0	2025-12-04	44.0	801.0	Male	75.0	LEVETIRACETAM	drug ineffective for unapproved indication	0	0	0.0	Adult	US	0.05714285714285714	5	0	42	0	0	0	0	0	0	0	5	2025	12	4	3	0.08073634859349145	2.5142857142857142	0.0
690	26121692	EU	EU	1	1.0	0	0	0	0	2025-12-04	50.0	801.0	Female	80.0	CLINDAMYCIN	suicide attempt	1	0	0.0	Adult	EU	0.0	1	0	15	0	0	0	0	0	0	0	2	2025	12	4	3	0.08073634859349145	0.0	0.0
691	25819351	US	US	1	2.0	0	0	0	0	2025-09-18	60.0	801.0	Female	75.0	DUPIXENT	osteoporosis	0	0	0.0	MidAge	US	0.015513897866839042	221	0	12	0	0	0	0	0	0	0	1	2025	9	18	3	0.08073634859349145	0.9308338720103425	0.015513897866839042
692	25821848	US	US	2	2.0	0	0	0	0	2025-09-19	57.0	801.0	Female	75.0	DAYBUE	insomnia	0	0	0.0	MidAge	US	0.0	1	0	8	0	0	0	0	0	0	0	1	2025	9	19	4	0.08936301793444651	0.0	0.0
693	25827222	EU	EU	1	1.0	0	0	0	0	2025-09-20	57.0	801.0	Female	75.0	CYCLOSPORINE	inappropriate antidiuretic hormone secretion	1	0	0.0	MidAge	EU	0.0	5	0	44	0	0	0	0	0	0	0	4	2025	9	20	5	0.08073634859349145	0.0	0.0
694	25828032	US	US	1	1.0	0	0	0	0	2025-09-21	78.0	801.0	Female	75.0	ORENCIA	product storage error	1	0	0.0	Senior	US	0.10204081632653061	14	0	21	0	0	0	0	0	0	0	3	2025	9	21	6	0.08073634859349145	7.959183673469388	0.10204081632653061
695	25831797	EU	EU	2	1.0	0	0	1	0	2025-09-22	43.0	801.0	Male	75.0	COSENTYX	crohn^s disease	1	3	0.21428571428571427	Adult	EU	0.05714285714285714	10	0	15	0	0	0	0	0	0	0	2	2025	9	22	0	0.08936301793444651	2.457142857142857	0.0
696	25833498	NG	NG	1	1.0	1	0	1	0	2025-09-22	35.0	801.0	Male	75.0	GLIVEC	death	1	8	0.5714285714285714	Young	Other	0.5714285714285714	1	1	5	0	0	1	0	0	0	0	1	2025	9	22	0	0.08073634859349145	20.0	0.0
697	24232935	CA	CA	1	1.0	0	0	0	0	2024-08-21	36.0	801.0	Female	75.0	DICLOFENAC POTASSIUM	ankylosing spondylitis	1	0	0.0	Adult	CA	0.0	1	0	22	0	0	0	0	0	0	0	2	2024	8	21	2	0.08073634859349145	0.0	0.0
698	24238348	US	US	3	2.0	0	0	0	0	2024-08-22	57.0	801.0	Male	75.0	FILSPARI	blepharospasm	0	0	0.0	MidAge	US	0.0	4	0	13	0	0	0	0	0	0	0	1	2024	8	22	3	0.17857142857142855	0.0	0.0
699	24239253	US	US	3	2.0	0	0	0	0	2024-08-22	45.0	801.0	Female	75.0	FILSPARI	dizziness	0	0	0.0	Adult	US	0.0	4	0	9	0	0	0	0	0	0	0	1	2024	8	22	3	0.17857142857142855	0.0	0.0
700	24249540	US	US	1	2.0	0	0	0	0	2024-08-26	57.0	801.0	Male	113.38	DUPIXENT	dry skin	0	0	0.0	MidAge	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	2	2024	8	26	0	0.08073634859349145	0.8842921784098254	0.0
701	24319982	US	US	2	2.0	0	0	0	0	2024-09-14	44.0	801.0	Female	75.0	VEDOLIZUMAB	product dose omission issue	0	0	0.0	Adult	US	0.057692307692307696	26	0	27	0	0	0	0	0	0	0	4	2024	9	14	5	0.08936301793444651	2.5384615384615388	0.057692307692307696
702	24375157	EU	EU	1	1.0	0	0	0	0	2024-09-28	36.0	801.0	Male	75.0	PRAVASTATIN SODIUM	dizziness	1	0	0.0	Adult	EU	0.0	1	0	9	0	0	0	0	0	0	0	1	2024	9	28	5	0.08073634859349145	0.0	0.0
703	24393988	US	US	2	1.0	0	0	0	0	2024-10-03	70.0	801.0	Female	75.0	CREON	hip fracture	1	0	0.0	Senior	US	0.03296703296703297	13	0	12	0	0	0	0	0	0	0	2	2024	10	3	3	0.08936301793444651	2.307692307692308	0.03296703296703297
704	24427511	US	US	1	2.0	0	0	0	0	2024-10-11	2.0	801.0	Male	75.0	DUPIXENT	rhinorrhoea	0	0	0.0	Child	US	0.015513897866839042	221	0	11	0	0	0	0	0	0	0	1	2024	10	11	4	0.08073634859349145	0.031027795733678084	0.0
705	24432991	US	US	1	2.0	0	0	0	0	2024-10-14	57.0	801.0	Female	46.712	DUPIXENT	drug intolerance	0	0	0.0	MidAge	US	0.015513897866839042	221	0	16	0	0	0	0	0	0	0	2	2024	10	14	0	0.08073634859349145	0.8842921784098254	0.015513897866839042
706	24448233	CA	Unknown	2	1.0	0	0	0	0	2024-10-16	57.0	801.0	Female	75.0	CERTOLIZUMAB PEGOL	ankylosing spondylitis	1	0	0.0	MidAge	CA	0.04285714285714286	5	0	22	0	0	0	0	0	0	0	2	2024	10	16	2	0.08936301793444651	2.442857142857143	0.04285714285714286
707	24461531	US	US	1	1.0	0	0	0	0	2024-10-18	37.0	801.0	Female	86.168	BIMZELX	psoriasis	1	0	0.0	Adult	US	0.0	22	0	9	0	0	0	0	0	0	0	1	2024	10	18	4	0.08073634859349145	0.0	0.0
708	24528490	US	US	2	1.0	0	0	0	0	2024-10-21	30.0	801.0	Female	118.37	NURTEC ODT	maternal exposure during pregnancy	1	0	0.0	Young	US	0.0	2	0	34	0	0	0	0	0	0	0	4	2024	10	21	0	0.08936301793444651	0.0	0.0
709	24547969	CA	CA	2	1.0	0	0	1	0	2024-10-25	57.0	801.0	Female	75.0	VEDOLIZUMAB	anal abscess	1	3	0.21428571428571427	MidAge	CA	0.057692307692307696	26	0	12	0	0	0	0	0	0	0	2	2024	10	25	4	0.08936301793444651	3.2884615384615388	0.057692307692307696
710	26122664	US	US	1	1.0	1	0	0	0	2025-12-04	58.0	801.0	Female	75.0	POMALYST	death	1	5	0.35714285714285715	MidAge	US	0.11428571428571428	5	0	5	0	0	1	0	0	0	0	1	2025	12	4	3	0.08073634859349145	6.628571428571428	0.11428571428571428
711	26124756	AU	AU	1	1.0	0	0	0	0	2025-12-05	63.0	801.0	Male	75.0	DARATUMUMAB	thrombocytopenia	1	0	0.0	MidAge	AU	0.14285714285714285	3	1	16	0	0	0	0	0	0	0	1	2025	12	5	4	0.08073634859349145	9.0	0.0
712	25902448	ZA	ZA	2	1.0	0	0	1	0	2025-10-09	53.0	801.0	Male	75.0	BUDESONIDE\FORMOTEROL	cardiac disorder	1	3	0.21428571428571427	MidAge	ZA	0.10714285714285714	2	0	16	0	0	0	0	0	0	0	2	2025	10	9	3	0.08936301793444651	5.678571428571428	0.0
713	25902839	US	US	2	1.0	0	0	0	0	2025-10-09	82.0	801.0	Male	62.0	VENCLEXTA	acute myeloid leukaemia	1	0	0.0	Senior	US	0.18571428571428572	5	1	23	0	0	0	0	0	0	0	3	2025	10	9	3	0.08936301793444651	15.22857142857143	0.0
714	25903878	JP	JP	1	1.0	0	0	1	0	2025-10-10	78.0	801.0	Male	75.0	TREPROSTINIL	dyspnoea	1	3	0.21428571428571427	Senior	JP	0.2857142857142857	2	1	8	0	0	0	0	0	0	0	1	2025	10	10	4	0.08073634859349145	22.285714285714285	0.0
715	25904325	US	US	1	1.0	0	0	0	0	2025-10-10	68.0	801.0	Female	74.83	ALBUTEROL SULFATE	wrong technique in product usage process	1	0	0.0	Senior	US	0.0	8	0	40	0	0	0	0	0	0	0	6	2025	10	10	4	0.08073634859349145	0.0	0.0
716	26127348	US	US	1	1.0	0	0	1	0	2025-12-05	60.0	801.0	Female	75.0	DUPIXENT	staphylococcal infection	1	3	0.21428571428571427	MidAge	US	0.015513897866839042	221	0	24	0	1	0	0	0	0	0	2	2025	12	5	4	0.08073634859349145	0.9308338720103425	0.015513897866839042
717	26127968	JP	JP	1	1.0	0	0	0	0	2025-12-06	4.0	801.0	Female	75.0	LEVETIRACETAM	drug ineffective	1	0	0.0	Child	JP	0.05714285714285714	5	0	16	0	0	0	0	0	0	0	2	2025	12	6	5	0.08073634859349145	0.22857142857142856	0.05714285714285714
718	26128105	US	US	1	2.0	0	0	0	0	2025-12-07	56.0	801.0	Female	75.0	DUPIXENT	vomiting	0	0	0.0	MidAge	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	1	2025	12	7	6	0.08073634859349145	0.8687782805429863	0.015513897866839042
719	26128172	US	US	1	2.0	0	0	0	0	2025-12-07	21.0	801.0	Male	75.0	DUPIXENT	pruritus	0	0	0.0	Young	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	1	2025	12	7	6	0.08073634859349145	0.32579185520361986	0.0
720	26128806	US	US	1	1.0	0	0	0	0	2025-12-08	19.0	801.0	Female	75.0	ISOTRETINOIN	abortion spontaneous	1	0	0.0	Young	US	0.023809523809523808	9	0	20	0	0	0	0	0	0	0	2	2025	12	8	0	0.08073634859349145	0.45238095238095233	0.023809523809523808
721	26129616	AU	AU	1	1.0	0	0	0	0	2025-12-08	57.0	801.0	Female	75.0	CABERGOLINE	blood prolactin increased	1	0	0.0	MidAge	AU	0.0	1	0	25	0	0	0	0	0	0	0	3	2025	12	8	0	0.08073634859349145	0.0	0.0
722	26130588	US	Unknown	1	1.0	0	0	1	0	2025-12-05	57.0	801.0	Female	75.0	VELTASSA	therapy interrupted	1	3	0.21428571428571427	MidAge	US	0.2619047619047619	3	1	19	0	0	0	0	0	0	0	2	2025	12	5	4	0.08073634859349145	14.928571428571429	0.2619047619047619
723	25909872	US	US	1	2.0	0	0	0	0	2025-10-12	57.0	801.0	Female	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	MidAge	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	10	12	6	0.08073634859349145	0.8842921784098254	0.015513897866839042
724	24608222	US	US	1	1.0	0	0	1	0	2024-11-12	65.0	801.0	Female	75.0	IBRANCE	lower limb fracture	1	3	0.21428571428571427	MidAge	US	0.07142857142857142	3	0	19	0	0	0	0	0	0	0	3	2024	11	12	1	0.08073634859349145	4.642857142857142	0.07142857142857142
725	24615040	JP	JP	2	1.0	0	0	0	0	2024-11-13	74.0	801.0	Male	57.9	OPDIVO	immune-mediated enterocolitis	1	0	0.0	Senior	JP	0.08928571428571429	4	0	29	0	0	0	0	0	0	0	2	2024	11	13	2	0.08936301793444651	6.607142857142858	0.0
726	24617185	US	US	1	1.0	0	0	0	0	2024-11-14	29.0	801.0	Female	79.365	PARAGARD T 380A	reproductive complication associated with device	1	0	0.0	Young	US	0.0	4	0	48	0	0	0	0	0	0	0	5	2024	11	14	3	0.08073634859349145	0.0	0.0
727	24620277	US	US	1	2.0	0	0	0	0	2024-11-14	57.0	801.0	Female	75.0	CONTRAVE	headache	0	0	0.0	MidAge	US	0.0	1	0	8	0	0	0	0	0	0	0	1	2024	11	14	3	0.08073634859349145	0.0	0.0
728	24630201	EU	EU	1	1.0	0	0	0	0	2024-11-18	55.0	801.0	Female	75.0	DASATINIB	cytomegalovirus colitis	1	0	0.0	MidAge	EU	0.0	2	0	23	0	0	0	0	0	0	0	2	2024	11	18	0	0.08073634859349145	0.0	0.0
729	24650881	JP	JP	2	1.0	1	0	0	0	2024-11-22	47.0	801.0	Male	58.3	MARIBAVIR	infection	1	5	0.35714285714285715	Adult	JP	0.35714285714285715	1	1	9	0	1	0	0	0	0	0	1	2024	11	22	4	0.08936301793444651	16.785714285714285	0.0
730	24665528	US	US	1	1.0	0	0	0	0	2024-11-26	59.0	801.0	Female	75.0	VONJO	nephrolithiasis	1	0	0.0	MidAge	US	0.0	3	0	15	0	0	0	0	0	0	0	1	2024	11	26	1	0.08073634859349145	0.0	0.0
731	24674829	CA	CA	2	1.0	0	0	1	0	2024-11-28	64.0	801.0	Male	75.0	VEDOLIZUMAB	chronic obstructive pulmonary disease	1	3	0.21428571428571427	MidAge	CA	0.057692307692307696	26	0	37	0	0	0	0	0	0	0	4	2024	11	28	3	0.08936301793444651	3.6923076923076925	0.0
732	24677745	US	US	2	1.0	0	0	1	0	2024-11-29	58.0	801.0	Female	75.0	SKYRIZI	streptococcal infection	1	3	0.21428571428571427	MidAge	US	0.051587301587301584	36	0	23	0	1	0	0	0	0	0	2	2024	11	29	4	0.08936301793444651	2.992063492063492	0.051587301587301584
733	24686521	GB	GB	1	1.0	1	1	0	0	2024-12-02	57.0	801.0	Female	75.0	SILDENAFIL	death	1	9	0.6428571428571429	MidAge	GB	0.6428571428571429	1	1	5	0	0	1	0	0	0	0	1	2024	12	2	0	0.08073634859349145	36.642857142857146	0.6428571428571429
734	24723686	US	US	1	2.0	0	0	0	0	2024-12-11	12.0	801.0	Male	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	Child	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2024	12	11	2	0.08073634859349145	0.1861667744020685	0.0
735	24757720	US	Unknown	1	2.0	0	0	0	0	2024-12-20	44.0	801.0	Female	126.98	BIMZELX	dry skin	0	0	0.0	Adult	US	0.0	22	0	8	0	0	0	0	0	0	0	2	2024	12	20	4	0.08073634859349145	0.0	0.0
736	24757801	US	Unknown	1	2.0	0	0	0	0	2024-12-20	57.0	801.0	Female	79.365	BIMZELX	joint swelling	0	0	0.0	MidAge	US	0.0	22	0	14	0	0	0	0	0	0	0	2	2024	12	20	4	0.08073634859349145	0.0	0.0
737	24757854	US	Unknown	1	2.0	0	0	0	0	2024-12-20	31.0	801.0	Female	75.0	BIMZELX	psoriasis	0	0	0.0	Young	US	0.0	22	0	9	0	0	0	0	0	0	0	1	2024	12	20	4	0.08073634859349145	0.0	0.0
738	24758125	US	US	1	2.0	0	0	0	0	2024-12-20	43.0	801.0	Female	75.0	BIMZELX	fatigue	0	0	0.0	Adult	US	0.0	22	0	7	0	0	0	0	0	0	0	1	2024	12	20	4	0.08073634859349145	0.0	0.0
739	26131493	US	US	2	1.0	1	0	0	0	2025-12-08	79.0	801.0	Male	75.0	VENCLEXTA	death	1	5	0.35714285714285715	Senior	US	0.18571428571428572	5	1	5	0	0	1	0	0	0	0	1	2025	12	8	0	0.08936301793444651	14.671428571428573	0.0
740	26132412	EU	EU	1	1.0	0	0	0	0	2025-12-08	49.0	801.0	Male	75.0	AMLODIPINE BESYLATE	depressed mood	1	0	0.0	Adult	EU	0.0	1	0	14	0	0	0	0	0	0	0	2	2025	12	8	0	0.08073634859349145	0.0	0.0
741	26133060	US	Unknown	2	1.0	0	0	0	0	2025-12-09	67.0	801.0	Female	75.0	LENALIDOMIDE	b-cell type acute leukaemia	1	0	0.0	Senior	US	0.15413533834586465	19	1	27	0	0	0	0	0	0	0	4	2025	12	9	1	0.08936301793444651	10.327067669172932	0.15413533834586465
742	26134409	EU	EU	1	1.0	0	0	1	0	2025-12-09	29.0	801.0	Female	75.0	PREDNISOLONE	blood corticotrophin decreased	1	3	0.21428571428571427	Young	EU	0.35714285714285715	2	1	30	0	0	0	0	0	0	0	3	2025	12	9	1	0.08073634859349145	10.357142857142858	0.35714285714285715
743	25840168	US	US	1	1.0	0	0	0	0	2025-09-24	57.0	801.0	Female	75.0	NUCALA	underdose	1	0	0.0	MidAge	US	0.0	2	0	9	0	0	0	0	0	0	0	1	2025	9	24	2	0.08073634859349145	0.0	0.0
744	25843408	US	US	1	2.0	0	0	0	0	2025-09-24	59.0	801.0	Female	75.0	DUPIXENT	fatigue	0	0	0.0	MidAge	US	0.015513897866839042	221	0	7	0	0	0	0	0	0	0	1	2025	9	24	2	0.08073634859349145	0.9153199741435035	0.015513897866839042
745	25845028	EU	EU	1	1.0	0	0	1	0	2025-09-25	57.0	801.0	Female	75.0	METOPROLOL SUCCINATE	upper respiratory tract infection	1	3	0.21428571428571427	MidAge	EU	0.21428571428571427	1	1	33	0	1	0	0	0	0	0	4	2025	9	25	3	0.08073634859349145	12.214285714285714	0.21428571428571427
746	25851737	IN	IN	2	1.0	0	0	1	0	2025-09-26	65.0	801.0	Female	75.0	PERJETA	off label use	1	3	0.21428571428571427	MidAge	IN	0.21428571428571427	2	1	13	0	0	0	0	0	0	0	3	2025	9	26	4	0.08936301793444651	13.928571428571427	0.21428571428571427
747	25852075	EU	EU	1	1.0	0	0	1	0	2025-09-26	57.0	801.0	Female	75.0	DIAZEPAM	drug ineffective	1	3	0.21428571428571427	MidAge	EU	0.2619047619047619	3	1	16	0	0	0	0	0	0	0	2	2025	9	26	4	0.08073634859349145	14.928571428571429	0.2619047619047619
748	25853519	US	US	1	2.0	0	0	0	0	2025-09-26	57.0	801.0	Female	75.0	JOENJA	ear infection	0	0	0.0	MidAge	US	0.0	3	0	13	0	1	0	0	0	0	0	2	2025	9	26	4	0.08073634859349145	0.0	0.0
749	25854787	US	US	1	2.0	0	0	0	0	2025-09-27	75.0	801.0	Female	62.142	CREON	paraesthesia	0	0	0.0	Senior	US	0.03296703296703297	13	0	12	0	0	0	0	0	0	0	1	2025	9	27	5	0.08073634859349145	2.4725274725274726	0.03296703296703297
750	26134733	EU	EU	1	1.0	0	0	1	0	2025-12-09	63.0	801.0	Male	75.0	CYCLOPHOSPHAMIDE	sars-cov-2 test positive	1	3	0.21428571428571427	MidAge	EU	0.21428571428571427	2	1	24	0	0	0	0	0	0	0	3	2025	12	9	1	0.08073634859349145	13.5	0.0
751	26135381	US	US	1	2.0	0	0	0	0	2025-12-09	57.0	801.0	Female	68.027	ESTRADIOL	product ineffective	0	0	0.0	MidAge	US	0.0	8	0	19	0	0	0	0	0	0	0	2	2025	12	9	1	0.08073634859349145	0.0	0.0
752	26136610	US	US	1	2.0	0	0	0	0	2025-12-09	57.0	801.0	Female	75.0	RYBREVANT	adverse event	0	0	0.0	MidAge	US	0.05357142857142857	4	0	13	0	0	0	0	0	0	0	2	2025	12	9	1	0.08073634859349145	3.0535714285714284	0.05357142857142857
753	26138311	US	Unknown	2	1.0	1	0	0	0	2025-12-10	57.0	801.0	Female	75.0	LENALIDOMIDE	death	1	5	0.35714285714285715	MidAge	US	0.15413533834586465	19	1	5	0	0	1	0	0	0	0	1	2025	12	10	2	0.08936301793444651	8.785714285714285	0.15413533834586465
754	25917123	CA	CA	1	1.0	0	0	1	0	2025-10-14	57.0	801.0	Female	75.0	INFLIXIMAB	faecal vomiting	1	3	0.21428571428571427	MidAge	CA	0.07142857142857142	9	0	15	0	0	0	0	0	0	0	2	2025	10	14	1	0.08073634859349145	4.071428571428571	0.07142857142857142
755	25918539	EU	EU	1	1.0	0	0	1	0	2025-10-14	17.0	801.0	Female	75.0	PREGABALIN	drug use disorder	1	3	0.21428571428571427	Child	EU	0.10714285714285714	6	0	17	0	0	0	0	0	0	0	3	2025	10	14	1	0.08073634859349145	1.8214285714285714	0.10714285714285714
756	25862591	EU	EU	1	1.0	0	0	1	0	2025-09-30	78.0	801.0	Male	170.0	RITONAVIR	confusional state	1	3	0.21428571428571427	Senior	EU	0.21428571428571427	1	1	17	0	0	0	0	0	0	0	2	2025	9	30	1	0.08073634859349145	16.71428571428571	0.0
757	25866937	US	US	1	2.0	0	0	0	0	2025-10-01	72.0	801.0	Female	64.853	TYVASO	dyspnoea	0	0	0.0	Senior	US	0.0	2	0	8	0	0	0	0	0	0	0	1	2025	10	1	2	0.08073634859349145	0.0	0.0
758	25867895	US	US	1	1.0	0	0	0	1	2025-10-01	58.0	801.0	Female	75.0	CARBOPLATIN	deafness	1	2	0.14285714285714285	MidAge	US	0.12244897959183673	7	0	8	0	0	0	0	0	0	0	1	2025	10	1	2	0.08073634859349145	7.1020408163265305	0.12244897959183673
759	25868180	US	US	2	1.0	0	0	1	0	2025-10-01	72.0	801.0	Male	75.0	SKYRIZI	balance disorder	1	3	0.21428571428571427	Senior	US	0.051587301587301584	36	0	16	0	0	0	0	0	0	0	2	2025	10	1	2	0.08936301793444651	3.714285714285714	0.0
760	25868490	US	US	1	2.0	0	0	0	0	2025-10-01	57.0	801.0	Female	75.0	SYMBICORT	cough	0	0	0.0	MidAge	US	0.0	2	0	5	0	0	0	0	0	0	0	1	2025	10	1	2	0.08073634859349145	0.0	0.0
761	25918634	US	Unknown	1	2.0	0	0	0	0	2025-10-10	57.0	801.0	Female	75.0	ZYPREXA	treatment failure	0	0	0.0	MidAge	US	0.0	1	0	17	0	0	0	0	1	0	0	2	2025	10	10	4	0.08073634859349145	0.0	0.0
762	25918810	US	US	1	2.0	0	0	0	0	2025-10-14	57.0	801.0	Female	75.0	ESTRADIOL	device adhesion issue	0	0	0.0	MidAge	US	0.0	8	0	21	0	0	0	0	0	0	0	3	2025	10	14	1	0.08073634859349145	0.0	0.0
763	25919701	ZA	ZA	2	1.0	0	0	1	0	2025-10-14	54.0	801.0	Male	75.0	INSULIN GLARGINE	gangrene	1	3	0.21428571428571427	MidAge	ZA	0.21428571428571427	1	1	8	0	0	0	0	0	0	0	1	2025	10	14	1	0.08936301793444651	11.571428571428571	0.0
764	25920310	CA	CA	1	1.0	0	0	0	0	2025-10-14	8.0	801.0	Male	75.0	MYCOPHENOLATE MOFETIL	post transplant lymphoproliferative disorder	1	0	0.0	Child	CA	0.10150375939849625	19	0	44	0	0	0	0	0	0	0	4	2025	10	14	1	0.08073634859349145	0.81203007518797	0.0
765	25921335	US	US	1	2.0	0	0	0	0	2025-10-14	62.0	801.0	Female	98.41	KEVZARA	inflammation	0	0	0.0	MidAge	US	0.14285714285714285	4	1	12	0	0	0	0	0	0	0	1	2025	10	14	1	0.08073634859349145	8.857142857142856	0.14285714285714285
766	25921779	US	US	1	2.0	0	0	0	0	2025-10-14	57.0	801.0	Male	80.907	TYVASO DPI	inappropriate schedule of product administration	0	0	0.0	MidAge	US	0.0	4	0	48	0	0	0	0	0	0	0	5	2025	10	14	1	0.08073634859349145	0.0	0.0
767	25922536	US	US	1	2.0	0	0	0	0	2025-10-15	57.0	801.0	Female	75.0	IQIRVO	nausea	0	0	0.0	MidAge	US	0.0	2	0	6	0	0	0	0	0	0	0	1	2025	10	15	2	0.08073634859349145	0.0	0.0
768	25922927	US	US	1	2.0	0	0	0	0	2025-10-15	18.0	801.0	Male	75.0	DUPIXENT	rash erythematous	0	0	0.0	Child	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	10	15	2	0.08073634859349145	0.27925016160310273	0.0
769	25869772	US	US	1	2.0	0	0	0	0	2025-10-01	57.0	801.0	Female	75.0	XEOMIN	drug ineffective	0	0	0.0	MidAge	US	0.08928571428571429	4	0	16	0	0	0	0	0	0	0	2	2025	10	1	2	0.08073634859349145	5.089285714285714	0.08928571428571429
770	25871191	EU	EU	1	1.0	0	1	1	0	2025-10-01	71.0	801.0	Female	75.0	MYCOPHENOLATE MOFETIL	meningitis listeria	1	7	0.5	Senior	EU	0.10150375939849625	19	0	19	0	0	0	0	0	0	0	2	2025	10	1	2	0.08073634859349145	7.206766917293233	0.10150375939849625
771	25872244	US	US	1	2.0	0	0	0	0	2025-10-02	57.0	801.0	Female	75.0	DUPIXENT	injection site pain	0	0	0.0	MidAge	US	0.015513897866839042	221	0	19	1	0	0	0	0	0	0	3	2025	10	2	3	0.08073634859349145	0.8842921784098254	0.015513897866839042
772	25874565	IN	IN	1	1.0	0	0	0	0	2025-10-02	21.0	801.0	Male	75.0	ACETAMINOPHEN	acute generalised exanthematous pustulosis	1	0	0.0	Young	IN	0.10267857142857142	16	0	42	0	0	0	0	0	0	0	4	2025	10	2	3	0.08073634859349145	2.15625	0.0
773	25875012	US	US	1	1.0	0	0	0	0	2025-10-02	79.0	801.0	Female	75.3	REVLIMID	rash	1	0	0.0	Senior	US	0.05357142857142857	4	0	4	0	0	0	0	0	0	0	1	2025	10	2	3	0.08073634859349145	4.232142857142857	0.05357142857142857
774	25875713	US	US	1	2.0	0	0	0	0	2025-10-03	83.0	801.0	Female	75.0	DUPIXENT	dyspnoea	0	0	0.0	Senior	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	1	2025	10	3	4	0.08073634859349145	1.2876535229476405	0.015513897866839042
775	25876361	US	US	2	1.0	0	0	1	0	2025-10-03	68.0	801.0	Female	75.0	TREMFYA	spinal stenosis	1	3	0.21428571428571427	Senior	US	0.10714285714285714	2	0	15	0	0	0	0	0	0	0	2	2025	10	3	4	0.08936301793444651	7.285714285714286	0.10714285714285714
776	25876914	US	US	1	2.0	0	0	0	0	2025-10-03	57.0	801.0	Female	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	MidAge	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	10	3	4	0.08073634859349145	0.8842921784098254	0.015513897866839042
777	25876981	CN	CN	1	1.0	0	0	1	0	2025-10-03	57.0	801.0	Male	75.0	MYCOPHENOLATE MOFETIL	white blood cell count decreased	1	3	0.21428571428571427	MidAge	CN	0.10150375939849625	19	0	32	0	0	0	0	0	0	0	5	2025	10	3	4	0.08073634859349145	5.7857142857142865	0.0
778	25877076	US	US	1	2.0	0	0	0	0	2025-10-03	24.0	801.0	Male	75.0	DUPIXENT	eczema	0	0	0.0	Young	US	0.015513897866839042	221	0	6	0	0	0	0	0	0	0	1	2025	10	3	4	0.08073634859349145	0.372333548804137	0.0
779	25877238	VE	VE	2	1.0	0	0	0	0	2025-10-03	57.0	801.0	Female	75.0	ENOXAPARIN SODIUM	pulmonary embolism	1	0	0.0	MidAge	Other	0.0	2	0	18	0	0	0	0	0	0	0	2	2025	10	3	4	0.08936301793444651	0.0	0.0
780	25927597	US	US	1	2.0	0	0	0	0	2025-10-16	57.0	801.0	Female	75.0	JEMPERLI	chest discomfort	0	0	0.0	MidAge	US	0.0	1	0	16	0	0	0	0	0	0	0	2	2025	10	16	3	0.08073634859349145	0.0	0.0
781	25927759	US	US	1	1.0	0	0	1	0	2025-10-16	63.0	801.0	Female	75.0	TACROLIMUS	hypogammaglobulinaemia	1	3	0.21428571428571427	MidAge	US	0.09183673469387754	7	0	22	0	0	0	0	0	0	0	1	2025	10	16	3	0.08073634859349145	5.785714285714285	0.09183673469387754
782	25929636	US	Unknown	1	1.0	0	0	1	0	2025-10-15	47.0	801.0	Male	75.0	TACROLIMUS	transplant rejection	1	3	0.21428571428571427	Adult	US	0.09183673469387754	7	0	20	0	0	0	0	0	0	0	2	2025	10	15	2	0.08073634859349145	4.316326530612244	0.0
783	25878400	US	US	1	2.0	0	0	0	0	2025-10-03	29.0	801.0	Female	75.0	ZEPBOUND	tooth fracture	0	0	0.0	Young	US	0.0	2	0	14	0	0	0	0	0	0	0	2	2025	10	3	4	0.08073634859349145	0.0	0.0
784	25878439	US	US	1	2.0	0	0	0	0	2025-10-03	61.0	801.0	Female	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	MidAge	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	10	3	4	0.08073634859349145	0.9463477698771816	0.015513897866839042
785	25878897	EU	EU	1	1.0	0	0	1	0	2025-10-03	57.0	801.0	Female	75.0	OMEPRAZOLE	cerebellar syndrome	1	3	0.21428571428571427	MidAge	EU	0.07142857142857142	3	0	19	0	0	0	0	0	0	0	2	2025	10	3	4	0.08073634859349145	4.071428571428571	0.07142857142857142
786	25879816	US	US	1	2.0	0	0	0	0	2025-10-03	3.0	801.0	Female	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	Child	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	10	3	4	0.08073634859349145	0.046541693600517124	0.015513897866839042
787	25880182	US	US	1	2.0	0	0	0	0	2025-10-04	57.0	801.0	Male	75.0	OTEZLA	therapeutic product effect incomplete	0	0	0.0	MidAge	US	0.0	4	0	37	0	0	0	0	0	0	0	4	2025	10	4	5	0.08073634859349145	0.0	0.0
788	26155011	US	US	1	2.0	0	0	0	0	2025-12-15	57.0	801.0	Male	75.0	KISUNLA	muscle spasms	0	0	0.0	MidAge	US	0.0	1	0	13	0	0	0	0	0	0	0	2	2025	12	15	0	0.08073634859349145	0.0	0.0
789	26155402	AU	AU	1	2.0	0	0	0	0	2025-12-15	32.0	801.0	Female	75.0	AZATHIOPRINE	parvovirus b19 infection	0	0	0.0	Young	AU	0.0	2	0	24	0	1	0	0	0	0	0	3	2025	12	15	0	0.08073634859349145	0.0	0.0
790	25893209	EU	EU	1	1.0	0	0	0	0	2025-10-08	55.0	801.0	Female	49.0	LETROZOLE	migraine	1	0	0.0	MidAge	EU	0.07142857142857142	3	0	8	0	0	0	0	0	0	0	1	2025	10	8	2	0.08073634859349145	3.9285714285714284	0.07142857142857142
791	25893276	US	US	1	2.0	0	0	0	0	2025-10-08	42.0	801.0	Female	75.0	DUPIXENT	tremor	0	0	0.0	Adult	US	0.015513897866839042	221	0	6	0	0	0	0	0	0	0	1	2025	10	8	2	0.08073634859349145	0.6515837104072397	0.015513897866839042
792	25271098	US	US	2	1.0	0	0	0	0	2025-05-06	57.0	801.0	Male	75.0	EPIDIOLEX	bipolar disorder	1	0	0.0	MidAge	US	0.14285714285714285	3	1	16	0	0	0	0	0	0	0	2	2025	5	6	1	0.08936301793444651	8.142857142857142	0.0
793	25273933	US	US	1	1.0	0	0	0	0	2025-05-06	57.0	801.0	Male	75.0	VONJO	foreign body in throat	1	0	0.0	MidAge	US	0.0	3	0	22	0	0	0	0	0	0	0	4	2025	5	6	1	0.08073634859349145	0.0	0.0
794	25283181	EU	EU	1	1.0	0	1	1	0	2025-05-08	23.0	801.0	Male	75.0	LACOSAMIDE	blood creatine phosphokinase increased	1	7	0.5	Young	EU	0.16666666666666666	3	1	38	0	0	0	0	0	0	0	4	2025	5	8	3	0.08073634859349145	3.833333333333333	0.0
795	25291524	US	US	1	1.0	0	0	1	0	2025-05-10	52.0	801.0	Female	94.8	DUPIXENT	sepsis	1	3	0.21428571428571427	MidAge	US	0.015513897866839042	221	0	6	0	0	0	0	0	0	0	1	2025	5	10	5	0.08073634859349145	0.8067226890756302	0.015513897866839042
796	25293979	US	US	1	2.0	0	0	0	0	2025-05-10	62.0	801.0	Male	75.0	DUPIXENT	cough	0	0	0.0	MidAge	US	0.015513897866839042	221	0	5	0	0	0	0	0	0	0	1	2025	5	10	5	0.08073634859349145	0.9618616677440206	0.0
797	25299878	US	US	1	1.0	0	0	1	0	2025-05-12	77.0	801.0	Female	75.0	ORENCIA	hospitalisation	1	3	0.21428571428571427	Senior	US	0.10204081632653061	14	0	15	0	0	0	0	0	0	0	1	2025	5	12	0	0.08073634859349145	7.857142857142858	0.10204081632653061
798	25307872	CA	CA	2	1.0	0	0	1	0	2025-05-13	58.0	801.0	Male	75.0	VEDOLIZUMAB	intestinal stenosis	1	3	0.21428571428571427	MidAge	CA	0.057692307692307696	26	0	19	0	0	0	0	0	0	0	2	2025	5	13	1	0.08936301793444651	3.3461538461538463	0.0
799	25321265	US	US	2	1.0	0	0	0	0	2025-05-15	52.0	801.0	Male	75.0	SKYRIZI	bladder cancer recurrent	1	0	0.0	MidAge	US	0.051587301587301584	36	0	24	0	0	0	1	0	0	0	3	2025	5	15	3	0.08936301793444651	2.6825396825396823	0.0
800	25326530	US	US	1	2.0	0	0	0	0	2025-05-16	16.0	801.0	Male	75.0	DUPIXENT	incorrect dose administered	0	0	0.0	Child	US	0.015513897866839042	221	0	27	0	0	0	0	0	0	0	3	2025	5	16	4	0.08073634859349145	0.24822236586942467	0.0
801	25344026	US	US	1	2.0	0	0	0	0	2025-05-21	29.0	801.0	Male	75.0	DUPIXENT	nasal congestion	0	0	0.0	Young	US	0.015513897866839042	221	0	16	0	0	0	0	0	0	0	2	2025	5	21	2	0.08073634859349145	0.4499030381383322	0.0
802	25355257	US	US	1	2.0	0	0	0	0	2025-05-24	57.0	801.0	Female	75.0	RUCONEST	weight decreased	0	0	0.0	MidAge	US	0.0	1	0	16	0	0	0	0	0	0	0	2	2025	5	24	5	0.08073634859349145	0.0	0.0
803	25367865	EU	EU	1	1.0	0	0	0	0	2025-05-28	38.0	801.0	Female	75.0	DULOXETINE	drug abuse	1	0	0.0	Adult	EU	0.0	2	0	10	0	0	0	0	0	0	0	2	2025	5	28	2	0.08073634859349145	0.0	0.0
804	25382110	US	US	1	2.0	0	0	0	0	2025-05-31	57.0	801.0	Female	75.0	ZYMFENTRA	vein rupture	0	0	0.0	MidAge	US	0.0	1	0	12	0	0	0	0	0	0	0	2	2025	5	31	5	0.08073634859349145	0.0	0.0
805	25446449	US	Unknown	1	2.0	0	0	0	0	2025-06-17	57.0	801.0	Female	75.0	BIMZELX	acne cystic	0	0	0.0	MidAge	US	0.0	22	0	11	0	0	0	0	0	0	0	2	2025	6	17	1	0.08073634859349145	0.0	0.0
806	25446692	US	Unknown	1	2.0	0	0	0	0	2025-06-17	54.0	801.0	Female	75.0	BIMZELX	migraine	0	0	0.0	MidAge	US	0.0	22	0	8	0	0	0	0	0	0	0	1	2025	6	17	1	0.08073634859349145	0.0	0.0
807	25446759	US	Unknown	1	2.0	0	0	0	0	2025-06-17	57.0	801.0	Female	75.0	BIMZELX	candida infection	0	0	0.0	MidAge	US	0.0	22	0	17	0	1	0	0	0	0	0	2	2025	6	17	1	0.08073634859349145	0.0	0.0
808	25449460	US	US	1	1.0	0	0	0	0	2025-06-18	42.0	801.0	Female	74.83	PARAGARD T 380A	surgery	1	0	0.0	Adult	US	0.0	4	0	7	0	0	0	0	0	0	0	1	2025	6	18	2	0.08073634859349145	0.0	0.0
809	25449851	US	Unknown	1	2.0	0	0	0	0	2025-06-18	41.0	801.0	Female	75.0	BIMZELX	injection site pain	0	0	0.0	Adult	US	0.0	22	0	19	1	0	0	0	0	0	0	3	2025	6	18	2	0.08073634859349145	0.0	0.0
810	25465350	CA	CA	2	1.0	0	0	0	0	2025-06-22	53.0	801.0	Male	75.0	REMICADE	prostatomegaly	1	0	0.0	MidAge	CA	0.0	3	0	14	0	0	0	0	0	0	0	1	2025	6	22	6	0.08936301793444651	0.0	0.0
811	25485019	EU	EU	1	1.0	0	0	0	0	2025-06-26	13.0	801.0	Female	68.0	SERTRALINE	multiple acyl-coenzyme a dehydrogenase deficiency	1	0	0.0	Child	EU	0.0	1	0	49	0	0	0	0	0	0	0	5	2025	6	26	3	0.08073634859349145	0.0	0.0
812	25491566	US	US	2	1.0	0	0	0	0	2025-06-29	77.0	801.0	Female	75.0	SKYRIZI	mastectomy	1	0	0.0	Senior	US	0.051587301587301584	36	0	10	0	0	0	0	0	0	0	1	2025	6	29	6	0.08936301793444651	3.972222222222222	0.051587301587301584
813	25501814	US	US	2	1.0	0	0	0	0	2025-07-02	57.0	801.0	Male	75.0	RINVOQ	back pain	1	0	0.0	MidAge	US	0.0	3	0	9	1	0	0	0	0	0	0	2	2025	7	2	2	0.08936301793444651	0.0	0.0
814	25509724	JP	JP	2	1.0	1	0	0	0	2025-07-03	57.0	801.0	Female	75.0	EFGARTIGIMOD ALFA	sudden death	1	5	0.35714285714285715	MidAge	JP	0.35714285714285715	1	1	12	0	0	1	0	0	0	0	2	2025	7	3	3	0.08936301793444651	20.357142857142858	0.35714285714285715
815	26172708	US	US	1	1.0	0	0	0	0	2025-12-18	49.0	801.0	Male	75.0	ORENCIA	erythema	1	0	0.0	Adult	US	0.10204081632653061	14	0	8	0	0	0	0	0	0	0	1	2025	12	18	3	0.08073634859349145	5.0	0.0
816	26173909	CN	CN	1	1.0	0	0	1	0	2025-12-18	49.0	801.0	Female	75.0	PERJETA	myelosuppression	1	3	0.21428571428571427	Adult	CN	0.21428571428571427	2	1	16	0	0	0	0	0	0	0	1	2025	12	18	3	0.08073634859349145	10.5	0.21428571428571427
817	26174032	CA	CA	2	1.0	0	0	0	0	2025-12-18	80.0	801.0	Female	75.0	VEDOLIZUMAB	haematochezia	1	0	0.0	Senior	CA	0.057692307692307696	26	0	13	0	0	0	0	0	0	0	1	2025	12	18	3	0.08936301793444651	4.615384615384616	0.057692307692307696
818	26174423	US	US	1	2.0	0	0	0	0	2025-12-18	57.0	801.0	Male	75.0	DUPIXENT	drug ineffective	0	0	0.0	MidAge	US	0.015513897866839042	221	0	16	0	0	0	0	0	0	0	2	2025	12	18	3	0.08073634859349145	0.8842921784098254	0.0
819	26174476	US	US	1	2.0	0	0	0	0	2025-12-18	52.0	801.0	Male	75.0	VASCEPA	hypertension	0	0	0.0	MidAge	US	0.0	2	0	12	0	0	0	0	0	0	0	1	2025	12	18	3	0.08073634859349145	0.0	0.0
820	25907331	JP	JP	1	1.0	0	0	1	0	2025-10-10	84.0	801.0	Female	49.9	TAVNEOS	drug-induced liver injury	1	3	0.21428571428571427	Senior	JP	0.21428571428571427	1	1	25	0	0	0	0	0	0	0	3	2025	10	10	4	0.08073634859349145	18.0	0.21428571428571427
821	25907803	GB	GB	1	1.0	0	0	1	0	2025-10-10	65.0	801.0	Female	99.0	DOCETAXEL	cardiotoxicity	1	3	0.21428571428571427	MidAge	GB	0.061224489795918366	7	0	14	0	0	0	0	0	0	0	1	2025	10	10	4	0.08073634859349145	3.9795918367346936	0.061224489795918366
822	25908895	US	US	1	2.0	0	0	0	0	2025-10-11	71.0	801.0	Female	75.0	HUMALOG	blood glucose increased	0	0	0.0	Senior	US	0.05357142857142857	4	0	23	0	0	0	0	0	0	0	3	2025	10	11	5	0.08073634859349145	3.8035714285714284	0.05357142857142857
823	25910557	US	US	1	2.0	0	0	0	0	2025-10-13	47.0	801.0	Female	75.0	DUPIXENT	psoriasis	0	0	0.0	Adult	US	0.015513897866839042	221	0	9	0	0	0	0	0	0	0	1	2025	10	13	0	0.08073634859349145	0.729153199741435	0.015513897866839042
824	25956595	GB	GB	1	1.0	0	0	0	0	2025-10-24	74.0	801.0	Male	99.0	BISOPROLOL FUMARATE	wheezing	1	0	0.0	Senior	GB	0.0	1	0	8	0	0	0	0	0	0	0	1	2025	10	24	4	0.08073634859349145	0.0	0.0
825	25957123	GB	GB	1	1.0	0	0	0	0	2025-10-24	57.0	801.0	Male	75.0	CLOZARIL	eosinophilia	1	0	0.0	MidAge	GB	0.10714285714285714	4	0	12	0	0	0	0	0	0	0	1	2025	10	24	4	0.08073634859349145	6.107142857142857	0.0
826	25958243	EU	EU	1	1.0	0	0	0	0	2025-10-24	95.0	801.0	Male	75.0	MIRTAZAPINE	wrong product administered	1	0	0.0	Senior	EU	0.19047619047619047	3	1	26	0	0	0	0	0	0	0	3	2025	10	24	4	0.08073634859349145	18.095238095238095	0.0
827	25958715	JP	JP	1	1.0	0	0	1	0	2025-10-24	71.0	801.0	Male	75.0	GAZYVA	pneumonia	1	3	0.21428571428571427	Senior	JP	0.21428571428571427	1	1	9	0	0	0	0	0	1	0	1	2025	10	24	4	0.08073634859349145	15.214285714285714	0.0
828	25531675	CA	CA	2	1.0	0	0	1	0	2025-07-09	88.0	801.0	Male	75.0	VEDOLIZUMAB	diarrhoea	1	3	0.21428571428571427	Senior	CA	0.057692307692307696	26	0	9	0	0	0	0	0	0	0	1	2025	7	9	2	0.08936301793444651	5.0769230769230775	0.0
829	25544406	CA	CA	2	1.0	0	0	1	0	2025-07-11	65.0	801.0	Male	75.0	ADALIMUMAB	device issue	1	3	0.21428571428571427	MidAge	CA	0.07142857142857142	3	0	12	0	0	0	0	0	0	0	2	2025	7	11	4	0.08936301793444651	4.642857142857142	0.0
830	25555961	US	US	1	2.0	0	0	0	0	2025-07-15	53.0	801.0	Female	75.0	DUPIXENT	asthma	0	0	0.0	MidAge	US	0.015513897866839042	221	0	6	0	0	0	0	0	0	0	1	2025	7	15	1	0.08073634859349145	0.8222365869424693	0.015513897866839042
831	25567759	US	US	2	1.0	0	0	0	0	2025-07-16	58.0	801.0	Female	75.0	VEDOLIZUMAB	colitis ulcerative	1	0	0.0	MidAge	US	0.057692307692307696	26	0	18	0	0	0	0	0	0	0	2	2025	7	16	2	0.08936301793444651	3.3461538461538463	0.057692307692307696
832	25574038	JP	JP	1	1.0	0	0	0	0	2025-07-17	57.0	801.0	Male	75.0	LENVIMA	hepatic function abnormal	1	0	0.0	MidAge	JP	0.07142857142857142	2	0	25	0	0	0	0	0	0	0	3	2025	7	17	3	0.08073634859349145	4.071428571428571	0.0
833	25581638	CN	CN	1	1.0	0	1	0	0	2025-07-19	61.0	801.0	Female	75.0	DEXAMETHASONE	neutropenia	1	4	0.2857142857142857	MidAge	CN	0.1857142857142857	5	1	11	0	0	0	0	0	0	0	1	2025	7	19	5	0.08073634859349145	11.328571428571427	0.1857142857142857
834	26175705	US	US	1	2.0	0	0	0	0	2025-12-18	57.0	801.0	Male	86.36	DUPIXENT	enterobiasis	0	0	0.0	MidAge	US	0.015513897866839042	221	0	12	0	0	0	0	0	0	0	1	2025	12	18	3	0.08073634859349145	0.8842921784098254	0.0
835	26176744	US	US	1	2.0	0	0	0	0	2025-12-18	57.0	801.0	Male	75.0	SKYRIZI	nephrolithiasis	0	0	0.0	MidAge	US	0.051587301587301584	36	0	15	0	0	0	0	0	0	0	1	2025	12	18	3	0.08073634859349145	2.9404761904761902	0.0
836	26176959	US	US	1	2.0	0	0	0	0	2025-12-18	57.0	801.0	Female	75.0	PLUVICTO	general physical health deterioration	0	0	0.0	MidAge	US	0.0	8	0	37	0	0	0	0	0	0	0	4	2025	12	18	3	0.08073634859349145	0.0	0.0
837	26177297	US	US	1	2.0	0	0	0	0	2025-12-19	57.0	801.0	Female	75.0	FLUOXETINE	depression	0	0	0.0	MidAge	US	0.0	1	0	10	0	0	0	0	0	0	0	1	2025	12	19	4	0.08073634859349145	0.0	0.0
838	26177783	US	US	1	1.0	0	0	0	0	2025-12-19	57.0	801.0	Male	75.0	RISPERDAL	galactorrhoea	1	0	0.0	MidAge	US	0.0	1	0	13	0	0	0	0	0	0	0	1	2025	12	19	4	0.08073634859349145	0.0	0.0
839	26178621	US	US	1	2.0	0	0	0	0	2025-12-19	57.0	801.0	Female	75.0	DUPIXENT	pain in extremity	0	0	0.0	MidAge	US	0.015513897866839042	221	0	17	1	0	0	0	0	0	0	3	2025	12	19	4	0.08073634859349145	0.8842921784098254	0.015513897866839042
840	26178836	US	US	1	2.0	0	0	0	0	2025-12-19	57.0	801.0	Female	75.0	SELINEXOR	pneumonia	0	0	0.0	MidAge	US	0.0	1	0	9	0	0	0	0	0	1	0	1	2025	12	19	4	0.08073634859349145	0.0	0.0
841	26178850	EU	EU	1	1.0	0	1	1	0	2025-12-19	42.0	801.0	Female	53.0	VENLAFAXINE	cardio-respiratory arrest	1	7	0.5	Adult	EU	0.25	2	1	25	0	0	0	0	0	0	0	2	2025	12	19	4	0.08073634859349145	10.5	0.25
842	25911691	US	US	2	1.0	0	0	0	0	2025-10-13	57.0	801.0	Female	75.0	SKYRIZI	cataract	1	0	0.0	MidAge	US	0.051587301587301584	36	0	8	0	0	0	0	0	0	0	1	2025	10	13	0	0.08936301793444651	2.9404761904761902	0.051587301587301584
843	25911705	US	US	1	2.0	0	0	0	0	2025-10-13	21.0	801.0	Female	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	Young	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	10	13	0	0.08073634859349145	0.32579185520361986	0.015513897866839042
844	25912205	US	US	1	2.0	0	0	0	0	2025-10-13	43.0	801.0	Female	75.0	DUPIXENT	extra dose administered	0	0	0.0	Adult	US	0.015513897866839042	221	0	23	0	0	0	0	0	0	0	3	2025	10	13	0	0.08073634859349145	0.6670976082740788	0.015513897866839042
845	25913244	US	US	1	2.0	0	0	0	0	2025-10-13	41.0	801.0	Female	75.0	XOLAIR	product storage error	0	0	0.0	Adult	US	0.14285714285714285	4	1	21	0	0	0	0	0	0	0	3	2025	10	13	0	0.08073634859349145	5.857142857142857	0.14285714285714285
846	25959888	US	US	1	2.0	0	0	0	0	2025-10-26	15.0	801.0	Male	75.0	DUPIXENT	dysphagia	0	0	0.0	Child	US	0.015513897866839042	221	0	9	0	0	0	0	0	0	0	1	2025	10	26	6	0.08073634859349145	0.23270846800258563	0.0
847	25959983	US	US	1	2.0	0	0	0	0	2025-10-26	57.0	801.0	Male	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	MidAge	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	10	26	6	0.08073634859349145	0.8842921784098254	0.0
848	25960039	US	US	1	2.0	0	0	0	0	2025-10-26	57.0	801.0	Female	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	MidAge	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	10	26	6	0.08073634859349145	0.8842921784098254	0.015513897866839042
849	25963265	US	US	1	1.0	0	0	1	0	2025-10-27	53.0	801.0	Male	75.0	HUMALOG	renal failure	1	3	0.21428571428571427	MidAge	US	0.05357142857142857	4	0	13	0	0	0	0	1	0	0	2	2025	10	27	0	0.08073634859349145	2.839285714285714	0.0
850	25963980	CA	CA	1	1.0	0	0	0	0	2025-10-27	53.0	801.0	Female	75.0	GABAPENTIN	treatment failure	1	0	0.0	MidAge	CA	0.061224489795918366	7	0	17	0	0	0	0	1	0	0	2	2025	10	27	0	0.08073634859349145	3.2448979591836733	0.061224489795918366
851	26180336	CA	CA	2	1.0	0	0	0	0	2025-12-19	78.0	801.0	Male	58.05	METHOTREXATE SODIUM	bronchiectasis	1	0	0.0	Senior	CA	0.125	4	1	14	0	0	0	0	0	0	0	1	2025	12	19	4	0.08936301793444651	9.75	0.0
852	26180794	EU	EU	1	1.0	0	0	1	0	2025-12-21	84.0	801.0	Female	75.0	WELLBUTRIN XL	vertigo	1	3	0.21428571428571427	Senior	EU	0.21428571428571427	1	1	7	0	0	0	0	0	0	0	1	2025	12	21	6	0.08073634859349145	18.0	0.21428571428571427
853	26180808	EU	EU	1	1.0	0	0	0	0	2025-12-21	72.0	801.0	Male	75.0	LENALIDOMIDE	diabetes mellitus	1	0	0.0	Senior	EU	0.15413533834586465	19	1	17	0	0	0	0	0	0	0	2	2025	12	21	6	0.08073634859349145	11.097744360902254	0.0
854	26181241	US	US	1	2.0	0	0	0	0	2025-12-21	57.0	801.0	Female	75.0	PLUVICTO	general physical health deterioration	0	0	0.0	MidAge	US	0.0	8	0	37	0	0	0	0	0	0	0	4	2025	12	21	6	0.08073634859349145	0.0	0.0
855	26181403	US	US	1	2.0	0	0	0	0	2025-12-21	57.0	801.0	Male	75.0	SUTAB	pain	0	0	0.0	MidAge	US	0.0	2	0	4	1	0	0	0	0	0	0	1	2025	12	21	6	0.08073634859349145	0.0	0.0
856	26182886	GB	GB	1	1.0	0	0	0	0	2025-12-21	30.0	801.0	Female	55.0	DYSPORT	laryngospasm	1	0	0.0	Young	GB	0.0	1	0	12	0	0	0	0	0	0	0	1	2025	12	21	6	0.08073634859349145	0.0	0.0
857	25915903	EU	EU	1	1.0	0	0	0	0	2025-10-13	85.0	801.0	Male	82.0	DARZALEX	pleurisy	1	0	0.0	Senior	EU	0.0	2	0	8	0	0	0	0	0	0	0	1	2025	10	13	0	0.08073634859349145	0.0	0.0
858	25916375	US	US	1	2.0	0	0	0	0	2025-10-14	59.0	801.0	Female	75.0	COPAXONE	treatment failure	0	0	0.0	MidAge	US	0.0	2	0	17	0	0	0	0	1	0	0	2	2025	10	14	1	0.08073634859349145	0.0	0.0
859	25918023	CA	CA	1	1.0	0	0	0	0	2025-10-14	57.0	801.0	Female	75.0	INFLIXIMAB	basal cell carcinoma	1	0	0.0	MidAge	CA	0.07142857142857142	9	0	20	0	0	0	0	0	0	0	3	2025	10	14	1	0.08073634859349145	4.071428571428571	0.07142857142857142
860	25918076	US	US	1	2.0	0	0	0	0	2025-10-14	57.0	801.0	Female	75.0	ALBUTEROL SULFATE	wrong technique in product usage process	0	0	0.0	MidAge	US	0.0	8	0	40	0	0	0	0	0	0	0	6	2025	10	14	1	0.08073634859349145	0.0	0.0
861	25595556	EG	EG	2	1.0	0	0	1	0	2025-07-23	65.0	801.0	Female	48.0	LONSURF	decreased immune responsiveness	1	3	0.21428571428571427	MidAge	Other	0.21428571428571427	1	1	31	0	0	0	0	0	0	0	3	2025	7	23	2	0.08936301793444651	13.928571428571427	0.21428571428571427
862	25596366	GB	GB	1	1.0	0	0	0	0	2025-07-23	19.0	802.0	Female	75.0	CYCLOSPORINE	adenovirus infection	1	0	0.0	Young	GB	0.0	5	0	20	0	1	0	0	0	0	0	2	2025	7	23	2	0.08073634859349145	0.0	0.0
863	25600148	US	US	1	1.0	0	0	0	0	2025-07-24	57.0	801.0	Female	41.723	FIRDAPSE	cholecystectomy	1	0	0.0	MidAge	US	0.0	3	0	15	0	0	0	0	0	0	0	1	2025	7	24	3	0.08073634859349145	0.0	0.0
864	25604575	US	US	1	2.0	0	0	0	0	2025-07-25	57.0	801.0	Female	75.0	VYLOY	face oedema	0	0	0.0	MidAge	US	0.0	1	0	11	0	0	0	0	0	0	0	2	2025	7	25	4	0.08073634859349145	0.0	0.0
865	25626607	US	US	1	2.0	0	0	0	0	2025-07-31	56.0	801.0	Female	75.0	HYRIMOZ	injection site haemorrhage	0	0	0.0	MidAge	US	0.0	1	0	26	0	0	0	0	0	0	0	3	2025	7	31	3	0.08073634859349145	0.0	0.0
866	25628847	US	US	1	1.0	0	0	1	0	2025-07-31	73.0	801.0	Male	111.11	TRULICITY	intestinal obstruction	1	3	0.21428571428571427	Senior	US	0.04285714285714286	5	0	22	0	0	0	0	0	0	0	2	2025	7	31	3	0.08073634859349145	3.1285714285714286	0.0
867	25633182	EU	EU	1	1.0	0	0	1	0	2025-08-01	38.0	801.0	Female	75.0	MAGNESIUM SULFATE	respiratory failure	1	3	0.21428571428571427	Adult	EU	0.21428571428571427	1	1	19	0	0	0	0	1	0	0	2	2025	8	1	4	0.08073634859349145	8.142857142857142	0.21428571428571427
868	25645804	US	US	1	1.0	0	0	0	0	2025-08-05	34.0	801.0	Female	158.73	PARAGARD T 380A	surgery	1	0	0.0	Young	US	0.0	4	0	7	0	0	0	0	0	0	0	1	2025	8	5	1	0.08073634859349145	0.0	0.0
869	25648315	JP	JP	1	1.0	0	0	1	0	2025-08-06	57.0	801.0	Female	75.0	NEMOLIZUMAB	vomiting	1	3	0.21428571428571427	MidAge	JP	0.21428571428571427	1	1	8	0	0	0	0	0	0	0	1	2025	8	6	2	0.08073634859349145	12.214285714285714	0.21428571428571427
870	26183467	US	US	1	1.0	0	0	0	0	2025-12-21	57.0	801.0	Female	78.005	ORENITRAM	renal function test abnormal	1	0	0.0	MidAge	US	0.0	2	0	28	0	0	0	0	0	0	0	4	2025	12	21	6	0.08073634859349145	0.0	0.0
871	26183953	EU	EU	3	1.0	0	0	1	0	2025-12-22	57.0	801.0	Female	75.0	DIAZEPAM	drug use disorder	1	3	0.21428571428571427	MidAge	EU	0.2619047619047619	3	1	17	0	0	0	0	0	0	0	3	2025	12	22	0	0.17857142857142855	14.928571428571429	0.2619047619047619
872	26185911	US	US	1	1.0	0	0	0	0	2025-12-22	54.0	801.0	Male	105.69	POMALYST	abdominal pain	1	0	0.0	MidAge	US	0.11428571428571428	5	0	14	1	0	0	0	0	0	0	2	2025	12	22	0	0.08073634859349145	6.171428571428571	0.0
873	26186640	US	Unknown	1	1.0	0	0	1	0	2025-12-19	84.0	801.0	Male	102.0	APIXABAN	gastrointestinal haemorrhage	1	3	0.21428571428571427	Senior	US	0.07142857142857142	3	0	28	0	0	0	0	0	0	0	2	2025	12	19	4	0.08073634859349145	6.0	0.0
874	26186679	US	US	1	2.0	0	0	0	0	2025-12-22	69.0	801.0	Female	75.0	DUPIXENT	sinusitis	0	0	0.0	Senior	US	0.015513897866839042	221	0	9	0	0	0	0	0	0	0	1	2025	12	22	0	0.08073634859349145	1.070458952811894	0.015513897866839042
875	26186802	SG	SG	1	1.0	0	0	1	0	2025-12-22	38.0	801.0	Female	106.5	FLUDARABINE	covid-19 pneumonia	1	3	0.21428571428571427	Adult	Other	0.21428571428571427	1	1	18	0	0	0	0	0	1	0	2	2025	12	22	0	0.08073634859349145	8.142857142857142	0.21428571428571427
876	25964804	EU	EU	1	1.0	0	0	0	0	2025-10-27	57.0	801.0	Female	75.0	NUBEQA	myocardial ischaemia	1	0	0.0	MidAge	EU	0.0	1	0	20	0	0	0	0	0	0	0	2	2025	10	27	0	0.08073634859349145	0.0	0.0
877	25965195	US	US	1	2.0	0	0	0	0	2025-10-27	57.0	801.0	Female	75.0	DUPIXENT	product storage error	0	0	0.0	MidAge	US	0.015513897866839042	221	0	21	0	0	0	0	0	0	0	3	2025	10	27	0	0.08073634859349145	0.8842921784098254	0.015513897866839042
878	25967692	EU	EU	1	1.0	0	0	1	0	2025-10-28	46.0	801.0	Male	75.0	OXALIPLATIN	acute kidney injury	1	3	0.21428571428571427	Adult	EU	0.08571428571428572	5	0	19	0	0	0	0	0	0	0	3	2025	10	28	1	0.08073634859349145	3.942857142857143	0.0
879	25651340	JP	JP	1	1.0	0	0	0	0	2025-08-06	57.0	801.0	Female	75.0	OPDIVO	adrenal insufficiency	1	0	0.0	MidAge	JP	0.08928571428571429	4	0	21	0	0	0	0	0	0	0	2	2025	8	6	2	0.08073634859349145	5.089285714285714	0.08928571428571429
880	25652460	JP	JP	1	1.0	0	0	0	0	2025-08-07	69.0	801.0	Male	75.0	LIVTENCITY	cerebral infarction	1	0	0.0	Senior	JP	0.0	1	0	19	0	0	0	0	0	0	0	2	2025	8	7	3	0.08073634859349145	0.0	0.0
881	25652985	US	US	2	1.0	0	0	0	0	2025-08-07	64.0	801.0	Female	75.0	SKYRIZI	rotator cuff repair	1	0	0.0	MidAge	US	0.051587301587301584	36	0	19	0	0	0	0	0	0	0	3	2025	8	7	3	0.08936301793444651	3.3015873015873014	0.051587301587301584
882	25668537	US	US	1	1.0	0	0	1	0	2025-08-12	57.0	801.0	Female	39.692	REVUFORJ	fungal infection	1	3	0.21428571428571427	MidAge	US	0.21428571428571427	1	1	16	0	1	0	0	0	0	0	2	2025	8	12	1	0.08073634859349145	12.214285714285714	0.21428571428571427
883	25676651	US	US	1	2.0	0	0	0	0	2025-08-13	57.0	801.0	Female	75.0	ESTRADIOL	device adhesion issue	0	0	0.0	MidAge	US	0.0	8	0	21	0	0	0	0	0	0	0	3	2025	8	13	2	0.08073634859349145	0.0	0.0
884	25678042	US	US	1	2.0	0	0	0	0	2025-08-13	23.0	801.0	Female	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	Young	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	8	13	2	0.08073634859349145	0.35681965093729795	0.015513897866839042
885	25679067	JP	JP	1	1.0	0	1	1	0	2025-08-14	41.0	801.0	Male	75.0	DAPRODUSTAT	platelet count decreased	1	7	0.5	Adult	JP	0.5	1	1	24	0	0	0	0	0	0	0	3	2025	8	14	3	0.08073634859349145	20.5	0.0
886	25679500	US	US	2	1.0	0	0	1	0	2025-08-14	73.0	801.0	Female	75.0	NUPLAZID	rectal ulcer haemorrhage	1	3	0.21428571428571427	Senior	US	0.09523809523809523	6	0	24	0	0	0	0	0	0	0	3	2025	8	14	3	0.08936301793444651	6.952380952380952	0.09523809523809523
887	25689192	EU	EU	2	1.0	0	0	1	0	2025-08-18	72.0	801.0	Female	55.0	ENHERTU	hyperpyrexia	1	3	0.21428571428571427	Senior	EU	0.21428571428571427	1	1	12	0	0	0	0	0	0	0	1	2025	8	18	0	0.08936301793444651	15.428571428571427	0.21428571428571427
888	25923760	US	US	1	2.0	0	0	0	0	2025-10-15	57.0	801.0	Male	75.0	COLUMVI	product administration error	0	0	0.0	MidAge	US	0.0	1	0	28	0	0	0	0	0	0	0	3	2025	10	15	2	0.08073634859349145	0.0	0.0
889	25923841	US	US	1	2.0	0	0	0	0	2025-10-15	34.0	801.0	Female	75.0	ACCRUFER	maternal exposure during pregnancy	0	0	0.0	Young	US	0.07142857142857142	3	0	34	0	0	0	0	0	0	0	4	2025	10	15	2	0.08073634859349145	2.4285714285714284	0.07142857142857142
890	25925137	US	US	1	2.0	0	0	0	0	2025-10-15	57.0	801.0	Female	75.0	IQIRVO	product dose omission issue	0	0	0.0	MidAge	US	0.0	2	0	27	0	0	0	0	0	0	0	4	2025	10	15	2	0.08073634859349145	0.0	0.0
891	25925676	US	US	1	2.0	0	0	0	0	2025-10-15	51.0	801.0	Female	75.0	DUPIXENT	dry skin	0	0	0.0	MidAge	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	2	2025	10	15	2	0.08073634859349145	0.7912087912087912	0.015513897866839042
892	25926123	EU	EU	1	1.0	0	0	0	0	2025-10-15	58.0	801.0	Female	65.0	VALACYCLOVIR HYDROCHLORIDE	neuropathy peripheral	1	0	0.0	MidAge	EU	0.0	1	0	21	0	0	0	0	0	0	0	2	2025	10	15	2	0.08073634859349145	0.0	0.0
893	25969016	EU	EU	1	1.0	0	0	0	0	2025-10-28	57.0	801.0	Female	75.0	ALPRAZOLAM	hallucination	1	0	0.0	MidAge	EU	0.14285714285714285	3	1	13	0	0	0	0	0	0	0	1	2025	10	28	1	0.08073634859349145	8.142857142857142	0.14285714285714285
894	25970326	US	US	2	1.0	0	0	0	0	2025-10-28	76.0	801.0	Female	75.0	CREON	medical procedure	1	0	0.0	Senior	US	0.03296703296703297	13	0	17	0	0	0	0	0	0	0	2	2025	10	28	1	0.08936301793444651	2.5054945054945055	0.03296703296703297
895	25970474	US	US	1	2.0	0	0	0	0	2025-10-28	57.0	801.0	Male	54.431	HUMIRA	drug ineffective	0	0	0.0	MidAge	US	0.17857142857142858	2	1	16	0	0	0	0	0	0	0	2	2025	10	28	1	0.08073634859349145	10.178571428571429	0.0
896	25970960	US	US	1	2.0	0	0	0	0	2025-10-28	67.0	801.0	Male	75.0	METHOTREXATE SODIUM	drug ineffective	0	0	0.0	Senior	US	0.125	4	1	16	0	0	0	0	0	0	0	2	2025	10	28	1	0.08073634859349145	8.375	0.0
897	25928444	IN	IN	3	1.0	0	0	1	0	2025-10-16	29.0	801.0	Male	75.0	CYCLOPHOSPHAMIDE	therapeutic response unexpected	1	3	0.21428571428571427	Young	IN	0.21428571428571427	2	1	31	0	0	0	0	0	0	0	3	2025	10	16	3	0.17857142857142855	6.2142857142857135	0.0
898	25928754	US	US	1	1.0	0	0	0	0	2025-10-16	84.0	801.0	Male	75.0	ACCRUFER	choking	1	0	0.0	Senior	US	0.07142857142857142	3	0	7	0	0	0	0	0	0	0	1	2025	10	16	3	0.08073634859349145	6.0	0.0
899	25930793	EU	EU	2	1.0	1	0	0	0	2025-10-16	79.0	801.0	Female	75.0	CARBIDOPA	death	1	5	0.35714285714285715	Senior	EU	0.35714285714285715	1	1	5	0	0	1	0	0	0	0	1	2025	10	16	3	0.08936301793444651	28.214285714285715	0.35714285714285715
900	25931941	US	US	1	2.0	0	0	0	0	2025-10-16	58.0	801.0	Female	75.0	VUEWAY	rash	0	0	0.0	MidAge	US	0.0	1	0	4	0	0	0	0	0	0	0	1	2025	10	16	3	0.08073634859349145	0.0	0.0
901	26192324	US	US	1	2.0	0	0	0	0	2025-12-23	82.0	801.0	Male	75.0	DUPIXENT	injection site pain	0	0	0.0	Senior	US	0.015513897866839042	221	0	19	1	0	0	0	0	0	0	3	2025	12	23	1	0.08073634859349145	1.2721396250808015	0.0
902	26195307	US	US	1	1.0	0	0	1	0	2025-12-24	65.0	801.0	Female	75.0	TACROLIMUS	west nile viral infection	1	3	0.21428571428571427	MidAge	US	0.09183673469387754	7	0	25	0	1	0	0	0	0	0	4	2025	12	24	2	0.08073634859349145	5.969387755102041	0.09183673469387754
903	26195589	TW	TW	1	1.0	0	0	1	0	2025-12-24	23.0	801.0	Male	75.0	CELECOXIB	toxicity to various agents	1	3	0.21428571428571427	Young	Other	0.21428571428571427	1	1	26	0	0	0	0	0	0	0	4	2025	12	24	2	0.08073634859349145	4.928571428571428	0.0
904	25981881	EU	EU	1	1.0	0	0	0	0	2025-10-31	57.0	801.0	Female	75.0	RITUXIMAB	disease progression	1	0	0.0	MidAge	EU	0.12406015037593986	19	0	19	0	0	0	0	0	0	0	2	2025	10	31	4	0.08073634859349145	7.071428571428572	0.12406015037593986
905	25982800	AU	AU	1	1.0	0	0	0	0	2025-10-31	75.0	801.0	Male	75.0	CARBOPLATIN	diffuse large b-cell lymphoma	1	0	0.0	Senior	AU	0.12244897959183673	7	0	29	0	0	0	0	0	0	0	4	2025	10	31	4	0.08073634859349145	9.183673469387754	0.0
906	25983920	US	Unknown	1	2.0	0	0	0	0	2025-10-31	57.0	801.0	Female	75.0	WINREVAIR	adverse event	0	0	0.0	MidAge	US	0.2619047619047619	3	1	13	0	0	0	0	0	0	0	2	2025	10	31	4	0.08073634859349145	14.928571428571429	0.2619047619047619
907	25984325	RU	RU	1	1.0	1	0	0	0	2025-10-31	62.0	801.0	Male	75.0	POLATUZUMAB VEDOTIN	neutropenia	1	5	0.35714285714285715	MidAge	Other	0.35714285714285715	1	1	11	0	0	0	0	0	0	0	1	2025	10	31	4	0.08073634859349145	22.142857142857142	0.0
908	25761553	US	US	1	1.0	0	0	0	0	2025-09-04	57.0	801.0	Female	75.0	SUBOXONE	suicidal ideation	1	0	0.0	MidAge	US	0.0	1	0	17	0	0	0	0	0	0	0	2	2025	9	4	3	0.08073634859349145	0.0	0.0
909	25769854	JP	JP	1	1.0	0	0	0	0	2025-09-07	7.0	800.0	Female	75.0	KEYTRUDA	malignant neoplasm progression	1	0	0.0	Child	JP	0.11904761904761905	3	0	30	0	0	0	0	0	0	0	3	2025	9	7	6	0.08073634859349145	0.8333333333333334	0.11904761904761905
910	25773675	US	US	1	2.0	0	0	0	0	2025-09-08	57.0	801.0	Female	75.0	ESTRADIOL	circumstance or information capable of leading to device use error	0	0	0.0	MidAge	US	0.0	8	0	66	0	0	0	0	0	0	0	10	2025	9	8	0	0.08073634859349145	0.0	0.0
911	25942376	US	US	2	1.0	0	0	0	0	2025-10-21	42.0	801.0	Male	75.0	SPRAVATO	respiratory depression	1	0	0.0	Adult	US	0.026785714285714284	8	0	22	0	0	0	0	0	0	0	2	2025	10	21	1	0.08936301793444651	1.125	0.0
912	25942714	CN	CN	2	1.0	0	0	0	0	2025-10-21	57.0	801.0	Female	75.0	RITUXIMAB	infusion related reaction	1	0	0.0	MidAge	CN	0.12406015037593986	19	0	25	0	0	0	0	0	0	0	3	2025	10	21	1	0.08936301793444651	7.071428571428572	0.12406015037593986
913	25942943	EU	EU	1	1.0	0	0	1	0	2025-10-21	74.0	801.0	Male	72.0	RISEDRONATE SODIUM	small intestinal ulcer haemorrhage	1	3	0.21428571428571427	Senior	EU	0.21428571428571427	1	1	34	0	0	0	0	0	0	0	4	2025	10	21	1	0.08073634859349145	15.857142857142856	0.0
914	25944859	US	US	1	2.0	0	0	0	0	2025-10-21	57.0	801.0	Female	75.0	VOQUEZNA	alopecia	0	0	0.0	MidAge	US	0.0	2	0	8	0	0	0	0	0	0	0	1	2025	10	21	1	0.08073634859349145	0.0	0.0
915	25945010	US	US	1	2.0	0	0	0	0	2025-10-21	59.0	801.0	Female	75.0	VOQUEZNA	neuralgia	0	0	0.0	MidAge	US	0.0	2	0	9	0	0	0	0	0	0	0	1	2025	10	21	1	0.08073634859349145	0.0	0.0
916	26202072	US	US	1	2.0	0	0	0	0	2025-12-26	20.0	801.0	Male	75.0	DUPIXENT	respiratory tract infection	0	0	0.0	Young	US	0.015513897866839042	221	0	27	0	1	0	0	0	0	0	3	2025	12	26	4	0.08073634859349145	0.3102779573367808	0.0
917	26202153	US	US	1	2.0	0	0	0	0	2025-12-26	20.0	801.0	Female	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	Young	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	12	26	4	0.08073634859349145	0.3102779573367808	0.015513897866839042
918	25985621	EU	EU	1	1.0	1	0	0	0	2025-10-31	32.0	801.0	Male	75.0	DIAZEPAM	high risk sexual behaviour	1	5	0.35714285714285715	Young	EU	0.2619047619047619	3	1	26	0	0	0	0	0	0	0	4	2025	10	31	4	0.08073634859349145	8.380952380952381	0.0
919	25987012	US	US	1	2.0	0	0	0	0	2025-11-03	87.0	801.0	Female	75.0	HUMALOG	visual impairment	0	0	0.0	Senior	US	0.05357142857142857	4	0	17	0	0	0	0	0	0	0	2	2025	11	3	0	0.08073634859349145	4.660714285714286	0.05357142857142857
920	25987766	EU	EU	1	1.0	0	0	0	0	2025-11-03	27.0	801.0	Female	75.0	IBUPROFEN	laryngeal oedema	1	0	0.0	Young	EU	0.11607142857142858	8	0	16	0	0	0	0	0	0	0	2	2025	11	3	0	0.08073634859349145	3.1339285714285716	0.11607142857142858
921	25988523	EU	EU	2	1.0	0	0	1	0	2025-11-03	6.0	800.0	Female	75.0	RITUXIMAB	rheumatoid arthritis	1	3	0.21428571428571427	Child	EU	0.12406015037593986	19	0	20	0	0	0	0	0	0	0	2	2025	11	3	0	0.08936301793444651	0.7443609022556391	0.12406015037593986
922	25778993	US	US	1	2.0	0	0	0	0	2025-09-09	45.0	801.0	Female	75.0	ORENCIA	arthralgia	0	0	0.0	Adult	US	0.10204081632653061	14	0	10	0	0	0	0	0	0	0	1	2025	9	9	1	0.08073634859349145	4.591836734693878	0.10204081632653061
923	25786015	US	US	2	1.0	0	0	0	0	2025-09-10	57.0	801.0	Female	75.0	KESIMPTA	multiple sclerosis	1	0	0.0	MidAge	US	0.0	2	0	18	0	0	0	0	0	0	0	2	2025	9	10	2	0.08936301793444651	0.0	0.0
924	25789146	EU	EU	1	1.0	0	0	1	0	2025-09-11	47.0	801.0	Female	75.0	FULVESTRANT	electrolyte imbalance	1	3	0.21428571428571427	Adult	EU	0.21428571428571427	1	1	21	0	0	0	0	0	0	0	2	2025	9	11	3	0.08073634859349145	10.071428571428571	0.21428571428571427
925	25793992	US	US	1	2.0	0	0	0	0	2025-09-12	62.0	801.0	Female	146.51	ACTEMRA	back pain	0	0	0.0	MidAge	US	0.17857142857142858	6	1	9	1	0	0	0	0	0	0	2	2025	9	12	4	0.08073634859349145	11.071428571428571	0.17857142857142858
926	25803310	US	US	1	1.0	0	0	0	0	2025-09-15	31.0	801.0	Female	73.016	HAEGARDA	maternal exposure during pregnancy	1	0	0.0	Young	US	0.0	1	0	34	0	0	0	0	0	0	0	4	2025	9	15	0	0.08073634859349145	0.0	0.0
927	25803983	EU	EU	1	1.0	0	0	1	0	2025-09-15	60.0	801.0	Female	86.0	RITUXIMAB	leukocytosis	1	3	0.21428571428571427	MidAge	EU	0.12406015037593986	19	0	12	0	0	0	0	0	0	0	1	2025	9	15	0	0.08073634859349145	7.443609022556392	0.12406015037593986
928	25807008	US	US	2	2.0	0	0	0	0	2025-09-16	57.0	801.0	Male	75.0	OMNITROPE	circumstance or information capable of leading to medication error	0	0	0.0	MidAge	US	0.0	5	0	66	0	0	0	0	0	0	0	9	2025	9	16	1	0.08936301793444651	0.0	0.0
929	26206513	GB	GB	1	1.0	0	0	1	0	2025-12-29	42.0	801.0	Male	75.0	NAPROXEN	acute kidney injury	1	3	0.21428571428571427	Adult	GB	0.2857142857142857	2	1	19	0	0	0	0	0	0	0	3	2025	12	29	0	0.08073634859349145	12.0	0.0
930	26206661	US	US	1	2.0	0	0	0	0	2025-12-29	40.0	801.0	Female	75.0	DUPIXENT	condition aggravated	0	0	0.0	Adult	US	0.015513897866839042	221	0	20	0	0	0	0	0	0	0	2	2025	12	29	0	0.08073634859349145	0.6205559146735616	0.015513897866839042
931	25989009	US	US	1	2.0	0	0	0	0	2025-11-03	49.0	801.0	Female	136.05	ALBUTEROL SULFATE	dyspnoea	0	0	0.0	Adult	US	0.0	8	0	8	0	0	0	0	0	0	0	1	2025	11	3	0	0.08073634859349145	0.0	0.0
932	25989467	EU	EU	1	1.0	0	0	1	0	2025-11-03	69.0	801.0	Female	68.0	LETROZOLE	dental operation	1	3	0.21428571428571427	Senior	EU	0.07142857142857142	3	0	16	0	0	0	0	0	0	0	2	2025	11	3	0	0.08073634859349145	4.928571428571428	0.07142857142857142
933	25989562	CN	CN	1	1.0	0	0	1	0	2025-11-03	57.0	801.0	Female	75.0	METHIMAZOLE	antithyroid arthritis syndrome	1	3	0.21428571428571427	MidAge	CN	0.21428571428571427	1	1	30	0	0	0	0	0	0	0	3	2025	11	3	0	0.08073634859349145	12.214285714285714	0.21428571428571427
934	25990104	EU	EU	1	1.0	0	0	1	0	2025-11-03	57.0	801.0	Female	75.0	BUPRENORPHINE	urinary retention	1	3	0.21428571428571427	MidAge	EU	0.2857142857142857	2	1	17	0	0	0	0	0	0	0	2	2025	11	3	0	0.08073634859349145	16.285714285714285	0.2857142857142857
935	25991277	US	US	1	2.0	0	0	0	0	2025-11-03	57.0	801.0	Female	75.0	DUPIXENT	inappropriate schedule of product administration	0	0	0.0	MidAge	US	0.015513897866839042	221	0	48	0	0	0	0	0	0	0	5	2025	11	3	0	0.08073634859349145	0.8842921784098254	0.015513897866839042
936	25991992	US	US	1	2.0	0	0	0	0	2025-11-03	80.0	801.0	Female	75.0	SOLIQUA 100/33	pruritus	0	0	0.0	Senior	US	0.0	1	0	8	0	0	0	0	0	0	0	1	2025	11	3	0	0.08073634859349145	0.0	0.0
937	25992492	US	US	1	2.0	0	0	0	0	2025-11-03	57.0	801.0	Female	75.0	DOXYLAMINE SUCCINATE	fatigue	0	0	0.0	MidAge	US	0.0	1	0	7	0	0	0	0	0	0	0	1	2025	11	3	0	0.08073634859349145	0.0	0.0
938	25950490	US	US	2	1.0	1	0	0	0	2025-10-23	69.0	801.0	Female	75.0	SYNTHROID	renal failure	1	5	0.35714285714285715	Senior	US	0.17857142857142858	2	1	13	0	0	0	0	1	0	0	2	2025	10	23	3	0.08936301793444651	12.321428571428571	0.17857142857142858
939	25950557	GB	GB	2	1.0	0	0	1	0	2025-10-23	78.0	801.0	Female	75.0	CARBIDOPA\LEVODOPA	faecaloma	1	3	0.21428571428571427	Senior	GB	0.3333333333333333	3	1	9	0	0	0	0	0	0	0	1	2025	10	23	3	0.08936301793444651	26.0	0.3333333333333333
940	25950571	EU	EU	1	1.0	0	0	1	0	2025-10-23	78.0	801.0	Female	68.2	RYBREVANT	mucosal inflammation	1	3	0.21428571428571427	Senior	EU	0.05357142857142857	4	0	20	0	0	0	0	0	0	0	2	2025	10	23	3	0.08073634859349145	4.178571428571428	0.05357142857142857
941	25950638	US	US	1	2.0	0	0	0	0	2025-10-23	57.0	801.0	Female	75.0	DUPIXENT	dry skin	0	0	0.0	MidAge	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	2	2025	10	23	3	0.08073634859349145	0.8842921784098254	0.015513897866839042
942	25950962	JP	JP	1	1.0	0	0	1	0	2025-10-23	57.0	801.0	Female	75.0	METHYLPHENIDATE HYDROCHLORIDE	hospitalisation	1	3	0.21428571428571427	MidAge	JP	0.10714285714285714	2	0	15	0	0	0	0	0	0	0	1	2025	10	23	3	0.08073634859349145	6.107142857142857	0.10714285714285714
943	25951529	GB	GB	1	1.0	0	1	0	0	2025-10-23	57.0	801.0	Female	75.0	DIMETHYL FUMARATE	leukaemia	1	4	0.2857142857142857	MidAge	GB	0.2857142857142857	1	1	9	0	0	0	0	0	0	0	1	2025	10	23	3	0.08073634859349145	16.285714285714285	0.2857142857142857
944	25952043	CA	CA	2	1.0	0	0	1	0	2025-10-23	53.0	801.0	Male	75.0	SKYRIZI	acute myocardial infarction	1	3	0.21428571428571427	MidAge	CA	0.051587301587301584	36	0	27	0	0	0	0	0	0	0	3	2025	10	23	3	0.08936301793444651	2.734126984126984	0.0
945	26209725	EU	EU	1	1.0	0	0	0	0	2025-12-29	90.0	801.0	Female	77.0	ALDACTONE	neutropenia	1	0	0.0	Senior	EU	0.0	1	0	11	0	0	0	0	0	0	0	1	2025	12	29	0	0.08073634859349145	0.0	0.0
946	26212493	US	US	1	1.0	0	0	0	0	2025-12-30	71.0	801.0	Female	80.726	FIRDAPSE	chondropathy	1	0	0.0	Senior	US	0.0	3	0	12	0	0	0	0	0	0	0	1	2025	12	30	1	0.08073634859349145	0.0	0.0
947	25809572	US	US	1	2.0	0	0	0	0	2025-09-16	62.0	801.0	Male	75.0	DUPIXENT	no adverse event	0	0	0.0	MidAge	US	0.015513897866839042	221	0	16	0	0	0	0	0	0	0	3	2025	9	16	1	0.08073634859349145	0.9618616677440206	0.0
948	25813326	BA	BA	1	1.0	0	1	1	0	2025-09-17	50.0	801.0	Male	88.0	FRAGMIN	drug ineffective	1	7	0.5	Adult	Other	0.5	1	1	16	0	0	0	0	0	0	0	2	2025	9	17	2	0.08073634859349145	25.0	0.0
949	25815027	EU	EU	1	1.0	0	0	0	0	2025-09-18	58.0	801.0	Female	75.0	DOCETAXEL	infusion related reaction	1	0	0.0	MidAge	EU	0.061224489795918366	7	0	25	0	0	0	0	0	0	0	3	2025	9	18	3	0.08073634859349145	3.5510204081632653	0.061224489795918366
950	25820588	US	US	2	1.0	0	0	1	0	2025-09-19	57.0	801.0	Female	63.946	ISTURISA	cardiac failure	1	3	0.21428571428571427	MidAge	US	0.21428571428571427	1	1	15	0	0	0	0	1	0	0	2	2025	9	19	4	0.08936301793444651	12.214285714285714	0.21428571428571427
951	25824948	US	US	1	1.0	0	0	0	0	2025-09-19	68.0	801.0	Female	75.0	XELJANZ XR	neuropathy peripheral	1	0	0.0	Senior	US	0.0	9	0	21	0	0	0	0	0	0	0	2	2025	9	19	4	0.08073634859349145	0.0	0.0
952	25827473	CA	Unknown	2	1.0	0	0	0	0	2025-09-20	57.0	801.0	Female	75.0	CERTOLIZUMAB PEGOL	ankylosing spondylitis	1	0	0.0	MidAge	CA	0.04285714285714286	5	0	22	0	0	0	0	0	0	0	2	2025	9	20	5	0.08936301793444651	2.442857142857143	0.04285714285714286
953	25827554	EU	EU	1	1.0	0	0	0	0	2025-09-20	57.0	801.0	Female	75.0	PROCYSBI	endocarditis	1	0	0.0	MidAge	EU	0.0	1	0	12	0	0	0	0	0	0	0	1	2025	9	20	5	0.08073634859349145	0.0	0.0
954	25829336	US	US	1	2.0	0	0	0	0	2025-09-22	57.0	801.0	Female	75.0	TIOTROPIUM BROMIDE	drug ineffective	0	0	0.0	MidAge	US	0.0	1	0	16	0	0	0	0	0	0	0	2	2025	9	22	0	0.08073634859349145	0.0	0.0
955	25837612	US	US	1	2.0	0	0	0	0	2025-09-23	10.0	801.0	Female	75.0	OMNITROPE	circumstance or information capable of leading to medication error	0	0	0.0	Child	US	0.0	5	0	66	0	0	0	0	0	0	0	9	2025	9	23	1	0.08073634859349145	0.0	0.0
956	25993464	US	US	1	1.0	0	0	0	0	2025-11-04	57.0	801.0	Female	92.517	SYMBICORT	hypothyroidism	1	0	0.0	MidAge	US	0.0	2	0	14	0	0	0	0	0	0	0	1	2025	11	4	1	0.08073634859349145	0.0	0.0
957	25996218	US	US	1	1.0	0	0	1	0	2025-11-04	67.0	801.0	Female	75.0	CARBOPLATIN	emphysematous cystitis	1	3	0.21428571428571427	Senior	US	0.12244897959183673	7	0	22	0	0	0	0	0	0	0	2	2025	11	4	1	0.08073634859349145	8.204081632653061	0.12244897959183673
958	25953945	EU	EU	1	1.0	0	0	1	0	2025-10-23	69.0	801.0	Female	45.0	PEMETREXED	dermatitis bullous	1	3	0.21428571428571427	Senior	EU	0.21428571428571427	3	1	18	0	0	0	0	0	0	0	2	2025	10	23	3	0.08073634859349145	14.785714285714285	0.21428571428571427
959	25955389	EU	EU	1	1.0	0	0	0	0	2025-10-24	39.0	801.0	Male	75.0	PAROXETINE	drug abuse	1	0	0.0	Adult	EU	0.0	2	0	10	0	0	0	0	0	0	0	2	2025	10	24	4	0.08073634859349145	0.0	0.0
960	25955970	US	US	1	2.0	0	0	0	0	2025-10-24	57.0	801.0	Female	75.0	ALBUTEROL SULFATE	wrong technique in product usage process	0	0	0.0	MidAge	US	0.0	8	0	40	0	0	0	0	0	0	0	6	2025	10	24	4	0.08073634859349145	0.0	0.0
961	25956632	CA	CA	1	1.0	0	0	1	0	2025-10-24	74.0	801.0	Male	102.0	AZACITIDINE	colitis	1	3	0.21428571428571427	Senior	CA	0.21428571428571427	1	1	7	0	0	0	0	0	0	0	1	2025	10	24	4	0.08073634859349145	15.857142857142856	0.0
962	25958252	US	US	1	2.0	0	0	0	0	2025-10-24	64.0	801.0	Male	96.0	VYEPTI	chest discomfort	0	0	0.0	MidAge	US	0.0	1	0	16	0	0	0	0	0	0	0	2	2025	10	24	4	0.08073634859349145	0.0	0.0
963	25958467	US	US	1	2.0	0	0	0	0	2025-10-24	67.0	801.0	Female	54.422	NICOTINE POLACRILEX	expired product administered	0	0	0.0	Senior	US	0.0	1	0	28	0	0	0	0	0	0	0	3	2025	10	24	4	0.08073634859349145	0.0	0.0
964	25959668	US	US	1	1.0	0	0	0	0	2025-10-26	75.0	801.0	Male	75.0	DUPIXENT	loss of consciousness	1	0	0.0	Senior	US	0.015513897866839042	221	0	21	0	0	0	0	0	0	0	3	2025	10	26	6	0.08073634859349145	1.1635423400129281	0.0
965	25960062	US	US	1	2.0	0	0	0	0	2025-10-26	18.0	801.0	Female	75.0	DUPIXENT	incorrect dose administered	0	0	0.0	Child	US	0.015513897866839042	221	0	27	0	0	0	0	0	0	0	3	2025	10	26	6	0.08073634859349145	0.27925016160310273	0.015513897866839042
966	25960453	US	US	1	2.0	0	0	0	0	2025-10-27	10.0	801.0	Male	75.0	OMNITROPE	circumstance or information capable of leading to medication error	0	0	0.0	Child	US	0.0	5	0	66	0	0	0	0	0	0	0	9	2025	10	27	0	0.08073634859349145	0.0	0.0
967	25960763	CN	CN	1	1.0	1	0	0	0	2025-10-27	86.0	801.0	Male	69.0	SEVOFLURANE	anaphylactic shock	1	5	0.35714285714285715	Senior	CN	0.35714285714285715	1	1	18	0	0	0	0	0	0	0	2	2025	10	27	0	0.08073634859349145	30.714285714285715	0.0
968	25961115	US	US	1	2.0	0	0	0	0	2025-10-27	71.0	801.0	Male	75.0	BASAGLAR	nephrolithiasis	0	0	0.0	Senior	US	0.0	2	0	15	0	0	0	0	0	0	0	1	2025	10	27	0	0.08073634859349145	0.0	0.0
969	25961964	EU	EU	1	1.0	0	0	1	0	2025-10-27	67.0	801.0	Male	75.0	IBUPROFEN	acute kidney injury	1	3	0.21428571428571427	Senior	EU	0.11607142857142858	8	0	19	0	0	0	0	0	0	0	3	2025	10	27	0	0.08073634859349145	7.776785714285714	0.0
970	25850248	GB	GB	1	1.0	0	0	1	0	2025-09-26	57.0	801.0	Female	75.0	PREGABALIN	post-traumatic stress disorder	1	3	0.21428571428571427	MidAge	GB	0.10714285714285714	6	0	30	0	0	0	0	0	0	0	3	2025	9	26	4	0.08073634859349145	6.107142857142857	0.10714285714285714
971	25851139	US	US	1	1.0	0	0	0	0	2025-09-26	57.0	801.0	Female	75.0	RYBREVANT	infusion related reaction	1	0	0.0	MidAge	US	0.05357142857142857	4	0	25	0	0	0	0	0	0	0	3	2025	9	26	4	0.08073634859349145	3.0535714285714284	0.05357142857142857
972	25851935	US	US	1	2.0	0	0	0	0	2025-09-26	57.0	801.0	Female	58.503	LEVOTHYROXINE SODIUM	thyroid disorder	0	0	0.0	MidAge	US	0.0	3	0	16	0	0	0	0	0	0	0	2	2025	9	26	4	0.08073634859349145	0.0	0.0
973	25852798	EU	EU	1	1.0	0	0	0	0	2025-09-26	57.0	801.0	Male	75.0	ADCETRIS	malignant neoplasm progression	1	0	0.0	MidAge	EU	0.0	2	0	30	0	0	0	0	0	0	0	3	2025	9	26	4	0.08073634859349145	0.0	0.0
974	25853407	CN	CN	1	1.0	0	0	0	0	2025-09-26	57.0	801.0	Female	75.0	RYBREVANT	myelosuppression	1	0	0.0	MidAge	CN	0.05357142857142857	4	0	16	0	0	0	0	0	0	0	1	2025	9	26	4	0.08073634859349145	3.0535714285714284	0.05357142857142857
975	25998539	US	US	1	2.0	0	0	0	0	2025-11-05	53.0	801.0	Male	75.0	ORGOVYX	abdominal discomfort	0	0	0.0	MidAge	US	0.0	4	0	20	0	0	0	0	0	0	0	2	2025	11	5	2	0.08073634859349145	0.0	0.0
976	25999282	US	US	1	1.0	0	0	1	0	2025-11-05	57.0	801.0	Female	68.31	DUPIXENT	haemoptysis	1	3	0.21428571428571427	MidAge	US	0.015513897866839042	221	0	11	0	0	0	0	0	0	0	1	2025	11	5	2	0.08073634859349145	0.8842921784098254	0.015513897866839042
977	25999497	EU	EU	1	1.0	0	0	1	0	2025-11-05	71.0	801.0	Female	46.0	LORMETAZEPAM	poisoning deliberate	1	3	0.21428571428571427	Senior	EU	0.21428571428571427	1	1	20	0	0	0	0	0	0	0	2	2025	11	5	2	0.08073634859349145	15.214285714285714	0.21428571428571427
978	26000095	AU	AU	1	1.0	0	0	1	0	2025-11-05	56.0	801.0	Male	116.9	VINCRISTINE	rib fracture	1	3	0.21428571428571427	MidAge	AU	0.21428571428571427	1	1	12	0	0	0	0	0	0	0	2	2025	11	5	2	0.08073634859349145	12.0	0.0
979	26000567	US	Unknown	1	1.0	0	0	1	0	2025-11-04	57.0	801.0	Male	97.2	WINREVAIR	catheter site haemorrhage	1	3	0.21428571428571427	MidAge	US	0.2619047619047619	3	1	25	0	0	0	0	0	0	0	3	2025	11	4	1	0.08073634859349145	14.928571428571429	0.0
980	25962288	AU	AU	1	1.0	1	0	0	0	2025-10-27	57.0	801.0	Male	75.0	ALCOHOL (ALCOHOL)	intentional overdose	1	5	0.35714285714285715	MidAge	AU	0.35714285714285715	1	1	20	0	0	0	0	0	0	0	2	2025	10	27	0	0.08073634859349145	20.357142857142858	0.0
981	25962383	EU	EU	1	1.0	0	0	1	0	2025-10-27	71.0	801.0	Male	75.0	ADRENALIN	condition aggravated	1	3	0.21428571428571427	Senior	EU	0.21428571428571427	1	1	20	0	0	0	0	0	0	0	2	2025	10	27	0	0.08073634859349145	15.214285714285714	0.0
982	25964503	US	US	1	1.0	0	0	1	0	2025-10-27	13.0	801.0	Female	75.0	METHOTREXATE	neurotoxicity	1	3	0.21428571428571427	Child	US	0.17346938775510204	7	1	13	0	0	0	0	0	0	0	1	2025	10	27	0	0.08073634859349145	2.2551020408163267	0.17346938775510204
983	25964880	US	US	1	1.0	0	0	1	0	2025-10-27	57.0	801.0	Female	75.0	WEGOVY	intestinal obstruction	1	3	0.21428571428571427	MidAge	US	0.14285714285714285	4	1	22	0	0	0	0	0	0	0	2	2025	10	27	0	0.08073634859349145	8.142857142857142	0.14285714285714285
984	25965232	US	US	1	2.0	0	0	0	0	2025-10-27	57.0	801.0	Female	75.0	DUPIXENT	pruritus	0	0	0.0	MidAge	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	1	2025	10	27	0	0.08073634859349145	0.8842921784098254	0.015513897866839042
985	25965528	US	US	1	2.0	0	0	0	0	2025-10-27	15.0	801.0	Male	75.0	DUPIXENT	fear of injection	0	0	0.0	Child	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	3	2025	10	27	0	0.08073634859349145	0.23270846800258563	0.0
986	25965609	US	US	1	2.0	0	0	0	0	2025-10-27	51.0	801.0	Male	75.0	DUPIXENT	eosinophilic oesophagitis	0	0	0.0	MidAge	US	0.015513897866839042	221	0	25	0	0	0	0	0	0	0	2	2025	10	27	0	0.08073634859349145	0.7912087912087912	0.0
987	25965919	US	US	1	2.0	0	0	0	0	2025-10-27	57.0	801.0	Female	79.55	DUPIXENT	product use in unapproved indication	0	0	0.0	MidAge	US	0.015513897866839042	221	0	36	0	0	0	0	0	0	0	5	2025	10	27	0	0.08073634859349145	0.8842921784098254	0.015513897866839042
988	26003335	EU	EU	1	1.0	0	0	1	0	2025-11-06	52.0	801.0	Female	75.0	CLONAZEPAM	drug abuse	1	3	0.21428571428571427	MidAge	EU	0.07142857142857142	3	0	10	0	0	0	0	0	0	0	2	2025	11	6	3	0.08073634859349145	3.714285714285714	0.07142857142857142
989	26003564	US	US	1	2.0	0	0	0	0	2025-11-06	1.0	801.0	Female	75.0	DUPIXENT	maternal exposure during breast feeding	0	0	0.0	Child	US	0.015513897866839042	221	0	39	0	0	0	0	0	0	0	5	2025	11	6	3	0.08073634859349145	0.015513897866839042	0.015513897866839042
990	26003807	US	US	1	2.0	0	0	0	0	2025-11-06	57.0	801.0	Female	60.45	DUPIXENT	pruritus	0	0	0.0	MidAge	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	1	2025	11	6	3	0.08073634859349145	0.8842921784098254	0.015513897866839042
991	26004198	US	US	1	2.0	0	0	0	0	2025-11-06	57.0	801.0	Female	79.37	DUPIXENT	maternal exposure during pregnancy	0	0	0.0	MidAge	US	0.015513897866839042	221	0	34	0	0	0	0	0	0	0	4	2025	11	6	3	0.08073634859349145	0.8842921784098254	0.015513897866839042
992	26004279	US	US	1	2.0	0	0	0	0	2025-11-06	57.0	801.0	Male	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	MidAge	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	11	6	3	0.08073634859349145	0.8842921784098254	0.0
993	25861426	US	US	2	1.0	0	0	0	0	2025-09-29	57.0	801.0	Female	79.0	HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN	mycobacterium avium complex infection	1	0	0.0	MidAge	US	0.07142857142857142	3	0	37	0	1	0	0	0	0	0	4	2025	9	29	0	0.08936301793444651	4.071428571428571	0.07142857142857142
994	25861479	CA	CA	2	1.0	0	0	0	0	2025-09-30	57.0	801.0	Female	75.0	SIMPONI	rheumatoid arthritis	1	0	0.0	MidAge	CA	0.0	2	0	20	0	0	0	0	0	0	0	2	2025	9	30	1	0.08936301793444651	0.0	0.0
995	25861574	VN	VN	2	1.0	0	0	0	0	2025-09-30	55.0	801.0	Male	75.0	DARZALEX	leukopenia	1	0	0.0	MidAge	Other	0.0	2	0	10	0	0	0	0	0	0	0	1	2025	9	30	1	0.08936301793444651	0.0	0.0
996	25867473	US	US	2	1.0	0	0	1	0	2025-10-01	72.0	801.0	Male	75.0	CREON	sepsis	1	3	0.21428571428571427	Senior	US	0.03296703296703297	13	0	6	0	0	0	0	0	0	0	1	2025	10	1	2	0.08936301793444651	2.3736263736263736	0.0
997	25868498	PR	PR	2	1.0	0	0	1	0	2025-10-01	74.0	801.0	Female	75.0	VENCLEXTA	white blood cell count decreased	1	3	0.21428571428571427	Senior	Other	0.18571428571428572	5	1	32	0	0	0	0	0	0	0	5	2025	10	1	2	0.08936301793444651	13.742857142857144	0.18571428571428572
998	25868889	US	US	1	1.0	0	0	0	0	2025-10-01	62.0	801.0	Male	75.0	HYDRALAZINE HYDROCHLORIDE	glomerulonephritis	1	0	0.0	MidAge	US	0.0	1	0	18	0	0	0	0	0	0	0	1	2025	10	1	2	0.08073634859349145	0.0	0.0
999	25868917	CA	CA	1	1.0	1	0	1	1	2025-10-01	40.0	801.0	Female	75.0	ACTEMRA	contraindicated product administered	1	10	0.7142857142857143	Adult	CA	0.17857142857142858	6	1	36	0	0	0	0	0	0	0	3	2025	10	1	2	0.08073634859349145	7.142857142857143	0.17857142857142858
1000	25967296	US	US	2	1.0	0	0	0	0	2025-10-28	57.0	801.0	Female	75.0	SKYRIZI	nephrolithiasis	1	0	0.0	MidAge	US	0.051587301587301584	36	0	15	0	0	0	0	0	0	0	1	2025	10	28	1	0.08936301793444651	2.9404761904761902	0.051587301587301584
1001	25969078	EU	EU	1	1.0	0	0	0	0	2025-10-28	57.0	801.0	Male	75.0	DOCETAXEL	hepatotoxicity	1	0	0.0	MidAge	EU	0.061224489795918366	7	0	14	0	0	0	0	0	0	0	1	2025	10	28	1	0.08073634859349145	3.489795918367347	0.0
1002	25969173	CA	CA	3	1.0	0	0	0	0	2025-10-28	48.0	801.0	Male	75.0	MYCOPHENOLATE MOFETIL	lymphadenopathy	1	0	0.0	Adult	CA	0.10150375939849625	19	0	15	0	0	0	0	0	0	0	1	2025	10	28	1	0.17857142857142855	4.87218045112782	0.0
1003	25969430	JP	JP	1	1.0	0	0	1	0	2025-10-28	78.0	801.0	Male	75.0	METHYLPREDNISOLONE	cerebral infarction	1	3	0.21428571428571427	Senior	JP	0.14285714285714285	3	1	19	0	0	0	0	0	0	0	2	2025	10	28	1	0.08073634859349145	11.142857142857142	0.0
1004	26005494	EU	EU	1	1.0	1	0	1	0	2025-11-06	48.0	801.0	Male	75.0	DOLUTEGRAVIR	pancytopenia	1	8	0.5714285714285714	Adult	EU	0.5714285714285714	1	1	12	0	0	0	0	0	0	0	1	2025	11	6	3	0.08073634859349145	27.428571428571427	0.0
1005	26006075	US	US	1	2.0	0	0	0	0	2025-11-06	20.0	801.0	Male	75.0	ADDERALL XR	restlessness	0	0	0.0	Young	US	0.0	2	0	12	0	0	0	0	0	0	0	1	2025	11	6	3	0.08073634859349145	0.0	0.0
1006	26007195	US	US	2	2.0	0	0	0	0	2025-11-06	70.0	801.0	Female	75.0	ZENATANE	product use issue	0	0	0.0	Senior	US	0.0	1	0	17	0	0	0	0	0	0	0	3	2025	11	6	3	0.08936301793444651	0.0	0.0
1007	26007924	US	Unknown	1	1.0	0	0	0	0	2025-11-05	73.0	801.0	Male	72.03	INSULIN LISPRO	device malfunction	1	0	0.0	Senior	US	0.0	1	0	18	0	0	0	0	0	0	0	2	2025	11	5	2	0.08073634859349145	0.0	0.0
1008	26008505	US	US	1	2.0	0	0	0	0	2025-11-06	41.0	801.0	Female	75.0	DUPIXENT	eosinophilic oesophagitis	0	0	0.0	Adult	US	0.015513897866839042	221	0	25	0	0	0	0	0	0	0	2	2025	11	6	3	0.08073634859349145	0.6360698125404007	0.015513897866839042
1009	26008572	CA	CA	1	1.0	0	0	0	0	2025-11-06	57.0	801.0	Female	75.0	VASCEPA	choking	1	0	0.0	MidAge	CA	0.0	2	0	7	0	0	0	0	0	0	0	1	2025	11	6	3	0.08073634859349145	0.0	0.0
1010	25871308	EU	EU	1	1.0	0	0	1	0	2025-10-01	73.0	801.0	Female	64.0	GEMCITABINE	lung disorder	1	3	0.21428571428571427	Senior	EU	0.21428571428571427	1	1	13	0	0	0	0	0	0	0	2	2025	10	1	2	0.08073634859349145	15.642857142857142	0.21428571428571427
1011	25871403	US	US	1	2.0	0	0	0	0	2025-10-01	85.0	801.0	Female	81.633	DUPIXENT	foreign body sensation in eyes	0	0	0.0	Senior	US	0.015513897866839042	221	0	30	0	0	0	0	0	0	0	5	2025	10	1	2	0.08073634859349145	1.3186813186813187	0.015513897866839042
1012	25872576	US	US	1	2.0	0	0	0	0	2025-10-02	45.0	801.0	Female	75.0	DUPIXENT	off label use	0	0	0.0	Adult	US	0.015513897866839042	221	0	13	0	0	0	0	0	0	0	3	2025	10	2	3	0.08073634859349145	0.6981254040077569	0.015513897866839042
1013	25970469	EU	EU	2	1.0	0	0	1	0	2025-10-28	57.0	801.0	Female	75.0	METHOTREXATE	knee arthroplasty	1	3	0.21428571428571427	MidAge	EU	0.17346938775510204	7	1	17	0	0	0	0	0	0	0	2	2025	10	28	1	0.08936301793444651	9.887755102040817	0.17346938775510204
1014	25971455	CA	CA	1	1.0	0	0	0	0	2025-10-28	52.0	801.0	Female	75.0	TADALAFIL	condition aggravated	1	0	0.0	MidAge	CA	0.0	2	0	20	0	0	0	0	0	0	0	2	2025	10	28	1	0.08073634859349145	0.0	0.0
1015	25972265	EU	EU	1	1.0	0	0	0	0	2025-10-29	81.0	801.0	Female	75.0	CIPROFLOXACIN	mobility decreased	1	0	0.0	Senior	EU	0.07142857142857142	3	0	18	0	0	0	0	0	0	0	2	2025	10	29	2	0.08073634859349145	5.785714285714286	0.07142857142857142
1016	25973695	US	US	1	2.0	0	0	0	0	2025-10-29	57.0	801.0	Female	75.0	PROGESTERONE	headache	0	0	0.0	MidAge	US	0.0	1	0	8	0	0	0	0	0	0	0	1	2025	10	29	2	0.08073634859349145	0.0	0.0
1017	26010153	JP	JP	1	1.0	0	0	0	0	2025-11-07	57.0	801.0	Female	75.0	DENOSUMAB	carcinoembryonic antigen increased	1	0	0.0	MidAge	JP	0.0	1	0	34	0	0	0	0	0	0	0	3	2025	11	7	4	0.08073634859349145	0.0	0.0
1018	26010759	GB	GB	1	1.0	0	0	0	0	2025-11-07	68.0	801.0	Female	80.0	ATORVASTATIN	gastrointestinal disorder	1	0	0.0	Senior	GB	0.10714285714285714	2	0	25	0	0	0	0	0	0	0	2	2025	11	7	4	0.08073634859349145	7.285714285714286	0.10714285714285714
1019	26011435	US	US	1	2.0	0	0	0	0	2025-11-07	57.0	801.0	Female	75.0	ALBUTEROL SULFATE	circumstance or information capable of leading to medication error	0	0	0.0	MidAge	US	0.0	8	0	66	0	0	0	0	0	0	0	9	2025	11	7	4	0.08073634859349145	0.0	0.0
1020	26012164	CA	CA	1	1.0	1	0	0	0	2025-11-07	43.0	801.0	Female	68.0	ACTEMRA	condition aggravated	1	5	0.35714285714285715	Adult	CA	0.17857142857142858	6	1	20	0	0	0	0	0	0	0	2	2025	11	7	4	0.08073634859349145	7.678571428571429	0.17857142857142858
1021	25874196	BR	BR	2	1.0	0	0	0	0	2025-10-02	56.0	801.0	Female	69.0	VEDOLIZUMAB	colitis ulcerative	1	0	0.0	MidAge	BR	0.057692307692307696	26	0	18	0	0	0	0	0	0	0	2	2025	10	2	3	0.08936301793444651	3.230769230769231	0.057692307692307696
1022	25874925	GB	GB	1	1.0	0	0	0	0	2025-10-02	57.0	801.0	Male	75.0	VENETOCLAX	cytopenia	1	0	0.0	MidAge	GB	0.0	1	0	9	0	0	0	0	0	0	0	1	2025	10	2	3	0.08073634859349145	0.0	0.0
1023	25877531	CN	CN	1	1.0	0	0	0	0	2025-10-03	87.0	801.0	Female	57.0	TISLELIZUMAB	myelosuppression	1	0	0.0	Senior	CN	0.0	3	0	16	0	0	0	0	0	0	0	1	2025	10	3	4	0.08073634859349145	0.0	0.0
1024	25878570	US	US	1	1.0	0	0	1	0	2025-10-03	70.0	801.0	Male	75.0	LENALIDOMIDE	cardiac disorder	1	3	0.21428571428571427	Senior	US	0.15413533834586465	19	1	16	0	0	0	0	0	0	0	2	2025	10	3	4	0.08073634859349145	10.789473684210526	0.0
1025	25879151	EU	EU	1	1.0	0	0	1	0	2025-10-03	55.0	801.0	Male	72.0	CIPROFLOXACIN	dysbiosis	1	3	0.21428571428571427	MidAge	EU	0.07142857142857142	3	0	9	0	0	0	0	0	0	0	1	2025	10	3	4	0.08073634859349145	3.9285714285714284	0.0
1026	25881042	US	US	1	2.0	0	0	0	0	2025-10-04	57.0	801.0	Male	75.0	DUPIXENT	hypersensitivity	0	0	0.0	MidAge	US	0.015513897866839042	221	0	16	0	0	0	0	0	0	0	1	2025	10	4	5	0.08073634859349145	0.8842921784098254	0.0
1027	25975653	US	Unknown	1	1.0	0	0	1	0	2025-10-29	87.0	801.0	Female	75.0	LENALIDOMIDE	intentional dose omission	1	3	0.21428571428571427	Senior	US	0.15413533834586465	19	1	25	0	0	0	0	0	0	0	3	2025	10	29	2	0.08073634859349145	13.409774436090224	0.15413533834586465
1028	25976153	CA	CA	1	1.0	1	0	0	0	2025-10-29	43.0	801.0	Female	68.0	COSENTYX	confusional state	1	5	0.35714285714285715	Adult	CA	0.05714285714285714	10	0	17	0	0	0	0	0	0	0	2	2025	10	29	2	0.08073634859349145	2.457142857142857	0.05714285714285714
1029	25976382	GB	GB	1	1.0	0	0	0	0	2025-10-29	57.0	801.0	Female	75.0	COSENTYX	osteonecrosis	1	0	0.0	MidAge	GB	0.05714285714285714	10	0	13	0	0	0	0	0	0	0	1	2025	10	29	2	0.08073634859349145	3.257142857142857	0.05714285714285714
1030	25976463	US	US	1	2.0	0	0	0	0	2025-10-29	57.0	801.0	Male	75.0	TRELEGY ELLIPTA	visual impairment	0	0	0.0	MidAge	US	0.0	4	0	17	0	0	0	0	0	0	0	2	2025	10	29	2	0.08073634859349145	0.0	0.0
1031	14520544	US	US	2	1.0	0	0	1	0	2018-02-12	78.0	801.0	Female	75.0	VEDOLIZUMAB	hip fracture	1	3	0.21428571428571427	Senior	US	0.057692307692307696	26	0	12	0	0	0	0	0	0	0	2	2018	2	12	0	0.08936301793444651	4.5	0.057692307692307696
1032	15082980	US	US	1	2.0	0	0	0	0	2018-06-28	41.0	801.0	Female	75.0	SUBLOCADE	dysgeusia	0	0	0.0	Adult	US	0.0	1	0	9	0	0	0	0	0	0	0	1	2018	6	28	3	0.08073634859349145	0.0	0.0
1033	17707771	US	US	2	1.0	0	0	1	0	2020-04-24	26.0	801.0	Female	56.0	HUMAN IMMUNOGLOBULIN G	covid-19 pneumonia	1	3	0.21428571428571427	Young	US	0.10714285714285714	8	0	18	0	0	0	0	0	1	0	2	2020	4	24	4	0.08936301793444651	2.7857142857142856	0.10714285714285714
1034	17806834	CA	CA	1	1.0	0	0	0	0	2020-05-20	53.0	801.0	Female	53.0	ACTEMRA	abdominal pain	1	0	0.0	MidAge	CA	0.17857142857142858	6	1	14	1	0	0	0	0	0	0	2	2020	5	20	2	0.08073634859349145	9.464285714285715	0.17857142857142858
1035	17966309	US	US	2	1.0	0	0	1	0	2020-06-30	64.0	801.0	Male	76.0	HUMAN IMMUNOGLOBULIN G	diverticulitis	1	3	0.21428571428571427	MidAge	US	0.10714285714285714	8	0	14	0	0	0	0	0	0	0	1	2020	6	30	1	0.08936301793444651	6.857142857142857	0.0
1036	18512710	US	US	2	1.0	0	0	0	0	2020-11-17	67.0	801.0	Female	75.0	HUMAN IMMUNOGLOBULIN G	suspected covid-19	1	0	0.0	Senior	US	0.10714285714285714	8	0	18	0	0	0	0	0	0	0	2	2020	11	17	1	0.08936301793444651	7.178571428571428	0.10714285714285714
1037	25883268	US	US	1	2.0	0	0	0	0	2025-10-06	23.0	801.0	Male	75.0	IBUPROFEN	drug ineffective	0	0	0.0	Young	US	0.11607142857142858	8	0	16	0	0	0	0	0	0	0	2	2025	10	6	0	0.08073634859349145	2.669642857142857	0.0
1038	25883673	US	US	1	2.0	0	0	0	0	2025-10-06	57.0	801.0	Female	75.0	PLUVICTO	general physical health deterioration	0	0	0.0	MidAge	US	0.0	8	0	37	0	0	0	0	0	0	0	4	2025	10	6	0	0.08073634859349145	0.0	0.0
1039	25979055	EU	EU	1	1.0	0	0	0	0	2025-10-30	79.0	801.0	Female	70.0	CAPECITABINE	chest pain	1	0	0.0	Senior	EU	0.10714285714285714	2	0	10	1	0	0	0	0	0	0	2	2025	10	30	3	0.08073634859349145	8.464285714285714	0.10714285714285714
1040	25981270	US	US	1	2.0	0	0	0	0	2025-10-30	57.0	801.0	Female	75.0	NEMLUVIO	device malfunction	0	0	0.0	MidAge	US	0.0	1	0	18	0	0	0	0	0	0	0	2	2025	10	30	3	0.08073634859349145	0.0	0.0
1041	25982471	US	US	1	1.0	0	0	0	0	2025-10-31	57.0	801.0	Male	75.0	TRELEGY ELLIPTA	product dose omission issue	1	0	0.0	MidAge	US	0.0	4	0	27	0	0	0	0	0	0	0	4	2025	10	31	4	0.08073634859349145	0.0	0.0
1042	25982929	EU	EU	1	1.0	0	0	0	0	2025-10-31	43.0	801.0	Female	75.0	ASCIMINIB	blast crisis in myelogenous leukaemia	1	0	0.0	Adult	EU	0.0	1	0	37	0	0	0	0	0	0	0	5	2025	10	31	4	0.08073634859349145	0.0	0.0
1043	26040958	US	US	1	1.0	0	0	1	0	2025-11-13	57.0	801.0	Female	75.0	DUPIXENT	road traffic accident	1	3	0.21428571428571427	MidAge	US	0.015513897866839042	221	0	21	0	0	0	0	0	0	0	3	2025	11	13	3	0.08073634859349145	0.8842921784098254	0.015513897866839042
1044	26041849	US	US	1	2.0	0	0	0	0	2025-11-13	30.0	801.0	Male	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	Young	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	11	13	3	0.08073634859349145	0.46541693600517126	0.0
1045	20225402	CA	CA	1	1.0	0	0	0	0	2021-12-24	50.0	801.0	Female	75.0	AMLODIPINE	extrapyramidal disorder	1	0	0.0	Adult	CA	0.16964285714285715	8	1	23	0	0	0	0	0	0	0	2	2021	12	24	4	0.08073634859349145	8.482142857142858	0.16964285714285715
1046	20582718	US	US	1	2.0	0	0	0	0	2022-03-11	65.0	801.0	Female	63.0	PREMARIN	oropharyngeal discomfort	0	0	0.0	MidAge	US	0.0	1	0	24	0	0	0	0	0	0	0	2	2022	3	11	4	0.08073634859349145	0.0	0.0
1047	20689596	EU	EU	1	1.0	1	0	0	0	2022-04-08	7.0	801.0	Female	75.0	KYMRIAH	condition aggravated	1	5	0.35714285714285715	Child	EU	0.35714285714285715	1	1	20	0	0	0	0	0	0	0	2	2022	4	8	4	0.08073634859349145	2.5	0.35714285714285715
1048	20711941	US	US	1	2.0	0	0	0	0	2022-04-14	57.0	801.0	Female	75.0	CRYSVITA	blood phosphorus decreased	0	0	0.0	MidAge	US	0.0	1	0	26	0	0	0	0	0	0	0	3	2022	4	14	3	0.08073634859349145	0.0	0.0
1049	20795424	IL	IL	1	1.0	0	0	0	0	2022-05-06	42.0	801.0	Male	75.0	ELELYSO	hip arthroplasty	1	0	0.0	Adult	Other	0.0	1	0	16	0	0	0	0	0	0	0	2	2022	5	6	4	0.08073634859349145	0.0	0.0
1050	20865961	US	US	2	1.0	0	0	1	0	2022-05-24	55.0	801.0	Female	38.0	EPIDIOLEX	cystitis	1	3	0.21428571428571427	MidAge	US	0.14285714285714285	3	1	8	0	0	0	0	0	0	0	1	2022	5	24	1	0.08936301793444651	7.857142857142857	0.14285714285714285
1051	21022604	GB	Unknown	2	1.0	0	0	1	0	2022-06-29	57.0	801.0	Female	75.0	CERTOLIZUMAB PEGOL	otitis externa	1	3	0.21428571428571427	MidAge	GB	0.04285714285714286	5	0	14	0	0	0	0	0	0	0	2	2022	6	29	2	0.08936301793444651	2.442857142857143	0.04285714285714286
1052	25987236	GB	GB	1	1.0	0	0	0	0	2025-11-03	43.0	801.0	Female	84.0	IBUPROFEN	rash	1	0	0.0	Adult	GB	0.11607142857142858	8	0	4	0	0	0	0	0	0	0	1	2025	11	3	0	0.08073634859349145	4.991071428571429	0.11607142857142858
1053	25987627	GB	GB	1	1.0	0	0	0	0	2025-11-03	57.0	801.0	Male	75.0	RAMIPRIL	muscle spasms	1	0	0.0	MidAge	GB	0.0	1	0	13	0	0	0	0	0	0	0	2	2025	11	3	0	0.08073634859349145	0.0	0.0
1054	25988518	EU	EU	3	1.0	1	0	0	0	2025-11-03	57.0	801.0	Female	75.0	ACETAMINOPHEN	drug use disorder	1	5	0.35714285714285715	MidAge	EU	0.10267857142857142	16	0	17	0	0	0	0	0	0	0	3	2025	11	3	0	0.17857142857142855	5.852678571428571	0.10267857142857142
1055	25988666	EU	EU	1	1.0	0	0	0	0	2025-11-03	64.0	801.0	Female	75.0	MEROPENEM	linear iga disease	1	0	0.0	MidAge	EU	0.0	1	0	18	0	0	0	0	0	0	0	3	2025	11	3	0	0.08073634859349145	0.0	0.0
1056	25989180	EU	EU	1	1.0	0	0	1	0	2025-11-03	39.0	801.0	Female	75.0	METFORMIN	maternal exposure during breast feeding	1	3	0.21428571428571427	Adult	EU	0.21428571428571427	2	1	39	0	0	0	0	0	0	0	5	2025	11	3	0	0.08073634859349145	8.357142857142856	0.21428571428571427
1057	25989247	CR	CR	2	1.0	0	0	0	1	2025-11-03	57.0	801.0	Male	75.0	EXFORGE HCT	pollakiuria	1	2	0.14285714285714285	MidAge	Other	0.14285714285714285	1	1	11	0	0	0	0	0	0	0	1	2025	11	3	0	0.08936301793444651	8.142857142857142	0.0
1058	25989328	EU	EU	1	1.0	0	0	0	0	2025-11-03	57.0	801.0	Female	75.0	INFLIXIMAB	colitis ulcerative	1	0	0.0	MidAge	EU	0.07142857142857142	9	0	18	0	0	0	0	0	0	0	2	2025	11	3	0	0.08073634859349145	4.071428571428571	0.07142857142857142
1059	25989786	US	US	1	1.0	0	0	0	0	2025-11-03	58.0	801.0	Male	75.0	PREDNISONE	cystoid macular oedema	1	0	0.0	MidAge	US	0.1607142857142857	8	1	22	0	0	0	0	0	0	0	3	2025	11	3	0	0.08073634859349145	9.321428571428571	0.0
1060	25995026	JP	JP	1	1.0	0	0	1	0	2025-11-04	17.0	801.0	Female	75.0	VENLAFAXINE HYDROCHLORIDE	altered state of consciousness	1	3	0.21428571428571427	Child	JP	0.21428571428571427	1	1	30	0	0	0	0	0	0	0	4	2025	11	4	1	0.08073634859349145	3.642857142857143	0.21428571428571427
1061	25915682	US	US	1	2.0	0	0	0	0	2025-10-13	57.0	801.0	Female	75.0	JOENJA	chronic sinusitis	0	0	0.0	MidAge	US	0.0	3	0	17	0	0	0	0	0	0	0	2	2025	10	13	0	0.08073634859349145	0.0	0.0
1062	25915844	US	US	1	2.0	0	0	0	0	2025-10-13	65.0	801.0	Female	75.0	DATROWAY	off label use	0	0	0.0	MidAge	US	0.0	2	0	13	0	0	0	0	0	0	0	3	2025	10	13	0	0.08073634859349145	0.0	0.0
1063	25916249	US	US	1	2.0	0	0	0	0	2025-10-14	54.0	801.0	Male	75.0	COSENTYX	wrong technique in device usage process	0	0	0.0	MidAge	US	0.05714285714285714	10	0	39	0	0	0	0	0	0	0	6	2025	10	14	1	0.08073634859349145	3.0857142857142854	0.0
1064	25917383	CA	CA	1	1.0	0	0	0	0	2025-10-14	57.0	801.0	Female	75.0	INFLIXIMAB	infusion site extravasation	1	0	0.0	MidAge	CA	0.07142857142857142	9	0	27	0	0	0	0	0	0	0	3	2025	10	14	1	0.08073634859349145	4.071428571428571	0.07142857142857142
1065	21465146	CA	CA	1	1.0	0	0	1	0	2022-10-17	37.0	801.0	Female	75.0	VICTOZA	blood potassium decreased	1	3	0.21428571428571427	Adult	CA	0.21428571428571427	1	1	25	0	0	0	0	0	0	0	3	2022	10	17	0	0.08073634859349145	7.928571428571428	0.21428571428571427
1066	21759553	EU	EU	1	1.0	0	0	0	0	2022-12-21	52.0	801.0	Female	66.0	LEVOFLOXACIN	pain in extremity	1	0	0.0	MidAge	EU	0.25	4	1	17	1	0	0	0	0	0	0	3	2022	12	21	2	0.08073634859349145	13.0	0.25
1067	21770192	EU	EU	2	1.0	0	0	0	0	2022-12-23	66.0	801.0	Male	88.0	ENCORAFENIB	insomnia	1	0	0.0	Senior	EU	0.0	1	0	8	0	0	0	0	0	0	0	1	2022	12	23	4	0.08936301793444651	0.0	0.0
1068	21784487	US	US	1	1.0	0	0	0	0	2022-12-27	74.0	801.0	Male	95.25	BRAFTOVI	haematemesis	1	0	0.0	Senior	US	0.0	1	0	12	0	0	0	0	0	0	0	1	2022	12	27	1	0.08073634859349145	0.0	0.0
1069	21919609	AU	AU	2	1.0	0	0	1	0	2023-01-27	51.0	801.0	Female	75.0	TEDUGLUTIDE	duodenal polyp	1	3	0.21428571428571427	MidAge	AU	0.14285714285714285	3	1	14	0	0	0	0	0	0	0	2	2023	1	27	4	0.08936301793444651	7.285714285714286	0.14285714285714285
1070	21995654	US	US	1	2.0	0	0	0	0	2023-02-15	35.0	801.0	Male	75.0	DUPIXENT	pain in extremity	0	0	0.0	Young	US	0.015513897866839042	221	0	17	1	0	0	0	0	0	0	3	2023	2	15	2	0.08073634859349145	0.5429864253393665	0.0
1071	22238358	CA	CA	2	1.0	0	0	0	0	2023-04-21	57.0	801.0	Female	75.0	RITUXIMAB	pulmonary embolism	1	0	0.0	MidAge	CA	0.12406015037593986	19	0	18	0	0	0	0	0	0	0	2	2023	4	21	4	0.08936301793444651	7.071428571428572	0.12406015037593986
1072	25920112	US	Unknown	1	1.0	0	0	0	0	2025-10-14	45.0	801.0	Female	75.0	MYCOPHENOLIC ACID	dizziness	1	0	0.0	Adult	US	0.0	1	0	9	0	0	0	0	0	0	0	1	2025	10	14	1	0.08073634859349145	0.0	0.0
1073	25920408	US	US	1	1.0	1	0	1	0	2025-10-14	57.0	801.0	Female	75.0	YUTREPIA	pulmonary fibrosis	1	8	0.5714285714285714	MidAge	US	0.5714285714285714	1	1	18	0	0	0	0	0	0	0	2	2025	10	14	1	0.08073634859349145	32.57142857142857	0.5714285714285714
1074	25921056	EU	EU	1	1.0	0	1	1	0	2025-10-14	59.0	801.0	Female	75.0	TUKYSA	cardiac failure	1	7	0.5	MidAge	EU	0.5	1	1	15	0	0	0	0	1	0	0	2	2025	10	14	1	0.08073634859349145	29.5	0.5
1075	25921285	US	US	1	2.0	0	0	0	0	2025-10-14	57.0	801.0	Female	75.0	DUPIXENT	wheezing	0	0	0.0	MidAge	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	1	2025	10	14	1	0.08073634859349145	0.8842921784098254	0.015513897866839042
1076	25921542	US	US	1	2.0	0	0	0	0	2025-10-14	21.0	801.0	Female	75.0	DUPIXENT	injection site irritation	0	0	0.0	Young	US	0.015513897866839042	221	0	25	0	0	0	0	0	0	0	3	2025	10	14	1	0.08073634859349145	0.32579185520361986	0.015513897866839042
1077	25922891	US	US	1	2.0	0	0	0	0	2025-10-15	57.0	801.0	Male	75.0	DUPIXENT	loss of personal independence in daily activities	0	0	0.0	MidAge	US	0.015513897866839042	221	0	49	0	0	0	0	0	0	0	7	2025	10	15	2	0.08073634859349145	0.8842921784098254	0.0
1078	25923148	US	US	2	1.0	0	0	0	0	2025-10-15	57.0	801.0	Female	75.0	CREON	cerebrovascular accident	1	0	0.0	MidAge	US	0.03296703296703297	13	0	24	0	0	0	0	0	0	0	2	2025	10	15	2	0.08936301793444651	1.879120879120879	0.03296703296703297
1079	25926550	EU	EU	1	1.0	0	0	0	0	2025-10-15	64.0	801.0	Male	75.0	AMLODIPINE	erythema	1	0	0.0	MidAge	EU	0.16964285714285715	8	1	8	0	0	0	0	0	0	0	1	2025	10	15	2	0.08073634859349145	10.857142857142858	0.0
1080	25926684	US	US	1	2.0	0	0	0	0	2025-10-15	65.0	801.0	Male	75.0	XELJANZ XR	covid-19	0	0	0.0	MidAge	US	0.0	9	0	8	0	0	0	0	0	0	0	1	2025	10	15	2	0.08073634859349145	0.0	0.0
1081	25927399	CN	CN	2	1.0	0	0	1	0	2025-10-15	53.0	801.0	Female	54.0	DARATUMUMAB	pyrexia	1	3	0.21428571428571427	MidAge	CN	0.14285714285714285	3	1	7	0	0	0	0	0	0	0	1	2025	10	15	2	0.08936301793444651	7.571428571428571	0.14285714285714285
1082	25928103	US	US	1	2.0	0	0	0	0	2025-10-16	24.0	801.0	Female	75.0	DUPIXENT	urticaria	0	0	0.0	Young	US	0.015513897866839042	221	0	9	0	0	0	0	0	0	0	1	2025	10	16	3	0.08073634859349145	0.372333548804137	0.015513897866839042
1083	25928385	US	US	1	2.0	0	0	0	0	2025-10-16	69.0	801.0	Female	75.0	TRELEGY ELLIPTA	muscle spasms	0	0	0.0	Senior	US	0.0	4	0	13	0	0	0	0	0	0	0	2	2025	10	16	3	0.08073634859349145	0.0	0.0
1084	25929438	EU	EU	1	1.0	0	0	1	0	2025-10-16	8.0	801.0	Male	30.0	XOLAIR	scrotal oedema	1	3	0.21428571428571427	Child	EU	0.14285714285714285	4	1	14	0	0	0	0	0	0	0	2	2025	10	16	3	0.08073634859349145	1.1428571428571428	0.0
1085	25930142	US	US	1	1.0	0	0	1	0	2025-10-16	54.0	801.0	Female	61.0	FLUOROURACIL	colitis	1	3	0.21428571428571427	MidAge	US	0.21428571428571427	1	1	7	0	0	0	0	0	0	0	1	2025	10	16	3	0.08073634859349145	11.571428571428571	0.21428571428571427
1086	25930748	US	US	1	2.0	0	0	0	0	2025-10-16	45.0	801.0	Female	75.0	ORENCIA	loss of therapeutic response	0	0	0.0	Adult	US	0.10204081632653061	14	0	28	0	0	0	0	0	0	0	4	2025	10	16	3	0.08073634859349145	4.591836734693878	0.10204081632653061
1087	25930829	EU	EU	1	1.0	0	0	0	0	2025-10-16	13.0	801.0	Male	75.0	DUPILUMAB	ocular surface disease	1	0	0.0	Child	EU	0.04285714285714286	5	0	22	0	0	0	0	0	0	0	3	2025	10	16	3	0.08073634859349145	0.5571428571428572	0.0
1088	25931910	US	US	1	1.0	0	0	1	0	2025-10-16	57.0	801.0	Male	85.45	DUPIXENT	pneumonia	1	3	0.21428571428571427	MidAge	US	0.015513897866839042	221	0	9	0	0	0	0	0	1	0	1	2025	10	16	3	0.08073634859349145	0.8842921784098254	0.0
1089	25932234	EU	EU	1	1.0	0	0	1	0	2025-10-16	68.0	801.0	Female	84.0	FUROSEMIDE	orthostatic hypotension	1	3	0.21428571428571427	Senior	EU	0.21428571428571427	1	1	23	0	0	0	0	0	0	0	2	2025	10	16	3	0.08073634859349145	14.571428571428571	0.21428571428571427
1090	25934784	US	Unknown	1	2.0	0	0	0	0	2025-10-17	73.0	801.0	Female	59.864	JAKAFI	pruritus	0	0	0.0	Senior	US	0.0	3	0	8	0	0	0	0	0	0	0	1	2025	10	17	4	0.08073634859349145	0.0	0.0
1091	25934999	US	US	2	2.0	0	0	0	0	2025-10-17	14.0	801.0	Male	75.0	OMNITROPE	injection site erythema	0	0	0.0	Child	US	0.0	5	0	23	0	0	0	0	0	0	0	3	2025	10	17	4	0.08936301793444651	0.0	0.0
1092	22969302	CA	CA	1	1.0	0	0	1	0	2023-09-22	61.0	801.0	Female	86.0	CISPLATIN	fluid intake reduced	1	3	0.21428571428571427	MidAge	CA	0.10714285714285714	2	0	20	0	0	0	0	0	0	0	3	2023	9	22	4	0.08073634859349145	6.535714285714286	0.10714285714285714
1093	23150136	US	US	2	1.0	0	0	1	0	2023-11-06	64.0	801.0	Female	86.168	LANADELUMAB	faecaloma	1	3	0.21428571428571427	MidAge	US	0.12857142857142856	5	1	9	0	0	0	0	0	0	0	1	2023	11	6	0	0.08936301793444651	8.228571428571428	0.12857142857142856
1094	23244501	CA	Unknown	2	1.0	0	0	0	0	2023-11-30	66.0	801.0	Female	75.0	CERTOLIZUMAB PEGOL	bladder operation	1	0	0.0	Senior	CA	0.04285714285714286	5	0	17	0	0	0	0	0	0	0	2	2023	11	30	3	0.08936301793444651	2.8285714285714287	0.04285714285714286
1095	23245445	US	US	1	2.0	0	0	0	0	2023-11-30	57.0	801.0	Female	75.0	TERIPARATIDE	device use error	0	0	0.0	MidAge	US	0.0	1	0	16	0	0	0	0	0	0	0	3	2023	11	30	3	0.08073634859349145	0.0	0.0
1096	23318507	JP	JP	1	1.0	1	0	0	0	2023-12-20	57.0	801.0	Female	75.0	VENCLEXTA	death	1	5	0.35714285714285715	MidAge	JP	0.18571428571428572	5	1	5	0	0	1	0	0	0	0	1	2023	12	20	2	0.08073634859349145	10.585714285714285	0.18571428571428572
1097	23662905	EU	EU	1	1.0	0	0	0	0	2024-03-22	41.0	801.0	Male	75.0	PREGABALIN	condition aggravated	1	0	0.0	Adult	EU	0.10714285714285714	6	0	20	0	0	0	0	0	0	0	2	2024	3	22	4	0.08073634859349145	4.392857142857142	0.0
1098	23763116	CA	CA	1	1.0	0	0	0	0	2024-04-19	69.0	801.0	Female	75.0	PANTOPRAZOLE	blood magnesium decreased	1	0	0.0	Senior	CA	0.0	1	0	25	0	0	0	0	0	0	0	3	2024	4	19	4	0.08073634859349145	0.0	0.0
1099	26007676	US	US	1	1.0	0	0	1	0	2025-11-06	57.0	801.0	Female	75.0	DUPIXENT	hospitalisation	1	3	0.21428571428571427	MidAge	US	0.015513897866839042	221	0	15	0	0	0	0	0	0	0	1	2025	11	6	3	0.08073634859349145	0.8842921784098254	0.015513897866839042
1100	26008271	US	US	1	2.0	0	0	0	0	2025-11-06	54.0	801.0	Female	75.0	DUPIXENT	injection site pain	0	0	0.0	MidAge	US	0.015513897866839042	221	0	19	1	0	0	0	0	0	0	3	2025	11	6	3	0.08073634859349145	0.8377504848093082	0.015513897866839042
1101	26009067	US	US	1	2.0	0	0	0	0	2025-11-07	35.0	801.0	Male	75.0	DUPIXENT	wisdom teeth removal	0	0	0.0	Young	US	0.015513897866839042	221	0	20	0	0	0	0	0	0	0	3	2025	11	7	4	0.08073634859349145	0.5429864253393665	0.0
1102	26009081	US	US	1	2.0	0	0	0	0	2025-11-07	33.0	801.0	Female	75.0	DUPIXENT	injection site pain	0	0	0.0	Young	US	0.015513897866839042	221	0	19	1	0	0	0	0	0	0	3	2025	11	7	4	0.08073634859349145	0.5119586296056884	0.015513897866839042
1103	26010997	US	US	2	1.0	0	0	0	0	2025-11-07	63.0	801.0	Male	75.0	SKYRIZI	surgery	1	0	0.0	MidAge	US	0.051587301587301584	36	0	7	0	0	0	0	0	0	0	1	2025	11	7	4	0.08936301793444651	3.25	0.0
1104	26057644	US	Unknown	1	2.0	0	0	0	0	2025-11-18	57.0	801.0	Female	75.0	LACOSAMIDE	hypersensitivity	0	0	0.0	MidAge	US	0.16666666666666666	3	1	16	0	0	0	0	0	0	0	1	2025	11	18	1	0.08073634859349145	9.5	0.16666666666666666
1105	26058049	US	US	1	2.0	0	0	0	0	2025-11-18	57.0	801.0	Male	75.0	OTEZLA	dry skin	0	0	0.0	MidAge	US	0.0	4	0	8	0	0	0	0	0	0	0	2	2025	11	18	1	0.08073634859349145	0.0	0.0
1106	26058454	EU	EU	1	1.0	0	0	1	0	2025-11-18	52.0	801.0	Female	75.0	GABAPENTIN	hepatic cytolysis	1	3	0.21428571428571427	MidAge	EU	0.061224489795918366	7	0	17	0	0	0	0	0	0	0	2	2025	11	18	1	0.08073634859349145	3.183673469387755	0.061224489795918366
1107	26059507	JP	JP	1	1.0	0	0	0	0	2025-11-18	35.0	801.0	Male	75.0	MOUNJARO	retinal haemorrhage	1	0	0.0	Young	JP	0.2142857142857143	4	1	19	0	0	0	0	0	0	0	2	2025	11	18	1	0.08073634859349145	7.500000000000001	0.0
1108	26011835	CA	CA	3	1.0	0	0	1	0	2025-11-07	57.0	801.0	Female	75.0	DOXORUBICIN HYDROCHLORIDE	acute hepatic failure	1	3	0.21428571428571427	MidAge	CA	0.21428571428571427	1	1	21	0	0	0	0	1	0	0	3	2025	11	7	4	0.17857142857142855	12.214285714285714	0.21428571428571427
1109	26014980	US	US	1	2.0	0	0	0	0	2025-11-09	69.0	801.0	Male	75.0	DUPIXENT	vision blurred	0	0	0.0	Senior	US	0.015513897866839042	221	0	14	0	0	0	0	0	0	0	2	2025	11	9	6	0.08073634859349145	1.070458952811894	0.0
1110	26015075	US	US	1	2.0	0	0	0	0	2025-11-09	42.0	801.0	Female	75.0	DUPIXENT	injection site pain	0	0	0.0	Adult	US	0.015513897866839042	221	0	19	1	0	0	0	0	0	0	3	2025	11	9	6	0.08073634859349145	0.6515837104072397	0.015513897866839042
1111	26015251	US	US	1	2.0	0	0	0	0	2025-11-09	7.0	801.0	Female	75.0	DUPIXENT	injection site erythema	0	0	0.0	Child	US	0.015513897866839042	221	0	23	0	0	0	0	0	0	0	3	2025	11	9	6	0.08073634859349145	0.10859728506787329	0.015513897866839042
1112	26062127	US	US	2	1.0	0	0	0	0	2025-11-19	52.0	801.0	Female	75.0	NUPLAZID	mental impairment	1	0	0.0	MidAge	US	0.09523809523809523	6	0	17	0	0	0	0	0	0	0	2	2025	11	19	2	0.08936301793444651	4.9523809523809526	0.09523809523809523
1113	26063328	BR	BR	1	1.0	0	0	0	0	2025-11-19	57.0	801.0	Female	56.0	CLONAZEPAM	diabetes mellitus	1	0	0.0	MidAge	BR	0.07142857142857142	3	0	17	0	0	0	0	0	0	0	2	2025	11	19	2	0.08073634859349145	4.071428571428571	0.07142857142857142
1114	26019178	US	US	1	2.0	0	0	0	0	2025-11-10	57.0	801.0	Female	75.0	LENALIDOMIDE	product dose omission issue	0	0	0.0	MidAge	US	0.15413533834586465	19	1	27	0	0	0	0	0	0	0	4	2025	11	10	0	0.08073634859349145	8.785714285714285	0.15413533834586465
1115	26020125	US	US	1	2.0	0	0	0	0	2025-11-10	57.0	801.0	Female	75.0	POLYETHYLENE GLYCOL 3350	therapeutic product effect delayed	0	0	0.0	MidAge	US	0.0	4	0	34	0	0	0	0	0	0	0	4	2025	11	10	0	0.08073634859349145	0.0	0.0
1116	26020435	US	US	1	2.0	0	0	0	0	2025-11-10	57.0	801.0	Female	75.0	POLYETHYLENE GLYCOL 3350	drug ineffective	0	0	0.0	MidAge	US	0.0	4	0	16	0	0	0	0	0	0	0	2	2025	11	10	0	0.08073634859349145	0.0	0.0
1117	25936027	US	US	2	1.0	0	0	0	0	2025-10-17	67.0	801.0	Male	75.0	AUSTEDO XR	aspiration	1	0	0.0	Senior	US	0.0	1	0	10	0	0	0	0	0	0	0	1	2025	10	17	4	0.08936301793444651	0.0	0.0
1118	25936351	CA	CA	2	1.0	0	0	0	0	2025-10-17	32.0	801.0	Female	75.0	VEDOLIZUMAB	rectal haemorrhage	1	0	0.0	Young	CA	0.057692307692307696	26	0	18	0	0	0	0	0	0	0	2	2025	10	17	4	0.08936301793444651	1.8461538461538463	0.057692307692307696
1119	25936823	JP	JP	1	1.0	0	0	1	0	2025-10-17	73.0	801.0	Male	75.0	VYXEOS	pneumonia	1	3	0.21428571428571427	Senior	JP	0.21428571428571427	1	1	9	0	0	0	0	0	1	0	1	2025	10	17	4	0.08073634859349145	15.642857142857142	0.0
1120	25937309	US	US	2	1.0	0	0	0	0	2025-10-17	55.0	801.0	Female	75.0	SKYRIZI	drug-induced liver injury	1	0	0.0	MidAge	US	0.051587301587301584	36	0	25	0	0	0	0	0	0	0	3	2025	10	17	4	0.08936301793444651	2.837301587301587	0.051587301587301584
1121	25937457	US	US	2	2.0	0	0	0	0	2025-10-18	66.0	801.0	Male	75.0	SKYRIZI	cough	0	0	0.0	Senior	US	0.051587301587301584	36	0	5	0	0	0	0	0	0	0	1	2025	10	18	5	0.08936301793444651	3.4047619047619047	0.0
1122	25937714	CN	CN	1	1.0	0	0	0	0	2025-10-18	67.0	801.0	Male	75.0	TADALAFIL	drug ineffective	1	0	0.0	Senior	CN	0.0	2	0	16	0	0	0	0	0	0	0	2	2025	10	18	5	0.08073634859349145	0.0	0.0
1123	26021326	US	US	1	1.0	0	0	0	0	2025-11-10	31.0	801.0	Female	75.0	METHOTREXATE	drug ineffective	1	0	0.0	Young	US	0.17346938775510204	7	1	16	0	0	0	0	0	0	0	2	2025	11	10	0	0.08073634859349145	5.377551020408164	0.17346938775510204
1124	26022499	US	US	1	1.0	0	0	1	0	2025-11-10	79.0	801.0	Female	82.55	REVLIMID	blood calcium abnormal	1	3	0.21428571428571427	Senior	US	0.05357142857142857	4	0	22	0	0	0	0	0	0	0	3	2025	11	10	0	0.08073634859349145	4.232142857142857	0.05357142857142857
1125	26022703	US	US	1	2.0	0	0	0	0	2025-11-10	57.0	801.0	Female	75.0	LEVOTHYROXINE SODIUM	alopecia	0	0	0.0	MidAge	US	0.0	3	0	8	0	0	0	0	0	0	0	1	2025	11	10	0	0.08073634859349145	0.0	0.0
1126	26064596	US	US	1	2.0	0	0	0	0	2025-11-19	4.0	801.0	Male	75.0	DUPIXENT	eczema	0	0	0.0	Child	US	0.015513897866839042	221	0	6	0	0	0	0	0	0	0	1	2025	11	19	2	0.08073634859349145	0.06205559146735617	0.0
1127	26064624	US	US	1	2.0	0	0	0	0	2025-11-19	23.0	801.0	Male	75.0	DUPIXENT	feeling abnormal	0	0	0.0	Young	US	0.015513897866839042	221	0	16	0	0	0	0	0	0	0	2	2025	11	19	2	0.08073634859349145	0.35681965093729795	0.0
1128	26064691	US	US	1	2.0	0	0	0	0	2025-11-19	57.0	801.0	Female	75.0	DUPIXENT	illness	0	0	0.0	MidAge	US	0.015513897866839042	221	0	7	0	0	0	0	0	0	0	1	2025	11	19	2	0.08073634859349145	0.8842921784098254	0.015513897866839042
1129	26065649	US	Unknown	1	1.0	0	0	1	0	2025-11-19	56.0	801.0	Female	75.0	AMJEVITA	abdominal operation	1	3	0.21428571428571427	MidAge	US	0.21428571428571427	1	1	19	0	0	0	0	0	0	0	2	2025	11	19	2	0.08073634859349145	12.0	0.21428571428571427
1130	26066811	CA	CA	1	1.0	0	0	0	0	2025-11-19	57.0	801.0	Female	75.0	TRIAMCINOLONE ACETONIDE	irritable bowel syndrome	1	0	0.0	MidAge	CA	0.19047619047619047	3	1	24	0	0	0	0	0	0	0	3	2025	11	19	2	0.08073634859349145	10.857142857142856	0.19047619047619047
1131	26067188	US	US	2	1.0	0	0	0	0	2025-11-19	61.0	801.0	Female	75.0	SKYRIZI	rotator cuff syndrome	1	0	0.0	MidAge	US	0.051587301587301584	36	0	21	0	0	0	0	0	0	0	3	2025	11	19	2	0.08936301793444651	3.1468253968253967	0.051587301587301584
1132	26067889	EU	EU	1	1.0	0	0	1	0	2025-11-20	57.0	801.0	Male	75.0	PEMETREXED	acute kidney injury	1	3	0.21428571428571427	MidAge	EU	0.21428571428571427	3	1	19	0	0	0	0	0	0	0	3	2025	11	20	3	0.08073634859349145	12.214285714285714	0.0
1133	26068202	US	US	1	2.0	0	0	0	0	2025-11-20	43.0	801.0	Female	109.0	NEULASTA	device malfunction	0	0	0.0	Adult	US	0.0	5	0	18	0	0	0	0	0	0	0	2	2025	11	20	3	0.08073634859349145	0.0	0.0
1134	25939859	GB	Unknown	1	1.0	0	0	0	1	2025-10-20	57.0	801.0	Female	66.0	EZETIMIBE AND SIMVASTATIN	dizziness postural	1	2	0.14285714285714285	MidAge	GB	0.14285714285714285	1	1	18	0	0	0	0	0	0	0	2	2025	10	20	0	0.08073634859349145	8.142857142857142	0.14285714285714285
1135	25940334	US	US	1	1.0	0	0	0	0	2025-10-20	57.0	801.0	Female	75.0	JAYPIRCA	malignant neoplasm progression	1	0	0.0	MidAge	US	0.0	1	0	30	0	0	0	0	0	0	0	3	2025	10	20	0	0.08073634859349145	0.0	0.0
1136	25941010	US	US	2	2.0	0	0	0	0	2025-10-20	57.0	801.0	Male	75.0	CORTICOTROPIN	skin irritation	0	0	0.0	MidAge	US	0.0	3	0	15	0	0	0	0	0	0	0	2	2025	10	20	0	0.08936301793444651	0.0	0.0
1137	25942884	US	US	1	2.0	0	0	0	0	2025-10-21	57.0	801.0	Female	75.0	DUPIXENT	weight increased	0	0	0.0	MidAge	US	0.015513897866839042	221	0	16	0	0	0	0	0	0	0	2	2025	10	21	1	0.08073634859349145	0.8842921784098254	0.015513897866839042
1138	26026387	US	US	1	2.0	0	0	0	0	2025-11-11	57.0	801.0	Female	75.0	DUPIXENT	injection site scar	0	0	0.0	MidAge	US	0.015513897866839042	221	0	19	0	0	0	0	0	0	0	3	2025	11	11	1	0.08073634859349145	0.8842921784098254	0.015513897866839042
1139	26026644	US	US	1	2.0	0	0	0	0	2025-11-11	81.0	801.0	Female	75.0	DUPIXENT	urticaria	0	0	0.0	Senior	US	0.015513897866839042	221	0	9	0	0	0	0	0	0	0	1	2025	11	11	1	0.08073634859349145	1.2566257272139625	0.015513897866839042
1140	26026725	US	US	1	2.0	0	0	0	0	2025-11-11	72.0	801.0	Male	75.0	DUPIXENT	incorrect dose administered	0	0	0.0	Senior	US	0.015513897866839042	221	0	27	0	0	0	0	0	0	0	3	2025	11	11	1	0.08073634859349145	1.117000646412411	0.0
1141	26069713	CA	CA	1	1.0	0	0	0	0	2025-11-20	34.0	801.0	Male	75.0	GABAPENTIN	crohn^s disease	1	0	0.0	Young	CA	0.061224489795918366	7	0	15	0	0	0	0	0	0	0	2	2025	11	20	3	0.08073634859349145	2.0816326530612246	0.0
1142	26069766	US	US	2	1.0	0	0	0	0	2025-11-20	53.0	801.0	Male	75.0	CREON	gallbladder operation	1	0	0.0	MidAge	US	0.03296703296703297	13	0	21	0	0	0	0	0	0	0	2	2025	11	20	3	0.08936301793444651	1.7472527472527473	0.0
1143	26070065	CA	CA	2	1.0	0	0	0	0	2025-11-20	57.0	801.0	Female	75.0	RITUXIMAB	abdominal operation	1	0	0.0	MidAge	CA	0.12406015037593986	19	0	19	0	0	0	0	0	0	0	2	2025	11	20	3	0.08936301793444651	7.071428571428572	0.12406015037593986
1144	26070146	US	US	1	1.0	0	0	1	0	2025-11-20	15.0	801.0	Female	75.0	PREDNISONE	immune-mediated myositis	1	3	0.21428571428571427	Child	US	0.1607142857142857	8	1	24	0	0	0	0	0	0	0	2	2025	11	20	3	0.08073634859349145	2.4107142857142856	0.1607142857142857
1145	26070470	US	US	1	1.0	0	0	0	0	2025-11-20	57.0	801.0	Female	75.0	DUPIXENT	crohn^s disease	1	0	0.0	MidAge	US	0.015513897866839042	221	0	15	0	0	0	0	0	0	0	2	2025	11	20	3	0.08073634859349145	0.8842921784098254	0.015513897866839042
1146	26070995	US	US	1	2.0	0	0	0	0	2025-11-20	15.0	801.0	Female	75.0	DUPIXENT	injection site pain	0	0	0.0	Child	US	0.015513897866839042	221	0	19	1	0	0	0	0	0	0	3	2025	11	20	3	0.08073634859349145	0.23270846800258563	0.015513897866839042
1147	26033677	EU	EU	1	1.0	1	0	1	0	2025-11-12	73.0	801.0	Male	75.0	CARBIDOPA\LEVODOPA	pneumonia	1	8	0.5714285714285714	Senior	EU	0.3333333333333333	3	1	9	0	0	0	0	0	1	0	1	2025	11	12	2	0.08073634859349145	24.333333333333332	0.0
1148	26034663	US	US	1	1.0	0	0	1	0	2025-11-12	15.0	801.0	Female	75.0	MYCOPHENOLATE MOFETIL	gastrointestinal disorder	1	3	0.21428571428571427	Child	US	0.10150375939849625	19	0	25	0	0	0	0	0	0	0	2	2025	11	12	2	0.08073634859349145	1.5225563909774438	0.10150375939849625
1149	26035068	US	US	1	2.0	0	0	0	0	2025-11-12	16.0	801.0	Female	75.0	DUPIXENT	injection site swelling	0	0	0.0	Child	US	0.015513897866839042	221	0	23	0	0	0	0	0	0	0	3	2025	11	12	2	0.08073634859349145	0.24822236586942467	0.015513897866839042
1150	26035730	US	US	1	1.0	0	0	0	0	2025-11-12	57.0	801.0	Male	75.0	CARVYKTI	immunodeficiency	1	0	0.0	MidAge	US	0.0	1	0	16	0	0	0	0	0	0	0	1	2025	11	12	2	0.08073634859349145	0.0	0.0
1151	26036311	EU	EU	1	1.0	0	0	0	0	2025-11-12	59.0	801.0	Male	75.0	BINIMETINIB	autoimmune colitis	1	0	0.0	MidAge	EU	0.0	1	0	18	0	0	0	0	0	0	0	2	2025	11	12	2	0.08073634859349145	0.0	0.0
1152	26037107	EU	EU	1	1.0	0	0	0	0	2025-11-12	57.0	801.0	Female	75.0	METHOTREXATE	cerebral infarction	1	0	0.0	MidAge	EU	0.17346938775510204	7	1	19	0	0	0	0	0	0	0	2	2025	11	12	2	0.08073634859349145	9.887755102040817	0.17346938775510204
1153	25945180	US	US	1	2.0	0	0	0	0	2025-10-21	57.0	801.0	Female	75.0	XEOMIN	urticaria	0	0	0.0	MidAge	US	0.08928571428571429	4	0	9	0	0	0	0	0	0	0	1	2025	10	21	1	0.08073634859349145	5.089285714285714	0.08928571428571429
1154	25946758	US	US	1	1.0	0	0	0	0	2025-10-22	57.0	801.0	Female	75.0	COBENFY	serotonin syndrome	1	0	0.0	MidAge	US	0.0	1	0	18	0	0	0	0	0	0	0	2	2025	10	22	2	0.08073634859349145	0.0	0.0
1155	25946987	GB	GB	1	1.0	0	0	0	0	2025-10-22	57.0	801.0	Female	75.0	PREGABALIN	decreased appetite	1	0	0.0	MidAge	GB	0.10714285714285714	6	0	18	0	0	0	0	0	0	0	2	2025	10	22	2	0.08073634859349145	6.107142857142857	0.10714285714285714
1156	25947177	EU	EU	1	1.0	0	0	1	0	2025-10-22	37.0	801.0	Male	75.0	OLANZAPINE	intentional overdose	1	3	0.21428571428571427	Adult	EU	0.11904761904761905	6	0	20	0	0	0	0	0	0	0	2	2025	10	22	2	0.08073634859349145	4.404761904761905	0.0
1157	26037822	US	US	1	1.0	0	0	0	0	2025-11-12	57.0	801.0	Male	75.0	LUMASON	hypersensitivity	1	0	0.0	MidAge	US	0.25	2	1	16	0	0	0	0	0	0	0	1	2025	11	12	2	0.08073634859349145	14.25	0.0
1158	26038199	US	US	1	1.0	0	0	1	0	2025-11-13	63.0	801.0	Female	69.85	OPSUMIT	dyspnoea	1	3	0.21428571428571427	MidAge	US	0.10714285714285714	2	0	8	0	0	0	0	0	0	0	1	2025	11	13	3	0.08073634859349145	6.75	0.10714285714285714
1159	26038847	GB	GB	1	1.0	0	0	0	0	2025-11-13	49.0	801.0	Female	70.0	LEVETIRACETAM	dyspnoea	1	0	0.0	Adult	GB	0.05714285714285714	5	0	8	0	0	0	0	0	0	0	1	2025	11	13	3	0.08073634859349145	2.8	0.05714285714285714
1160	26039442	US	US	1	2.0	0	0	0	0	2025-11-13	20.0	801.0	Female	75.0	AMOXICILLIN	maternal exposure during pregnancy	0	0	0.0	Young	US	0.0	1	0	34	0	0	0	0	0	0	0	4	2025	11	13	3	0.08073634859349145	0.0	0.0
1161	26039914	EU	EU	2	1.0	0	0	0	0	2025-11-13	57.0	801.0	Male	94.0	UPTRAVI	renal impairment	1	0	0.0	MidAge	EU	0.0	1	0	16	0	0	0	0	0	0	0	2	2025	11	13	3	0.08936301793444651	0.0	0.0
1162	26040833	US	Unknown	1	1.0	0	0	1	0	2025-11-13	22.0	801.0	Male	70.3	DEXAMETHASONE	pancreatitis	1	3	0.21428571428571427	Young	US	0.1857142857142857	5	1	12	0	0	0	0	0	0	0	1	2025	11	13	3	0.08073634859349145	4.085714285714285	0.0
1163	26041333	US	US	1	1.0	0	0	0	0	2025-11-13	53.0	801.0	Female	75.0	AYVAKIT	toe operation	1	0	0.0	MidAge	US	0.0	2	0	13	0	0	0	0	0	0	0	2	2025	11	13	3	0.08073634859349145	0.0	0.0
1164	24422928	JP	JP	1	2.0	0	0	0	0	2024-10-10	57.0	801.0	Male	75.0	NGENLA	patient-device incompatibility	0	0	0.0	MidAge	JP	0.0	1	0	30	0	0	0	0	0	0	0	2	2024	10	10	3	0.08073634859349145	0.0	0.0
1165	24533750	US	US	1	2.0	0	0	0	0	2024-10-22	57.0	801.0	Female	75.0	ILUVIEN	device difficult to use	0	0	0.0	MidAge	US	0.0	3	0	23	0	0	0	0	0	0	0	4	2024	10	22	1	0.08073634859349145	0.0	0.0
1166	24533789	US	US	1	2.0	0	0	0	0	2024-10-22	69.0	801.0	Female	75.0	ILUVIEN	device malfunction	0	0	0.0	Senior	US	0.0	3	0	18	0	0	0	0	0	0	0	2	2024	10	22	1	0.08073634859349145	0.0	0.0
1167	24598913	US	US	1	1.0	0	0	1	0	2024-11-10	71.0	801.0	Female	75.0	DUPIXENT	infection	1	3	0.21428571428571427	Senior	US	0.015513897866839042	221	0	9	0	1	0	0	0	0	0	1	2024	11	10	6	0.08073634859349145	1.101486748545572	0.015513897866839042
1168	24607675	EU	EU	1	1.0	0	0	1	0	2024-11-12	50.0	801.0	Female	75.0	LORAZEPAM	suicide attempt	1	3	0.21428571428571427	Adult	EU	0.21428571428571427	1	1	15	0	0	0	0	0	0	0	2	2024	11	12	1	0.08073634859349145	10.714285714285714	0.21428571428571427
1169	24610147	US	US	1	2.0	0	0	0	0	2024-11-12	52.0	801.0	Male	75.0	DUPIXENT	bone pain	0	0	0.0	MidAge	US	0.015513897866839042	221	0	9	1	0	0	0	0	0	0	2	2024	11	12	1	0.08073634859349145	0.8067226890756302	0.0
1170	24632299	US	Unknown	1	2.0	0	0	0	0	2024-11-18	23.0	801.0	Female	83.9	REVCOVI	weight increased	0	0	0.0	Young	US	0.0	1	0	16	0	0	0	0	0	0	0	2	2024	11	18	0	0.08073634859349145	0.0	0.0
1171	24645921	US	US	1	2.0	0	0	0	0	2024-11-21	48.0	801.0	Female	75.0	VERZENIO	taste disorder	0	0	0.0	Adult	US	0.0	1	0	14	0	0	0	0	0	0	0	2	2024	11	21	3	0.08073634859349145	0.0	0.0
1172	25952456	CN	CN	1	1.0	0	0	0	0	2025-10-23	57.0	801.0	Female	75.0	CARBOPLATIN	neoplasm progression	1	0	0.0	MidAge	CN	0.12244897959183673	7	0	20	0	0	0	0	0	0	0	2	2025	10	23	3	0.08073634859349145	6.979591836734694	0.12244897959183673
1173	25953347	US	Unknown	1	1.0	1	0	0	0	2025-10-23	84.0	801.0	Male	75.0	LENALIDOMIDE	death	1	5	0.35714285714285715	Senior	US	0.15413533834586465	19	1	5	0	0	1	0	0	0	0	1	2025	10	23	3	0.08073634859349145	12.94736842105263	0.0
1174	25955224	US	US	1	2.0	0	0	0	0	2025-10-24	57.0	801.0	Female	75.0	SPRAVATO	drug monitoring procedure incorrectly performed	0	0	0.0	MidAge	US	0.026785714285714284	8	0	47	0	0	0	0	0	0	0	5	2025	10	24	4	0.08073634859349145	1.5267857142857142	0.026785714285714284
1175	25955534	US	US	2	1.0	0	0	0	0	2025-10-24	66.0	801.0	Male	75.0	IXAZOMIB	plasma cell myeloma	1	0	0.0	Senior	US	0.0	2	0	19	0	0	0	0	0	0	0	3	2025	10	24	4	0.08936301793444651	0.0	0.0
1176	26078137	EU	EU	3	1.0	0	0	1	0	2025-11-22	57.0	801.0	Female	75.0	ACETAMINOPHEN	depressed level of consciousness	1	3	0.21428571428571427	MidAge	EU	0.10267857142857142	16	0	32	0	0	0	0	0	0	0	4	2025	11	22	5	0.17857142857142855	5.852678571428571	0.10267857142857142
1177	26078313	US	US	1	2.0	0	0	0	0	2025-11-22	8.0	801.0	Male	75.0	DUPIXENT	eczema	0	0	0.0	Child	US	0.015513897866839042	221	0	6	0	0	0	0	0	0	0	1	2025	11	22	5	0.08073634859349145	0.12411118293471234	0.0
1178	26046651	EU	EU	1	1.0	0	0	1	0	2025-11-14	72.0	801.0	Male	65.0	NINTEDANIB	large granular lymphocytosis	1	3	0.21428571428571427	Senior	EU	0.21428571428571427	1	1	28	0	0	0	0	0	0	0	3	2025	11	14	4	0.08073634859349145	15.428571428571427	0.0
1179	26048905	EU	EU	1	1.0	1	0	0	0	2025-11-15	57.0	801.0	Female	75.0	RITUXIMAB	multiple organ dysfunction syndrome	1	5	0.35714285714285715	MidAge	EU	0.12406015037593986	19	0	35	0	0	0	0	0	0	0	4	2025	11	15	5	0.08073634859349145	7.071428571428572	0.12406015037593986
1180	26048972	US	US	1	1.0	0	0	0	0	2025-11-15	57.0	801.0	Male	90.703	TYVASO DPI	pneumonia	1	0	0.0	MidAge	US	0.0	4	0	9	0	0	0	0	0	1	0	1	2025	11	15	5	0.08073634859349145	0.0	0.0
1181	26049500	US	US	1	2.0	0	0	0	0	2025-11-15	52.0	801.0	Male	75.0	TRULICITY	tremor	0	0	0.0	MidAge	US	0.04285714285714286	5	0	6	0	0	0	0	0	0	0	1	2025	11	15	5	0.08073634859349145	2.2285714285714286	0.0
1182	25957936	EU	EU	1	1.0	0	0	1	0	2025-10-24	41.0	801.0	Male	163.0	INFLIXIMAB	drug-induced liver injury	1	3	0.21428571428571427	Adult	EU	0.07142857142857142	9	0	25	0	0	0	0	0	0	0	3	2025	10	24	4	0.08073634859349145	2.9285714285714284	0.0
1183	25958665	CA	CA	1	1.0	0	0	1	0	2025-10-24	93.0	801.0	Male	75.0	SEMAGLUTIDE	incontinence	1	3	0.21428571428571427	Senior	CA	0.14285714285714285	3	1	12	0	0	0	0	0	0	0	1	2025	10	24	4	0.08073634859349145	13.285714285714285	0.0
1184	26049768	US	US	1	2.0	0	0	0	0	2025-11-15	10.0	801.0	Male	75.0	DUPIXENT	dry eye	0	0	0.0	Child	US	0.015513897866839042	221	0	7	0	0	0	0	0	0	0	2	2025	11	15	5	0.08073634859349145	0.1551389786683904	0.0
1185	26050148	US	US	3	2.0	0	0	0	0	2025-11-16	57.0	801.0	Male	75.0	FILSPARI	fatigue	0	0	0.0	MidAge	US	0.0	4	0	7	0	0	0	0	0	0	0	1	2025	11	16	6	0.17857142857142855	0.0	0.0
1186	26050324	US	US	1	2.0	0	0	0	0	2025-11-16	57.0	801.0	Female	53.64	DUPIXENT	injection site pain	0	0	0.0	MidAge	US	0.015513897866839042	221	0	19	1	0	0	0	0	0	0	3	2025	11	16	6	0.08073634859349145	0.8842921784098254	0.015513897866839042
1187	26051620	US	US	1	2.0	0	0	0	0	2025-11-17	43.0	801.0	Male	75.0	DUPIXENT	injection site bruising	0	0	0.0	Adult	US	0.015513897866839042	221	0	23	0	0	0	0	0	0	0	3	2025	11	17	0	0.08073634859349145	0.6670976082740788	0.0
1188	26052254	US	US	1	2.0	0	0	0	0	2025-11-17	76.0	801.0	Female	75.0	COSENTYX	injection site pain	0	0	0.0	Senior	US	0.05714285714285714	10	0	19	1	0	0	0	0	0	0	3	2025	11	17	0	0.08073634859349145	4.3428571428571425	0.05714285714285714
1189	26052807	US	Unknown	1	1.0	0	0	1	0	2025-11-14	79.0	801.0	Female	62.1	CABOMETYX	coronary arterial stent insertion	1	3	0.21428571428571427	Senior	US	0.10714285714285714	4	0	33	0	0	0	0	0	0	0	4	2025	11	14	4	0.08073634859349145	8.464285714285714	0.10714285714285714
1190	26053226	TH	TH	2	1.0	0	0	0	0	2025-11-17	57.0	801.0	Female	75.0	BEVACIZUMAB	sepsis	1	0	0.0	MidAge	Other	0.17857142857142858	2	1	6	0	0	0	0	0	0	0	1	2025	11	17	0	0.08936301793444651	10.178571428571429	0.17857142857142858
1191	26081458	AU	AU	1	1.0	0	0	0	0	2025-11-24	57.0	801.0	Female	75.0	LACOSAMIDE	cardiac septal defect	1	0	0.0	MidAge	AU	0.16666666666666666	3	1	21	0	0	0	0	0	0	0	3	2025	11	24	0	0.08073634859349145	9.5	0.16666666666666666
1192	26081500	US	US	1	2.0	0	0	0	0	2025-11-24	57.0	801.0	Female	79.09	DUPIXENT	injection site pain	0	0	0.0	MidAge	US	0.015513897866839042	221	0	19	1	0	0	0	0	0	0	3	2025	11	24	0	0.08073634859349145	0.8842921784098254	0.015513897866839042
1193	26082349	US	US	1	2.0	0	0	0	0	2025-11-24	57.0	801.0	Male	75.0	METHYLPHENIDATE HYDROCHLORIDE	drug ineffective	0	0	0.0	MidAge	US	0.10714285714285714	2	0	16	0	0	0	0	0	0	0	2	2025	11	24	0	0.08073634859349145	6.107142857142857	0.0
1194	26082363	US	Unknown	1	1.0	0	0	0	1	2025-11-23	36.0	801.0	Female	49.05	CIPROFLOXACIN HYDROCHLORIDE	tendonitis	1	2	0.14285714285714285	Adult	US	0.14285714285714285	1	1	10	0	0	0	0	0	0	0	1	2025	11	23	6	0.08073634859349145	5.142857142857142	0.14285714285714285
1195	26082659	US	US	1	2.0	0	0	0	0	2025-11-24	57.0	801.0	Female	75.0	ESTRADIOL	device adhesion issue	0	0	0.0	MidAge	US	0.0	8	0	21	0	0	0	0	0	0	0	3	2025	11	24	0	0.08073634859349145	0.0	0.0
1196	26082673	US	Unknown	1	1.0	0	0	1	0	2025-11-22	57.0	801.0	Male	75.0	LENALIDOMIDE	pneumonia bacterial	1	3	0.21428571428571427	MidAge	US	0.15413533834586465	19	1	19	0	0	0	0	0	1	0	2	2025	11	22	5	0.08073634859349145	8.785714285714285	0.0
1197	26083511	US	Unknown	1	2.0	0	0	0	0	2025-11-24	57.0	801.0	Female	75.0	ADDERALL XR	heart rate increased	0	0	0.0	MidAge	US	0.0	2	0	20	0	0	0	0	0	0	0	3	2025	11	24	0	0.08073634859349145	0.0	0.0
1198	26053765	US	US	1	2.0	0	0	0	0	2025-11-17	65.0	801.0	Male	75.0	DUPIXENT	pyrexia	0	0	0.0	MidAge	US	0.015513897866839042	221	0	7	0	0	0	0	0	0	0	1	2025	11	17	0	0.08073634859349145	1.0084033613445378	0.0
1199	26054117	US	US	2	2.0	0	0	0	0	2025-11-17	48.0	801.0	Female	130.0	NEULASTA	device adhesion issue	0	0	0.0	Adult	US	0.0	5	0	21	0	0	0	0	0	0	0	3	2025	11	17	0	0.08936301793444651	0.0	0.0
1200	26055480	GB	GB	1	1.0	0	0	0	0	2025-11-17	86.0	801.0	Female	99.0	XARELTO	ageusia	1	0	0.0	Senior	GB	0.0	1	0	7	0	0	0	0	0	0	0	1	2025	11	17	0	0.08073634859349145	0.0	0.0
1201	26056209	EU	EU	1	1.0	0	0	1	0	2025-11-18	55.0	801.0	Male	74.0	BACTRIM	rash morbilliform	1	3	0.21428571428571427	MidAge	EU	0.21428571428571427	1	1	17	0	0	0	0	0	0	0	2	2025	11	18	1	0.08073634859349145	11.785714285714285	0.0
1202	26057114	US	US	1	2.0	0	0	0	0	2025-11-18	57.0	801.0	Female	75.0	ISOTRETINOIN	adverse drug reaction	0	0	0.0	MidAge	US	0.023809523809523808	9	0	21	0	0	0	0	0	0	0	3	2025	11	18	1	0.08073634859349145	1.357142857142857	0.023809523809523808
1203	25959785	US	US	1	2.0	0	0	0	0	2025-10-26	2.0	801.0	Female	75.0	DUPIXENT	dry skin	0	0	0.0	Child	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	2	2025	10	26	6	0.08073634859349145	0.031027795733678084	0.015513897866839042
1204	25961704	CA	CA	2	1.0	0	0	0	0	2025-10-27	57.0	801.0	Female	75.0	TEZEPELUMAB	swollen tongue	1	0	0.0	MidAge	CA	0.10714285714285714	2	0	14	0	0	0	0	0	0	0	2	2025	10	27	0	0.08936301793444651	6.107142857142857	0.10714285714285714
1205	25961919	CN	CN	1	1.0	0	0	0	0	2025-10-27	35.0	801.0	Female	75.0	ETANERCEPT	carotid artery stenosis	1	0	0.0	Young	CN	0.0	1	0	23	0	0	0	0	0	0	0	3	2025	10	27	0	0.08073634859349145	0.0	0.0
1206	25962514	US	Unknown	1	1.0	1	0	0	0	2025-10-24	53.0	801.0	Male	75.0	CABENUVA	sepsis	1	5	0.35714285714285715	MidAge	US	0.35714285714285715	1	1	6	0	0	0	0	0	0	0	1	2025	10	24	4	0.08073634859349145	18.92857142857143	0.0
1207	25963229	US	US	1	2.0	0	0	0	0	2025-10-27	57.0	801.0	Female	75.0	ATENOLOL	heart rate decreased	0	0	0.0	MidAge	US	0.0	1	0	20	0	0	0	0	0	0	0	3	2025	10	27	0	0.08073634859349145	0.0	0.0
1208	26084617	US	US	1	2.0	0	0	0	0	2025-11-24	66.0	801.0	Female	75.0	DUPIXENT	pruritus	0	0	0.0	Senior	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	1	2025	11	24	0	0.08073634859349145	1.0239172592113768	0.015513897866839042
1209	26085913	EU	EU	1	2.0	0	0	0	0	2025-11-25	68.0	801.0	Female	75.0	METFORMIN HYDROCHLORIDE	potentiating drug interaction	0	0	0.0	Senior	EU	0.0	1	0	29	0	0	0	0	0	0	0	3	2025	11	25	1	0.08073634859349145	0.0	0.0
1210	26086466	EU	EU	1	1.0	0	0	0	0	2025-11-25	77.0	801.0	Female	75.0	PACLITAXEL	pneumonitis	1	0	0.0	Senior	EU	0.07142857142857142	3	0	11	0	0	0	0	0	0	0	1	2025	11	25	1	0.08073634859349145	5.5	0.07142857142857142
1211	24700004	US	US	1	2.0	0	0	0	0	2024-12-05	57.0	801.0	Female	75.0	YUTIQ	circumstance or information capable of leading to medication error	0	0	0.0	MidAge	US	0.0	1	0	66	0	0	0	0	0	0	0	9	2024	12	5	3	0.08073634859349145	0.0	0.0
1212	24701744	US	US	1	2.0	0	0	0	0	2024-12-05	40.0	801.0	Female	75.0	DUPIXENT	stress	0	0	0.0	Adult	US	0.015513897866839042	221	0	6	0	0	0	0	0	0	0	1	2024	12	5	3	0.08073634859349145	0.6205559146735616	0.015513897866839042
1213	24757888	US	Unknown	1	2.0	0	0	0	0	2024-12-20	57.0	801.0	Female	75.0	BIMZELX	pain	0	0	0.0	MidAge	US	0.0	22	0	4	1	0	0	0	0	0	0	1	2024	12	20	4	0.08073634859349145	0.0	0.0
1214	24798092	JP	JP	1	1.0	0	0	0	0	2025-01-02	57.0	801.0	Male	56.9	ACTEMRA	blood immunoglobulin e abnormal	1	0	0.0	MidAge	JP	0.17857142857142858	6	1	31	0	0	0	0	0	0	0	4	2025	1	2	3	0.08073634859349145	10.178571428571429	0.0
1215	24836905	US	US	2	1.0	0	0	0	0	2025-01-13	36.0	801.0	Female	75.0	VEDOLIZUMAB	colitis ulcerative	1	0	0.0	Adult	US	0.057692307692307696	26	0	18	0	0	0	0	0	0	0	2	2025	1	13	0	0.08936301793444651	2.076923076923077	0.057692307692307696
1216	24839201	US	US	2	1.0	0	0	0	0	2025-01-14	53.0	801.0	Female	93.44	LANADELUMAB	spinal fracture	1	0	0.0	MidAge	US	0.12857142857142856	5	1	15	0	0	0	0	0	0	0	2	2025	1	14	1	0.08936301793444651	6.814285714285713	0.12857142857142856
1217	24855454	GB	GB	1	1.0	0	0	0	1	2025-01-17	59.0	801.0	Male	100.0	LOSARTAN	pain in extremity	1	2	0.14285714285714285	MidAge	GB	0.2857142857142857	2	1	17	1	0	0	0	0	0	0	3	2025	1	17	4	0.08073634859349145	16.857142857142858	0.0
1218	26089368	US	US	1	2.0	0	0	0	0	2025-11-25	64.0	801.0	Female	75.0	DUPIXENT	rhinorrhoea	0	0	0.0	MidAge	US	0.015513897866839042	221	0	11	0	0	0	0	0	0	0	1	2025	11	25	1	0.08073634859349145	0.9928894634776987	0.015513897866839042
1219	26089463	US	US	1	2.0	0	0	0	0	2025-11-25	66.0	801.0	Male	75.0	DUPIXENT	arthralgia	0	0	0.0	Senior	US	0.015513897866839042	221	0	10	0	0	0	0	0	0	0	1	2025	11	25	1	0.08073634859349145	1.0239172592113768	0.0
1220	26090100	US	US	1	2.0	0	0	0	0	2025-11-26	35.0	801.0	Female	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	Young	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	11	26	2	0.08073634859349145	0.5429864253393665	0.015513897866839042
1221	26090382	GB	GB	1	1.0	0	0	0	0	2025-11-26	67.0	801.0	Female	75.0	CYPROTERONE ACETATE	meningioma	1	0	0.0	Senior	GB	0.0	1	0	10	0	0	0	0	0	0	0	1	2025	11	26	2	0.08073634859349145	0.0	0.0
1222	26090706	US	US	2	1.0	0	0	1	0	2025-11-26	54.0	801.0	Female	89.811	CREON	trigeminal neuralgia	1	3	0.21428571428571427	MidAge	US	0.03296703296703297	13	0	20	0	0	0	0	0	0	0	2	2025	11	26	2	0.08936301793444651	1.7802197802197803	0.03296703296703297
1223	26091893	CN	CN	1	1.0	0	1	0	0	2025-11-26	57.0	801.0	Female	75.0	PREDNISONE	febrile neutropenia	1	4	0.2857142857142857	MidAge	CN	0.1607142857142857	8	1	19	0	0	0	0	0	0	0	2	2025	11	26	2	0.08073634859349145	9.160714285714285	0.1607142857142857
1224	26091907	US	Unknown	1	1.0	0	0	1	0	2025-11-25	57.0	801.0	Female	75.0	MYCOPHENOLATE MOFETIL	pneumonia aspiration	1	3	0.21428571428571427	MidAge	US	0.10150375939849625	19	0	20	0	0	0	0	0	1	0	2	2025	11	25	1	0.08073634859349145	5.7857142857142865	0.10150375939849625
1225	26093284	US	US	1	2.0	0	0	0	0	2025-11-26	42.0	801.0	Female	75.0	DUPIXENT	arthralgia	0	0	0.0	Adult	US	0.015513897866839042	221	0	10	0	0	0	0	0	0	0	1	2025	11	26	2	0.08073634859349145	0.6515837104072397	0.015513897866839042
1226	26093756	US	US	1	2.0	0	0	0	0	2025-11-26	45.0	801.0	Female	148.0	NEULASTA	unintentional medical device removal	0	0	0.0	Adult	US	0.0	5	0	36	0	0	0	0	0	0	0	4	2025	11	26	2	0.08073634859349145	0.0	0.0
1227	26093985	JP	JP	2	1.0	0	0	0	0	2025-11-26	51.0	801.0	Male	60.0	LEUPROLIDE ACETATE	erectile dysfunction	1	0	0.0	MidAge	JP	0.38095238095238093	3	1	20	0	0	0	0	0	0	0	2	2025	11	26	2	0.08936301793444651	19.428571428571427	0.0
1228	26094108	GB	GB	1	1.0	0	0	0	0	2025-11-26	68.0	801.0	Female	75.0	MYCOPHENOLATE MOFETIL	diffuse large b-cell lymphoma	1	0	0.0	Senior	GB	0.10150375939849625	19	0	29	0	0	0	0	0	0	0	4	2025	11	26	2	0.08073634859349145	6.902255639097745	0.10150375939849625
1229	26095686	US	US	1	1.0	0	0	0	0	2025-11-27	58.0	801.0	Female	75.0	TACROLIMUS	delirium	1	0	0.0	MidAge	US	0.09183673469387754	7	0	8	0	0	0	0	0	0	0	1	2025	11	27	3	0.08073634859349145	5.326530612244897	0.09183673469387754
1230	26096281	US	US	1	1.0	0	0	0	0	2025-11-27	57.0	801.0	Male	97.506	TYVASO DPI	insomnia	1	0	0.0	MidAge	US	0.0	4	0	8	0	0	0	0	0	0	0	1	2025	11	27	3	0.08073634859349145	0.0	0.0
1231	26096524	EU	EU	1	1.0	0	0	1	0	2025-11-27	72.0	801.0	Male	75.0	RIVAROXABAN	haematoma	1	3	0.21428571428571427	Senior	EU	0.21428571428571427	2	1	9	0	0	0	0	0	0	0	1	2025	11	27	3	0.08073634859349145	15.428571428571427	0.0
1232	24911143	KR	KR	2	1.0	0	0	0	0	2025-01-31	75.0	801.0	Female	60.0	LAZERTINIB	embolism	1	0	0.0	Senior	Other	0.0	1	0	8	0	0	0	0	0	0	0	1	2025	1	31	4	0.08936301793444651	0.0	0.0
1233	24942367	US	Unknown	1	1.0	0	0	0	0	2025-02-07	61.0	801.0	Female	75.0	JAKAFI	bone pain	1	0	0.0	MidAge	US	0.0	3	0	9	1	0	0	0	0	0	0	2	2025	2	7	4	0.08073634859349145	0.0	0.0
1234	24966491	US	US	2	1.0	0	0	0	0	2025-02-13	72.0	801.0	Female	76.0	.ALPHA.1-PROTEINASE INHIBITOR HUMAN	diabetes mellitus	1	0	0.0	Senior	US	0.0	1	0	17	0	0	0	0	0	0	0	2	2025	2	13	3	0.08936301793444651	0.0	0.0
1235	24979923	US	US	2	1.0	0	0	0	0	2025-02-18	57.0	801.0	Male	75.0	RAVULIZUMAB	diabetes mellitus	1	0	0.0	MidAge	US	0.0	1	0	17	0	0	0	0	0	0	0	2	2025	2	18	1	0.08936301793444651	0.0	0.0
1236	24987065	JP	JP	2	1.0	1	1	1	0	2025-02-19	73.0	801.0	Female	45.6	ELRANATAMAB	plasma cell myeloma	1	12	0.8571428571428571	Senior	JP	0.8571428571428571	1	1	19	0	0	0	0	0	0	0	3	2025	2	19	2	0.08936301793444651	62.57142857142857	0.8571428571428571
1237	25967441	US	US	1	1.0	1	0	1	0	2025-10-28	57.0	801.0	Female	75.0	WINREVAIR	death	1	8	0.5714285714285714	MidAge	US	0.2619047619047619	3	1	5	0	0	1	0	0	0	0	1	2025	10	28	1	0.08073634859349145	14.928571428571429	0.2619047619047619
1238	25967670	GB	GB	1	1.0	0	0	1	0	2025-10-28	74.0	801.0	Female	75.0	AMLODIPINE	gastroenteritis salmonella	1	3	0.21428571428571427	Senior	GB	0.16964285714285715	8	1	26	0	0	0	0	0	0	0	2	2025	10	28	1	0.08073634859349145	12.553571428571429	0.16964285714285715
1239	25002592	US	US	1	2.0	0	0	0	0	2025-02-24	57.0	801.0	Female	85.714	TYVASO	flushing	0	0	0.0	MidAge	US	0.0	2	0	8	0	0	0	0	0	0	0	1	2025	2	24	0	0.08073634859349145	0.0	0.0
1240	25046871	GB	GB	2	1.0	0	0	0	0	2025-03-06	36.0	801.0	Male	75.0	COPAXONE	confusional state	1	0	0.0	Adult	GB	0.0	2	0	17	0	0	0	0	0	0	0	2	2025	3	6	3	0.08936301793444651	0.0	0.0
1241	25048167	US	US	2	2.0	0	0	0	0	2025-03-06	66.0	801.0	Female	75.0	RINVOQ	aphonia	0	0	0.0	Senior	US	0.0	3	0	7	0	0	0	0	0	0	0	1	2025	3	6	3	0.08936301793444651	0.0	0.0
1242	25068970	US	US	1	2.0	0	0	0	0	2025-03-12	34.0	801.0	Female	75.0	DUPIXENT	rash erythematous	0	0	0.0	Young	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	3	12	2	0.08073634859349145	0.5274725274725274	0.015513897866839042
1243	25070241	US	US	1	2.0	0	0	0	0	2025-03-12	61.0	801.0	Female	75.0	OPZELURA	product dose omission issue	0	0	0.0	MidAge	US	0.0	2	0	27	0	0	0	0	0	0	0	4	2025	3	12	2	0.08073634859349145	0.0	0.0
1244	25071886	EU	EU	1	1.0	0	0	0	0	2025-03-13	11.0	801.0	Male	23.0	TACROLIMUS	hypogammaglobulinaemia	1	0	0.0	Child	EU	0.09183673469387754	7	0	22	0	0	0	0	0	0	0	1	2025	3	13	3	0.08073634859349145	1.010204081632653	0.0
1245	25074249	EU	EU	1	1.0	0	0	0	0	2025-03-13	8.0	801.0	Female	75.0	DORZOLAMIDE\TIMOLOL	dry eye	1	0	0.0	Child	EU	0.0	1	0	7	0	0	0	0	0	0	0	2	2025	3	13	3	0.08073634859349145	0.0	0.0
1246	26097105	EU	EU	1	1.0	0	0	0	0	2025-11-27	27.0	801.0	Male	75.0	DASATINIB	pulmonary hypertension	1	0	0.0	Young	EU	0.0	2	0	22	0	0	0	0	0	0	0	2	2025	11	27	3	0.08073634859349145	0.0	0.0
1247	26097334	US	US	1	2.0	0	0	0	0	2025-11-27	74.0	801.0	Female	75.0	DATROWAY	off label use	0	0	0.0	Senior	US	0.0	2	0	13	0	0	0	0	0	0	0	3	2025	11	27	3	0.08073634859349145	0.0	0.0
1248	26097873	US	US	1	2.0	0	0	0	0	2025-11-27	28.0	801.0	Female	75.0	DUPIXENT	eczema	0	0	0.0	Young	US	0.015513897866839042	221	0	6	0	0	0	0	0	0	0	1	2025	11	27	3	0.08073634859349145	0.43438914027149317	0.015513897866839042
1249	26098401	US	US	1	2.0	0	0	0	0	2025-11-27	29.0	801.0	Female	75.0	XELJANZ	drug ineffective	0	0	0.0	Young	US	0.0	3	0	16	0	0	0	0	0	0	0	2	2025	11	27	3	0.08073634859349145	0.0	0.0
1250	26099183	US	US	1	2.0	0	0	0	0	2025-11-28	13.0	801.0	Female	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	Child	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	11	28	4	0.08073634859349145	0.20168067226890754	0.015513897866839042
1251	26099345	US	US	1	2.0	0	0	0	0	2025-11-28	57.0	801.0	Female	75.0	AMLODIPINE	adverse drug reaction	0	0	0.0	MidAge	US	0.16964285714285715	8	1	21	0	0	0	0	0	0	0	3	2025	11	28	4	0.08073634859349145	9.669642857142858	0.16964285714285715
1252	25968385	CN	CN	1	1.0	0	0	0	0	2025-10-28	9.0	801.0	Male	75.0	DEXAMETHASONE	gene mutation	1	0	0.0	Child	CN	0.1857142857142857	5	1	13	0	0	0	0	0	0	0	2	2025	10	28	1	0.08073634859349145	1.6714285714285713	0.0
1253	25968466	GB	GB	2	1.0	0	0	0	0	2025-10-28	57.0	801.0	Female	75.0	COSENTYX	crohn^s disease	1	0	0.0	MidAge	GB	0.05714285714285714	10	0	15	0	0	0	0	0	0	0	2	2025	10	28	1	0.08936301793444651	3.257142857142857	0.05714285714285714
1254	25971963	CA	CA	1	1.0	1	0	0	0	2025-10-29	57.0	801.0	Female	75.0	TUMS ULTRA	hip arthroplasty	1	5	0.35714285714285715	MidAge	CA	0.35714285714285715	1	1	16	0	0	0	0	0	0	0	2	2025	10	29	2	0.08073634859349145	20.357142857142858	0.35714285714285715
1255	25102021	US	US	1	1.0	0	0	0	0	2025-03-20	27.0	801.0	Male	75.0	ALTUVIIIO	ankle operation	1	0	0.0	Young	US	0.0	1	0	15	0	0	0	0	0	0	0	2	2025	3	20	3	0.08073634859349145	0.0	0.0
1256	25110174	AU	AU	2	1.0	0	0	0	0	2025-03-24	38.0	801.0	Female	75.0	VEDOLIZUMAB	uveitis	1	0	0.0	Adult	AU	0.057692307692307696	26	0	7	0	0	0	0	0	0	0	1	2025	3	24	0	0.08936301793444651	2.1923076923076925	0.057692307692307696
1257	25112657	US	Unknown	1	2.0	0	0	0	0	2025-03-24	66.0	801.0	Female	75.0	BIMZELX	diarrhoea	0	0	0.0	Senior	US	0.0	22	0	9	0	0	0	0	0	0	0	1	2025	3	24	0	0.08073634859349145	0.0	0.0
1258	25112981	US	Unknown	1	2.0	0	0	0	0	2025-03-24	42.0	801.0	Female	75.0	BIMZELX	anxiety	0	0	0.0	Adult	US	0.0	22	0	7	0	0	0	0	0	0	0	1	2025	3	24	0	0.08073634859349145	0.0	0.0
1259	25114615	US	US	1	2.0	0	0	0	0	2025-03-24	23.0	801.0	Male	75.0	DUPIXENT	illness	0	0	0.0	Young	US	0.015513897866839042	221	0	7	0	0	0	0	0	0	0	1	2025	3	24	0	0.08073634859349145	0.35681965093729795	0.0
1260	25118165	US	US	1	1.0	0	0	0	0	2025-03-25	82.0	801.0	Female	54.0	REFRESH OPTIVE GEL DROPS	corneal scar	1	0	0.0	Senior	US	0.0	1	0	12	0	0	0	0	0	0	0	2	2025	3	25	1	0.08073634859349145	0.0	0.0
1261	25124335	US	US	1	2.0	0	0	0	0	2025-03-26	85.0	801.0	Female	75.0	IBRANCE	fatigue	0	0	0.0	Senior	US	0.07142857142857142	3	0	7	0	0	0	0	0	0	0	1	2025	3	26	2	0.08073634859349145	6.071428571428571	0.07142857142857142
1262	25138387	US	US	1	1.0	0	0	1	0	2025-03-30	72.0	801.0	Female	75.0	TYMLOS	depression suicidal	1	3	0.21428571428571427	Senior	US	0.21428571428571427	1	1	19	0	0	0	0	0	0	0	2	2025	3	30	6	0.08073634859349145	15.428571428571427	0.21428571428571427
1263	25138482	US	US	1	1.0	0	0	0	0	2025-03-30	4.0	801.0	Male	75.0	IDELVION	haemorrhage	1	0	0.0	Child	US	0.10714285714285714	2	0	11	0	0	0	0	0	0	0	1	2025	3	30	6	0.08073634859349145	0.42857142857142855	0.0
1264	25142074	EU	EU	1	1.0	0	0	0	0	2025-03-31	39.0	801.0	Female	75.0	CEFIDEROCOL	encephalitis	1	0	0.0	Adult	EU	0.0	1	0	12	0	0	0	0	0	0	0	1	2025	3	31	0	0.08073634859349145	0.0	0.0
1265	25144328	BR	BR	2	1.0	0	0	1	0	2025-04-01	15.0	801.0	Male	45.0	INFLIXIMAB	disseminated tuberculosis	1	3	0.21428571428571427	Child	BR	0.07142857142857142	9	0	25	0	0	0	0	0	0	0	2	2025	4	1	1	0.08936301793444651	1.0714285714285714	0.0
1266	25148850	US	US	2	2.0	0	0	0	0	2025-04-02	71.0	801.0	Male	75.0	ORGOVYX	hypersomnia	0	0	0.0	Senior	US	0.0	4	0	11	0	0	0	0	0	0	0	1	2025	4	2	2	0.08936301793444651	0.0	0.0
1267	25152132	US	US	2	1.0	0	0	0	0	2025-04-02	68.0	801.0	Female	75.0	TREMFYA	liver function test increased	1	0	0.0	Senior	US	0.10714285714285714	2	0	29	0	0	0	0	0	0	0	4	2025	4	2	2	0.08936301793444651	7.285714285714286	0.10714285714285714
1268	25170949	EU	EU	1	1.0	0	0	0	0	2025-04-08	44.0	801.0	Female	65.0	LYNPARZA	haemoglobin decreased	1	0	0.0	Adult	EU	0.0	1	0	21	0	0	0	0	0	0	0	2	2025	4	8	1	0.08073634859349145	0.0	0.0
1269	26101211	US	US	2	1.0	0	0	0	0	2025-11-28	57.0	801.0	Male	75.0	SKYRIZI	skin cancer	1	0	0.0	MidAge	US	0.051587301587301584	36	0	11	0	0	0	1	0	0	0	2	2025	11	28	4	0.08936301793444651	2.9404761904761902	0.0
1270	26101493	CN	CN	1	1.0	0	0	0	0	2025-11-28	35.0	801.0	Female	70.0	PALIPERIDONE	blood prolactin increased	1	0	0.0	Young	CN	0.0	1	0	25	0	0	0	0	0	0	0	3	2025	11	28	4	0.08073634859349145	0.0	0.0
1271	26101912	US	US	2	1.0	0	0	0	0	2025-11-28	57.0	801.0	Female	75.0	SKYRIZI	skin disorder	1	0	0.0	MidAge	US	0.051587301587301584	36	0	13	0	0	0	0	0	0	0	2	2025	11	28	4	0.08936301793444651	2.9404761904761902	0.051587301587301584
1272	26102102	CA	CA	1	1.0	0	0	0	0	2025-11-28	58.0	801.0	Female	75.0	APIXABAN	deep vein thrombosis	1	0	0.0	MidAge	CA	0.07142857142857142	3	0	20	0	0	0	0	0	0	0	3	2025	11	28	4	0.08073634859349145	4.142857142857142	0.07142857142857142
1273	26102627	US	US	1	2.0	0	0	0	0	2025-11-28	57.0	801.0	Female	75.0	DUPIXENT	injection site exfoliation	0	0	0.0	MidAge	US	0.015513897866839042	221	0	26	0	0	0	0	0	0	0	3	2025	11	28	4	0.08073634859349145	0.8842921784098254	0.015513897866839042
1274	26102722	GB	GB	1	1.0	0	0	0	0	2025-11-28	57.0	801.0	Female	75.0	DOXYCYCLINE	depression	1	0	0.0	MidAge	GB	0.19642857142857142	4	1	10	0	0	0	0	0	0	0	1	2025	11	28	4	0.08073634859349145	11.196428571428571	0.19642857142857142
1275	26103127	US	US	1	2.0	0	0	0	0	2025-11-29	57.0	801.0	Female	75.0	LEVOTHYROXINE SODIUM	abdominal discomfort	0	0	0.0	MidAge	US	0.0	3	0	20	0	0	0	0	0	0	0	2	2025	11	29	5	0.08073634859349145	0.0	0.0
1276	26104652	JP	JP	1	1.0	0	0	0	0	2025-11-30	57.0	801.0	Female	75.0	DUPIXENT	breast cancer	1	0	0.0	MidAge	JP	0.015513897866839042	221	0	13	0	0	0	1	0	0	0	2	2025	11	30	6	0.08073634859349145	0.8842921784098254	0.015513897866839042
1277	25973192	JP	JP	1	1.0	0	0	1	0	2025-10-29	62.0	801.0	Female	75.0	DOCETAXEL	hemiparesis	1	3	0.21428571428571427	MidAge	JP	0.061224489795918366	7	0	11	0	0	0	0	0	0	0	1	2025	10	29	2	0.08073634859349145	3.7959183673469385	0.061224489795918366
1278	25975499	EU	EU	1	1.0	0	0	0	0	2025-10-29	62.0	801.0	Male	54.0	MYCOPHENOLATE MOFETIL	deep vein thrombosis	1	0	0.0	MidAge	EU	0.10150375939849625	19	0	20	0	0	0	0	0	0	0	3	2025	10	29	2	0.08073634859349145	6.2932330827067675	0.0
1279	25176848	US	US	1	1.0	0	0	0	0	2025-04-09	57.0	801.0	Female	75.0	CREXONT	cholelithiasis	1	0	0.0	MidAge	US	0.0	1	0	14	0	0	0	0	0	0	0	1	2025	4	9	2	0.08073634859349145	0.0	0.0
1280	25179010	US	US	1	2.0	0	0	0	0	2025-04-09	13.0	801.0	Male	75.0	DUPIXENT	rash	0	0	0.0	Child	US	0.015513897866839042	221	0	4	0	0	0	0	0	0	0	1	2025	4	9	2	0.08073634859349145	0.20168067226890754	0.0
1281	25183842	US	US	1	2.0	0	0	0	0	2025-04-10	33.0	801.0	Female	75.0	DUPIXENT	dermatitis atopic	0	0	0.0	Young	US	0.015513897866839042	221	0	17	0	0	0	0	0	0	0	2	2025	4	10	3	0.08073634859349145	0.5119586296056884	0.015513897866839042
1282	25199838	CL	CL	2	1.0	0	0	0	0	2025-04-15	35.0	801.0	Female	75.0	SIMPONI	pneumonia	1	0	0.0	Young	Other	0.0	2	0	9	0	0	0	0	0	1	0	1	2025	4	15	1	0.08936301793444651	0.0	0.0
1283	25203687	US	US	1	2.0	0	0	0	0	2025-04-16	77.0	801.0	Male	75.0	DUPIXENT	erythema	0	0	0.0	Senior	US	0.015513897866839042	221	0	8	0	0	0	0	0	0	0	1	2025	4	16	2	0.08073634859349145	1.1945701357466063	0.0
1284	25210748	US	US	1	2.0	0	0	0	0	2025-04-17	80.0	801.0	Female	75.0	OLANZAPINE	sedation	0	0	0.0	Senior	US	0.11904761904761905	6	0	8	0	0	0	0	0	0	0	1	2025	4	17	3	0.08073634859349145	9.523809523809524	0.11904761904761905
1285	25211653	US	US	2	1.0	0	0	1	0	2025-04-18	57.0	801.0	Male	75.0	EPIDIOLEX	hospitalisation	1	3	0.21428571428571427	MidAge	US	0.14285714285714285	3	1	15	0	0	0	0	0	0	0	1	2025	4	18	4	0.08936301793444651	8.142857142857142	0.0
1286	25213301	CA	CA	1	1.0	0	0	0	0	2025-04-18	3.0	801.0	Male	75.0	RITUXIMAB	abdominal discomfort	1	0	0.0	Child	CA	0.12406015037593986	19	0	20	0	0	0	0	0	0	0	2	2025	4	18	4	0.08073634859349145	0.37218045112781956	0.0
1287	25226934	EU	EU	1	1.0	0	0	0	1	2025-04-22	21.0	801.0	Male	75.0	CLOZAPINE	general physical health deterioration	1	2	0.14285714285714285	Young	EU	0.23214285714285715	4	1	37	0	0	0	0	0	0	0	4	2025	4	22	1	0.08073634859349145	4.875	0.0
1288	25237383	EU	EU	1	1.0	0	0	0	0	2025-04-25	57.0	801.0	Male	2.49	GENTAMICIN	neonatal respiratory distress syndrome	1	0	0.0	MidAge	EU	0.0	1	0	38	0	0	0	0	0	0	0	4	2025	4	25	4	0.08073634859349145	0.0	0.0